WO2005003084A1 - 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same - Google Patents

4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same Download PDF

Info

Publication number
WO2005003084A1
WO2005003084A1 PCT/KR2004/001641 KR2004001641W WO2005003084A1 WO 2005003084 A1 WO2005003084 A1 WO 2005003084A1 KR 2004001641 W KR2004001641 W KR 2004001641W WO 2005003084 A1 WO2005003084 A1 WO 2005003084A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
methylsulfonylamino
fluoro
propionamide
butylbenzyl
Prior art date
Application number
PCT/KR2004/001641
Other languages
French (fr)
Inventor
Jee Woo Lee
Young Ho Kim
Hee Kim
Hyun Kyung Choi
Hee Jin Ha
Original Assignee
Grunenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grunenthal Gmbh filed Critical Grunenthal Gmbh
Priority to IL172671A priority Critical patent/IL172671A/en
Priority to NZ544943A priority patent/NZ544943A/en
Priority to CA2533547A priority patent/CA2533547C/en
Priority to AU2004253808A priority patent/AU2004253808B2/en
Priority to US10/562,698 priority patent/US8642657B2/en
Priority to JP2006518539A priority patent/JP4850702B2/en
Priority to EP04748386A priority patent/EP1658265A4/en
Priority to BRPI0412229-1A priority patent/BRPI0412229A/en
Publication of WO2005003084A1 publication Critical patent/WO2005003084A1/en
Priority to IS8216A priority patent/IS8216A/en
Priority to NO20060122A priority patent/NO332602B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/38—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reaction of ammonia or amines with sulfonic acids, or with esters, anhydrides, or halides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C335/12—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/14—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
    • C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes

Definitions

  • the present invention relates to novel 4-(methylsulfonylamino)phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same.
  • NR1 is a member of the transient receptor potential (TRP) superfamily.
  • TRP transient receptor potential
  • Members of this family are non-voltage activated cation channel proteins that play critical roles in processes ranging from sensory physiology to vasorelaxation and male fertility. They share structural similarities such as six transmembrane segments and an oligmeric structure (Montell, C. et al., Cell, 108, p595, 2002).
  • the vanilloid or capsaicin receptor (NR1 or TRPN1) has been cloned from dorsal root ganglia (DRG) of the rat, the human, the chicken, the guinea pig, and the rabbit (Szallasi, A. et al., Pharmacol.
  • DDG dorsal root ganglia
  • Vanilloid receptor homologues have also been cloned but are not believed to be sensitive to vanilloids (Gunthorpe, M. J. et al, Trends in Pharmacol. Sci., 23, pl83, 2002).
  • NR1 which is expressed predominantly on thin, unmyelinated sensory nerve fibers (C-fibers) and small A fibers in the dorsal root, trigeminal, and nodose ganglia, is a molecular integrator of nociceptive stimuli.
  • NR1 is activated by protons, heat, natural exogenous ligands such as capsaicin (CAP) or resiniferatoxin (RTX), and endogenous substances such as anandamide and the lipoxygenase product 12-HPETE (Tominaga M. et al., Neuron, 21, p531; 1998; Caterina, M. J. et al., Nature, 389, p816, 1997; Walpole C. S. J.
  • VR1 chronic stimulation of VR1 leads to desensitization / defunctionalization of the neurons, probably reflecting multiple mechanisms.
  • the involvement of VR1 in both pathological and physiological conditions suggests that the blocking of this receptor, by desensitization or by antagonism, would have considerable therapeutic utility.
  • pain is of particular interest.
  • the validation of VR1 as a molecular target for the treatment of chronic pain was confirmed using transgenic mice lacking functional VR1 receptors. These mice exhibited impairment in the perception of thermal and inflammatory pain(Caterina, M. J. et al., Science, 288, p306, 2000).
  • the therapeutical advantage of VR1 antagonism over desensitization subsequent to agonism is that it avoids the initial excitatory effect preceding the desensitization.
  • 5-Iodo-RTX, SC0030, halogenated capsaicin analogues, BCTC, SB-366791, 7-hydroxynaphthalen-l-yl urea, and LBTU were characterized in detail as potent VR1 competitive antagonists(Wahl, P. et al., Mol. Pharmacol, 59, p9, 2001; Seabrook, G. R. et al., J. Pharmacol. Exp. Ther. 303, pl052, 2002; Wang, Y. et al., Mol. Pharmacol., 62, p947, 2002; Suh, Y-G. et al, Bioorg. Med. Chem.
  • ⁇ -[2-(3,4-dimethylbenzyl)-3-pivaloyloxypropy ⁇ ]- N'-[4-(methylsulfonylamino)benzyl]thiourea (1) showed a high binding affinity with a K; value of 29.3 nM for the inhibition of [ 3 H]RTX binding and potent antagonism with an IC 50 value of 67 nM for the inhibition of 45 Ca 2+ uptake in response to capsaicin, displaying partial agonism (Wang, Y et al., Pharm., 64, p325, 2003).
  • the present inventors have been extensively endeavored to discover novel analgesic agents based on the above studies and finally completed the present invention by synthesizing novel 4-(methylsulfonylamino)phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same.
  • Ri to R is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring;
  • R and R 6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R 5 and Re are not hydrogen atom simultaneously;
  • B is a group selected from a group selected from
  • R 7 to R 17 is independently at least one selected from a hydrogen, halogen atom and straight or branched alkyl group having 1 to 6 carbon atoms optionally substituted with more than one halogen atom
  • C is a group selected from alkyl, alkenyl and alkynyl group having 1 to 5 carbon atoms which may includes one or more heteroatoms, m, n, p, q, r and s is an integer of 0 to 3; an asteric mark * and ( ) mark indicate a chiral carbon atom, and double bond or single bond chain respectively.
  • alkyl group used herein include, but are not limited to, methyl, ethyl, propyl and the like
  • heterocyclic ring used herein include, but are not limited to, pyrrole, pyrazole, pyrazine, purine, pyridine, piperazine, piperidine, thazole, morpholine, dioxane and the like.
  • Preferable groups in general formula (I) of the present invention are the group in which R 5 or R 6 is methyl, ethyl, propyl, isopropyl, phenyl or benzyl and R 7 or R 8 is isopropyl, t-butyl or sec-butyl group, but are limited thereto.
  • the compounds of general formula (I) of the present invention comprise all the compounds represented by following formula (I) to (N) in accordance with the definition of A group. Accordingly, the present invention provides novel compounds represented by the following formula ( II ), the pharmaceutically acceptable salt or the isomer thereof:
  • Ri to R 4 is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring;
  • R 5 and R 6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R 5 and R 6 are not hydrogen atom simultaneously;
  • B is a group selected from the group (1-1) to (1-6) defined in general formula (I); the aster
  • the most preferred compound is one selected from the group consisting of; N-(4-tert-butylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(l- 51, MJ-372), N-(4-tert-butylbenzyl)-2-[3-chloro-4-
  • Ri to R- t is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring providing that all of Ri to R 4 are not hydrogen atoms simultaneously;
  • R 5 and R 6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R 5 and R 6 are not hydrogen atom simultaneously;
  • B is a group selected from the group
  • the most preferred compound is one selected from the group consisting of; N-(4-tert-butylbenzyl)-N , - ⁇ 1 -[3 -fluoro-4- (methylsulfonylamino)phenyl]ethyl ⁇ thiourea(15-l, LJO-328), N-(4-tert-butylbenzy ⁇ )- N - ⁇ l-[3-chloro-4-(methylsulfonylamino)phenyl]ethyl ⁇ thiourea(15-2, CHK-992), N-(4- tert-butylbenzyl)-N , - ⁇ l-[3-methoxy-4-(methylsulfonylamino)phenyl]ethyl ⁇ thiourea(15- 3, CHK-575), N-(4-tert-butylbenzyl)-N ⁇ - ⁇ l-[3-(methoxycarbonyl
  • Ri to R is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring;
  • R 5 and R 6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R 5 and R 6 are not hydrogen atom simultaneously;
  • B is a group selected from the group (1-1) to (1-6) defined in general formula (I); the asteric
  • the most preferred compound is one selected from the group consisting of; ⁇ -(4-tert-butylbenzyl)- ⁇ , - ⁇ l-[4-(methylsulfonylamino)phenyl]ethyl ⁇ urea (23-1. MK-82), N-(4-tert-butylbenzyl)-N ⁇ - ⁇ 1 -[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl ⁇ urea (23-2, MK-205)
  • R ⁇ to R 4 is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring;
  • R 5 and R 6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R 5 and R 6 are not hydrogen atom simultaneously;
  • B is a group selected from the group (1-1) to (1-6) defined in general formula (I); the
  • the most preferred compound is one selected from the group consisting of; N- ⁇ l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl ⁇ -3-(4-tert- butyl ⁇ henyl)acetamide (24-1, KMJ-586), N- ⁇ 1 -[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl ⁇ -3-(4-tert- butyl ⁇ henyl)prophanamide (24-2, KMJ-552), N- ⁇ l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl ⁇ -3-(4-tert-butylphenyl)-2- prophenamide (24-3, KMJ-570), N- ⁇ 1 - [3 -fluoro-4-(methylsulfonylamino)phenyl] ethyl ⁇ -3 -(3 ,
  • salt used herein comprises all the pharmaceutically salts well known in the art.
  • inventive compounds represented by general formula ( I ) to (V) can be transformed into their pharmaceutically acceptable salt and solvates by the conventional method well known in the art.
  • acid-addition salt thereof formed by a pharmaceutically acceptable free acid thereof is useful and can be prepared by the conventional method.
  • the salts are precipitated by the water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile to prepare acid addition salt thereof and further the mixture of equivalent amount of compound and diluted acid with water or alcohol such as glycol monomethylether, can be heated and subsequently dried by evaporation or filtrated under reduced pressure to obtain dried salt form thereof.
  • water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile
  • water or alcohol such as glycol monomethylether
  • organic acid or inorganic acid can be used.
  • organic acid such as methansulfonic acid, -toluensulfonic acid, acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonylic acid, vanillic acid, hydroiodic acid and the like, and inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid and the like can be used herein.
  • organic acid such as methansulfonic acid, -toluensulfonic acid, acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, gluta
  • the pharmaceutically acceptable metal salt form of inventive compounds may be prepared by using base.
  • the alkali metal or alkali-earth metal salt thereof can be prepared by the conventional method, for example, after dissolving the compound in the excess amount of alkali metal hydroxide or alkali-earth metal hydroxide solution, the insoluble salts are filtered and remaining filtrate is subjected to evaporation and drying to obtain the metal salt thereof.
  • sodium, potassium or calcium salt are pharmaceutically suitable and the corresponding silver salt can be prepared by reacting alkali metal salt or alkali-earth metal salt with suitable silver salt such as silver nitrate.
  • the pharmaceutically acceptable salt of the compound represented by general formula ( I ) to (V) comprise all the acidic or basic salt which may be present at the compounds, if it does not indicated specifically herein.
  • the pharmaceutically acceptable salt of the present invention comprise the salt of hydroxyl group such as the sodium, calcium and potassium salt thereof; the salt of amino group such as the hydrogen bromide salt, sulfuric acid salt, hydrogen sulfuric acid salt, phosphate salt, hydrogen phosphate salt, dihydrophosphate salt, acetate salt, succinate salt, citrate salt, tartarate salt, lactate salt, mandelate salt, methanesulfonate(mesylate) salt and -toluenesulfonate (tosylate) salt etc, which can be prepared by the conventional method well known in the art.
  • the term "isomer” used herein comprises all the isomers, for example, stereoisomer, optically active isomer, racemic mixture, enantiomer and the like well known in the art.
  • the compounds of the present invention comprise all the optically active isomers, R or S stereoisomers and the mixtures thereof.
  • Present invention also comprises all the uses of the racemic mixture, one or more optically active isomer and the mixtures thereof as well as all the preparation methods for preparing the isomers, for example, imsyrrimetric synthesis, and isolation methods for isolating the isomers, for example, partitioned re- crystalization method, chromatographic method well known in the art or the method disclosed herein.
  • the present invention provides a process for preparing novel compounds represented by general formula (I) to (V) described herein comprising the methods explained by following preferred embodiments or examples.
  • the compounds of the invention of formula ( I ) to (V) may be chemically synthesized by the methods which will be explained by following reaction schemes hereinafter, which are merely exemplary and in no way limit the invention.
  • the reaction schemes show the steps for preparing the representative compounds of the present invention, and the other compounds also may be produced by following the steps with appropriate modifications of reagents and starting materials, which are envisaged by those skilled in the art.
  • the reaction is stopped by acid e.g., 1N-HC1, diluted with water and repeatedly extracted with diethyether to obtain organic solvent layer.
  • the organic solvent layer is washed with water and saline water, dried, concentrated in vacuo and the residue is further purified with flash column chromatographic method to obtain ethyl 2-(3-halo-4-nitrophenyl) propionate intermediate compound (1-1 to 1-12) through the alkylation of 4-position in phenyl ring; at 2 nd step, the propionate intermediate compound (1-1 to 1-12) is reduced with reducing agent for example, 10% Pd/C (hydrogenation reaction, method A) or Fe ion in the presence with acetic acid (method B).
  • reducing agent for example, 10% Pd/C (hydrogenation reaction, method A) or Fe ion in the presence with acetic acid (method B).
  • the resulting product is filtered and the filtrates is dried in vacuo and purified with purified with flash column chromatographic method to obtain ethyl 2-(4-amino-3-halo phenyl) propionate intermediate compound (1-13 to 1-25) through reducing nitro group to amino group;
  • the propionate compound (1-13 to 1-25) is reacted with sulfonyl halide, preferably, methanesulfonychloride dissolved in pyridine solvent with stirring and the resulting product is washed with water and purified with flash column chromatographic method to obtain ethyl 2-(3-halo-4(methylsulfonyamino)phenyl) propionate intermediate compound (1-26 to 1-37) through sulfonylation process;
  • the propionate compound (1-26 to 1-37) dissolved in solvent mixture mixed with water and THF is reacted with metal hydroxide such as lithium hydroxide dropwisely with stirring and acidified with acidic
  • the compound represented by general formula (II) having A group (NHCO), R 5 (methyl) and R 6 (H) can be prepared by following procedure: conventionally available 2(4-nitrophenyl)propionic acid is coupling with amine (RNH 2 ) to produce amide (2-1 to 2-3) and the amide is reduced to produce amine compound (2-4 to 2-6). Finally, the amine is subjected to methylsulfonylation to obtain final product (2-7 to 2-9).
  • the compound represented by general formula (II) can comprises various optical isomers e.g., enantiomer, stereoisomer, diastereomer etc, according to the B moiety containing chiral carbon and the various isomers can be synthesized and isolated by the procedure explained by following Scheme 3 and 4.
  • the compound having halogen atom at any of R 1 and R 4 can prepared as follows:
  • the ester (1-13) is reacted with appropriate alkylating agent i.e., methyl iodide, in the presence of DMF and hydrogenated metal such as NaH to obtain dimethyl compound (7-1), and similar reactions to the steps ranging from 2nd step to 4 th step in Scheme 1 is further performed to produce the compound represented by general formula (II) having dimethyl group (7-4).
  • the compound having lower alkoxy group or hydrogen atom at any of Ri and R 4 and methyl groups at both of R 5 and R 6 can prepared by the procedure depicted in above Scheme 8.
  • the compound having NHCO group at A moiety and methyl groups at both of R 5 and Re can prepared by the procedure depicted in above Scheme 9.
  • the carboxylic acid (8-11, 7-4, 8-12) is reacted with amine having appropriate B substituents in the presence of EDC to produce purposed compound represented by general formula (II) having NHCO group at B moiety.
  • Scheme 10
  • the compound represented by general formula (II) having cycloalkane at R 5 and R ⁇ , and methoxyl group at any of Ri and R can prepared by the procedure depicted in Scheme 11.
  • the ester (8-3. 8-4) is reacted with dihaloalkane reagent such as 1,2- dibromoethane in the presence of metal hydride such as NaH to produce cycloalkyl intermediates (11-1, 11-2) and serial steps comprising reduction, mesylation and alkylation reactions is performed to obtain final carboxylic acid product (11-7, 11-8).
  • dihaloalkane reagent such as 1,2- dibromoethane
  • metal hydride such as NaH
  • the carboxylic acid product (11-7, 11-8) is reacted with amine having appropriate B moiet in the presence of EDC to obtain final compound represented by general formula (II) having cycloalkyl group at R 5 and R ⁇ .
  • the compound represented by general formula (III) and general formula (IV) having methyl group and hydrogen at R 5 and Rg, can prepared by the procedure depicted in Schemes 13 to 15.
  • the reaction consists of four steps as follows: at 1 st step, the 4-iodo amine compound (13-1 to 13-2) dissolved in pyridine is reacted with a sulfonylating agent, e.g., methane sulfonyl chloride with stirring.
  • a sulfonylating agent e.g., methane sulfonyl chloride
  • the resulting organic solvent layer is extracted, dried, concentrated in vacuo and the residue is further purified with flash column chromatographic method to obtain sulfonyl amine compound (13-3 to 13-4) through the reducing amine to sulfonyl group; at 2 nd step, the sulfonyl amine compound (13-3 to 13-4) dissolved in DMF is reacted with metal acetate, preferably, Pd (II) acetate or Tl (I) acetate, in the presence of DPPP (1,3-bisdiphenylphospinopropane) and butylvinylether at the temperature ranging from 60 to 110 ° C in the period ranging from 5 to 24 hours and the reaction mixture is cooled at the temperature ranging from 0°C to room temperature.
  • metal acetate preferably, Pd (II) acetate or Tl (I) acetate
  • ketone compound (13-5 to 13-7) Acidic solution such as 10%-HCl is added thereto and stirred.
  • the reaction mixture is diluted with ethylacetate, washed with ammonium chloride solution, concentrated with vacuo and purified with flash column chromatographic method to obtain ketone compound (13-5 to 13-7); at 3 rd step, the ketone compound and acid halide salt are dissolved in pyridine and heated at the temperature ranging from 40 to 90 ° C, preferably, 70 ° C, in the period ranging from 30 mins to 5 hours.
  • the reaction mixture is cooled, diluted and the resulting organic layer is purified with flash column chromatographic method to obtain oxime derivatives (13-8 to 13-10) through substituting ketone with oxime group; at 4 step, the oxime derivatives is hydrogenated with reducing agent, for example, 10% Pd/c dissolved in lower alcohol e.g., methanol.
  • reducing agent for example, 10% Pd/c dissolved in lower alcohol e.g., methanol.
  • the resultant is filtrated and the filtrate is purified with flash column chromatographic method to obtain amine intermediate compound (13-11 to 13-13) through reducing nitro group to amine group as can be seen in Scheme 13.
  • the thiourea compound represented by general formula (III) and urea compound general formula (IN) can prepared by the procedure depicted in Scheme- 15. As depicted as Scheme 15, the amine compound obtained in Scheme 14 and isothiocyanate compound (B- ⁇ CS) or cyanate compound (B- ⁇ CO) having appropriate B moiety is dissolved in DMF and stirred at the temperature ranging from 0 ° C to room temperature, in the period ranging from 30 mins to 4 hours, preferably, 2hours.
  • reaction mixture is diluted with water and the organic solvent layer is extracted, dried, concentrated in vacuo and purified with flash column chromatographic method to obtain purposed thiourea compound or urea compounds (15-1 to 15-5, 18-1 to 18-6, 19-5 to 19-12, 23-1 to 23-2) through coupling reaction.
  • the mine is further reacted with 1,1-thiocarbonyl diimidazole(TCD) in the presence of DMF solvent to produce isothiocyanate (19-3, 19-4).
  • the isocyanate is reacted with (R) or (S) alpha-methyl-4-nitrobenzyl amine HC1 in the presence of base e.g., TEA, reduced with reducing agent, for example, Al-Hg and mesylated to obtain (IS, 2R), (IS, 2S), (1R, 2R) and (1R, 2S) thiourea represented by general formula (III) or urea represented by general formula (IN) (19-13 to 19-16).
  • base e.g., TEA
  • reducing agent for example, Al-Hg and mesylated to obtain (IS, 2R), (IS, 2S), (1R, 2R) and (1R, 2S) thiourea represented by general formula (III) or urea represented by general formula (IN) (19-13 to 19
  • the amine intermediate compound (13-11 to 13-13) can be prepared by the procedure depicted in following Scheme 20.
  • the resulting compound is reacted with sulfonylating agent such as methane sulfonyl chloride in the presence of pyridine solvent to produce N-(2-fluoro-4- vinylphenyl)methanesulfoneamide (20-2) and oxidized with oxidizing agent e.g., osmium tetroxide and sodium periodate in the presence of acetone-water mixture solvent to aldehyde intermediate (20-3).
  • sulfonylating agent such as methane sulfonyl chloride in the presence of pyridine solvent to produce N-(2-fluoro-4- vinylphenyl)methanesulfoneamide (20-2)
  • oxidizing agent e.g., osmium tetroxide and sodium periodate in the presence of acetone-water mixture solvent to aldehyde intermediate (20-3).
  • the aldehyde compound is reacted with Grignard reagent to obtain alcohol intermediate (2-4 to 20-7) and further reacted with DPPA(diphenylphosphorylazide) and DBU(l,8-diazabicyclo[5,4,0]undec-7-ene) in the presence with toluene solvent to produce azide compound (20-8 to 20-11).
  • the azide intermediate is finally reduced with reducing agent such as Pd/C to produce purposed amine derivative (13-11 1 13-13) selectively.
  • the thiourea compound represented by general formula (III) or urea compound represented by general formula (IN) having methyl groups at both R 5 and R 6 can be prepared by the procedure shown in following Scheme 21.
  • the carbamates compound is subjected to reduction process with reducing agent such as Pd/C in H 2 gas to obtain amine intemediate (21-4 to 21-6) and coupling reaction shown in Scheme 15 is further subjected to obtain purposed amine is reacted with benzyl amine in the presence of EDC to obtain final thiourea compound represented by general formula (III) or urea compound represented by general formula (IV).
  • reducing agent such as Pd/C in H 2 gas
  • Scheme 15 is further subjected to obtain purposed amine is reacted with benzyl amine in the presence of EDC to obtain final thiourea compound represented by general formula (III) or urea compound represented by general formula (IV).
  • the carbamates compound is subjected to reduction process with reducing agent such as Pd/C in H gas to obtain amine intemediate (21-4 to 21-6) and coupling reaction shown in Scheme 15 is further subjected to obtain purposed amine is reacted with benzyl amine in the presence of EDC to obtain final thiourea compound represented by general formula (III) or urea compound represented by general formula (IV).
  • reducing agent such as Pd/C in H gas
  • Scheme 15 is further subjected to obtain purposed amine is reacted with benzyl amine in the presence of EDC to obtain final thiourea compound represented by general formula (III) or urea compound represented by general formula (IV).
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula ( I ) to (N) or a pharmaceutically acceptable salt thereof as an active ingredient for an antagonist of vanilloid receptor.
  • the compound of formula ( I ) to (N) according to the present invention has potent analgesic and anti-inflammatory activity, and the pharmaceutical composition of the present invention thus may be employed to alleviate or relieve acute, chronic or inflammatory pains or to suppress inflammation and to treat urgent urinary incontinence.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the compound selected from the group consisting of compounds of formula ( I ) to (N) or the pharmaceutical acceptable salts thereof for preventing and treating pain diseases or inflammatory diseases.
  • Pain diseases or inflammatory diseases comprise at least one selected from the group consisting of pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and the like.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the compound selected from the group consisting of compounds of formula ( I ) to (N) or the pharmaceutical acceptable salts thereof for preventing and treating urgent urinary incontinence.
  • the pharmaceutical composition of the present invention comprises the inventive compounds between 0.0001 to 10% by weight, preferably 0.0001 to 1% by weight based on the total weight of the composition.
  • the present invention also provides an use of compound selected from the group consisting of compounds of formula ( I ) to (N) or the pharmaceutical acceptable salts thereof as antagonists of vanilloid receptors.
  • a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease or urgent urinary incontinence.
  • the compound of formula ( I ) to (N) according to the present invention can be provided as a pharmaceutical composition comprising pharmaceutically acceptable carriers, adjuvants or diluents.
  • the compounds of the present invention can be dissolved in oils, propylene glycol or other solvents, which are commonly used to produce an injection. Suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not limited to them.
  • the compounds of the present invention can be formulated in the form of ointments and creams.
  • the compounds of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
  • the compounds of the present invention may be formulated into preparations for injections by dissolving, suspending, or emulsifying them in aqueous solvents such as normal saline, 5% Dextrose, or non-aqueous solvent such as vegetable oil, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol.
  • aqueous solvents such as normal saline, 5% Dextrose, or non-aqueous solvent such as vegetable oil, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol.
  • the formulation may include conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.
  • the desirable dose of the inventive compounds varies depending on the condition and the weight of the subject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer at the amount ranging 0.0001 - 100 mg/kg, preferably 0.001 - 100 mg/kg by weight/day of the inventive compounds of the present invention.
  • the dose may be administered in single or divided into several times per day.
  • the compounds should be present between 0.0001 to 10% by weight, preferably 0.0001 to 1% by weight based on the total weight of the composition.
  • composition of present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) via various routes. All modes of administration are contemplated, for example, administration can be made orally, rectally or by intravenous, intramuscular, subcutaneous, intrathecal, epidural or intracerebroventricular injection.
  • it is an object of the present invention to provide a method of treating or preventing pain disease and inflammatory disease by showing vanilloid receptor- antagonistic activity in a mammal comprising administering to said mammal an effective amount of the above-mentioned compound of the present invention together with a pharmaceutically acceptable carrier thereof.
  • Step 1-1 Preparation of ethyl 2-( " 3-fluoro-4-nitrophenyl propionate (1-1, SU-654
  • a stirred solution of potassium t-butoxide (20 mmol) in DMF (20 mL) was added a mixture of 2-fluoro-nitrobenzene (10 mmol) and ethyl-2-chloropropionate (10 mmol) at 0 °C dropwise.
  • the mixture was quenched by 1 N HC1 solution, diluted with water and extracted with diethyl ether several times. The combined organic layers were washed with water and brine, dried over MgSO 4 , and concentrated in vacuo.
  • Step 1-2 Preparation of ethyl- 2-(4-amino-3-fluorophenyl propionate (1-13, SU-656
  • a suspension of 2-(3-fluoro-4-nitrophenyl)propionate(l-l, 5 mmol) and 10% Pd-C (500 mg) in EtOH (30 mL) was hydrogenated under a balloon of hydrogen for 1 h and filtered through Celite.
  • the filtrate was concentrated in vacuo and the residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:4) as eluant to afford 2-(4-amino-3-fluorophenyl)propionate compound(l-13, SU-656).
  • Step 1-3 Preparation of ethyl 2-[3-fluoro-4-fmetylsulfonylamino phenyl]propionate comrJoundd-26. SU-658)
  • a solution of 2-(4-amino-3-fluorophenyl)propionate (1-13, 4mM) and pyridine (10ml) was dissoluted with methansulfonylchloride (6mM) and was stirred at 0 ° C for 10 minutes.
  • Step 1-4 Preparation of 2-[3-fluoro-4-(metylsulfonylamino)pheny ⁇ ⁇
  • a solution of ethyl 2-[3-fluoro-4-(metylsulfonylamino)phenyl]propionate (1-26, 2 mmol) in H 2 O and THF (1 :2, 30 mL) was treated with lithium hydroxide (6 mmol) and stirred for 4 h at room temperature.
  • the mixture was diluted with H 2 O and CH C1 2 , acidified by 1 N HC1 solution and extracted with CH 2 C1 2 several times.
  • Example 2 Preparation of N-(4-tert-Butylbenzyl)-2-[3-chloro-4- (methylsulfonylamino)phenyl]propionamide (1-52 KMJ-470)
  • Example 3 Preparation of N-(4-tert-Butylbenzyl)-2-[3-bromo-4- (methylsulfonyIamino)phenyl]propionamide (1-53 SH-173)
  • Example 5 Preparation of N-(4-tert-Butylbenzyl)-2-[3,5-difluoro-4- (methylsulfonylamino)phenyi]propionamide (1-55 SH-285)
  • Example 6 Preparation of N-(4-tert-Butylbenzy ⁇ )-2-[3-cyano-4- (methylsulfonylamino)phenyl]propionamide (1-56 SH-219)
  • Example 7 Preparation of N-(4-tert-Butylbenzy ⁇ )-2-[3-(t-butoxycarbony ⁇ )-4- (methylsulfonylamino)phenyl]propionamide (1-57 KMJ-806)
  • Example 8 Preparation of N-(4-tert-Butylbenzy ⁇ )-2-[3-carboxyl-4- (methylsulfonylamino)phenyl]propionamide (1-58 KMJ-788)
  • the compound 1-58 was prepared from N-(4-tert-Butylbenzyl)-2-[3-(t- butoxycarbonyl)-4-(methylsulfonylamino)phenyl]propionamide(l-57) by trifluoro acid hydrolysis.
  • Example 9 Preparation of N-(4-tert-Butylbenzyl)-2-[3-(methoxycarbonyl)-4- (methylsulfonylamino)phenyl]propionamide (1-59 KMJ-838)
  • Example 10 Preparation of N-(4-tert-Butylbenzyl)-2-[3-(benzylamino)carbonyl-4- (methylsulfonylamino)phenyl]propionamide (1-60, J-836) N-(4-tert-Butylbenzyl)-2-[3-(benzylamino)carbonyl-4- (methylsulfonylamino)phenyl]propionamide (1-60) was prepared from 1-58 by general amino coupling with benzyl amine.
  • Example 11 Preparation of N-(4-tert-Butylbenzyl)-2-[3-piperidino-4- (methyIsulfonylamino)phenyl]propionamide (1-61 YS-65)
  • Example 12 Preparation of N-(4-t:ert-Butylbenzyl)-2-[3-morpholino-4- (methylsulfonylamino)phenyl]propionamide (1-62 YS-49)
  • Example 13 Preparation of N-(4-tert-Butylbenzyl)-2-[3-( ⁇ -boc)piperazino-4- (methylsulfonylamino)phenyl]propionamide (1-63 YS-76)
  • Example 14 Preparation of N-(4-tert-Butylbenzyl)-2-[3-piperazino-4- (methylsulfonylamino)phenyl]propionamide (1-64 YS-79)
  • Example 15 Preparation of N-(4-tfert-Butylbenzy ⁇ )-2-[3-methoxy-4- (methylsulfonylamino)phenyl]propionamide (1-65, CHK-717)
  • Example 17 Preparation of N-(4-tert-Butylbenzyl)-2-[2-chloro-4- (methylsulfonylamino)phenyl]propionamide (1-67 KMJ-698)
  • N-(4-tert-ButylbenzylV2-(4-aminophenyl)propionamide (2-4 KMJ-740)
  • N-(4-tert-Butylbenzyl)-2-(4-nitrophenyl)propionamide as a starting material
  • Step 21-1 N-( ' (lS)-l-Benzyl-2-hvdroxyethyn-(2S)-2-
  • Step 22-2 (2R)-[3-Fluoro-4-(methylsulfonylamino phenyl]propionic acid (3-4, SU-732
  • (2R)-[3-Fluoro-[3-Fluoro-(methylsulfonylamino phenyl]propionic acid (3-4, SU-732
  • Example 26 Preparation of N-(3,4-DichIorobenzy ⁇ )-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-4, SH-94)
  • Example 27 Preparation of N-(3,4-Dichlorobenzy ⁇ )-2-[3-chIoro-4- (methylsulfonylamino)phenyl]propionamide (4-5, SH-286)
  • Example 28 Preparation of N-(3,4-DiehlorobenzyI)-2-[3-bromo-4- (methylsulfonylamino)phenyl]propionamide (4-6, SH-337)
  • Example 30 Preparation of N-(4-Isopropylbenzyl)-2-[3-fluoro-4- (methylsuIfonylamino)phenyl]propionamide (4-8, KMJ-928)
  • Example 31 Preparation of N-(4-Methoxybenzyl)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-9, SH-353)
  • Example 32 Preparation of N-(4-TrifluoromethyIbenzyI)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-10, SH-93)
  • Example 33 Preparation of N ⁇ (4-Biphenylmethy ⁇ )-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-11, KMJ-498)
  • Example 34 Preparation of N-(l- ⁇ aphthylmethy ⁇ )-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-12, SH-92)
  • Example 35 Preparation of N-(l,2,3,4-Tetrahydro-l-naphthalenyl)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-13, SH-112)
  • N-(l,2,3,4-Tetrahydro-l- naphthalenyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 73% yield, white solid, mp 116-117 °C 1H ⁇ MR (CDC1 3 ) ⁇ 7.51 (m, 1 H), 6.8-7.2 (m, 6 H
  • Example 36 Preparation of N-[2-(4-t-Butylphenyl)ethyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-14, KMJ-374)
  • Example 37 Preparation of N-[3-(3,4-Dimethylphenyl)propyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-15, SU-770)
  • Example 38 Preparation of N-[3-(3,4-Dimethylphenyl)propyl]-(2R)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-16, SU-774)
  • 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 3-(3,4- Dimethylphenyl)propyl]-R-amine compound as a starting material N-[3-(3,4- Dimethylphenyl)propyl]-(2R)-2-[3-fluoro-4-
  • Example 39 Preparation of N-[3-(3,4-Dimethylphenyl)propyl]-(2S)-2-[3-fluoro-4- (methylsnlfonylamino)phenyl]propionamide (4-17, SU-776)
  • 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 3-(3,4- Dimethylphenyl)propyl]-S-amine compound as a starting material N-[3-(3,4- Dimethylphenyl)propyl]-(2S)-2-[3-fluoro-4-
  • Example 40 Preparation of N-[3-(3,4-DimethyIpheny ⁇ )-2-propenyI]-2-[3-fluoro-4- (methylsulfonylamino)phenyl] propionamide (4-18, KMJ-686)
  • 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 3-(3,4- Dimethylphenyl)-2-prophenylamine compound as a starting material, N-[3-(3,4- Dimethylphenyl)-2-propenyl]-2-[3-fluoro-4-
  • Example 41 Preparation of N-[3-(4-Chlorophenyl)propyl]-2-[3-fiuoro-4- (methylsulfonylamino)phenyljpropionamide (4-19, KMJ-518)
  • Example 42 Preparation of N-[3-(4-ChIorophenyI)-2-propenyI]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-20, KMJ-732)
  • Example 45 Preparation of N-(2,2-Diphenylethyl)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-23, SH-116)
  • Example 46 Preparation of N-(3,3-Diphenylpropyl)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-24, KMJ-378)
  • Example 48 Preparation of N-[3,3-Di(4 ⁇ methylphenyI)-2-propenyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyI]propionamide (4-26, KMJ-908)
  • Example 49 Preparation of N-[3,3-Di(4-fluorophenyi)-2-propenyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-27, SH-135)
  • Example 50 Preparation of N-[2-(10,ll-Dihydro-5jf ⁇ -dibenzo[ ⁇ ,t jcyclol ⁇ epten-5- yliden)ethyI]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-28, SH- 199)
  • Example 51 Preparation of N ⁇ [2-(3,4-Dimethylbenzy ⁇ )-3-pivaloyloxypropyl]-2-[4- (methylsulfonylamino)phenyl]propionamide (5-1, CHK-512) The N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-2-[4-
  • Example 53 Preparation of 2-[3-Fluoro-4-(methylsulfonylamino)phenyl]-N-[2- (3,4-dimethylbenzyl)-3-pivaloyloxypropyl]propionamide (5-3, SU-542)
  • the 2-[3-Fluoro-4-(methylsulfonylamino)phenyl]-N-[2-(3,4-dimethylbenzyl)-3- pivaloyloxypropyljpropionamide was prepared by the similar procedure with that described in above Example 1-5.
  • Example 54 Preparation of 2-[3-Fluoro-4-(methylsulfonylamino)phenyl]-N-[2-(4- tert-butylbenzyI)-3 ⁇ pivaIoyIoxypropyI]propionamide (5-4, SU-564)
  • the 2-[3-Fluoro-4-(methylsulfonylamino)phenyl]-N-[2-(4-tert-butylbenzyl)-3- pivaloyloxypropyljpropionamide was prepared by the similar procedure with that described in above Example 1-5.
  • Example 55 Preparation of N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl] ⁇ 2-[3- metnoxy-4-(methylsuIfonylamino)phenyl]propionamide (5-5, CHK-479)
  • Example 56 Preparation of N-[2-(4-fer -Butylbenzy ⁇ )-3-pivaloyloxypropyl]-2-[3- methoxy-4-(methyIsuIfonyIamino)phenyl]propionamide (5-6, CHK-499) The N-[2-(4-tert-Butylbenzyl)-3-pivaloyloxypropyl]-2-[3-methoxy-4-
  • Example 57 Preparation of N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-2-[3- chIoro-4-(methylsulfonylamino)phenyl]propionamide (5-7, KMJ-472) The N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-2-[3-chloro-4-
  • Example 58 Preparation of N-[2-(4-terf-ButylbenzyI) ⁇ 3-pivaloyIoxypropyI]-2-[3- chloro-4-(methylsulfonylamino)phenyl]propionamide (5-8, KMJ-690)
  • Example 59 Preparation of N-[(R)-l-Benzyl-2-(pivaloyloxy)ethyl]-(S)-2-[3-fluoro- 4-(methylsuIfonyIamino)phenyI]propionamide (6-1, SU-730) The N-[(R)-l-Benzyl-2-(pivaloyloxy)ethyl]-(S)-2-[3-fluoro-4-
  • Example 60 Preparation of N-[(S)-l-BenzyI-2-(pivaloyloxy)ethyl]-(S)-2-[3-fluoro- 4-(methylsulfonylamino)phenyl]propionamide (6-2, SU-634) The N-[(S)-1 -Benzyl-2-(pivaloyloxy)ethyl]-(S)-2-[3-fluoro-4-
  • Example 61 Preparation of N-[(S)-l-Benzyl-2-(pivaloyloxy)ethyl]-(R)-2-[3-fmoro- 4-(methyIsulfonylamino)phenyl]propionamide (6-3, SU-636) The N-[(S)-1 -Benzyl-2-(pivaloyloxy)ethyl]-(R)-2-[3-fluoro-4-
  • Example 62 Preparation of N-[(R)-l-Benzyl-2-(pivaloyloxy)ethyl]-(R)-2-[3-fh ⁇ oro- 4-(methylsulfonylamino)phenyl]propionamide (6-4, SU-728) The N-[(R)-1 -Benzyl-2-(pivaloyloxy)ethyl]-(R)-2-[3-fluoro-4-
  • Example 63 Preparation of N-[(2R)-2-Benzyl-3-(pivaloyloxy)propyl]-(2S)-2-[3- fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-5, SU-826) The N-[(2R)-2-Benzyl-3-( ⁇ ivaloyloxy)pro ⁇ yl]-(2S)-2-[3-fluoro-4-
  • Example 64 Preparation of N-[(2S)-2-Benzyl-3-(pivaloyloxy)propyl]-(2S)-2-[3- fluoro-4-(methylsulfonylammo)phenyl]propionamide (6-6, SU-830) The N-[(2S)-2-Benzyl-3-(pivaloyloxy) ⁇ ropyl]-(2S)-2-[3-fluoro-4-
  • Example 65 Preparation of N-[(2S)-2-Benzyl-3-(pivaloyloxy)propyl]-(2R)-2-[3- fluoro-4-(methylsulfonylamino)phenyI]propionamide (6-7, SU-838)
  • Example 66 Preparation of N-[(2R)-2-Benzyl-3-(pivaloyloxy)propyl]-(2R)-2-[3- fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-8, SU-818) The N-[(2R)-2-Benzyl-3-(pivaloyloxy)pro ⁇ yl]-(2R)-2-[3-fluoro-4-
  • Example 68 Preparation of N-[(2S)-2-(4-t'-Butylbenzy ⁇ )-3-(pivaloyloxy)propyl]- (2S)-2-[3-fluoro-4-(methyIsulfonylamino)phenyl]propionamide (6-10, MK-272)
  • Example 70 Preparation of N-[(2R)-2-(4-/-Butylbenzyl)-3-(pivaloyloxy)propyl]- (2R)-2-[3-fluoro-4-(methyIsuIfonylamino)phenyl]propionamide (6-12, MK-452)
  • Example 71 Preparation of N-[(2R)-2-(4-/-Butylbenzyl)-3-(pivaloyloxy)propyI]- (2S)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (6-13, MK-453)
  • Example 72 Preparation of N-[(2S)-2-(4-t-Butylbenzyl)-3-(pivaloyloxy)propyl]- (2S)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (6-14, MK-451)
  • Step 73-2 Preparation of Ethyl 2-(4-amino-3-fluorophenyl)-2-methylpropionamide (7-2, CHK-633)
  • Step 73-3 Preparation of Ethyl 2-[3-fluoro-4-(methylsulfonylamino)phenvH-2- methylpropionamide (7-3, CHK-654)
  • Step 73-4 Preparation of 2-[3-Fluoro-4-(methylsulfonylamino ⁇ henyl]-2- methylpropionic acid (7-4, CHK-624)
  • 2-[3-Fluoro-4-(methylsulfonylamino ⁇ henyl]-2- methylpropionic acid (7-4, CHK-624) Through similar procedure to that in Example 1-4 excepting using Ethyl 2-[3-fluoro- 4-(methylsulfonylamino)phenyl]-2-methylpropionamide(7-3), 2-[3-Fluoro-4-
  • Step 74-1 Preparation of 4-Nitrobenzonitrile (8-1) 4-Nitrobenzonitrile is commercially available(sigma Aldrich, No .N 1,200-7)
  • Step 74-3 Preparation of Methyl 2-(4-nitrophenyl -2-methylpropionamide (8-5, CHK- 508)
  • Methyl 2-(4-nitrophenyl)-2-methylpropionamide (8-5, CHK-508) having following physicochemical properties was synthesized: 95 % yield, yellow oil 1H NMR (CDC1 3 ) ⁇ 8.18 (bd, 2 H), 7.50 (bd, 2 H), 3.72 (s, 3 H), 1.63 (s, 6 H)
  • Step 74-4 Preparation of Methyl 2-(4-aminophenyl)-2-methylpropionamide (8-7, CHK- 509)
  • Methyl 2-(4-aminophenyl)-2- methylpropionamide(8-7, CHK-509) having following physicochemical properties was synthesized: 80 % yield, yellow oil 1H NMR (CDC1 3 ) ⁇ 7.12 (bd, 2 H), 6.66 (bd, 2 H), 3.62 (s, 3 H), 1.52 (s, 6 H)
  • Step 74-5 Preparation of Methyl 2-[ " 4-(methylsulfonylamino phenyl]-2- methylpropionamide (8-9, CHK-516)
  • Methyl 2-(4- aminophenyl)-2-methylpropionamide (8-7) Methyl 2-[4-
  • Step 74-6 Preparation of 2-[4-(methylsulfonylamino phenyl]-2-methylpropionic acid (8-11, CHK-518)
  • Step 75-1 Preparation of 3-Methoxy-4-nitrobenzonitrile (8-2. CHK-78
  • Step 75-2 Preparation of Methyl (3-methoxy-4-nitrophenyl)acetate (8-4, CHK-143
  • Step 75-3 Preparation of Methyl 2-(3-methoxy-4-nitrophenyl)-2-methylpropionamide (8-6, CHK-469
  • Methyl 2-(3-methoxy-4-nitrophenyl)-2- methylpropionamide (8-6, CHK-469) having following physicochemical properties was synthesized: 82 % yield, yellow oil
  • Step 75-4 Preparation of Methyl 2-(3-methoxy-4-aminophenyl)-2-methylpropionamide (8-8. CHK-481
  • Step 75-5 Preparation of Methyl 2-(3-methoxy-4-(methylsulfonylamino)phenyl -2- methylpropionamide (8-10, CHK-489)
  • Methyl 2-(3-methoxy-4- (methylsulfonylamino)phenyl)-2-methylpropionamide (8-10, CHK-489) having following physicochemical properties was synthesized: 90 % yield, yellow oil
  • Step 75-6 Preparation of 2-(3-methoxy-4-(methylsulfonylamino phenyl)-2- methylpropionic acid (8-12. CHK-491
  • Example 76 Preparation of N-[2 ⁇ (3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-2-[4- (methylsulfonylamino)phenyl]-2-methylpropionamide (9-1, CHK-520)
  • Example 77 Preparation of N-[2-(3,4-Dimethylbenzy ⁇ )-3-pivaloyloxypropyl]-2-[3- fluoro-4-(methylsulfonylamino)phenyl]-2-metl ⁇ ylpropionamide (9-2, CHK-543)
  • Example 78 Preparation of N-[2-(3,4-Dimethylbenzyi)-3-pivaloyloxypropyl]-2-[3- methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-3, CHK-493)
  • Example 79 Preparation of N-[3-(3,4-DimethyIphenyl)propyl]-2 ⁇ [4- (methylsulfonylamino)phenyl]-2-methylpropionamide (9-4, CHK-591)
  • N-[3-(3,4-DimethyIphenyl)propyl]-2 ⁇ [4- (methylsulfonylamino)phenyl]-2-methylpropionamide (9-4, CHK-591) Through similar procedure to that in Example 1-5 excepting using 2-[4- (metylsulfonylamino)phenyl]-2-metylpropion acid(8-l 1), N-[3-(3,4-
  • Example 80 Preparation of N-[3-(3,4-Dimethylpheny ⁇ )propyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]-2-methylpropionamide (9-5,CHK-656)
  • 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]-2-methylpropionic acid (7-4) N-[3-(3,4-
  • Example 81 Preparation of N-[3-(3,4-Dimethylphenyl)propyl]-2-[3-methoxy-4- (methylsuIfonylamino)phenyl]-2-methylpropionamide (9-6, CHK-600)
  • N-[3-(3,4- Dimethylphenyl)propyl] -2- [3 -methoxy-4-(methylsulfonylamino)phenyl] -2- methylpropionamide (9-6, CHK-600) having following physicochemical properties was synthesized: 86% yield, white solid, mp 93-95 °C 1H ⁇ MR (CDC1 3 ) ⁇ 7.48 (d, 1 H), 6.75-7.05 (m, 6 H), 5.18 (
  • Example 82 Preparation of N-(4-fert-Butylbenzyl)-2-[4- (methylsulfonylamino)phenyl]-2-methylpropionamide (9-7, CHK-715)
  • Example 83 Preparation of N-(4-tert-Butylbenzyl)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]-2-methylpropionamide (9-8, CHK-655)
  • Example 84 Preparation of N-(4-tert-Butylbenzyl)-2-[3-methoxy-4- (methylsulfonylamino)phenyl]-2-methylpropionamide (9-9, CHK-1001)
  • N-(4-tert-Butylbenzyl)- 2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-9, CHK- 1001) having following physicochemical properties was synthesized: 76% yield, white solid, mp 56-58 °C 1H ⁇ MR (CDC1 3 ) ⁇ 7.46 (d, 1 H), 7.30 (d, 2 H), 7.09 (d, 2H), 6.98 (dd, 1 H), 6.83 (d, 1 H), 6.83 (d, 1 H), 6.77
  • Step 85-1 Preparation of methyl 2-(3-fluoro-4-nitophenyl)acetate (10-1, CHK-947) To a stirred slowly solution of nitric acid (11.48mM, 0.49mL) was added a mixture of 3-fluorophenyl acetate (11.48mM, 1930mg) on the market and H 2 SO 4 (3 mmol) at 0 °C dropwise. After being stirred for 2 hr, the mixture was diluted with iced-water and extracted with ethyl acetate. The combined organic layers were washed with water.
  • Step 85-2 Preparation of methyl l-(3-fluoro-4-nitophenyl cvcloprophancarboxylate (10-2, CHK-987)
  • methyl 2-(3-fluoro-4-nitophenyl)acetate 10-1, 300mg, 1.41 mmol
  • NaH 14.1 mM, 338mg
  • dibromoethane 7.05mM, 0.6mL
  • the reaction mixture was allowed to be warmed to room temperature for 30 min and quenched by saturated NH 4 C1 solution.
  • Step 85-3 Preparation of methyl l-(4-amino-3-fluorophenyl cycloprophancarboxylate (10-3, CHK-993)
  • Example 1-2 Through similar procedure to that in Example 1-2 excepting using methyl l-(3-fluoro-4- nitophenyl)cycloprophancarboxylate (10-2) with the corresponding 4- chlorobenzylamine compound as a starting material, methyl l-(4-amino-3- fluorophenyl)cycloprophancarboxylate (10-3, CHK-993) having following physicochemical properties was synthesized: 1H NMR (CDC1 3 ) ⁇ 6.9-7.0 (m, 2 H), 6.64 (m, 1 H), 3.89 (bs, 2H), 3.65 (s, 3H), 1.68 (dd, 2H), 1.18 (dd, 2H)
  • Step 85-4 Preparation of Methyl l-(4-amino-3-fluorophenyl cvclopropanecarboxylate
  • Methyl l-(4-amino-3-fluorophenyl cvclopropanecarboxylate having following physicochemical properties was synthesized: 1H NMR (CDC1 3 ) ⁇ 7.05-7.23 (m, 3 H), 6.51 (bs, 1 H), 3.68 (s, 3H), 3.31 (s, 3H), 1.77 (dd, 2H), 1.34 (dd, 2H)
  • Step 86-1 Preparation of Methyl l-(4-nitrophenyl)cyclopropanecarboxylate (11-1, CHK-521)
  • Step 87-1 Preparation of Methyl l-(3-methoxy-4-nitrophenyl cyclopropanecarboxylate (11-2, CHK-528
  • Methyl l-(3-methoxy-4-nitrophenyl)cyclopropanecarboxylate (11-2, CHK-528) having following physicochemical properties was synthesized: 70% yield, yellow oil
  • Step 87-2 Preparation of . Methyl l-(4-amino-3- methoxyphenvDcyclopropanecarboxylate (11-4, CHK-531)
  • Methyl 1- (4-amino-3-methoxyphenyl)cyclopropanecarboxylate (11-4, CHK-531) having following physicochemical properties was synthesized: 92% yield, redish oil 1H NMR (CDC1 3 ) ⁇ 6.6-6.8 (m, 3 H), 3.85 (s, 3 H), 3.77 (bs, 2 H), 3.62 (s, 3 H), 1.55 (dd, 2 H), 1.15 (dd, 2 H)
  • Example 88 Preparation of N-[2-(3,4-Dimethylbenzy ⁇ )-3-pivaloyloxypropyl]-l-[4- (methylsulfony ⁇ amino)phenyl]cyclopropanecarboxamide (12-l, CHK-533)
  • Example 89 Preparation of N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-l-[3- fluoro-4-(methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-2, CHK-538)
  • Example 90 Preparation of N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-l-[3- methoxy-4-(methylsulfonylamino)phenyl] cyclopropanecarboxamide (12-3, CHK- 541)
  • Example 92 Preparation of N-[3-(3,4-Dimethylphenyl)propyl]-l-[3-fluoro-4- (methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-5) Through similar procedure to that in Example 1-5 excepting using l-[3-fluoro-4- (methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (10-6) as a starting material, N- [3 -(3 ,4-Dimethylphenyl)propyl] - 1 - [3 -fluoro-4-
  • Example 93 Preparation of N-[3-(3,4-Dimethylphenyl)propyl]-l-[3-methoxy-4- (methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-6, CHK-632)
  • Example 95 Preparation of N-(4-tert-Butylbenzy ⁇ )-l-[3-fluoro-4- (methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-8, CHK-998) Through similar procedure to that in Example 1-5 excepting using Methyl l-[3- fluoro-4-(methylsulfonylamino)phenyl]cyclopropanecarboxylate (10-5) as a starting material, N-(4-tert-Butylbenzyl)-l-[3-fluoro-4-
  • Example 96 Preparation of N-(4-t ⁇ ?rt Butylbenzyl)-l-[3-methoxy-4- (methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-9, CHK-718) Through similar procedure to that in Example 1-5 excepting using l-[3-Methoxy-4- (methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (11-8) as a starting material, N-(4-tert-Butylbenzyl)-l-[3-methoxy-4-
  • Step 97-1 Preparation of 4 , -(Methylsulfonylamino)acetophenone (13-5, LJO-298 A cooled solution of 4'-aminoacetophenon (10 mmol) in pyridine (10 mL) at 0 °C was treated with methanesulfonyl chloride (15 mmol) and stirred at room temperature for 2 h. The reaction mixture was diluted with H 2 O and extracted with EtOAc several times. The combined organic layers were washed with H O and brine, dried over MgSO , filtered, and the filtrate was concentrated in vacuo.
  • Step 97-2 Preparation of 4'-(Methylsulfonylammo acetophenone oxime (13-8, LJO- 299)
  • a mixture of 4'-(Methylsulfonylamino)acetophenone (13-5, 5 mmol) and hydroxylamine hydrochloride (0.695 g, 10 mmol) in pyridine (5 mL) was heated at 70 °C for 3 h.
  • the reaction mixture was cooled to room temperature, diluted with H O, and extracted with EtOAc several times.
  • the combined organic layers were washed with H 2 O and brine, dried over MgSO 4 , filtered, and the filtrate was concentrated in vacuo.
  • Step 97-3 Preparation of l- 4-(Methylsulfonylamino phenyl ethyl amine (13-11, LJO- 302)
  • a suspension of 4'-(Methylsulfonylamino)acetophenone oxime (13-8, 5 mmol) and 10% palladium on carbon (150 mg) in MeOH (25 mL) was treated with concentrated hydrochloric acid (10 drops) was hydrogenated under a balloon of hydrogen for 6 h.
  • the reaction mixture was neutralized with solid NaHCO 3 , filtered and the filtrate was concentrated in vacuo.
  • Step 98-1 Preparation of N-(2-Fluoro-4-iodophenyl)methanesulfonamide (13-3. SH-14 Through similar procedure to that in Example 97-1 excepting using 2-Fluoro-4- iodoanylin (13-1) as a starting material, N-(2-Fluoro-4-iodophenyl)methanesulfonamide
  • Step 98-2 Preparation of 3 , -Fluoro-4 , -(methylsulfonylamino acetophenone (13-6, LJO- 363)
  • N-(2-Fluoro-4-iodophenyl)methanesulfonamide 13-3, 5 mmol
  • palladium(II)acetate 0.15nM, 0.034g
  • 1,3-bisdiphenyl phosphinoprophan 0.3mM, 0.124g
  • thallium(I)acetate 5.5mM, 1.450g
  • butylvinyl ether 1.3mL
  • reaction mixture was cooled to room temperature, diluted with THF, treated with 10% HCl (lOmL) and stirred at room temperature. A mixture was dilluted with EtOAc, washed with ammonium chloride solution three times and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes as eluant to 3'-Fluoro-4'- (methylsulfonylamino)acetophenone (13-6, LJO-363).
  • Step 98-3 Preparation of 3'-fluoro-4'-(methylsulfonylamino)acetophenone oxime (13-9, LJO-327)
  • Step 98-4 Preparation of l-r3-Fluoro-4-(methylsulfonylamino)phenyllethyl amine (13- 12, MK-232
  • 3'-fluoro-4'- (methylsulfonylamino)acetophenone oxime (13-9) as a starting material
  • Step 99-1 Preparation of N-(2-Fluoro-4-iodophenyl)methanesulfonamide (13-3, SH-14)
  • a solution of 2-amino-4-iodinebenzonic acid (11 mM) in MeOH (50 mL) was added HCl (20 mmol) and H 2 SO 4 (2mmol).
  • the reaction mixture was refluxed and concentrated for a night, diluted with ⁇ aHCO 3 and filtered with MgSO 4 several times.
  • the combined organic layers were washed with water, dried over MgSO , filtered, and the filtrate was concentrated in vacuo.
  • Step 99-2 Preparation of 3-(Methoxycarbonyl)-4'-(methylsulfonylamino acetophenone (13-7, YHS-176
  • N-[4-Iodo-2- (methoxycarbonyl)phenyl]methanesulfonamide (13-4, YHS-27) as a starting material
  • Step 99-3 Preparation of 3'-(Methoxycarbonv)-4 , -(methylsulfonylamino)acetophenone oxime (13-10, YHS-180)
  • Example 100 Preparation of l-[3-Methoxy-4-(methylsulfonylamino)phenyI] ethyl amine (14-3, CHK-570)
  • Step 100-1 Preparation of . Benzyl N- ⁇ 1 -
  • Step 100-2 Preparation of l-[3-Methoxy-4-(methylsulfonylamino)phenyl]ethyl amine (14-3, CHK-570
  • Step 101-2 Preparation of l- 3-Chloro-4-(methylsulfonylamino phenyllethyl amine (14-4)
  • Example 103 Preparation of N-(4-t'-ButylbenzyI)-N'- ⁇ l-[3-fluoro-4- (methylsulfonylamino)phenyl] ethyl ⁇ thiourea (15-2, CHK-992)
  • Example 104 Preparation of N-(4-t-Butylbenzyl)-JV- ⁇ l-[3-methoxy-4- (methylsulfonylamino)phenyI]ethyI ⁇ thiourea (15-3, CHK-575)
  • N-(4-t-Butylbenzyl)-JV- ⁇ l-[3-methoxy-4- (methylsulfonylamino)phenyI]ethyI ⁇ thiourea (15-3, CHK-575)
  • Example 105 Preparation of N-(4-t-Butylbenzyl)--V- ⁇ l-[3-(methoxycarbonyI)-4- (methylsulfonylamino)phenyl] ethyl ⁇ thiourea (15-4, YHS-187)
  • Example 106 Preparation of N-(4-t'-Butylbenzyl)-iV- ⁇ l-[3-carboxy-4- (methylsulfonylamino)phenyl] ethyl ⁇ thiourea (15-5, YHS-209) Through similar procedure to that in Example 1-4 excepting using N-(4-t- Butylbenzyl)-N- ⁇ l-[3-(methoxycarbonyl)-4-
  • Step 107-1 Preparation of N-(4-t-Butylbenzyl)-N-[(lR)-l-(4- nitrophenvDethyllthiourea (16-1. SU-354)
  • To a stirred solution of (R or S)-c--methyl-4-nitrobenzyl amine hydrochloride (203 mg, 1 mmol) in anhydrous CH 2 C1 2 (10 L) was added triethylamine (0.28 mL, 2 mmol) at room temperature. When the reaction mixture became clear, isothiocyanate (1 mmol) was added and stirred overnignt at room temperature.
  • Step 107-2 Preparation of N-(4-t-Butylbenzyl)-N , -r(lR)-l-(4- aminophenyl ethyl]thiourea (16-3. SU-358) Aluminium foil (0.05 mm thick, 406 mg, 15 mmol) was roughed with sand paper, cut into 0.5 cm squares, and weighed in the reaction flask, The aluminium was etched with 5%> KOH hydroxide solution until vigorous evolution of H 2 occurred and then the basic solution was removed by decantation. The Al was rinsed with H 2 and covered with 0.5% HgCl 2 solution for 2 min. The HgCl 2 solution was poured off and the Al was washed with H 2 O.
  • HgCl 2 solution was reintroduced for 2 min and the solution was decanted away. Al was washed with H 2 O followed by ethanol and diethyl ether several times. A solution of nitro (0.5 mmol) in diethyl ether (5 mL) was added to the freshly prepared amalgam and then a drop of H 2 O was introduced and the mixture was refluxed for 10 minutes. After the reaction was completed by TLC, the mixture was concentrated in vacuo.
  • Step 107-3 Preparation of N-(4-t-Butylbenzyl)-N , - ⁇ (lR)-l-r4-
  • Step 108-1 Preparation of N-(4-t-Butylbenzyl)-N , -
  • the N-(4-t-Butylbenzyl)-N'-[(lS)-l-(4-nitro ⁇ henyl)ethyl]thiourea (16-2, SU-366) was prepared by the similar procedure with that described in above Example 107-1.
  • a sticky white oil The spectral data of compound 16-2 were identical to those of compound 16-1.
  • Step 108-2 Preparation of N-(4-t-Butylbenzyl)-N , -r(lS)-l-(4- aminophenvDethvHthiourea (16-4, SU-394)
  • N-(4-t-Butylbenzyl)-N'-[(lS)-l-(4-amino ⁇ henyl)ethyl]thiourea (16-4, SU-394) was prepared by the similar procedure with that described in above Example 107-1. A faint yellow oil The spectral data of compound 16-4 were identical to those of compound 16-3.
  • Step 108-3 Preparation of N-(4-t-Butylbenzyl)-N-((lS)-l-[4-
  • Example 109 Preparation of (R)-N-(4-t-Butylbenzyl)-N'- ⁇ l-[3-fluoro-4- (methylsulfonylamino)phenyl] ethyl ⁇ thiourea (17-3, CJU-032) Step 109-1.
  • the mixture Upon completion, as determined by TLC, the mixture was cooled to room temperature and then to -40 °C before it was cannulated dropwise into a -40 °C solution of NaBH 4 (0.109 g. 2.88 mmol). The mixture was stirred at -40 °C for 12 h, and then MeOH was added dropwise until gas was no longer evolved. The resulting suspension was filtered through a plug of Celite and the filter cake was washed with EtOAc. The filtrate was washed with brine, and the brine layer was extracted with EtOAc. The combined organic portions were dried (Na 2 SO ), filtered, and concentrated.
  • Step 109-2 Preparation of (R)-l-l " 3-Fluoro-4-(methylsulfonylamino)phenyl]ethyl amine hydrochloride (17-2) To a (R)-sulfonamide (0.105 g, 0.31 mmol) was added 1:1 (v/v) MeOH and HCl dioxane solution (4.0 M, 0.22 mL). The mixture was stirred at room temperature for 30 minutes and was then concentrated to near dryness. Diethyl ether was added to precipitate the amine hydrochloride.
  • Step 109-3 Preparation of N- ⁇ 4-(l-r3-(4-tert-Butyl-benzyl -thioreido1-ethyl
  • 4-[4-(l-Amino-ethyl)-2-fluoro-phenyl]-methanesulfonamide hydrochloride 0.020 g, 0.075 mmol
  • DMF 1 mL
  • Et 3 N 13 ⁇ L, 0.09 mmol
  • 1-tert- butyl-4-isothiocyanatomethyl benzene 15 mg, 0.075 mmol
  • Step 110-1 Preparation of (S)-Sulfonamide (17-4)
  • Step 110-2 Preparation of (S)-l-[3-Fluoro-4-(methylsulfonylamino)phenyl1ethyl amine hydrochloride (17-5)
  • the compound 17-5 was prepared from (S)-Sulfonamide (17-4) by following the similar procedure with that described in Example 109-2. 88% yield, 97.9 ee%
  • the spectral data is identical to that of 17-2.
  • Step 110-3 Preparation of (S)-N-(4-t-Butylbenzyl)-N , - ⁇ l-r3-fluoro-4- (methylsulfonylamino)phenyl] ethyl) thiourea (17-6, CJU-039)
  • the spectral data is identical to that of 17-3.
  • Example 111 Preparation of N-[(2R)-2-Benzyl-3-(pivaloyloxy)propyl]-iV- ⁇ (lR)-l- [4-(methylsulfonylamino)phenyl]ethyI ⁇ thiourea (18-1, MK-229) The N-[(2R)-2-Benzyl-3-(pivaloyloxy)propyl]-N- ⁇ (lR)-l-[4-
  • Example 112 Preparation of N-[(2S)-2-Benzyl-3-(pivaloyloxy)propyI]-N'- ⁇ (lR)-l- [4-(methylsulfonylamino)phenyl] ethyl ⁇ thiourea (18-2, MK-202) The N-[(2S)-2-Benzyl-3-(pivaloyloxy)propyl]-N'- ⁇ (lR)-l-[4-
  • Example 113 Preparation of N-[(2R)-2-Benzyl-3-(pivaloyloxy)propyl]-N'- ⁇ (lS)-l- [4-(methylsulfonylamino)phenyl] ethyl ⁇ thiourea (18-3, MK-230) The N-[(2R)-2-Benzyl-3-(pivaloyloxy)propyl]-N'- ⁇ (lS)-l-[4-
  • Example 114 Preparation of N-[(2S)-2-Benzyl-3-(pivaloyloxy)propyl]-iV- ⁇ (lS)-l- [4-(methylsuIfonyIamino)phenyl]ethyl ⁇ thiourea (18-4, MK-228) The N-[(2S)-2-Benzyl-3-(pivaloyloxy)propyl]-N- ⁇ (lS)-l-[4-
  • Example 116 Preparation of N-[2-(3,4-Dimethylbenzyl)-3-(pivaloyloxy)propyl]-iV- ⁇ (lR)-l-[4-(methylsulfonylamino)phenyl]ethyl ⁇ thiourea (18-6, SU-472) The N-[2-(3,4-Dimethylbenzyl)-3-(pivaloyloxy)propyl]-N- ⁇ (lR)-l-[4-
  • Example 119 Preparation of N-[2-(4-tert-ButyIbenzyl)-3-(pivaloyloxy)propyl]-iV- ⁇ l-[4-(methylsulfonylamino)phenyl]ethyl ⁇ thiourea (18-9, LJO-401) The N-[2-(4-tert-Butylbenzyl)-3-(pivaloyloxy)propyl]-N'- ⁇ l-[4-
  • Example 120 Preparation of N-[2-(4-t'ert-Butylbenzyl)-3-(pivaloyloxy)propyl]-iV- ⁇ (lR)-l-[4-(methylsulfonylamino)phenyl]ethyl ⁇ thiourea (18-10, MK-296)
  • Example 122 Preparation of N-[(2S)-2-(4-tert-Butylbenzyl)-3-(pivaloyloxy)propyl]- iV- ⁇ (lR)-l-[4-(methylsulfonylamino)phenyl]ethyl ⁇ thiourea (18-12, MK-298) The N-[(2S)-2-(4-tert-Butylbenzyl)-3-(pivaloyloxy)propyl]-N- ⁇ (lR)-l-[4-
  • Example 123 Preparation of N-[2-(3,4-DimethylbenzyI)-3-(pivaloyloxy)propyl]-iV- ⁇ l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl ⁇ thiourea (18-13, LJO-344)
  • Example 124 Preparation of N-[2-(4-tert-Butylbenzyl)-3-(pivaloyloxy)propyl]-iV- ⁇ l-[3-fluoro-4-(methylsuIfonylamino)phenyl]ethyl ⁇ thiourea (18-14, LJO-366)
  • Step 125-1 Preparation of (2RV3 -phenyl- l-pivaloyloxy-2-propyl amine (19-1, YHS-43)
  • a solution of (2R)-N-(tert-butoxycarbonyl)phenylalaniol (3.323g) on the market in methylene chloride (50 mL) was added triethylamine (7.4mL) and pivaloy chloride (2.4 mL). The mixture was stirred for 4hr at room temperate.50 °C and then for 10 min. at room temperature.
  • the mixture was directly purified by column chromatography using EtOAc:hexanes (1:4) as eluant to afford ester compound.
  • Step 125-2 Preparation of (2R)-3 -phenyl- l-pivaloyloxy-2-propyl isothiocyanate (19-3, SU-684)
  • a solution of (2R)-3 -phenyl- l-pivaloyloxy-2 -propyl amine (19-1, lmmol) and Et 3 N (1 mmol) in DMF (1 mL) was added dropwise into the pre-dissolved solution of 1, 1- thiocarbonyl diimidazole (1.2 mmol) in DMF (2 mL) at 50 °C over 1 min. The mixture was stirred for 1 min. at 50 °C and then for 10 min. at room temperature.
  • Step 125-3 Preparation of N- r (2R -3-phenyl-l- ⁇ ivaloyloxy-2- ⁇ ro ⁇ yl1-N , -lYRy ⁇ - methyl-4-nitrobenzyl thiourea (19-5, SU-688)
  • Et 3 ⁇ 1.1 mmol
  • isothiocyanate (1 mmol) in CH 2 C1 2 (2 mL) was added. The mixture was stirred overnight at room temperature and concentrated in vacuo.
  • Step 125-4 Preparation of N-f(2R)-3- ⁇ henyl-l-pivaloyloxy-2-propyl1-N-r(R)- ⁇ - methyl-4-aminobenzylthiourea (19-9.
  • SU-690 Aluminium foil (0.05mm thick, 328 mg, 12.174 mmol) was roughed with sand bar, cut into 0.5 cm squares and was etched with 5 % KOH hydroxide solution until vigorous evolution of H2 occurred. The basic solution was removed by decantation and the Al was rinsed with H 2 O two times and was covered with 0.5 % HgCi 2 solution for 2 minutes.
  • Step 125-5 Preparation of N-r(2R)-3- ⁇ henyl-l-pivaloyloxy-2-propyl1-iV , -
  • a cooled solution of N-[(2R)-3-phenyl-l-pivaloyloxy-2-propyl]-N-[(R)- ⁇ -methyl- 4-aminobenzy]thiourea (19-9, 0.5 mmol) in pyridine (2 mL) at 0 °C was treated dropwise with methanesulfonyl chloride (0.75 mmol) and was stirred for 10 minutes at 0 °C.
  • Example 126 Preparation of N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-N'-[(R)- ⁇ - methyl-4-(methylsulfonylamino)benzy] thiourea (19-14, SU-704) Step 126-1. Preparation of N-f(2S)-3-phenyl-l-pivaloyloxy-2-propyll-N'-[(R - ⁇ -methyl- 4-nitrobenzylthiourea (19-6.
  • Step 126-2 Preparation of N-r(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-N'-[(R)- ⁇ -methyl- 4-aminobenzylthiourea (19-10, SU-702
  • Example 125-4 Through similar procedure to that in Example 125-4 excepting using N-[(2S)-3-phenyl- l-pivaloyloxy-2-propyl]-N-[(R)- ⁇ -methyl-4-nitrobenzy]thiourea (19-6) as a starting material, N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-iV-[(R)- ⁇ -methyl-4- aminobenzyjthiourea (19-10, SU-702) having following physicochemical properties was synthesized: 97%) yield, yellow oil The spectral data of this compound were identical to those of compound 19-9.
  • Step 126-3 Preparation of N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyll-N'-r(R)- ⁇ -methyl- 4-(methylsulfonylamino)benzv1thiourea (19-14, SU-704)
  • Example 127 Preparation of N-[(2R)-3-phenyl-l-pivaloyloxy-2-propyl]-iV-[(S)- ⁇ - methyI-4-(methyIsulfonylamino)benzy] thiourea (19-15, SU-720)
  • Step 127-1 Preparation of (2S)-3 -phenyl- l-pivaloyloxy-2-propyl amine (19-2, YHS-45)
  • the (2S)-3 -phenyl- l-pivaloyloxy-2 -propyl amine (19-2, YHS-45) was prepared by the similar procedure with that described in above Example 125-1. 94% yield, pale yellow oil 1H NMR (CDC1 3 ) ⁇ 7.15-7.38 (m, 5 H), 4.22 (dd of AB, 2H), 3.73 (bs, 1 H), 3.03 (ddd of AB, 2H), 1.22 (s, 9H)
  • Step 127-2 Preparation of (2S)-3-phenyl-l-pivaloyloxy-2-propyl isothiocyanate (19-4, SU-686)
  • the spectral data of compound 19-4 were identical to that of 19-3.
  • Step 127-3 Preparation of N-[(2R)-3-phenyl-l-pivaloyloxy-2-propyH-N-[(S)- ⁇ - methyl-4-nitiObenzylthiourea (19-7, SU-714)
  • Step 127-4 Preparation of N-r(2R)-3-phenyl-l-pivaloyloxy-2-propyl]-N'-[(S)- -methyl- 4-aminobenzylthiourea (19-11, SU-716
  • N-[(2R)-3- phenyl-l-pivaloyloxy-2-propyl]-N'-[(S)- ⁇ -methyl-4-nitrobenzy]thiourea (19-7) N- [(2R)-3 -phenyl- 1 -pivaloyloxy-2-propyl] -N 5 - [(S)- ⁇ -methyl-4- aminobenzyjthiourea (19-11, SU-716) having following physicochemical properties was synthesized: 86% yield, pale yellow oil 1H ⁇ MR (CDC1 3 ) ⁇ 6.95-7.25 (m, 7 H), 6.67 (d, 2 H, J
  • Step 127-5 Preparation of N-
  • Example 128 Preparation of N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-iV-[(S)- - methyl-4-(methylsulfonylamino)benzy]thiourea (19-16, SU-710)
  • Step 128-1 Preparation of N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-N , -r(S)- ⁇ -methyl- 4-nitrobenzyltl ⁇ ourea (19-8. SU-700)
  • N-[(2S)-3-phenyl-l- ⁇ ivaloyloxy-2-propyl]-N'-[(S)- ⁇ -methyl-4- nitrobenzy] thiourea (19-8, SU-700) was prepared by the similar procedure with that described in above Example 127-1, 127-2 and 127-3. 82% yield, yellow oil
  • the spectral data of this compound were identical to those of compound 19-7.
  • Step 128-2 Preparation of N-r(2S)-3-phenyl-l- ⁇ ivaloyloxy-2-propyll-N , -r(S)- ⁇ -methyl- 4-aminobenzylthiourea (19-12, SU-706)
  • N-[(2S)-3- phenyl-l-pivaloyloxy-2-propyl]-N-[(S)- ⁇ -methyl-4-nitrobenzy]thiourea (19-8) as a starting material N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-N'-[(S)- ⁇ -methyl-4- aminobenzy] thiourea (19-12, SU-706) having following physicochemical properties was synthesized: 93% yield, yellow oil The spectral data of this compound were identical to those of compound 19-11.
  • Step 128-3 Preparation of N-r(2S)-3-phenyl-l-pivaloyloxy-2-propyl1-N'-[(S)- ⁇ -methyl- 4-(methylsulfonylammo benzylthiourea (19-16, SU-710)
  • Step 129-1 Preparation of 2-Fluoro-4-vinylaniline (20-1, LJO-324)
  • a solution of 2-fluoro-4-iodoaniline (2.37 g, 10 mmol) in toluene (50 mL) was treated with tetrakis(triphenylphosphine)palladium (0.578 g, 0.5 mmol), tributylvinyltin (3.5 mL, 12 mmol) and a catalytic amount of 2,6-di-tert-butyl-4-methylphenol. After being heated at 100 ° C for 1 h, the reaction mixture was filtered through celite and the filtrate was concentrated in vacuo.
  • Step 129-2 Preparation of N-(2-Fluoro-4-vinylphenyl)methanesulfonamide (20-2, LJO- 325)
  • 2-Fluoro-4-vinylaniline (20-1, 0.96 g, 7 mmol) in pyridine (10 mL) at 0 ° C was treated with methanesulfonyl chloride (0.644 L, 8.4 mmol) and stirred at room temperature for 30 min.
  • the reaction mixture was diluted with water and extracted with EtOAc several times. The combined organic layers were washed with water and brine, dried over MgSO 4 , filtered, and the filtrate was concentrated in vacuo.
  • Step 129-3 Preparation of N-(2-Fluoro-4-formylphenyl methansulfonamide (20-3, LJO- 326)
  • a solution of N-(2-Fluoro-4-vinylphenyl)methansulfonamide (20-2, 1.076g, 5 mmol) in acetone and water (1:1, 20 mL) was treated with a catalytic amount of osmium tetroxide (4 wt% solution in hydroxyperoxide) and sodium periodate (2.139 g, 10 mmol). After being stirred at room temperature for 1 h, the mixture was concentrated into a small volume in vacuo.
  • Step 129-4 Preparation of N- 2-fluoro-4-(l-hydroxypropyl)phenyl1methansulfonamide (20-4, LJO-337)
  • a cooled solution of N-(2-Fluoro-4-formylphenyl)methansulfonamide (20-3, 0.424 g, 2 mmol) in THF (20 mL) at 0 ° C was treated with Grignard reagent (4 mmol) and stirred at 0 ° C for 30 min.
  • the reaction mixture was quenched with saturated ammonium chloride solution, diluted with water and extracted with EtOAc several times.
  • Step 129-5 Preparation of N- 2-fluoro-4-(l-azidopropyl)phenyl1methanesulfonamide (20-8, LJO-397 A cooled solution of the alcohol (1 mmol) in toluene (10 mL) at 0 ° C was treated with diphenylphosphorylazide (0.26 mL, 1.2 mmol) followed by 1,8- diazabicyclo[5,4,0]undec-7-ene (0.18 mL, 1.2 mmol) and stirred for 2 h at 0 °C . After being further stirred for 20 h at room temperature, the reaction mixture was diluted with EtOAc.
  • Step 129-6 Preparation of N-(4-t-Butylbenzyl -N'- ⁇ l-[4-(methylsulfonylamino)-3- fluorophenyllpropyl) thiourea (20-12. LJO-399)
  • a suspension of the azide (1 mmol) and 10% palladium on carbon (50 mg) in MeOH (10 mL) was hydrogenated under a balloon of hydrogen for 1 h.
  • the reaction mixture was filtered and the filtrate was concentrated in vacuo.
  • the residue was dissolved in DMF (3 mL) and then added 4-tert-butylbenzyl isothiocyanate (0.205 g, 1 mmol).
  • Example 130 Preparation of iV-(4- ⁇ '-Butylbenzyl)-N- ⁇ l-[4-(methyIsulfonylamino)- 3-fluorophenyl]-2-methylpropyl ⁇ thiourea (20-13, LJO-402)
  • Step 130-1 Preparation of N-
  • N-(2-Fluoro-4- formylphenyl)methanesulfonamide (20-3) as a starting material
  • Step 130-2 Preparation of N-[2-fluoro-4-(l-azido-2- methylpropyDphenyllmethanesulfonamide (20-9. LJO-398
  • N-[2-fluoro-4- (l-hydroxy-2-methylpropyl)phenyl]methanesulfonamide (20-5) as a starting material
  • Step 130-3 Preparation of N-(4-t-Butylbenzyl -N- ⁇ l-[4-(methylsulfonylamino)-3- fluorophenyll-2-methylpropyl ⁇ thiourea (20-13, LJO-402)
  • N-[2-fluoro-4- (l-azido-2-methylpropyl)phenyl]methanesulfonamide (20-9) as a starting material
  • Step 131-1 Preparation of N- ⁇ 2-fluoro-4- [hvdroxy(phenyl methyllphenyl ⁇ methanesulfonamide (20-6, LJO-330)
  • Step 131-2 Preparation of N- ⁇ 2-fluoro-4- [azido(phenyl)methyllphenyl)methanesulfonamide (20-10, LJO-335)
  • Step 131-3 Preparation of N-(4-t-Butylbenzyl -N'-([ ' 4-(methylsulfonylamino)-3- fluorophenylKphenypmethyl ⁇ thiourea (20-14, LJO-403)
  • N- ⁇ 2-fluoro-4- [hydroxy(phenyl)methyl]phenyl ⁇ methanesulfonamide (20-6) as a starting material
  • Step 132-1 Preparation of N- r 2-fluoro-4-(l-hvdroxy-2- phenylethyl)phenyl]methanesulfonamide (20-7, LJO-336)
  • Step 132-2 Preparation of . N-[2-fluoro-4-(l-azido-2- phenylethyl)phenyl]methanesulfonamide (20-11, LJO-394)
  • N-[2-fluoro-4- (l-hydroxy-2-phenylethyl)phenyl]methanesulfonamide (20-7) as a starting material
  • Step 132-3 Preparation of N-(4-t-Butylbenzyl)-N , -(l- 4-(methylsulfonylamino)-3- fluorophenyll-2- ⁇ henylethyl)thiourea (20-15, LJO-395)
  • N-[2-fluoro-4- (l-azido-2-phenylethyl)phenyl]methanesulfonamide (20-11) as a starting material
  • Example 133 Preparation of N-(4-t-Butylbenzyl)-iV- ⁇ l-methyl-l-[4- (methylsulfonylamino)phenyl]ethyl ⁇ thiourea (21-7, CHK-593) Step 133-1.
  • Step 133-2 Preparation ofN-(4-t-Butylbenzyl)-N-U-methyl-l-r4- (methylsulfonylamino)phenyll ethyl ⁇ thiourea (21-7, CHK-593) A suspension of Benzyl N- ⁇ 1 -Methyl- 1- [4-
  • Step 134-1 Preparation of Benzyl N-U-Methyl-l-r3-fluoro-4- (methylsulfonylamino)phenyl] ethyl) carbamate (21-2, CHK-657)
  • Step 134-2 Preparation of N-(4-t-Butylbenzyl)-N-a-methyl-l-r3-fluoro-4- (methylsulfonylamino phenyl "
  • Step 135-1 Preparation of Benzyl N- ⁇ 1 -Methyl-1- [3 -methoxy-4- (methylsulfonylamino)phenyllethyl) carbamate (21-3, CHK-646)
  • 2-(3-methoxy- 4-(methylsulfonylamino)phenyl)-2-methylpropionic acid (8-12) as a starting material
  • Step 136-2 Preparation of N-(4-t-Butylbenzyl)-N , - ⁇ l-[4-
  • Example 138 Preparation of N-(4- ⁇ -ButylbenzyI)-iV- ⁇ l-[3-methoxy-4- (methylsulfonylamino)phenyl] cyclopropyl ⁇ thiourea (22-9, CHK-631)
  • Step 138-1 Preparation of . Benzyl N- ⁇ 1 -[3-methoxy-4-
  • Step 138-2 Preparation of N-(4-t-Butylbenzyl)-N- ⁇ l-r3-methoxy-4- (methylsulfonylamino)phenyl1cvclopropyl ⁇ thiourea (22-9, CHK-631)
  • Example 140 Preparation of N-(4-t-Butylbenzyl)-N'- ⁇ l-[3-fluoro-4- (methylsulfonylamino)phenyl]ethyl ⁇ urea (23-2, MK-205)
  • Cells utilized for assays were grown in culture medium without antibiotic for 48 h before use. Cells were seeded in T75 cell culture flasks in media without antibiotics and grown to approximately 90% confluence. The flasks were then washed with PBS and harvested in 0.25% trypsin, 1 mM EDTA. The cells were pelleted by gentle centrifugation and stored at -20 °C until assay.
  • Binding studies with [ 3 H]resiniferatoxin (RTX) were carried out as described previously with minor modifications (Szallasi et al., 1992). Binding assay mixtures were set up on ice and contained 50-100 pM [ 3 H]RTX, various concentrations of competing ligands, 0.25 mg mL BSA (Cohn fraction N), and about 5x 10 5 VR1 - transfected cells. The final volume was adjusted to 350 ⁇ L with DPBS with Ca 2+ and Mg 2+ and 0.25 mg/mL bovine serum albumin. Non-specific binding was determined in the presence of 100 nM nonradioactive RTX.
  • the binding reaction was initiated by transferring the assay mixtures to a 37 °C water bath and was terminated after a 60 min incubation period by cooling the tubes on ice. To reduce non-specific binding, 200 ⁇ g/ml ⁇ -glycoprotein was added. Membrane-bound RTX was then separated from the free by pelleting the membranes in a Beckman 12 benchtop centrifuge (15 min, maximal velocity), the tips of the tubes containing the pellets were cut off, and the radioactivity was determined by scintillation counting. Equilibrium binding parameters (Kj and cooperativity) were determined by fitting the Hill equation to the measured values with the aid of the program MicroCal Origin 6.0.
  • a reduction in the number of writhing movements compared to the vehicle-treatment group (the mean number of writhing movements in this group was 35) was considered to be indicative of an antinociceptive effect of a compound.
  • ED 50 values were obtained based on dose-response curves using mean data and fitted to by nonlinear regression analysis (Winnonlin version 3.1, Pharsight Corp., Mountainview, CA) on a PC.
  • Table 1 shows the potencies of vanilloid ligands for binding to rat VR1 and for inducing calcium influx in CHO/VR1 cells.
  • mice mean body weight 25 ⁇ 5g
  • Sprague- Dawley rats 235 ⁇ lOg
  • mice or rats Each group consisting of 3 mice or rats was administrated intraperitoneally with 20 mg/kg, 10 mg/kg and 1 mg/kg of test compounds or solvents (0.2 mi, i.p.), respectively and observed for 24 hrs.
  • Powder preparation 500mg Corn Starch lOOmg Lactose lOOmg Talc lOmg Powder preparation was prepared by mixing above components and filling sealed package.
  • liquid Compound 35 1 g Sugar 10 g Citric acid 0.05-0.3% Vitamin C 0.1-1% Lemon flavor optimum amount Distilled water optimum amount Liquid preparation was prepared by dissolving active component, adding lemon flavor and distilled water and then filling all the components in 100 mi brown bottle and sterilizing by conventional liquid preparation method.
  • novel 4-(methylsulfonylamino) phenyl analogues as vanilloid antagonist and the pharmaceutical composition comprising same according to the present invention act as vanilloid receptor- 1 antagonists and analgesics so the inventive compounds are useful in the prevention, alleviation or treatment of pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease or urgent urinary incontinence, etc.
  • a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease or urgent urinary

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel 4-(methylsulfonylamino) phenyl analogue as a potent vanilloid receptor antagonist and the pharmaceutical compositions comprising the same. The inventive compound can be useful for analgesics to prevent, alleviate or treat pain diseases or inflammatory disease comprising pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease and urgent urinary incontinence.

Description

4-(METHYL SULFONYL AMINO) PHENYL ANALOGUES AS VANILLOID ANTAGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
Technical Field The present invention relates to novel 4-(methylsulfonylamino)phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same.
Background Art The vanilloid receptor (NR1) is a member of the transient receptor potential (TRP) superfamily. Members of this family are non-voltage activated cation channel proteins that play critical roles in processes ranging from sensory physiology to vasorelaxation and male fertility. They share structural similarities such as six transmembrane segments and an oligmeric structure (Montell, C. et al., Cell, 108, p595, 2002). The vanilloid or capsaicin receptor (NR1 or TRPN1) has been cloned from dorsal root ganglia (DRG) of the rat, the human, the chicken, the guinea pig, and the rabbit (Szallasi, A. et al., Pharmacol. Rev., 51, pl59, 1999; Caterina, M. J. et al., Nature, 389, ρ816, 1997; Hayes, P. et al., Pain, 88, ρ205, 2000; Jordt et al., Cell, 108, p421, 2002; Savidge, J. et al., Neuropharmacology, 43, p450, 2002; Gawa, Ν. R. et al., J. Biol. Chem., in press, 2004). Vanilloid receptor homologues have also been cloned but are not believed to be sensitive to vanilloids (Gunthorpe, M. J. et al, Trends in Pharmacol. Sci., 23, pl83, 2002). NR1, which is expressed predominantly on thin, unmyelinated sensory nerve fibers (C-fibers) and small A fibers in the dorsal root, trigeminal, and nodose ganglia, is a molecular integrator of nociceptive stimuli. NR1 is activated by protons, heat, natural exogenous ligands such as capsaicin (CAP) or resiniferatoxin (RTX), and endogenous substances such as anandamide and the lipoxygenase product 12-HPETE (Tominaga M. et al., Neuron, 21, p531; 1998; Caterina, M. J. et al., Nature, 389, p816, 1997; Walpole C. S. J. et al., Capsaicin in the Study of Pain, Academic Press, San Diego, CA., p63, 1993; Appendino, G. et al., Life Sci., 60, p681, 1997; Zygmunt, P. M. et al. , Nature, 400, p452, 1991; Hwang S. W. et al., Proc. Natl. Acad. Sci. U.S.A., 97, p6155, 2000). Since VR1 functions as a non-selective cation channel with high Ca2+ penneability, its activation by these agents leads to an increase in intracellular Ca + that results in excitation of primary sensory neurons and ultimately the central perception of pain. Chronic stimulation of VR1 leads to desensitization / defunctionalization of the neurons, probably reflecting multiple mechanisms. The involvement of VR1 in both pathological and physiological conditions suggests that the blocking of this receptor, by desensitization or by antagonism, would have considerable therapeutic utility. Among its therapeutic targets, pain is of particular interest. The validation of VR1 as a molecular target for the treatment of chronic pain was confirmed using transgenic mice lacking functional VR1 receptors. These mice exhibited impairment in the perception of thermal and inflammatory pain(Caterina, M. J. et al., Science, 288, p306, 2000). The therapeutical advantage of VR1 antagonism over desensitization subsequent to agonism is that it avoids the initial excitatory effect preceding the desensitization. The initial acute pain associated with capsaicin treatment has proven to be the limiting toxicity. After the discovery of capsazepine as the first VR1 antagonist(Walpole, C. S. J et al., J. Med. Chem., 37, pl942., 1994), a number of antagonists have been reported both with structures related and unrelated to agonists(Walpole, C. S. J. et al, J. Med. Chem., 37, pl942, 1994). Among them, 5-Iodo-RTX, SC0030, halogenated capsaicin analogues, BCTC, SB-366791, 7-hydroxynaphthalen-l-yl urea, and LBTU were characterized in detail as potent VR1 competitive antagonists(Wahl, P. et al., Mol. Pharmacol, 59, p9, 2001; Seabrook, G. R. et al., J. Pharmacol. Exp. Ther. 303, pl052, 2002; Wang, Y. et al., Mol. Pharmacol., 62, p947, 2002; Suh, Y-G. et al, Bioorg. Med. Chem. Lett, 13, p4389, 2003; Appendino, G. et al., Br. J. Pharmacol, 139, pl417, 2003; Valenzano, K. J. et al., J. Pharmacol. Exp. Ther., 306, p377, 2003; Pomonis, J. D. et al., J. Pharmacol. Exp. Ther., 306, p387, 2003; Sun, Q. et al, Bioorg. Med. Chem. Lett., 13, p3611, 2003; Gunthorpe, M. J. et al., Neuropharm., 46, pl33, 2004; McDonnell, M. E. et al., Bioorg. Med. Chem. Lett., 14, p531, 2004; Toth, A. et al., Mol. Pharm., 65, p282, 2004). We have previously reported that isosteric replacement of the phenolic hydroxyl group in potent vanilloid receptor agonists (Lee, J. et al., Chem., 9, pi 9, 2001) with the alkylsulfonamido group provided a series of compounds which are effective antagonists to the action of capsaicin on rat NR1 heterologously expressed in Chinese hamster ovary (CHO) cells. As a prototype, Ν-[2-(3,4-dimethylbenzyl)-3-pivaloyloxypropyι]- N'-[4-(methylsulfonylamino)benzyl]thiourea (1) showed a high binding affinity with a K; value of 29.3 nM for the inhibition of [3H]RTX binding and potent antagonism with an IC50 value of 67 nM for the inhibition of 45Ca2+ uptake in response to capsaicin, displaying partial agonism (Wang, Y et al., Pharm., 64, p325, 2003). Compound 2, 3- fluoro analogue, showed very potent antagonism with IC50 = 7.8 nM and analgesic activitiy in writhing test(Lee, J et al., Med. Chem., 46, p3116, 2003).
Figure imgf000004_0001
1 R =H 2 R =F
The present inventors have been extensively endeavored to discover novel analgesic agents based on the above studies and finally completed the present invention by synthesizing novel 4-(methylsulfonylamino)phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same.
Disclosure of the Invention Thus, the present invention provides novel compounds represented by the following formula (I), the pharmaceutically acceptable salt or the isomer thereof:
Figure imgf000004_0002
wherein, A is CONH, NHCO, NHC(=S)NH, NHC(=O)NH; Ri to R is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring; R and R6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R5 and Re are not hydrogen atom simultaneously; B is a group selected from
Figure imgf000005_0001
Figure imgf000006_0001
in which R7 to R17 is independently at least one selected from a hydrogen, halogen atom and straight or branched alkyl group having 1 to 6 carbon atoms optionally substituted with more than one halogen atom, C is a group selected from alkyl, alkenyl and alkynyl group having 1 to 5 carbon atoms which may includes one or more heteroatoms, m, n, p, q, r and s is an integer of 0 to 3; an asteric mark * and ( ) mark indicate a chiral carbon atom, and double bond or single bond chain respectively. Examples of "alkyl group" used herein include, but are not limited to, methyl, ethyl, propyl and the like, and Examples of "heterocyclic ring" used herein include, but are not limited to, pyrrole, pyrazole, pyrazine, purine, pyridine, piperazine, piperidine, thazole, morpholine, dioxane and the like. Preferable groups in general formula (I) of the present invention are the group in which R5 or R6 is methyl, ethyl, propyl, isopropyl, phenyl or benzyl and R7 or R8 is isopropyl, t-butyl or sec-butyl group, but are limited thereto. The compounds of general formula (I) of the present invention comprise all the compounds represented by following formula (I) to (N) in accordance with the definition of A group. Accordingly, the present invention provides novel compounds represented by the following formula ( II ), the pharmaceutically acceptable salt or the isomer thereof:
Figure imgf000006_0002
wherein, Ri to R4 is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring; R5 and R6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R5 and R6 are not hydrogen atom simultaneously; B is a group selected from the group (1-1) to (1-6) defined in general formula (I); the asteric mark * indicates a chiral carbon atom.
In preferred embodiment in general formula (II), the most preferred compound is one selected from the group consisting of; N-(4-tert-butylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(l- 51, MJ-372), N-(4-tert-butylbenzyl)-2-[3-chloro-4-
(methylsulfonylamino)phenyl]propionamide(l -52, KMJ-470), N-(4-tert-butylbenzyι)-2- [3-bromo-4-(methylsulfonylamino)phenyl]propionamide(l-53, SH-173), N-(4-tert- butylbenzyl)-2-[3-iodo-4-(methylsulfonylamino)phenyl]propionamide(l-54, SH-168), N-(4-tert-butylbenzyl)-2-[3,5-difluoro-4-
(methylsulfonylamino)phenyl]propionamide(l -55, SH-285), N-(4-tert-butylbenzyl)-2- [3-cyano-4-(methylsulfonylamino)phenyl]propionamide(l-56, SH-219), N-(4-tert- butylbenzyl)-2-[3-(tert-butoxycarbonyl-4-
(methylsulfonylamino)phenyl]propionamide(l-57, MJ-806), N-(4-tert-butylbenzyl)-2- [3-carboxyl-4-(methylsulfonylamino)phenyl]proρionamide(l-58, KMJ-788), N-(4-tert- butylbenzyl)-2-[3 -methoxycarbonyl-4-(methylsulfonylamino)phenyl]propionamide( 1 - 59, KMJ-838), N-(4-tert-butylbenzyl)-2-[3-(benzylamino)carbonyl-4- (methylsulfonylamino)phenyl]propionarnide(l -60, KMJ-836), N-(4-tert-butylbenzyl)-2- [3-piperidino-4-(methylsulfonylamino)phenyl]ρropionamide(l -61 , YS-65), N-(4-tert- butylbenzyl)-2-[3-morpholino-4-(methylsulfonylamino)phenyl]propionamide(l-62, YS- 49), N-(4-tert-butylbenzyl)-2-[3 -(N-Boc)piperazino-4-
(methylsulfonylamino)phenyl]propionamide( 1 -63 , YS-76), N-(4-tert-butylb enzyl)-2- [3 - piperazino-4-(methylsulfonylamino)phenyl]propionamide(l -64, YS-79), N-(4-tert- butylbenzyl)-2-[3-methoxy-4-(methylsulfonylamino)phenyl]propionamide(l-65, CHK- 717), N-(4-tert-butylbenzyl)-2-[2-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(l -66, KMJ-708), N-(4-tert-butylbenzyl)-2- [2-chloro-4-(methylsulfonylamino)phenyl]propionamide(l -67, KMJ-698), N-(4-tert- butylbenzyl)-2-[4-(methylsulfonylamino)phenyl]propionamide(2-7, KMJ-750), N-(4- chloro)-2-[4-(methylsulfonylamino)phenyl]propionamide (2-8, YS-85), N-(3,4- dichloro)-2-[4-(methylsulfonylamino)phenyl]propionamide (2-9, YS-97), N-(4-tert- butylbenzyl)-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(3-5, SU- 834), N-(4-tert-butylbenzyl)-(2R)-2-[3-fιuoro-4-
(methylsulfonylamino)phenyl]propionamide(3-6, SU-824), N-(4-chlorobenzyl)-2-[3- fluoro-4-(methylsulfonylamino)phenyl]propionamide(4- 1 , SH-291 ), N-(4- chlorobenzyl)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide(4-2, SH-290), N-(4-chlorobenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide(4-3, SH-335), N-(3,4-dichlorobenzyl)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-4, SH-94), N-(3,4-dichlorobenzyl)-2-[3- chloro-4-(methylsulfonylamino)phenyl]propionamide(4-5, SH-286), N-(3,4- dichlorobenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide(4-6, SH- 337), N-(4-methylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(4- 7, SH-351), N-(4-isoρropylbenzyl)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-8, KMJ-928), N-(4-methoxybenzyl)-2- [3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-9, SH-353), N-(4- trifluoromethylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-10, SH-93), N-(4-phenylbenzyl)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-l 1, KMJ-498), N-(l-naphthylmethyl)- [3-fluoro-4-(methylsulfonylamino)phenyl]piOpionamide(4-12, SH-92), N-(l, 2,3,4- tetrahydro-l-naphthalenyl)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-13, SH-112), N-[2-(4-tert- butylphenyl)ethy] -2- [3 -fluoro-4-(methylsulfonylamino)phenyl]propionamide(4- 14, KMJ-374), N-[3-(3,4-dimethylρhenyl)propyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(4-l 5, SU-770), N-[3-(3,4- dimethylphenyl)propyl]-(2R)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-16, SU-774), N-[3-(3,4- dimethylphenyl)propyl]-(2S)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-17, SU-776), N-[3-(3,4- dimethylphenyl)-2-prophenyl] -2- [3 -fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-18, KMJ-686), N-[3-(4- chlorophenyl)propyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-19, MJ-518), N-[3-(4-chlorophenyl)-2-prophenyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(4-20, KMJ-732), N-benzyloxy-2-[3- fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-21 , SH- 109), N-(benzhydryl)- 2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-22, SH-130), N-(2,2- diphenylethy)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-23, SH- 116), N-(3,3-diphenylρropyl)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-24, KMJ-378), N-(3,3-diphenyl-2- prophenyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-25, KMJ-724), N-[3,3-di(4-methylphenyl)-2-proρhenyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(4-26, KMJ-908), N-[3,3-di(4- fluorophenyl)-2-ρrophenyl]-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-27, SH-135), N-[2-(10,l l-dihydro-5H- dibenzo[a,d]cyclohepten-5-yliden)ethy]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(4-28, SH-199), N-[2-(3,4- dimethylbenzyl)-3-pivaloxypropyl]-2-[4-
(methylsulfonylamino)phenyl]propionamide(5-l, CHK-512), N-[2-(4-tert-butylbenzyl)- 3-pivaloxypropyl]-2-[4-(methylsulfonylamino)phenyl]propionamide(5-2, CHK-514), 2- [3-fluoro-4-(methylsulfonylamino)phenyl]-N-[2-(3,4-dimethylbenzyl)-3- pivaloxypropyl]propionamide(5-3, SU-542), 2-[3-fluoro-4- (methylsulfonylamino)phenyl]-N-[2-4-tert-butylbenzyl)-3- pivaloxypropyl]propionamide(5-4, SU-564), N-[2-(3,4-dimethylbenzyl)-3- pivaloxypropyl]-2-[3-methoxy-4-(methylsulfonylamino)phenyl]propionamide(5-5, CHK-479), N-[2-(4-tert-butylbenzyl)-3-pivaloxyproρyl]-2-[3-methoxy-4- (methylsulfonylamino)phenyl]propionamide(5-6, CHK-499), N-[2-(3,4- dimethylbenzyl)-3-pivaloxypropyl]-2-[3-chloro-4-
(methylsulfonylamino)phenyl]propionamide(5-7, KNJ-472), N-[2-(4-tert-butylbenzyl)- 3-pivaloxypropyl]-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide(5-8, KMJ-690), N-[(lR)-l-benzyl-2-(ρivaloxy)ethy]-(2S)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(6-l, SU-730), N-[(lS)-l-benzyl-2- (pivaloxy)ethy]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(6-2, SU-634), N-[(lS)-l-benzyl-2-(pivaloxy)ethy]-(2R)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(6-3, SU-636), N-[(lR)-l-benzyl-2- (pivaloxy)ethy]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(6-4, SU-728), N-[(2R)-2-benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(6-5, SU-826), N-[(2S)-2-benzyl-3- (pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(6-6, SU-830), N-[(2S)-2-benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(6-7, SU-838), N-[(2R)-2-benzyl-3- (pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(6-8, SU-818), N-[(2R)-2-(4-tert-butyl)benzyl-3-(ρivaloxy)propyl]-(2S)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(6-9, MK-271 ), N-[(2S)-2-(4-tert- butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(6- 10, MK-272), N-[(2S)-2-(4-tert- butyl)benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(6-l 1, MK-450), N-[(2R)-2-(4-tert- butyl)benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(6-12, MK-452), N-[(2R)-2-(4-tβrt- butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-chloro-4-
(methylsulfonylamino)phenyl]propionamide(6-13, MK-453), N-[(2S)-2-(4-tert- butyl)benzyl-3-(pivaloxy)propyι]-(2S)-2-[3-chloro-4- (methylsulfonylamino)phenyl]propionamide(6-14, MK-451), 2-[3-fluoro-4- (methylsulfonylamino)phenyl]-2-methylpropion acid(7-4, CHK-624), 2-[4- (methylsulfonylamino)phenyl]-2-methylpropion acid(8-l 1), 2-[3-methoxy-4- (methylsulfonylamino)phenyl]-2-methylpropion acid(8-12), N-[2-(3,4-dimethylbenzyl)- 3 -pivaloxypropyl] -2- [4-(methylsulfonylamino)phenyl] -2-methylpropionamide(9- 1 , CHK-520), N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]-2-methylpropionamide(9-2, CHK-543), N-[2-(3,4- dimethylbenzyl)-3-pivaloxypropyl]-2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2- methylpropionamide(9-3, CHK-493), N-[3-(3,4-dimethylphenyl)propyl]-2-[4- (methylsulfonylamino)phenyl]-2-methylpropionamide(9-4, CHK-591), N-[3-(3,4- dimethylphenyl)propyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2- methylpropionamide(9-5, CHK-656), N-[3-(3,4-dimethylphenyl)propyl]-2-[3-methoxy- 4-(methylsulfonylamino)phenyl] -2-methylpropionamide(9-6, CHK-600), N-(4-tert- butylbenzyl)-2-[4-(methylsulfonylamino)phenyl]-2-methylpropionamide(9-7, CHK- 715), N-(4-tert-butylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2- methylpropionamide(9-8, CHK-655), N-(4-tert-butylbenzyl)-2-[3-methoxy-4- (methylsulfonylamino)phenyl]-2-methylpropionamide(9-9), l-[3-fluoro-4- (methylsulfonylamino)phenyl]cycloprophan carboxic acid(10-5), l-[4- (methylsulfonylamino)phenyl]cycloprophan carboxic acid(l l-7, CHK-530), l-[3- methoxy-4-(methylsulfonylamino)phenyl]cycloprophan carboxic acid(l l-8), N-[2-(3,4- dimethylbenzyl)-3-pivaloxypropyl]-l-[4-(methylsulfonylamino)phenyl]cycloprophan carboxiamide(12-l , CHK-533), N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-l -[3- fluoro-4-(methylsulfonylammo)phenyl]cycloprophan carboxiamide(12-2, CHK-538), N-[2-(3 ,4-dimethylbenzyl)-3 -pivaloxypropyl]- 1 -[3 -methoxy-4- (methylsulfonylamino)phenyl]cycloprophan carboxiamide(12-3, CHK-541), N-[3-(3,4- dimethylphenyl)propyl]-l-[4-(methylsulfonylamino)phenyl]cycloprophan carboxiamide(12-4, CHK-590), N-[3-(3,4-dimethylphenyl)proρyl]-l-[3-fluoro-4- (methylsulfonylamino)phenyl]cycloprophan carboxiamide(12-5), N-[3-(3,4- dimethylphenyl)propyl] - 1 - [3 -methoxy-4-(methylsulfonylamino)phenyl] cycloprophan carboxiamide(12-6, CHK-632), N-(4-tert-butylbenzyl)-l-[4-
(methylsulfonylamino)phenyl]cycloprophan carboxiamide(12-7, CHK-719), N-(4-tert- butylbenzyl)-l-[3-fluoro-4-(methylsulfonylamino)phenyl]cycloprophan carboxiamide(12-8, CHK-659), N-(4-tert-butylbenzyl)-l-[3-methoxy-4- (methylsulfonylamino)phenyl]cycloprophan carboxiamide(12-9, CHK-718).
And, the present invention provides novel compounds represented by the following formula (HI).
Figure imgf000011_0001
wherein, Ri to R-t is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring providing that all of Ri to R4 are not hydrogen atoms simultaneously; R5 and R6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R5 and R6 are not hydrogen atom simultaneously; B is a group selected from the group (1-1) to (1-6) defined in general formula (I); the asteric mark * indicates a chiral carbon atom.
In preferred embodiment in general formula (III), the most preferred compound is one selected from the group consisting of; N-(4-tert-butylbenzyl)-N, - { 1 -[3 -fluoro-4- (methylsulfonylamino)phenyl]ethyl}thiourea(15-l, LJO-328), N-(4-tert-butylbenzyι)- N -{l-[3-chloro-4-(methylsulfonylamino)phenyl]ethyl}thiourea(15-2, CHK-992), N-(4- tert-butylbenzyl)-N,-{l-[3-methoxy-4-(methylsulfonylamino)phenyl]ethyl}thiourea(15- 3, CHK-575), N-(4-tert-butylbenzyl)-NΛ-{l-[3-(methoxycarbonyl)-4- (methylsulfonylamino)phenyl]ethyl}thiourea(l 5-4, YHS- 187), N-(4-tert-butylbenzyl)- N'-{l-[3-carboxy-4-(methylsulfonylamino)phenyl]ethyl}thiourea(15-5, YHS-209), N- (4-tert-butylbenzyl)-Nλ - { ( 1 R)- 1 - [4-(methylsulfonylamino)phenyl] ethyl} thiourea( 16-5, SU-388), N-(4-tert-butylbenzyl)-NΛ-{(lS)-l-[4-
(methylsulfonylamino)phenyl]ethyl}thiourea(16-6, SU-400), N-(4-tert-butylbenzyl)-N"- {(lR)-l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}thiourea(17-3, CJU-032), N- (4-tert-butylbenzyl)-NΛ-{(lS)-l-[3-fluoro-4-
(methylsulfonylamino)phenyl]ethyl}thiourea(17-6, CJU-039), N-[(2R)-2-benzyl-3- (pivaloyloxy)prophyl]-N -{(lR)-l-[4-(methylsulfonylamino)phenyl]ethyl}thiourea(18- l, MK-229), N-[(2S)-2-benzyl-3-(pivaloyloxy)prophyl]-Nλ-{(lR)-l-[4- (methylsulfonylamino)phenyl] ethyl} thiourea(l 8-2, MK-202), N-[(2R)-2-benzyl-3- (pivaloyloxy)ρrophyl]-N, -{(1S)-1 -[4-(methylsulfonylamino)phenyl] ethyl} thiourea(l 8-3 , MK-230), N-[(2S)-2-benzyl-3-(pivaloyloxy)prophyl]-Nλ-{(lS)-l-[4- (methylsulfonylamino)ρhenyl]ethyl}thiourea(l 8-4, MK-228), N-[2-(3,4- dimethylbenzyl)-3 -(pivaloyloxy)prophyl] -N" - { 1 - [4- (methylsulfonylamino)phenyl] ethyl} thiourea( 18-5, LJO-388), N-[2-(3 ,4- dimethylbenzyl)-3-(pivaloyloxy)prophyl]-N -{(lR)-l-[4- (methylsulfonylamino)phenyl]ethyl}thiourea(l 8-6, SU-472), N-[(2R)-2-(3,4- dimethylbenzyl)-3-(pivaloyloxy)prophyl]-N"-{(lR)-l-[4- (methylsulfonylamino)phenyl]ethyl}thiourea(l 8-7, SU-512), N-[(2S)-2-(3,4- dimethylbenzyl)-3-(pivaloyloxy)prophyl]-NΛ-{(lR)-l-[4- (methylsulfonylamino)phenyl]ethyl}thiourea(18-8), N-[2-(4-tert-butylbenzyl)-3- (pi valoyloxy)prophyl] -N" - { 1 - [4-(methylsulfonylamino)phenyl] ethyl} thiourea( 18-9, LJO-401), N-[2-(4-tert-butylbenzyl)-3-(pivaloyloxy)prophyl]-N -{l(R)-[4- (methylsulfonylamino)phenyl]ethyl}thiourea(18-10, MK-296), N-[2(R)-(4-tert- butylbenzyl)-3-(pivaloyloxy)prophyl]-Nλ - { 1 (R)-[4-
(methylsulfonylamino)phenyl]ethyl}thiourea(18-l 1, MK-334), N-[2(S)-(4-tert- butylbenzyl)-3 -(pivaloyloxy)prophyl] -N - { 1 (R)- [4- (methylsulfonylamino)phenyl]ethyl}thiourea(l 8-12, MK-298), N-[2-(3,4- (dimethylbenzyl)-3-(pivaloyloxy)prophyl]-Nλ- { 1 -[3-fluoro -4- (methylsulfonylamino)phenyl] ethyl} thiourea(l 8-13, LJO-344), N-[2-(4-tert- butylbenzyl)-3-(pivaloyloxy)prophyl]-NΛ - { 1 -[3-fluoro -4- (methylsulfonylamino)phenyl]ethyl}thiourea(18-14, LJO-366), N-[(2R)-3-phenyl-l- pivaloyloxy-2-ρrophyl] -N" - [(R)-o;-methyl-4-(methylsulfonylamino)benzyl]thiourea( 19- 13, SU-692), N-[(2S)-3-phenyl-l-pivaloyloxy-2-prophyl]-NΛ-[(R)-Q!-methyl-4- (methylsulfonylamino)benzyl]thiourea(19-14, SU-704), N-[(2R)-3-phenyl-l- pivaloyloxy-2-prophyl]-N"-[(S)-o;-methyl-4-(methylsulfonylammo)benzyl]thiourea(19- 15, SU-720), N-[(2S)-3-phenyl-l-pivaloyloxy-2-prophyl]-N,-[(S)-α!-methyl-4- (methylsulfonylamino)benzyl]thiourea(l 9- 16, SU-710), N-(4-tert-butylbenzyl)-NΛ - { 1 - [4-(methylsulfonylamino)-3-fluorophenyl]ρrophyl}thiourea(20-12, LJO-399), N-(4-tert- butylbenzyl)-Nλ - { 1 -[4-(methylsulfonylamino)-3 -fluorophenyl] -2- methylproρhyl}thiourea(20-13, LJO-402), N-(4-tert-butylbenzyl)-N,-{[4- (methylsulfonylamino)-3 -fluorophenyl] (phenyl)methyl} thiourea(20- 14, LJO-403), N- (4-tert-butylbenzyl)-N,-{l-[4-(methylsulfonylamino)-3-fluorophenyl]-2- phenylethyl} thiourea(20- 15 , LJO-395), N-(4-tert-butylbenzyl)-N - { 1 -methyl- 1 -[4- (methylsulfonylamino)phenyl] ethyl} thiourea(21-7, CHK-593), N-(4-tert-butylbenzyl)- N" - { 1 -methyl- 1 - [3 -fluoro-4-(methylsulfonylamino)phenyl] ethyl} thiourea(21 -8 , CHK- 660), N-(4-tert-butylbenzyl)-NΛ- { 1 -methyl- 1 -[3-methoxy-4-
(methylsulfonylamino)phenyl]ethyl}thiourea(21-9, CHK-629), N-(4-tert-butylbenzyl)- NΛ- {l-[4-(methylsulfonylamino)ρhenyl]cycloproρhyl}thiourea(22-7, CHK-579), N-(4- tert-butylbenzyl)-N, - { 1 -[3-fluoro-4-
(methylsulfonylamino)phenyl]cycloprophyl}thiourea(22-8), N-(4-tert-butylbenzyl)-N"- {l-[3-methoxy-4-(methylsulfonylamino)phenyl]cycloprophyl}thiourea(22-9, CHK-631).
And, the present invention provides novel compounds represented by the following formula (IN).
Figure imgf000013_0001
wherein, Ri to R is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring; R5 and R6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R5 and R6 are not hydrogen atom simultaneously; B is a group selected from the group (1-1) to (1-6) defined in general formula (I); the asteric mark * indicates a chiral carbon atom.
In preferred embodiment in general formula (IN), the most preferred compound is one selected from the group consisting of; Ν-(4-tert-butylbenzyl)-Ν,-{l-[4-(methylsulfonylamino)phenyl]ethyl}urea (23-1. MK-82), N-(4-tert-butylbenzyl)-NΛ - { 1 -[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}urea (23-2, MK-205)
And, the present invention provides novel compounds represented by the following formula (V).
Figure imgf000014_0001
wherein, R\ to R4 is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring; R5 and R6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R5 and R6 are not hydrogen atom simultaneously; B is a group selected from the group (1-1) to (1-6) defined in general formula (I); the asteric mark * indicates a chiral carbon atom.
In preferred embodiment in general formula (V), the most preferred compound is one selected from the group consisting of; N-{l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert- butylρhenyl)acetamide (24-1, KMJ-586), N- { 1 -[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl} -3-(4-tert- butylρhenyl)prophanamide (24-2, KMJ-552), N-{l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert-butylphenyl)-2- prophenamide (24-3, KMJ-570), N- { 1 - [3 -fluoro-4-(methylsulfonylamino)phenyl] ethyl} -3 -(3 ,4- dimethylρhenyl)prophanamide (24-4, CHK-602), N-{l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)-2- prophenamide (24-5, CHK-651), N- { 1 -[3 -fluoro-4-(methylsulfonylamino)phenyl] ethyl} -3 -(4- chlorophenyl)prophenamide (24-6, KMJ-534), N-{l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-chlorophenyl) -2- prophenamide (24-7, KMJ-558), N-{l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4- dimethylphenyl)buthanamide (24-8, CHK-647).
The term "salt" used herein comprises all the pharmaceutically salts well known in the art. The inventive compounds represented by general formula ( I ) to (V) can be transformed into their pharmaceutically acceptable salt and solvates by the conventional method well known in the art. For the salts, acid-addition salt thereof formed by a pharmaceutically acceptable free acid thereof is useful and can be prepared by the conventional method. For example, after dissolving the compound in the excess amount of acid solution, the salts are precipitated by the water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile to prepare acid addition salt thereof and further the mixture of equivalent amount of compound and diluted acid with water or alcohol such as glycol monomethylether, can be heated and subsequently dried by evaporation or filtrated under reduced pressure to obtain dried salt form thereof. As a free acid of above-described method, organic acid or inorganic acid can be used. For example, organic acid such as methansulfonic acid, -toluensulfonic acid, acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonylic acid, vanillic acid, hydroiodic acid and the like, and inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid and the like can be used herein.
Further, the pharmaceutically acceptable metal salt form of inventive compounds may be prepared by using base. The alkali metal or alkali-earth metal salt thereof can be prepared by the conventional method, for example, after dissolving the compound in the excess amount of alkali metal hydroxide or alkali-earth metal hydroxide solution, the insoluble salts are filtered and remaining filtrate is subjected to evaporation and drying to obtain the metal salt thereof. As a metal salt of the present invention, sodium, potassium or calcium salt are pharmaceutically suitable and the corresponding silver salt can be prepared by reacting alkali metal salt or alkali-earth metal salt with suitable silver salt such as silver nitrate.
The pharmaceutically acceptable salt of the compound represented by general formula ( I ) to (V) comprise all the acidic or basic salt which may be present at the compounds, if it does not indicated specifically herein. For example, the pharmaceutically acceptable salt of the present invention comprise the salt of hydroxyl group such as the sodium, calcium and potassium salt thereof; the salt of amino group such as the hydrogen bromide salt, sulfuric acid salt, hydrogen sulfuric acid salt, phosphate salt, hydrogen phosphate salt, dihydrophosphate salt, acetate salt, succinate salt, citrate salt, tartarate salt, lactate salt, mandelate salt, methanesulfonate(mesylate) salt and -toluenesulfonate (tosylate) salt etc, which can be prepared by the conventional method well known in the art. The term "isomer" used herein comprises all the isomers, for example, stereoisomer, optically active isomer, racemic mixture, enantiomer and the like well known in the art.
There may exist in the form of optically different diastereomers since the compounds of the present invention have one or more unsymmetrical centers (*), accordingly, the compounds of the present invention comprise all the optically active isomers, R or S stereoisomers and the mixtures thereof. Present invention also comprises all the uses of the racemic mixture, one or more optically active isomer and the mixtures thereof as well as all the preparation methods for preparing the isomers, for example, imsyrrimetric synthesis, and isolation methods for isolating the isomers, for example, partitioned re- crystalization method, chromatographic method well known in the art or the method disclosed herein. And, the present invention provides a process for preparing novel compounds represented by general formula (I) to (V) described herein comprising the methods explained by following preferred embodiments or examples. The compounds of the invention of formula ( I ) to (V) may be chemically synthesized by the methods which will be explained by following reaction schemes hereinafter, which are merely exemplary and in no way limit the invention. The reaction schemes show the steps for preparing the representative compounds of the present invention, and the other compounds also may be produced by following the steps with appropriate modifications of reagents and starting materials, which are envisaged by those skilled in the art.
GENERALSYNTHETICPROCEDURES
Scheme 1
A)
Figure imgf000018_0001
MsCI, Pyridine
Figure imgf000018_0002
1-51 R 1-38 Rt=F 1-26 =F 1-52 R 1-39 R,=CI 1-27 =CI 1-53 R 1-40 Ri=Bι 1-28 =Br 1-54 R =l 1-41 R1=! 1-29 =l 1-55 R F, R3=F 1-42 Rl=F> R3=F 1-30 =F, R3=F 1-56 R 1-43 R,=CN 1-31 =CN 1-57 R C02tBu 1-44 Rl=C02tBU 1-32 =C02iB 1-58 R C02H 1-45 ι=piperidine 1-33 =piperidine 1-69 R >C0 CH3 1-46 R)=moιpholine 1-34 =morpholine 1-60 R CONHBn 1-47 Rι=(N-6oc)piperaane 1-35 =(N-Bo iperazine 1J61 R :piperidine 1-48 R(=OCH3 1-36 R2=F 1-62 R ■morpholine 1-49 R2=F 1-37 R2=CI 1-63 R :(N-Boc)piperazine 1-50 R2=CI 1-64 R φiperidme 1-65 R OCH3 1-66 R2 <F 1-67 2 ■C\ As depicted in above Scheme 1, the reaction consists of five steps as follows: at 1st step, the mixture of nitrobenzene having various Ri to R4 substituents and ethyl-2- halogenpropiponate such as ethyl-2-chloropropionate is reacted with metal salt alkoxide solution such as potassium-t-butoxide dissolved in DMF dropwisely at the temperature ranging from 0°C to room temperature, in the period ranging from 3 to 30 min, preferably 10 mins. The reaction is stopped by acid e.g., 1N-HC1, diluted with water and repeatedly extracted with diethyether to obtain organic solvent layer. The organic solvent layer is washed with water and saline water, dried, concentrated in vacuo and the residue is further purified with flash column chromatographic method to obtain ethyl 2-(3-halo-4-nitrophenyl) propionate intermediate compound (1-1 to 1-12) through the alkylation of 4-position in phenyl ring; at 2nd step, the propionate intermediate compound (1-1 to 1-12) is reduced with reducing agent for example, 10% Pd/C (hydrogenation reaction, method A) or Fe ion in the presence with acetic acid (method B). The resulting product is filtered and the filtrates is dried in vacuo and purified with purified with flash column chromatographic method to obtain ethyl 2-(4-amino-3-halo phenyl) propionate intermediate compound (1-13 to 1-25) through reducing nitro group to amino group; at 3rd step, the propionate compound (1-13 to 1-25) is reacted with sulfonyl halide, preferably, methanesulfonychloride dissolved in pyridine solvent with stirring and the resulting product is washed with water and purified with flash column chromatographic method to obtain ethyl 2-(3-halo-4(methylsulfonyamino)phenyl) propionate intermediate compound (1-26 to 1-37) through sulfonylation process; at 4 step, the propionate compound (1-26 to 1-37) dissolved in solvent mixture mixed with water and THF is reacted with metal hydroxide such as lithium hydroxide dropwisely with stirring and acidified with acidic solution such as 1N-HC1 solution to obtain organic layer. The organic layer is extracted and dried to produce carboxylic acid compound (1- 38 to 1-50) through hydrolysis process; at 5th step, the 2-[3-halo-4- (methylsulfonylamino)phenyl]propionate is added dropwisely to EDC solution containing amine compound such as 4-t-butylbenzylamine at the temperature ranging from 0 °C to room temperature, stirred, filtrated, concentrated and the resulting residue is further purified with purified with flash column chromatographic method to obtain purposed final product, N-(4-t-butylbenzyl)-2-[2 or 3-substituted-4- (methylsulfonylamino)phenyl]propionamide compound (1-51 to 1-67), a derivative represented by general formula (II) having B group (1-2), through coupling acid with amine group. Scheme 2
Figure imgf000020_0001
H2. P -C
Figure imgf000020_0002
2-7 R=4-t-B U 2-4 R^4-t-Bu 2-8 R=4-CI 2-5 R=4-CI 2-9 R=3,4-C|2 2-6 R=3, 4-CI2
As depicted in above Scheme 2, the compound represented by general formula (II) having A group (NHCO), R5 (methyl) and R6 (H) can be prepared by following procedure: conventionally available 2(4-nitrophenyl)propionic acid is coupling with amine (RNH2) to produce amide (2-1 to 2-3) and the amide is reduced to produce amine compound (2-4 to 2-6). Finally, the amine is subjected to methylsulfonylation to obtain final product (2-7 to 2-9).
The compound represented by general formula (II) can comprises various optical isomers e.g., enantiomer, stereoisomer, diastereomer etc, according to the B moiety containing chiral carbon and the various isomers can be synthesized and isolated by the procedure explained by following Scheme 3 and 4.
Scheme 3
Figure imgf000021_0001
1-38 L-phenylalaninol EDC
Figure imgf000021_0002
As depicted in above Scheme 3, the carboxylic acid (1-19) obtained in Scheme 1, is reacted with L-phenylalaniol in the presence of EDC to produce amide (3-1). The amide is hydrolyzed with strong acid such as sulfuric acid to obtain specific R form (3-3) or S form (3-4) isomer and further reacted with amine to produce optically active R form (3- 5) or S form (3-6) enantiomers represented by general formula (II) having B moiety (I-
1).
Scheme 4
Figure imgf000021_0003
1-38 R=F 4-1-28 1-39 R=CI 1-40 R=Br
As depicted in above Scheme 4, the carboxylic acid (1-38 to 1-40) obtained in Scheme 1, is reacted with amine having appropriate B substituents in the presence of EDC to produce purposed amide compound represented by general formula (II) having B moiety (1-2). Scheme 5
Figure imgf000022_0001
5-1 Rl=H R2=3,4-Me2 5-2 Rl=H R2=4-t-Bu 5-3 Rl=F R2=3,4-Me2 5-4 R1=F R2=4-f-BU 5-5 Rl=OCH3 R2=3,4- e2 5-6 R1=0CH3 R2=4-f-Bu 5-7 R CI R2=3,4-Me2 5-8 Rl=CI R2=4-f-BU As depicted in above Scheme 5, the carboxylic acid obtained in Scheme 1, is reacted with amine having appropriate B substituents in the presence of EDC to produce purposed amide compound represented by general formula (II) having B moiety (1-2).
Scheme 6
Figure imgf000022_0002
As depicted in above Scheme 6, the carboxylic acid obtained in Scheme 1, is reacted with amine having appropriate B substituents in the presence of EDC to produce purposed optically active amide compound represented by general formula (II) having B moiety (1-2) containing chiral carbon. The B-NH moiety (1-2) having (R) form or (S) form enantiomers due to chiral carbon positioned at 2 is reacted with (R) form or (S) form of carboxylic acid obtained in Scheme 1 to produce various optically active stereoisomers, i.e., (IS, 2R), (IS, 2S), (1R, 2R) and (1R, 2S). The compound having lower alkyl group at R5 and R6 can be prepared by following procedures shown in Scheme 7 and Scheme 8:
Scheme 7
Figure imgf000023_0001
1-13 7-1 7-2 iwfeci
Figure imgf000023_0002
7-4 7-3 For example, as depicted in above Scheme 7, the compound having halogen atom at any of R1 and R4 can prepared as follows: The ester (1-13) is reacted with appropriate alkylating agent i.e., methyl iodide, in the presence of DMF and hydrogenated metal such as NaH to obtain dimethyl compound (7-1), and similar reactions to the steps ranging from 2nd step to 4th step in Scheme 1 is further performed to produce the compound represented by general formula (II) having dimethyl group (7-4).
Scheme 8
Figure imgf000024_0001
8-1 R1=H 8-3 R1=H 8-2 R^OO^, 8-4 R,=OCH3 I NaH 1 CH3I
Figure imgf000024_0002
I' NaOH- 1 THF
Figure imgf000024_0003
8-11 Rι=H 8-12 R)=OCH3
For example, the compound having lower alkoxy group or hydrogen atom at any of Ri and R4 and methyl groups at both of R5 and R6 can prepared by the procedure depicted in above Scheme 8.
Scheme 9
Figure imgf000024_0004
For example, the compound having NHCO group at A moiety and methyl groups at both of R5 and Re can prepared by the procedure depicted in above Scheme 9. As depicted in above Scheme 9, the carboxylic acid (8-11, 7-4, 8-12) is reacted with amine having appropriate B substituents in the presence of EDC to produce purposed compound represented by general formula (II) having NHCO group at B moiety. Scheme 10
H3CO2C
Figure imgf000025_0001
10-1 10-2
Figure imgf000025_0002
10-5 104 10-3
The compound represented by general formula (II) having cycloalkane at R5 and R& and halogen atoms at any of R1. and R4 can prepared by the procedure depicted in Scheme 10.
Scheme 11
Figure imgf000025_0003
MsCl pyridine
Figure imgf000025_0004
11-7 Rι=H 11-S Rι=H 11-8 Rι=0CH3 11-G R,=OCH3
The compound represented by general formula (II) having cycloalkane at R5 and R^, and methoxyl group at any of Ri and R can prepared by the procedure depicted in Scheme 11. For example, the ester (8-3. 8-4) is reacted with dihaloalkane reagent such as 1,2- dibromoethane in the presence of metal hydride such as NaH to produce cycloalkyl intermediates (11-1, 11-2) and serial steps comprising reduction, mesylation and alkylation reactions is performed to obtain final carboxylic acid product (11-7, 11-8). Scheme 12
Figure imgf000026_0001
As depicted as Scheme 12, the carboxylic acid product (11-7, 11-8) is reacted with amine having appropriate B moiet in the presence of EDC to obtain final compound represented by general formula (II) having cycloalkyl group at R5 and Rδ . The compound represented by general formula (III) and general formula (IV) having methyl group and hydrogen at R5 and Rg, can prepared by the procedure depicted in Schemes 13 to 15.
Scheme 13
'
Figure imgf000026_0002
13-1 R=F 13-3 R=F 13-5 R=H 13-2 R--CO2CH3 13-4 R=C02CH3 13-6 R=F 13-7 =C02CH3
Figure imgf000026_0003
13-11 R=H 13-8 R=H 13-12 R=F 13-9 R=F 13-13 R=C02CH3 13-10 R=C02CH3
As depicted in above Scheme 13, the reaction consists of four steps as follows: at 1st step, the 4-iodo amine compound (13-1 to 13-2) dissolved in pyridine is reacted with a sulfonylating agent, e.g., methane sulfonyl chloride with stirring. The resulting organic solvent layer is extracted, dried, concentrated in vacuo and the residue is further purified with flash column chromatographic method to obtain sulfonyl amine compound (13-3 to 13-4) through the reducing amine to sulfonyl group; at 2nd step, the sulfonyl amine compound (13-3 to 13-4) dissolved in DMF is reacted with metal acetate, preferably, Pd (II) acetate or Tl (I) acetate, in the presence of DPPP (1,3-bisdiphenylphospinopropane) and butylvinylether at the temperature ranging from 60 to 110°C in the period ranging from 5 to 24 hours and the reaction mixture is cooled at the temperature ranging from 0°C to room temperature. Acidic solution such as 10%-HCl is added thereto and stirred. The reaction mixture is diluted with ethylacetate, washed with ammonium chloride solution, concentrated with vacuo and purified with flash column chromatographic method to obtain ketone compound (13-5 to 13-7); at 3rd step, the ketone compound and acid halide salt are dissolved in pyridine and heated at the temperature ranging from 40 to 90 °C, preferably, 70 °C, in the period ranging from 30 mins to 5 hours. The reaction mixture is cooled, diluted and the resulting organic layer is purified with flash column chromatographic method to obtain oxime derivatives (13-8 to 13-10) through substituting ketone with oxime group; at 4 step, the oxime derivatives is hydrogenated with reducing agent, for example, 10% Pd/c dissolved in lower alcohol e.g., methanol. The resultant is filtrated and the filtrate is purified with flash column chromatographic method to obtain amine intermediate compound (13-11 to 13-13) through reducing nitro group to amine group as can be seen in Scheme 13.
Scheme 14
H0
Figure imgf000027_0001
14-1 R=0CH 3 14-3 R=0CH 3 14-2 R=CI 14-4 R=CI
The compound having chloro group or methoxyl group at any of Ri to R , can prepared by the procedure depicted in Scheme 14. Scheme 15
Figure imgf000028_0001
15-1 R=F 15-2 R=CI
Figure imgf000028_0002
The thiourea compound represented by general formula (III) and urea compound general formula (IN) can prepared by the procedure depicted in Scheme- 15. As depicted as Scheme 15, the amine compound obtained in Scheme 14 and isothiocyanate compound (B-ΝCS) or cyanate compound (B-ΝCO) having appropriate B moiety is dissolved in DMF and stirred at the temperature ranging from 0°C to room temperature, in the period ranging from 30 mins to 4 hours, preferably, 2hours. The reaction mixture is diluted with water and the organic solvent layer is extracted, dried, concentrated in vacuo and purified with flash column chromatographic method to obtain purposed thiourea compound or urea compounds (15-1 to 15-5, 18-1 to 18-6, 19-5 to 19-12, 23-1 to 23-2) through coupling reaction.
Scheme 16
Figure imgf000028_0003
Hz, Pd-C
Figure imgf000028_0004
16-5 R- isomer 16-3 R-isomer 16-6 S-isomer 16-4 S-isomer
The stereoisomers of the compound represented by general formula (III) and general formula (IV) having hydrogen atoms at all the
Figure imgf000028_0005
to R4, can prepared by the procedure depicted in Scheme 16 Scheme 17
Figure imgf000029_0001
I"
Figure imgf000029_0002
Figure imgf000029_0003
JHCl
Figure imgf000029_0004
The stereoisomers of the compound represented by general formula (III) and general formula (IV) having halogen atom at any of R\ to , can prepared by the procedure depicted in Schemes 17 and 18. As depicted in above Scheme 17, 3'-fluoro-4(methylsulfonylamino)acetophenone is coupled with optically active R form or S form sulfone amine respectively and reduced with reducing agent such as NaBH4 to synthesize R form or S form sulfone amine isomers (17-1 and 17-4) respectively. The amine isomers is further hydrolyzed in acidic condition to obtain optically active amine (17-2, 17-5). The procedure similar to the methods in Scheme 13 is performed to obtain optically active (R) or (S) thiourea represented by general formula (III) or urea represented by general formula (IV) (17-3 and 17-6). Scheme 18
Figure imgf000030_0001
18-1 1R .2R R ]=H R2=H 18-2 1R .2S Rl=H R2=H 18-3 1S.2R R,=H R2=H 18-4 1S.2S R,=H R2=H 18-5 mixture Rl=H R2=3,4-Me2 18-6 1R Rl=H R2=3,4-Me2 18-7 1R.2R R,=H R2=3,4-Me2 18-8 1R.2S R,=H R2=3,4-Me2 18-9 mi^iune Rl=H R2=4-f-Bu 18-10 1R Rt=H R2=4-f-Bu 18-11 1R.2R R ,=H R2=4-t-Bu 18-12 1R .2S R,=H R2=4-f-Bu 18-13 mixture R l=F R2=3,4-Me2 18-14 mixture R F R2=4-f-Bu
As depicted as Scheme 18, the amine is reacted with benzyl amine in the presence of EDC to obtain final thiourea compound represented by general formula (II) having (1-2) group at B moiety.
Scheme 19
Figure imgf000030_0002
19-1 R 19-3 R 19-2 S 19-4 S
Figure imgf000030_0003
19-13 1R.2R 19-14 1R .2S 19-5 1R.2R R=N02 19-S 1R.2R R=NH2 19-15 1S.2R 19-6 1 R.2S R=N02 19-10 1R.2S R=NH2 19-16 1S .2S 19-7 1S.2R R=N02 19-11 1S.2R R=NH2 19-8 1 S.2S R=N02 19-12 1S.2S R=NH2 As depicted in above Scheme 19, the alcohol is reacted with pivaloyl halide, e.g., pivaloyl chloride (Me3CCOCl) in acidic condition to obtain amine (19-1 and 19-2). The mine is further reacted with 1,1-thiocarbonyl diimidazole(TCD) in the presence of DMF solvent to produce isothiocyanate (19-3, 19-4). The isocyanate is reacted with (R) or (S) alpha-methyl-4-nitrobenzyl amine HC1 in the presence of base e.g., TEA, reduced with reducing agent, for example, Al-Hg and mesylated to obtain (IS, 2R), (IS, 2S), (1R, 2R) and (1R, 2S) thiourea represented by general formula (III) or urea represented by general formula (IN) (19-13 to 19-16).
The amine intermediate compound (13-11 to 13-13) can be prepared by the procedure depicted in following Scheme 20.
Scheme 20 Tributyl vinyrtin PdCPPh 3)4
Figure imgf000031_0002
Figure imgf000031_0001
20-1 20-2 4 0
Figure imgf000031_0003
20-8 R = CH2CH3 20-1 R = CH2CH3 20-3
H2, Pd-C 20-9 R = CH(CH3)2 20-5 R = CH(CH3)2 MeOH 20-10 R = Ph 20-6 R = Ph 20-11 R = CH2Ph 20-7 R = CH2Ph
Figure imgf000031_0004
20-12 R = CH2CH3 20-13 R = CH(CH3)2 20-14 R = Ph 20-15 R = CH2P h As depicted in above Scheme 20, 2-fluoro-4-iodoaniline is reacted with tertakis(triphenylphosphine)palladium and tributylvinyltin in the presence with catalitically amount of 2,6-di-tert-butyl-4-methylphenol to obtain 2-fluoro-4- vinylaniline(21-l). The resulting compound is reacted with sulfonylating agent such as methane sulfonyl chloride in the presence of pyridine solvent to produce N-(2-fluoro-4- vinylphenyl)methanesulfoneamide (20-2) and oxidized with oxidizing agent e.g., osmium tetroxide and sodium periodate in the presence of acetone-water mixture solvent to aldehyde intermediate (20-3). The aldehyde compound is reacted with Grignard reagent to obtain alcohol intermediate (2-4 to 20-7) and further reacted with DPPA(diphenylphosphorylazide) and DBU(l,8-diazabicyclo[5,4,0]undec-7-ene) in the presence with toluene solvent to produce azide compound (20-8 to 20-11). The azide intermediate is finally reduced with reducing agent such as Pd/C to produce purposed amine derivative (13-11 1 13-13) selectively. The thiourea compound represented by general formula (III) or urea compound represented by general formula (IN) having methyl groups at both R5 and R6 can be prepared by the procedure shown in following Scheme 21.
Scheme 21
Figure imgf000032_0001
8-11 R=H 7-4 R=F 21-2 R=F 8-12 =OCH3 21-3 =0CH3
Figure imgf000032_0002
21-7 R=H 21-4 R=H 21-8 R=F 21-5 R=F 21-9 =OCH3 21-6 R=OCH3 As depicted as Scheme 21, the carboxylic acid compound (8-11, 7-4, 8-12) is reacted with DDDPA (diphenylphosphorylazide) and molecular sieve in the presence with base such as TEA and organic solvent and benzyl alcohol is added to the reaction mixture to obtain carbamate (21-1 to 21-3) through Curtius reaction. The carbamates compound is subjected to reduction process with reducing agent such as Pd/C in H2 gas to obtain amine intemediate (21-4 to 21-6) and coupling reaction shown in Scheme 15 is further subjected to obtain purposed amine is reacted with benzyl amine in the presence of EDC to obtain final thiourea compound represented by general formula (III) or urea compound represented by general formula (IV). Scheme 22
11-7 R=H
Figure imgf000033_0001
Pd/C, H2 CH3OH
Figure imgf000033_0002
22-7 R=H 22-4 R=H 22-8 R=F 22-5 R=F 22-9 R=OC43 22-6 R=0CH3 The thiourea compound represented by general formula (III) or urea compound represented by general formula (IN) having cyclopropyl group at R5 and R6 can be prepared by the procedure shown in Scheme 22. As depicted as Scheme 22, the carboxylic acid compound (8-11, 7-4, 8-12) is reacted with DDDPA (diphenylphosphorylazide) and molecular sieve in the presence with base such as TEA and organic solvent and benzyl alcohol is added to the reaction mixture to obtain carbamate (21-1 to 21-3) through Curtius reaction. The carbamates compound is subjected to reduction process with reducing agent such as Pd/C in H gas to obtain amine intemediate (21-4 to 21-6) and coupling reaction shown in Scheme 15 is further subjected to obtain purposed amine is reacted with benzyl amine in the presence of EDC to obtain final thiourea compound represented by general formula (III) or urea compound represented by general formula (IV).
Scheme 23
Figure imgf000033_0003
13-11 R=H 23-1 R=H 13-12 R=F 23-2 R=F The urea compound represented by general formula (IV) having methyl or hydrogen at R5 and R6 can be prepared by the procedure shown in Scheme 23.
The present invention also provides a pharmaceutical composition comprising a compound of formula ( I ) to (N) or a pharmaceutically acceptable salt thereof as an active ingredient for an antagonist of vanilloid receptor.
The compound of formula ( I ) to (N) according to the present invention has potent analgesic and anti-inflammatory activity, and the pharmaceutical composition of the present invention thus may be employed to alleviate or relieve acute, chronic or inflammatory pains or to suppress inflammation and to treat urgent urinary incontinence.
The present invention also provides a pharmaceutical composition comprising the compound selected from the group consisting of compounds of formula ( I ) to (N) or the pharmaceutical acceptable salts thereof for preventing and treating pain diseases or inflammatory diseases.
Pain diseases or inflammatory diseases comprise at least one selected from the group consisting of pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and the like.
The present invention also provides a pharmaceutical composition comprising the compound selected from the group consisting of compounds of formula ( I ) to (N) or the pharmaceutical acceptable salts thereof for preventing and treating urgent urinary incontinence.
The pharmaceutical composition of the present invention comprises the inventive compounds between 0.0001 to 10% by weight, preferably 0.0001 to 1% by weight based on the total weight of the composition.
The present invention also provides an use of compound selected from the group consisting of compounds of formula ( I ) to (N) or the pharmaceutical acceptable salts thereof as antagonists of vanilloid receptors.
In accordance with another aspect of the present invention, there is also provided an use of the compound ( I ) to (N) for manufacture of medicines employed for alleviating or treating pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease or urgent urinary incontinence.
The compound of formula ( I ) to (N) according to the present invention can be provided as a pharmaceutical composition comprising pharmaceutically acceptable carriers, adjuvants or diluents. For example, the compounds of the present invention can be dissolved in oils, propylene glycol or other solvents, which are commonly used to produce an injection. Suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not limited to them. For topical administration, the compounds of the present invention can be formulated in the form of ointments and creams.
In accordance with another aspect of the present invention, there is also provided an method of alleviating or treating pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach- duodenal ulcer, inflammatory bowel disease, inflammatory disease or urgent urinary incontinence, wherein the method comprises administering a therapeutically effective amount of the compound of formula of ( I ) to (N) or the pharmaceutically acceptable salt thereof.
Hereinafter, the following formulation methods and excipients are merely exemplary and in no way limit the invention.
The compounds of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
The compounds of the present invention may be formulated into preparations for injections by dissolving, suspending, or emulsifying them in aqueous solvents such as normal saline, 5% Dextrose, or non-aqueous solvent such as vegetable oil, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol. The formulation may include conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.
The desirable dose of the inventive compounds varies depending on the condition and the weight of the subject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer at the amount ranging 0.0001 - 100 mg/kg, preferably 0.001 - 100 mg/kg by weight/day of the inventive compounds of the present invention. The dose may be administered in single or divided into several times per day. In terms of composition, the compounds should be present between 0.0001 to 10% by weight, preferably 0.0001 to 1% by weight based on the total weight of the composition.
The pharmaceutical composition of present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) via various routes. All modes of administration are contemplated, for example, administration can be made orally, rectally or by intravenous, intramuscular, subcutaneous, intrathecal, epidural or intracerebroventricular injection.
It is anther object of the present invention to provide a use of the above-mentioned compound of the present invention for the preparation of therapeutic agent for the preventing and treating pain disease or inflammatory disease by showing vanilloid receptor-antagonistic activity in human or mammal.
Additionally, it is an object of the present invention to provide a method of treating or preventing pain disease and inflammatory disease by showing vanilloid receptor- antagonistic activity in a mammal comprising administering to said mammal an effective amount of the above-mentioned compound of the present invention together with a pharmaceutically acceptable carrier thereof.
It will be apparent to those skilled in the art that various modifications and variations can be made in the compositions, use and preparations of the present invention without departing from the spirit or scope of the invention.
Best Mode for Carrying Out the Invention The present invention is more specifically explained by the following examples. However, it should be understood that the present invention is not limited to these examples in any manner.
EXAMPLES
Example 1 : Preparation of N-(4-tert-butylbenzyl)-2-[3-fluoro-4- (metylsul onylamino)phenyl] propionamide(l -51, KM J-372)
Step 1-1. Preparation of ethyl 2-("3-fluoro-4-nitrophenyl propionate (1-1, SU-654 To a stirred solution of potassium t-butoxide (20 mmol) in DMF (20 mL) was added a mixture of 2-fluoro-nitrobenzene (10 mmol) and ethyl-2-chloropropionate (10 mmol) at 0 °C dropwise. After being stirred for 10 min at 0 °C, the mixture was quenched by 1 N HC1 solution, diluted with water and extracted with diethyl ether several times. The combined organic layers were washed with water and brine, dried over MgSO4, and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:10) as eluant to afford ethyl 2-(3-fluoro-4- nitrophenyl)propionate (1-1, SU-654). 68% yield, yellow oil 1H NMR (CDCI3) δ 8.02 (dd, 1 H, J= 7.8, 8.0 Hz), 7.2-7.3 (m, 2 H), 4.14 (m, 2 H), 3.78 (q, 1 H, J= 7.1 Hz), 1.52 (d, 3 H, J= 7.1 Hz), 1.22 (t, 3 H, J= 7.08 Hz)
Step 1-2. Preparation of ethyl- 2-(4-amino-3-fluorophenyl propionate (1-13, SU-656 A suspension of 2-(3-fluoro-4-nitrophenyl)propionate(l-l, 5 mmol) and 10% Pd-C (500 mg) in EtOH (30 mL) was hydrogenated under a balloon of hydrogen for 1 h and filtered through Celite. The filtrate was concentrated in vacuo and the residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:4) as eluant to afford 2-(4-amino-3-fluorophenyl)propionate compound(l-13, SU-656). 94% yield, a colorless oil 1H MR (CDCI3) δ 6.96 (dd, 1 H, J= 1.7 Hz), 6.87 (dd, 1 H, J= 1.7, 8.3 Hz), 6.71 (dd, 1 H, J= 8.3, 11.9 Hz), 4.11 (m, 2 H), 3.58 (q, 1 H, J= 7.1 Hz), 3.45 (bs, 2 H), 1.43 (d, 3 H, J= 7.1 Hz), 1.20 (t, 3 H, J= 7.05 Hz)
Step 1-3. Preparation of ethyl 2-[3-fluoro-4-fmetylsulfonylamino phenyl]propionate comrJoundd-26. SU-658) A solution of 2-(4-amino-3-fluorophenyl)propionate (1-13, 4mM) and pyridine (10ml) was dissoluted with methansulfonylchloride (6mM) and was stirred at 0°C for 10 minutes. The combined organic layers were washed with H2O and residue was purified by flash column chromatography on silica gel with EtOAc/hexanes (1 :2) as eluant to afford ethyl 2-[3-fluoro-4-(metylsulfonylamino)phenyl]propionate compound(l-26, SU- 658). 91% yield, white solid mp = 81 °C 1H NMR (CDC13) δ 7.50 (t, 1 H, J= 8.3 Hz), 7.0-7.1 (m, 2 H), 6.55 (bs, 1 H), 4.12 (m, 2 H), 3.68 (q, 1 H, J= 7.1 Hz), 3.02 (s, 3 H), 1.48 (d, 3 H, J- 7.1 Hz), 1.22 (t, 3 H, J= 7.1 Hz)
Step 1-4. Preparation of 2-[3-fluoro-4-(metylsulfonylamino)phenyι~|propion acid compound(l-38. SU-660) A solution of ethyl 2-[3-fluoro-4-(metylsulfonylamino)phenyl]propionate (1-26, 2 mmol) in H2O and THF (1 :2, 30 mL) was treated with lithium hydroxide (6 mmol) and stirred for 4 h at room temperature. The mixture was diluted with H2O and CH C12, acidified by 1 N HC1 solution and extracted with CH2C12 several times. The combined organic layers were washed with water and brine, dried over MgSO4 and concentrated in vacuo. The residue was crystallized by diethyl ether and n-hexane to afford 2-[3- fluoro-4-(metylsulfonylamino)phenyl]propion acid compound(l-38, SU-660) 97% yield, white solid, mp = 120 °C 1H NMR (CDC13) δ 7.52 (t, 1 H, J = 8.04 Hz), 7.1-7.15 (m, 2 H), 6.60 (bs, 1 H), 3.73 (q, 1 H, J= 7.1 Hz), 3.03 (s, 3 H), 1.51 (d, 3 H, J= 7.1 Hz)
Step 1^5. Preparation of. N-(4-tert-ButylbenzylV2-r3-fluoro-4-
(methylsulfonylamino phenyl]propionamide (1-51, KMJ-372 A mixture consisting of 2-[3-Fluoro-4-(methylsulfonylamino)phenyl]propionic acid (1-38, 10 mmol), 4-t-butylbenzylamine (12 mmol) and EDC (12 mmol) in CH2C12 (20 mL) was stirred for 12 h at room temperature. The reaction mixture was filtered off and the filtrate was concentrated, the residue was purified by flash column chromatography on silica gel using EtOAc:hexanes as eluant to obtain N-(4-tert- butylbenzyl)-2-[3-fluoro-4-(metylsulfonylamino)phenyl]propionamide(l-51, KMJ-372) having following physicochemical properties: 78% yield, white solid, mp = 52-54 °C 1H NMR (CDC13) δ 7.48 (t, 1 H, J= 8.3 Hz,), 7.32 (bd, 2 H), 7.1-7.2 (m, 4 H), 6.73 (bs, 1 H), 5.83 (bt, 1 H), 4.36 (ddd of AB, 2 H), 3.52 (q, 1 H, J= 7.1 Hz), 3.00 (s, 3 H), 1.50 (d, 3 H, J= 7.1 Hz), 1.29 (s, 9 H) MS (FAB) m/z 407 (MF )
Example 2 : Preparation of N-(4-tert-Butylbenzyl)-2-[3-chloro-4- (methylsulfonylamino)phenyl]propionamide (1-52 KMJ-470) Through similar procedure to that in Example 1 excepting using 2-chloro- nitrobenzene as a starting material, N-(4-tert-Butylbenzyl)-2-[3-chloro-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 68% yield, white solid, mp = 126-129 °C 1H MR (CDC13) δ 7.60 (d, 1 H, J= 8.2 Hz), 7.43 (d, 1 H, J= 2 Hz), 7.34 (bd, 2 H,), 7.24 (dd, 1 H, J- 8.2, 2 Hz), 7.14 (bd, 2 H), 6.75 (bs, 1 H), 5.68 (bt, 1 H), 4.38 (ddd of AB, 2 H), 3.50 (q, 1 H, J= 7.1 Hz), 3.01 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz), 1.30 (s, 9 H) MS (FAB) m/z 423 (MH+)
Example 3 : Preparation of N-(4-tert-Butylbenzyl)-2-[3-bromo-4- (methylsulfonyIamino)phenyl]propionamide (1-53 SH-173) Through similar procedure to that in Example 1 excepting using 2-bromo- nitrobenzene as a starting material, N-(4-tert-Butylbenzyl)-2-[3-bromo-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 76% yield, white solid, mp = 66-67 °C 1H ΝMR (CDC13) δ 7.55-7.6 (m, 2 H), 7.33 (d, 2 H, J= 8.1 Hz), 7.27 (dd, 1 H, J = 1.8, 8.6 Hz), 7.12 (d, 2 H, J= 8.1 Hz), 6.80 (bs, 1 H), 5.91 (bt, 1 H), 4.36 (ddd of AB, 2 H), 3.50 (q, 1 H, J= 7.1 Hz), 2.98 (s, 3 H), 1.50 (d, 3 H, J= 7.1 Hz), 1.29 (s, 9 H) MS (FAB) m/z 467 (MH+)
Example 4 : Preparation of N-(4-tert-Butylbenzyι)-2-[3-iodo-4- (methylsulfonylamino)phenyl]propionamide (1-54 SH-168) Through similar procedure to that in Example 1 excepting using 2-iodo- nitrobenzene as a starting material, N-(4-tert-Butylbenzyl)-2-[3-iodo-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 75% yield, white solid, mp = 71 °C 1H NMR (CDC13) δ 7.80 (d, 1 H, J= 2 Hz), 7.59 (d, 1 H, J= 8.3 Hz), 7.3-7.37 (m, 3 H), 7.13 (d, 2 H, J= 8.1 Hzr), 6.60 (bs, 1 H), 5.67 (bt, 1 H), 4.39 (ddd of AB, 2 H), 3.48 (q, 1 H, J= 7.1 Hz), 3.01 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz), 1.30 (s, 9 H) MS (FAB) m/z 515 (MH+)
Example 5 : Preparation of N-(4-tert-Butylbenzyl)-2-[3,5-difluoro-4- (methylsulfonylamino)phenyi]propionamide (1-55 SH-285) Through similar procedure to that in Example 1 excepting using 2,6-difluoro- nitrobenzene as a starting material, N-(4-tert-Butylbenzyl)-2-[3,5-difluoro-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 70% yield, white solid, mp = 80-81 °C 1H ΝMR (CDC13) δ 7.35 (dt, 2 H), 7.15 (bd, 2 H), 6.99 (dt, 2 H), 6.16 (bs, 1 H), 5.76 (bt, 1 H), 4.38 (ddd of AB, 2 H), 4.12 (q, 1 H, J= 7.1 Hz), 3.02 (s, 3 H), 1.50 (d, 3 H, J = 7.1 Hz), 1.30 (s, 9 H) MS (FAB) m/z 425 (MH+)
Example 6 : Preparation of N-(4-tert-Butylbenzyι)-2-[3-cyano-4- (methylsulfonylamino)phenyl]propionamide (1-56 SH-219) Through similar procedure to that in Example 1 excepting using 2-cyano- nitrobenzene as a starting material, N-(4-tert-Butylbenzyl)-2-[3-cyano-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 30% yield, white solid, mp = 102-105 °C 1H ΝMR (CDC13) δ 7.67 (d, 1 H, J= 8.4 Hz), 7.63 (d, 1 H, J= 1.8 Hz), 7.58 (dd, 1 H), 7.35 (bd, 2 H), 7.15 (bd, 2 H), 5.73 (bt, 1 H), 4.38 (ddd of AB, 2 H), 3.51 (q, 1 H, J = 7.1 Hz), 3.11 (s, 3 H), 1.53 (d, 3 H, J= 7.1 Hz), 1.31 (s, 9 H) MS (FAB) m/z 414 (MH+)
Example 7 : Preparation of N-(4-tert-Butylbenzyι)-2-[3-(t-butoxycarbonyι)-4- (methylsulfonylamino)phenyl]propionamide (1-57 KMJ-806) Through similar procedure to that in Example 1 excepting using 2-tert- butoxycarbonyl-nitrobenzene as a starting material, N-(4-tert-Butylbenzyl)-2-[3-(t- butoxycarbonyl)-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 53% yield, white solid, mp = 75-77 °C 1H NMR (CDCI3) δ 7.90 (d, 1 H, J= 2.2 Hz), 7.67 (d, 1 H, J = 8.6 Hz), 7.50 (dd, 1 H, J= 8.6, 2.2 Hz), 7.33 (bd, 2 H), 7.13 (bd, 2 H), 5.74 (bt, 1 H), 4.38 (ddd of AB, 2 H), 3.55 (q, 1 H, J= 7.1 Hz), 3.04 (s, 3 H), 1.60 (s, 9 H), 1.53 (d, 3 H, J= 7.1 Hz), 1.30 (s, 9
H) MS (FAB) m/z 489 (MH+)
Example 8: Preparation of N-(4-tert-Butylbenzyϊ)-2-[3-carboxyl-4- (methylsulfonylamino)phenyl]propionamide (1-58 KMJ-788) The compound 1-58 was prepared from N-(4-tert-Butylbenzyl)-2-[3-(t- butoxycarbonyl)-4-(methylsulfonylamino)phenyl]propionamide(l-57) by trifluoro acid hydrolysis. 74% yield, white solid, mp = 180-183 °C 1H ΝMR (CD3OD) δ 8.45 (bt, 1 H), 8.12 (d, 1 H, J= 2.2 Hz), 7.64 (d, 1 H, J= 8.6 Hz), 7.56 (dd, 1 H, J= 8.6, 2.2 Hz), 7.30 (bd, 2 H), 7.11 (bd, 2 H), 4.29 (bs, 2 H), 3.69 (q, 1 H, J- 7.1 Hz), 3.04 (s, 3 H), 1.46 (d, 3 H, J= 7.1 Hz), 1.27 (s, 9 H) MS (FAB) m/z 433 (MH+)
Example 9: Preparation of N-(4-tert-Butylbenzyl)-2-[3-(methoxycarbonyl)-4- (methylsulfonylamino)phenyl]propionamide (1-59 KMJ-838) Through similar procedure to that in Example 1 excepting using 2- methoxycarbonyl-nitrobenzene as a starting material, N-(4-tert-Butylbenzyl)-2-[3- (methoxycarbonyl)-4-(methylsulfonylamino)phenyl]propionamide (1-59) having following physicochemical properties was synthesized: 79% yield, white solid, mp = 142-144 °C 1H ΝMR (CDCI3) δ 10.38 (s, 1 H), 8.03 (d, 1 H, J = 2.2 Hz), 7.70 (d, 1 H, J= 8.6 Hz), 7.51 (dd, 1 H, J= 8.6, 2.2 Hz), 7.33 (bd, 2 H), 7.13 (bd, 2 H), 5.69 (bt, 1 H), 4.38 (ddd of AB, 2 H), 3.94 (s, 3 H), 3.53 (q, 1 H, J= 7.1 Hz), 3.05 (s, 3 H), 1.54 (d, 3 H, J= 7.1 Hz), 1.30 (s, 9 H) MS (FAB) m/z 447 (MH+)
Example 10: Preparation of N-(4-tert-Butylbenzyl)-2-[3-(benzylamino)carbonyl-4- (methylsulfonylamino)phenyl]propionamide (1-60, J-836) N-(4-tert-Butylbenzyl)-2-[3-(benzylamino)carbonyl-4- (methylsulfonylamino)phenyl]propionamide (1-60) was prepared from 1-58 by general amino coupling with benzyl amine. 88%) yield, white solid, mp = 79-81 °C 1H NMR (CDC13) δ 7.65 (d, 1 H, J= 8.6 Hz), 7.61 (d, 1 H, J= 2.2 Hz), 7.3-7.38 (m, 8 H), 7.11 (bd, 2 H), 5.84 (bt, 1 H), 4.60 (d, 2 H, J= 6 Hz), 4.35 (ddd of AB, 2 H), 3.48 (q, 1 H, J= 7.1 Hz), 2.97 (s, 3 H), 1.50 (d, 3 H, J= 7.1 Hz), 1.29 (s, 9 H) MS (FAB) m/z 522 (MH+)
Example 11: Preparation of N-(4-tert-Butylbenzyl)-2-[3-piperidino-4- (methyIsulfonylamino)phenyl]propionamide (1-61 YS-65) Through similar procedure to that in Example 1 excepting using 2-piperidin- nitrobenzene as a starting material, N-(4-tβrt-Butylbenzyl)-2-[3-piperidino-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 86% yield, white solid, mp = 125 °C 1H ΝMR (CDCI3) δ 7.78 (bs, 1 H,), 7.45 (d, 1 H, J= 8.4 Hz), 7.31 (bd, 2 H), 7.15 (d, 1 H, J = 2 Hz), 7.10 (bd, 2 H), 7.05 (dd, 1 H, J= 8.4, 2 Hz), 5.59 (bt, 1 H), 4.38 (d of AB, 2 H, J- 5.7 Hz), 3.52 (q, 1 H, J= 7.1 Hz), 3.04 (s, 3 H), 2.75 (m, 4 H), 1.65-1.75 (m, 4 H), 1.6 (m, 2 H), 1.52 (d, 3 H, J= 7.1 Hz), 1.29 (s, 9 H) MS (FAB) m/z 472 (MH )
Example 12: Preparation of N-(4-t:ert-Butylbenzyl)-2-[3-morpholino-4- (methylsulfonylamino)phenyl]propionamide (1-62 YS-49) Through similar procedure to that in Example 1 excepting using 2-morpholin- nitrobenzene as a starting material, N-(4-tert-Butylbenzyl)-2-[3-morpholino-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 84% yield, white solid, mp = 78 °C 1H ΝMR (CDCI3) δ 7.69 (bs, 1 H), 7.46 (d, 1 H, J= 8.2 Hz), 7.32 (bd, 2 H), 7.18 (d, 1 H, J = 1.8 Hz), 7.08-7.15 (m, 3 H), 5.63 (bt, 1 H), 4.38 (d of AB, 2 H, J = 5.5 Hz), 3.85 (m, 4 H), 3.52 (q, 1 H, J= 7.1 Hz), 3.08 (s, 3 H), 2.84 (m, 4 H), 1.52 (d, 3 H, J = 7.1 Hz), 1.29 (s, 9 H) MS (FAB) m/z 474 (MH+)
Example 13: Preparation of N-(4-tert-Butylbenzyl)-2-[3-(Ν-boc)piperazino-4- (methylsulfonylamino)phenyl]propionamide (1-63 YS-76) Through similar procedure to that in Example 1 excepting using 2-(N- Boc)piperazine-nitrobenzene as a starting material, N-(4-tert-Butylbenzyl)-2-[3-(N- boc)piperazino-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 88% yield, white solid, mp = 103 °C 1H NMR (CDC13) δ 7.66 (bs, 1 H), 7.46 (d, 1 H, J= 8.2 Hz), 7.32 (bd, 2 H), 7.15 (d, 1 H, J= 1.8 Hz), 7.08-7.13 (m, 3 H), 5.60 (bt, 1 H), 4.38 (ddd of AB, 2 H), 3.58 (m, 4 H), 3.49 (q, 1 H, J= 7.1 Hz), 3.08 (s, 3 H), 2.79 (m, 4 H), 1.55 (d, 3 H, J= 7.1 Hz), 1.49 (s, 9 H), 1.30 (s, 9 H) MS (FAB) m/z 573 (MH+)
Example 14: Preparation of N-(4-tert-Butylbenzyl)-2-[3-piperazino-4- (methylsulfonylamino)phenyl]propionamide (1-64 YS-79) Through similar procedure to that in Example 1 excepting using 2-piperazine- nitrobenzene as a starting material, N-(4-tert-Butylbenzyl)-2-[3-piperazino-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 96% yield, white solid, mp = 92 °C 1H ΝMR (CDCI3) δ 7.46 (d, 1 H, J= 8.3 Hz), 7.32 (bd, 2 H), 7.18 (d, 1 H, J= 1.8 Hz), 7.08-7.13 (m, 3 H), 5.60 (bt, 1 H), 4.38 (d of AB, 2 H, J= 5 Hz), 3.52 (q, 1 H, J= 7.1 Hz), 3.06 (s, 3 H), 3.03 (m, 4 H), 2.80 (m, 4 H), 1.52 (d, 3 H, J= 7.1 Hz), 1.29 (s, 9 H) MS (FAB) m/z 473 (MH+)
Example 15: Preparation of N-(4-tfert-Butylbenzyι)-2-[3-methoxy-4- (methylsulfonylamino)phenyl]propionamide (1-65, CHK-717) Through similar procedure to that in Example 1 excepting using 2-[3-methoxy-4- (methylsulfonylamino)phenyl]propion acid as a starting material, N-(4-tert- Butylbenzyl)-2-[3-methoxy-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 83% yield, white solid, mp = 74-76 °C 1H ΝMR (CDCI3) δ 7.1-7.5 (m, 5 H), 6.85-6.9 (m, 2 H), 6.75 (bs, 1 H), 5.75 (bt, 1 H), 4.39 (ddd of AB, 2 H), 3.85 (s, 3 H), 3.54 (q, 1 H, J= 7.1 Hz), 2.94 (s, 3 H), 1.53 (d, 3 H, .7= 7.1 Hz), 1.31 (s, 9 H) MS (FAB) m/z 419 (MH+) Example 16: Preparation of N-(4-tert-ButyIbenzyl)-2-[2-fluoro-4-
(methylsulfonylamino)phenyl]propionamide (1-66 KMJ-708) Through similar procedure to that in Example 1 excepting using 3-fluoro- nitrobenzene as a starting material, N-(4-tert-Butylbenzyl)-2-[2-fluoro-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 63% yield, white solid, mp = 111-113 °C 1H ΝMR (CDC13) δ 7.3-7.38 (m, 3 H), 7.28 (bs, 1 H), 7.15 (bd, 2 H), 7.02 (dd, 1 H, J= 11.4, 2.2 Hz), 6.87 (dd, 1 H, J= 8.4, 2.2 Hz), 5.88 (bt, 1 H), 4.41 (ddd of AB, 2 H), 3.84 (q, 1 H, J= 7.1 Hz), 3.00 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz), 1.30 (s, 9 H) MS (FAB) m/z 407 (MH")
Example 17: Preparation of N-(4-tert-Butylbenzyl)-2-[2-chloro-4- (methylsulfonylamino)phenyl]propionamide (1-67 KMJ-698) Through similar procedure to that in Example 1 excepting using 3-fluoro- nitrobenzene as a starting material, N-(4-tert-Butylbenzyl)-2-[2-chloro-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 46% yield, white solid, mp = 134-136 °C 1H ΝMR (CDC13) δ 7.44 (d, 1 H, J= 8.4 Hz), 7.34 (bd, 2 H), 7.29 (d, 1 H, J= 2.2 Hz), 7.15 (bd, 2 H), 7.07 (dd, 1 H, J= 8.4, 2.2 Hz), 5.88 (bt, 1 H), 4.40 (ddd of AB, 2 H), 3.84 (q, 1 H, J= 7.1 Hz), 3.00 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz), 1.30 (s, 9 H) MS (FAB) m/z 423 (MH+)
Example 18: Preparation of N-(4-tβ#"t-ButyIbenzyϊ)-2-[4-
(methylsulfonylamino)phenyl]propionamide (2-7, KMJ-750)
Step 18-1. Preparation of N-(4-tert-Butylbenzyl)-2-(4-nitrophenyl propionamide (2-1,
KMJ-738 Through similar procedure to that in Example 1-5 excepting using 2-(4- nitrophenyl)-propionamide as a starting material, N-(4-tert-Butylbenzyl)-2-(4- nitrophenyl)propionamide having following physicochemical properties was synthesized: 84% yield, white solid, mp = 146-148 °C 1H ΝMR (CDC13) δ 8.16 (dt, 2 H), 7.49 (dt, 2 H), 7.32 (dt, 2 H), 7.10 (dt, 2 H), 5.86 (bt, 1 H), 4.37 (ddd, 2 H), 3.64 (q, 1 H, J= 7.1 Hz), 1.55 (d, 3 H, J= 7.1 Hz), 1.29 (s, 9 H) Step 18-2. Preparation of N-(4-tert-ButylbenzylV2-(4-aminophenyl)propionamide (2-4 KMJ-740) Through similar procedure to that in Example 1-2 excepting using N-(4-tert- Butylbenzyl)-2-(4-nitrophenyl)propionamide as a starting material, N-(4-tert- Butylbenzyl)-2-(4-aminophenyl)propionamide having following physicochemical properties was synthesized: 95% yield, colorless oil 1H ΝMR (CDC13) δ 7.31 (dt, 2 H), 7.05-7.1 (m, 4 H), 6.65 (dt, 2 H), 5.66 (bt, 1 H), 4.34 (ddd, 2 H), 3.66 (bs, 2 H), 3.49 (q, 1 H, J= 7.1 Hz), 1.51 (d, 3 H, J= 7.1 Hz,), 1.29 (s, 9 H)
Step 18-3. Preparation of. N-(4-tert-Butylbenzyl -2-r4-
(methylsulfonylamino phenyllpropionamide (2-7, KMJ-750 Through similar procedure to that in Example 1-3 excepting using N~(4-tert- Butylbenzyl)-2-(4-aminophenyl)propionamide as a starting material, N~(4-tert- Butylbenzyl)-2-[4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 93% yield, white solid, mp = 77-79 °C 1H ΝMR (CDC13) δ 7.32 (dt, 2 H), 7.27 (dt, 2 H), 7.18 (dt, 2 H), 7.11 (dt, 2 H), 6.96 (bs, 1 H), 5.73 (bt, 1 H), 4.38 (ddd, 2 H), 3.55 (q, 1 H, J= 7.1 Hz), 2.98 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz), 1.29 (s, 9 H) MS (El) m/z 388 (M+)
Example 19: Preparation of N-(4-Chlorobenzyl)-2-[4-
(methylsulfonylamino)phenyl]propionamide (2-8, YS-85) Through similar procedure to that in Example 18 excepting using 4-chlorobenzyl amine as a starting material, N-(4-Chlorobenzyl)-2-[4-
(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 94% yield, white solid, mp = 164 °C 1H ΝMR (CDC13) δ 7.24-7.32 (m, 4 H), 7.18 (dt, 2 H), 7.10 (dt, 2 H), 6.59 (bs, 1 H), 5.70 (bt, 1 H), 4.37 (ddd, 2 H), 3.56 (q, 1 H, J= 7.1 Hz), 3.01 (s, 3 H), 1.53 (d, 3 H, J= 7.1 Hz) MS (El) m/z 366 (M+) Example 20: Preparation of N-(3,4-Dichlorobenzyl)-2-[4-
(methylsulfonylamino)phenyl]propionamide (2-9, YS-97) Through similar procedure to that in Example 18 excepting using 3,4- dichlorobe zyl amine as a starting material, N-(3,4-Dichlorobenzyl)-2-[4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 96% yield, white solid, mp = 130 °C 1H ΝMR (CDCI3) δ 7.18-7.38 (m, 5 H), 7.01 (d, 1 H), 6.38 (bs, 1 H), 5.68 (bt, 1 H), 4.35 (d, 2 H, J= 5.8 Hz), 3.58 (q, 1 H, J= 7.1 Hz), 3.02 (s, 3 H), 1.53 (d, 3 H, J= 7.1 Hz) MS (El) m/z 400 (M+)
Example 21: Preparation of N-(4-tert-Butylbenzyl)-(2S)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (3-5, SU-834)
Step 21-1. N-('(lS)-l-Benzyl-2-hvdroxyethyn-(2S)-2-|'3-fluoro-4-
(methylsulfonylamino phenyl] propionamide (3-1, SU-632-H A mixture of 2-[3-fluoro-4-(methylsulfonylamino)phenyl]propion acid (100 mg, 0.234 mmol) and L-phenyl alaninol (71 mg, 0.468 mmol) in CH2C12 (3 mL) was refluxed for 3 h and concentrated in vacuo. The residue was dissolved in MeOH (2 mL) and purified by flash column chromatography on silica gel using EtOAc:hexanes (2:1) to EtOAc:MeOH (20:1) as eluant to afford N-[(lS)-l-Benzyl-2-hydroxyethyl]-(2S)-2- [3-fluoro-4-(methylsulfonylamino)phenyl] propionamide. mp = 150-153 °C, [α] = -20.36 (c 1.00, MeOH) 1H ΝMR (CD3OD) δ 7.36 (t, 1 H, J= 8.5 Hz), 7.0-7.28 (m, 7 H), 4.07 ( , 1 H), 3.56 (q, 1 H, J= 7.3 Hz), 3.48 (dd, 2 H, J= 1.2, 5.1 Hz), 2.9-3.0 (m, 4 H), 2.71 (dd, 1 H, J= 9, 14 Hz), 1.27 (d, 3 H, J= 7.05 Hz)
Step 21-2. (2S)-r3-Fluoro-4-(ιnethylsulfonylamino)phenyl]propionic acid (3-3, SU-668 A solution of N-[(lS)-l-Benzyl-2-hydroxyethyl]-(2S)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl] propionamide (100 mg, 0.234 mmol) in 3 Ν H2SO (1 mL) and 1,4-dioxane (1 mL) was heated to 100 °C for 5 h and cooled to room temperatue. The solution was diluted with water and extracted with CH2C12 several times. The combined organic layers were washed with water, dried over MgSO4, and concentrated in vacuo to afford (2S)-[3-Fluoro-4-
(methylsulfonylamino)phenyl]propionic acid. 73% yield 1H NMR (CDCI3) δ 7.52 (t, 1 H, J= 8.3 Hz), 7.1-7.2 (m, 2 H), 6.68 (bs, 1 H), 3.73 (q, 1 H, J= 7.3 Hz), 3.03 (s, 3 H), 1.51 (d, 3 H, J= 7.3 Hz) [α] = +29.76 (c 1.00, CHCI3)
Step 21^3- N-(4-tgrt-Butylbenzyl)-(2S)-2-r3-fluoro-4-
(methylsulfonylamino)phenyllpropionamide (3-5, SU-834) Through similar procedure to that in Example 1-5 excepting using (2S)-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid as a starting material, N-(4-tert- Butylbenzyl)-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 98% yield, white solid, mp 52-54 °C
Figure imgf000047_0001
1H ΝMR (CDCI3) δ 7.51 (t, 1 H, J= 8.3 Hz), 7.33 (m, 2 H), 7.06-7.2 (m, 4 H), 6.58 (bs, 1 H), 5.73 (bt, 1 H), 4.38 (ddd of AB, 2 H, J= 5.5, 14.6 Hz), 3.52 (q, 1 H, J= 7.1 Hz), 3.02 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz), 1.30 (s, 9 H) MS (FAB) m/z 407 (MH+)
Example 22: Preparation of N-(4-fert-Butylbenzyl)~(2R)~2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (3-6, SU-824)
Step 22i N-r(lS)-l-Benzyl-2-hvdroxyethyll-(2R -2- 3-fluoro-4-
(methylsulfonylamino)phenyl] propionamide (3-2, SU-632-L) Through similar procedure to that in Example 10, N-[(lS)-l-Benzyl-2- hydroxyethyl] -(2R)-2-[3 -fluoro-4-(methylsulfonylamino)phenyl] propionamide having following physicochemical properties was synthesized: mp = 164-166 °C, [α] = -25.48 (c 1.00, MeOH) 1H ΝMR (CD3OD) δ 7.33 (t, 1 H, J= 8.5 Hz), 6.9-7.12 (m, 7 H), 4.12 (m, 1 H), 3.5- 3.6 (m, 3 H), 2.98 (s, 3 H), 2.88 (dd, 1 H, J= 5.1, 14 Hz), 2.71 (dd, 1 H, J= 9.3, 14 Hz), 1.36 (d, 3 H, J= 7.05 Hz)
Step 22-2. (2R)-[3-Fluoro-4-(methylsulfonylamino phenyl]propionic acid (3-4, SU-732 Through similar procedure to that in Example 10-2 excepting using (2R)-[3-Fluoro-
4-(methylsulfonylamino)phenyl]propionic acid as a starting material, (2R)-[3-Fluoro-4-
(methylsulfonylamino)phenyl]propionic acid having following physicochemical properties was synthesized: The spectral data of this compound is identical to that of 3-3. [α] = -29.25 (c 1.00, CHCI3) Step 22^3, N-(4-tert-Butylbenzyl -(2R)-2-r3-fluoro-4-
(methylsulfonylamino phenyllpropionamide (3-6. SU-824 Through similar procedure to that in Example 10-3, N-(4-tert-Butylbenzyl)-(2R)-2- [3-fluoro-4-(methylsulfonylamino)ρhenyl]propionamide having following physicochemical properties was synthesized: 96°/o yield, white solid, mp = 52-54 °C [α] = +18.4 (c 0.5, CHC13) The spectral data is identical to those of compound 3-5 MS (FAB) m/z 407 (MH+)
Example 23: Preparation of N-(4-ChlorobenzyI)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide (4-1, SH-291) Through similar procedure to that in Example 1-5 excepting using 2-[3-fluoro-4- (metylsulfonylamino)phenyl]propion acid (1-39) with the corresponding 4- chlorobenzylamine compound as a starting material, N-(4-Chlorobenzyl)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 98% yield, white solid, mp = 129-130 °C 1H ΝMR (CDC13) δ 7.53 (t, 1 H, J= 8.3 Hz), 7.25-7.3 (m, 2 H), 7.06-7.2 (m, 4 H), 6.44 (bs, 1 H), 5.67 (bt, 1 H), 4.37 (ddd of AB, 2 H), 3.53 (q, 1 H, J= 7.1 Hz), 3.03 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 385 [M-H]+
Example 24: Preparation of N~(4-ChIorobenzyl)-2-[3-chIoro-4-
(methylsulfonylamino)phenyl]propionamide (4-2, SH-290) Through similar procedure to that in Example 1-5 excepting using 2-[3-fluoro-4- (metylsulfonylamino)phenyι]propion acid (1-39) with the corresponding 4- chlorobenzylamine compound as a starting material, N-(4-Chlorobenzyl)-2-[3-chloro-4- (methylsulfonylamino)phenyl]propionarnide having following physicochemical properties was synthesized: 98% yield, white solid, mp = 134-135 °C 1H ΝMR (CDC13) δ 7.61 (d, 1 H, J= 8.3 Hz), 7.41 (d, 1 H, J= 1.2 Hz), 7.2-7.3 (m, 3 H), 7.13 (d, 2 H), 6.73 (bs, 1 H), 5.68 (bt, 1 H), 4.38 (ddd of AB, 2 H), 3.52 (q, 1 H, J = 7.1 Hz), 3.02 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 402 (MH+) Example 25: Preparation of N-(4-Chlorobenzyl)-2-[3-bromo-4-
(methylsulfonyIamino)phenyι]propionamide (4-3, SH-335) Through similar procedure to that in Example 1-5 excepting using 2-[3-Bromo-4- (methylsulfonylamino)phenyl]propionic acid (1-40) with the corresponding 4- chlorobenzylamine compound as a starting material, N-(4-Chlorobenzyl)-2-[3-bromo-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 88% yield, white solid, mp = 147 °C 1H ΝMR (CDC13) δ 7.60 (d, 1 H, J= 8.4 Hz), 7.57 (d, 1 H, J = 1.2 Hz), 7.24-7.32 (m, 3 H), 7.13 (d, 2 H), 6.74 (bs, 1 H), 5.73 (bt, 1 H), 4.36 (ddd of AB, 2 H), 3.52 (q, 1 H, J= 7.1 Hz), 3.01 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 446 (MH+)
Example 26: Preparation of N-(3,4-DichIorobenzyι)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-4, SH-94) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 3,4- dichlorobenzylamine compound as a starting material, N-(3,4-Dichlorobenzyl)-2-[3- fluoro-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 76% yield, white solid, mp = 130-133 °C 1H ΝMR (CDC13) δ 7.53 (t, 1 H, J= 8.3 Hz), 7.36 (d, 1 H), 7.23 (d, 1 H), 7.16 (dd, 1 H), 7.10 (bd, 1 H), 7.02 (dd, 1 H), 6.51 (bs, 1 H), 5.76 (bt, 1 H), 4.36 (d of AB, 2 H), 3.54 (q, 1 H, J= 7.1 Hz), 3.03 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 419 (MH+)
Example 27: Preparation of N-(3,4-Dichlorobenzyι)-2-[3-chIoro-4- (methylsulfonylamino)phenyl]propionamide (4-5, SH-286) Through similar procedure to that in Example 1-5 excepting using 2-[3-chloro-4- (methylsulfonylamino)phenyl]propion acid (1-39) with the corresponding 3,4- dichlorobenzylamine compound as a starting material, N-(3,4-Dichlorobenzyl)-2-[3- chloro-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 85% yield, white solid, mp = 129-130 °C 1H ΝMR (CDC13) δ 7.59 (d, 1 H, J= 8.4 Hz), 7.41 (d, 1 H), 7.36 (d, 1 H), 7.2-7.25 (m, 2 H), 7.03 (dd, 1 H), 6.78 (bs, 1 H), 5.91 (bt, 1 H), 4.35 (d of AB, 2 H, J= 6 Hz), 3.54 (q, 1 H, J= 7.0 Hz), 3.02 (s, 3 H), 1.52 (d, 3 H, J= 7.0 Hz) MS (FAB) m/z 435 (M+)
Example 28: Preparation of N-(3,4-DiehlorobenzyI)-2-[3-bromo-4- (methylsulfonylamino)phenyl]propionamide (4-6, SH-337) Through similar procedure to that in Example 1-5 excepting using 2-[3-bromo-4- (methylsulfonylamino)phenyl]propion acid (1-40) with the corresponding 3,4- dichlorobenzylamine compound as a starting material, N-(3,4-Dichlorobenzyl)-2-[3- bromo-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 98% yield, white solid, mp = 161-162 °C 1H ΝMR (CDC13) δ 7.62 (d, 1 H, J= 8.4 Hz), 7.57 (d, 1 H, J= 1.8 Hz), 7.37 (d, 1 H, J= 8.4 Hz), 7.2-7.3 (m, 2 H), 7.04 (dd, 1 H, J= 1.8 & 8.2 Hz), 6.75 (bs, 1 H), 5.75 (bt, 1 H), 4.37 (d of AB, 2 H, J= 6 Hz), 3.53 (q, 1 H, J= 7.1 Hz), 3.02 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 481 (MH+)
Example 29: Preparation of N-(4-MethylbenzyI)-2-[3-fluoro-4-
(methyIsulfonylamino)phenyl]propionamide (4-7, SH-351) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 4- methylbenzylamine compound as a starting material, N-(4-Methylbenzyl)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 96% yield, white solid, mp = 166 °C 1H ΝMR (CDC13) δ 7.51 (t, 1 H, J= 8.3 Hz), 7.05-7.2 (m, 6 H), 6.50 (bs, 1 H), 5.66 (bt, 1 H), 4.36 (ddd of AB, 2 H), 3.51 (q, 1 H, J= 7.1 Hz), 3.02 (s, 3 H), 2.32 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 365 (MH+)
Example 30: Preparation of N-(4-Isopropylbenzyl)-2-[3-fluoro-4- (methylsuIfonylamino)phenyl]propionamide (4-8, KMJ-928) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 4- isoprophylbenzylamine compound as a starting material, N-(4-Isopropylbenzyl)-2-[3- fluoro-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 69% yield, white solid, mp = 137- 139 °C 1H NMR (CDC13) δ 7.49 (t, 1 H, J= 8.3 Hz), 7.05-7.2 (m, 6 H), 6.70 (bs, 1 H), 5.80 (bt, 1 H), 4.36 (ddd of AB, 2 H), 3.52 (q, 1 H, J= 7.1 Hz), 3.00 (s, 3 H), 2.88 (m, 2 H), 1.51 (d, 3 H, J= 7.1 Hz), 1.22 (d, 6 H) MS (FAB) m/z 393 (MH+)
Example 31: Preparation of N-(4-Methoxybenzyl)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-9, SH-353) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 4- metoxybenzylamine compound as a starting material, N-(4-Methoxybenzyl)-2-[3- fluoro-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 96% yield, white solid, mp = 138 °C 1H ΝMR (CDC13) δ 7.48 (t, 1 H, J= 8.3 Hz), 7.05-7.2 (m, 4 H), 6.82 (d, 2 H), 6.69 (bs, 1 H), 5.80 (bt, 1 H), 4.33 (ddd of AB, 2 H), 3.78 (s, 3 H), 3.52 (q, 1 H, J= 7.1 Hz), 3.01 (s, 3 H), 1.51 (d, 3 H, J= 7.1 Hz)
Figure imgf000051_0001
Example 32: Preparation of N-(4-TrifluoromethyIbenzyI)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-10, SH-93) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 4- trifluoromethylbenzylamine compound as a starting material, N-(4- Trifluoromethylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 81% yield, white solid, mp = 150-152 °C 1H ΝMR (CDC13) δ 7.5-7.6 (m, 3 H), 7.26 (d, 2 H), 7.05-7.2 (m, 2 H), 5.86 (bt, 1 H), 4.46 (ddd of AB, 2 H), 3.56 (q, 1 H, J= 7.1 Hz), 3.02 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 419 (MH+)
Example 33: Preparation of N~(4-Biphenylmethyι)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-11, KMJ-498) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 4- phenylbenzylamine compound as a starting material, N-(4-Biphenylmethyl)-2-[3-fluoro- 4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 78% yield, white solid, mp = 155-157 °C 1H ΝMR (CDC13) δ 7.1-7.58 (m, 12 H), 6.45 (bs, 1 H), 5.71 (bt, 1 H), 4.45 (ddd, 2 H), 3.55 (q, 1 H, J= 7.1 Hz), 3.01 (s, 3 H), 1.54 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 427 (MH+)
Example 34: Preparation of N-(l-Νaphthylmethyι)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-12, SH-92) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 4- chlorobenzylamine compound as a starting material, N-(l-Naphthylmethyl)-2-[3-fluoro- 4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 79% yield, white solid, mp = 159-161 °C 1H NMR (CDC13) δ 7.75-7.9 (m, 3 H), 7.3-7.5 (m, 5 H), 7.16 (dd, 1 H), 7.04 (bd, 1 H), 6.52 (bs, 1 H), 5.69 (bt, 1 H), 4.86 (ddd, 2 H), 3.49 (q, 1 H, J= 7.1 Hz), 2.96 (s, 3 H), 1.51 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 401 (MH+)
Example 35: Preparation of N-(l,2,3,4-Tetrahydro-l-naphthalenyl)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-13, SH-112) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 1,2,3,4 — tetrahydro-1-naphtalenamine compound as a starting material, N-(l,2,3,4-Tetrahydro-l- naphthalenyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 73% yield, white solid, mp = 116-117 °C 1H ΝMR (CDC13) δ 7.51 (m, 1 H), 6.8-7.2 (m, 6 H), 6.53 (bs, 1 H), 5.62 (bd, 1 H), 5.15 (m, 1 H), 3.51 (q, 1 H, J= 7.1 Hz), 3.00 (s, 3 H), 2.75 (m, 2 H), 1.7-1.9 (m, 4 H), 1.53 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 391 (MH+)
Example 36: Preparation of N-[2-(4-t-Butylphenyl)ethyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-14, KMJ-374) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 2-(4-t- Butyl)ethyl amine compound as a starting material, N-[2-(4-t-Butylρhenyl)ethyl]-2-[3- fluoro-4-(methylsulfonylammo)phenyl]propionamide having following physicochemical properties was synthesized: 64% yield, white solid, mp = 124-126 °C 1H ΝMR (CDC13) δ 7.50 <t, 1 H, J = 8.3 Hz), 7.29 (bd, 2 H), 6.95-7.15 (m, 4 H), 6.52 (bs, 1 H), 5.41 (bt, 1 H), 3.47 (m, 3 H), 3.03 (s, 3 H), 2.72 (t, 2 H, J= 6.8 Hz), 1.47 (d, 3 H, J= 7.3 Hz), 1.31 (s, 9 H) MS (FAB) m/z 421 (MH+)
Example 37: Preparation of N-[3-(3,4-Dimethylphenyl)propyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-15, SU-770) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 3-(3,4- Dimethylphenyl)propyl racemic amine compound as a starting material, N-[3-(3,4- Dimethylphenyl)propyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 95% yield, white solid, mp = 128-130 °C, 1H ΝMR (CDC13) δ 7.50 (t, 1 H, J= 8.3 Hz), 7.13 (dd, 1 H, J= 1.95, 11.2 H), 7.0- 7.07 (m, 2 H), 6.83-6.92 (m, 2 H), 6.57 (bs, 1 H), 3.41 (q, 1 H, J= 7.1 Hz), 3.2-3.3 (m, 2 H), 3.01 (s, 3 H), 2.51 (t, 2 H, J= 7.6 Hz), 2.22 (s, 6 H), 1.7-1.8 (m, 2 H), 1.45 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 407 (MH+)
Example 38: Preparation of N-[3-(3,4-Dimethylphenyl)propyl]-(2R)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-16, SU-774) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 3-(3,4- Dimethylphenyl)propyl]-R-amine compound as a starting material, N-[3-(3,4- Dimethylphenyl)propyl]-(2R)-2-[3-fluoro-4-
(memylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 96% yield, white solid, mp = 128-130 °C The spectral data of compound 4-16 are identical to those of compound 4-15. [α]= -4.23 (c 0.25, CHC13) MS (FAB) m/z 407 (MH+)
Example 39: Preparation of N-[3-(3,4-Dimethylphenyl)propyl]-(2S)-2-[3-fluoro-4- (methylsnlfonylamino)phenyl]propionamide (4-17, SU-776) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 3-(3,4- Dimethylphenyl)propyl]-S-amine compound as a starting material, N-[3-(3,4- Dimethylphenyl)propyl]-(2S)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 95% yield, white solid, mp = 128-130 °C The spectral data of compound 4-17 are identical to those of compound compound 4-15. [α] = +4.34 (c 0.25, CHC13) MS (FAB) m/z 407 (MH+)
Example 40: Preparation of N-[3-(3,4-DimethyIphenyι)-2-propenyI]-2-[3-fluoro-4- (methylsulfonylamino)phenyl] propionamide (4-18, KMJ-686) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 3-(3,4- Dimethylphenyl)-2-prophenylamine compound as a starting material, N-[3-(3,4- Dimethylphenyl)-2-propenyl]-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 78% yield, white solid, mp = 144-146 °C 1H ΝMR (CDC13) δ 7.52 (t, 1 H, J= 8.3 Hz), 7.0-7.2 (m, 5 H), 6.58 (bs, 1 H), 6.37 (d, 1 H, J= 15.8 Hz), 6.06 (dt, 1 H, J= 6.2, 15.8 Hz), 5.57 (bt, 1 H), 3.9-4.02 (m, 2 H), 3.53 (q, 1 H, J= 7.1 Hz), 3.01 (s, 3 H), 2.24 (s, 6 H), 1.52 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 405 (MH+)
Example 41: Preparation of N-[3-(4-Chlorophenyl)propyl]-2-[3-fiuoro-4- (methylsulfonylamino)phenyljpropionamide (4-19, KMJ-518) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 3-(4- Chlorophenyl)propyl amine compound as a starting material, N-[3-(4- Chlorophenyl)propyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]ρropionamide having following physicochemical properties was synthesized: 70% yield, white solid, mp = 141-143 °C 1H NMR (CDC13) δ 7.51 (t, 1 H, J = 8.3 Hz), 7.02-7.25 (m, 6 H), 6.52 (bs, 1 H), 5.38 (bt, 1 H), 3.44 (q, 1 H, J= 7.1 Hz), 3.24 (ddd, 2 H), 3.02 (s, 3 H), 2.55 (t, 2 H, J= 7.5 Hz), 1.76 (m, 2 H), 1.47 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 413 (MH+)
Example 42: Preparation of N-[3-(4-ChIorophenyI)-2-propenyI]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-20, KMJ-732) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 3-(4- Chlorophenyl)prophenyl amine compound as a starting material, N-[3-(4- Chlorophenyl)-2-propenyl]-2-[3-fluoror4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 72% yield, white solid, mp = 151-153 °C 1H ΝMR (CDCI3) δ 7.52 (t, 1 H, J= 8.3 Hz), 7.08-7.3 (m, 6 H), 6.60 (bs, 1 H), 6.37 (d, 1 H, J= 15.8 Hz), 6.10 (dt, 1 H, J= 6.2, 15.8 Hz), 5.61 (bt, 1 H), 3.9-4.1 (m, 2 H), 3.54 (q, 1 H, J= 7.1 Hz), 3.02 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz) MS (EI) rø/z 410 (M+)
Example 43: Preparation of N-Benzyloxy-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide (4-21, SH-109) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding benzyloxyamine compound as a starting material, N-Benzyloxy-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 76% yield, white solid, mp = 182-183 °C 1H ΝMR (CDC13) δ 7.94 (s, 1 H), 7.49 (t, 1 H, J= 8.3 Hz), 7.25-7.35 (m, 5 H), 7.12 (dd, 1 H, J= 2, 11.2 Hz), 7.02 (dd, 1 H, J= 2, 8.2 Hz), 6.52 (bs, 1 H), 4.87 (s, 2 H), 3.35 (q, 1 H, J= 7.1 Hz), 3.02 (s, 3 H), 1.46 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 367 (MH+)
Example 44: Preparation of N-BenzhydryI-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide (4-22, SH-130) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding benzhydrylamine compound as a starting material, N-Benzhydryl-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 79% yield, white solid, mp = 160-161 °C 1H ΝMR (CDC13) δ 7.51 (t, 1 H, J= 8.3 Hz), 7.0-7.4 (m, 10 H), 6.20 (d, 1 H), 6.04 (bt, 1 H), 3.58 (q, 1 H, J= 7.1 Hz), 3.00 (s, 3 H), 1.52 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 427 (MH+)
Example 45: Preparation of N-(2,2-Diphenylethyl)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-23, SH-116) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 2,2- Diphenylethylamine compound as a starting material, N-Benzhydryl-2-[3-fiuoro-4- (methylsulfonylamino)ρhenyl]propionamide having following physicochemical properties was synthesized: 64% yield, white solid, mp = 129 °C 1H ΝMR (CDC ) δ 7.42 (t, 1 H, J= 8.3 Hz), 7.1-7.3 (m, 10 H), 6.95 (dd, 1 H), 6.87 (d, 1 H), 6.50 (bs, 1 H), 5.28 (bt, 1 H), 4.12 (t, 1 H), 3.75-3.95 (m, 2 H), 3.37 (q, 1 H, J = 7.1 Hz), 3.01 (s, 3 H), 1.40 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 441 (MH+)
Example 46: Preparation of N-(3,3-Diphenylpropyl)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-24, KMJ-378) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 2,2- Diphenylprophylamine compound as a starting material, N-(3,3-Diphenylpropyl)-2-[3- fluoro-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 76% yield, white solid, mp = 66-68 °C 1H ΝMR (CDCI3) δ 7.51 (t, 1 H, J= 8.3 Hz), 7.0-7.3 (m, 12 H), 6.45 (bs, 1 H), 5.27 (bt, 1 H), 3.85 (t, 1 H, J= 7.8 Hz), 3.34 (q, 1 H, J= 7.1 Hz), 3.21 (ddd, 2 H), 3.01 (s, 3 H), 2.24 (dd, 2 H), 1.43 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 455 (MH+) Example 47: Preparation of N-(3,3-Diphenyl-2-propenyI)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-25, KMJ-724) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 3,3- Diphenyl-2-propenylamine compound as a starting material, N-(3,3-Diphenyl-2- propenyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 78% yield, white solid, mp = 155-157 °C 1H ΝMR (CDC13) δ 7.52 (t, 1 H, J = 8.3 Hz), 7.05-7.4 (m, 12 H), 6.50 (bs, 1 H),
6.00 (t, 1 H, J= 7.0 Hz), 5.44 (bt, 1 H), 3.85-4.0 (m, 2 H), 3.46 (q, 1 H, J= 7.1 Hz),
3.01 (s, 3 H), 1.48 (d, 3 H, J= 7.1 Hz) MS (El) m/z 452 (M+)
Example 48: Preparation of N-[3,3-Di(4~methylphenyI)-2-propenyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyI]propionamide (4-26, KMJ-908) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 3,3-Di(4- methylphenyl)-2-propenyl amine compound as a starting material, N-[3,3-Di(4- methylphenyl)-2-propenyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 72% yield, white solid, mp = 163-165 °C 1H ΝMR (CDCI3) δ 7.49 (t, 1 H, J = 8.3 Hz), 6.95-7.2 (m, 10 H), 5.93 (t, 1 H, J = 7.0 Hz), 5.56 (bt, 1 H), 3.8-4.0 (m, 2 H), 3.47 (q, 1 H, J= 7.1 Hz), 3.00 (s, 3 H), 2.34 (d, 6 H), 1.47 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 481 (MH+)
Example 49: Preparation of N-[3,3-Di(4-fluorophenyi)-2-propenyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide (4-27, SH-135) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 3,3-Di(4- fluorophenyl)-2-propenyl amine compound as a starting material, N-[3,3-Di(4- fluorophenyl)-2-propenyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide having following physicochemical properties was synthesized: 78% yield, white solid, mp = 57-60 °C 1H ΝMR (CDCI3) δ 7.49 (t, 1 H, J= 8.3 Hz), 6.9-7.2 (m, 10 H), 6.72 (bs, 1 H), 5.92 (t, 1 H, J= 7.0 Hz), 5.58 (bs, 1 H), 3.8-4.0 (m, 2 H), 3.48 (q, 1 H, J= 7.1 Hz), 3.02 (s, 3 H), 1.48 (d, 3 H, J= 7.1 Hz) MS (FAB) m/z 489 (MH1)
Example 50: Preparation of N-[2-(10,ll-Dihydro-5jfϊ-dibenzo[α,t jcyclolιepten-5- yliden)ethyI]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-28, SH- 199) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]propionic acid (1-38) with the corresponding 2-(10,l l- Dihydro-5H-dibenzo[α,-i]cyclohepten-5-ylidenethyl amine compound as a starting material, N-[2-(10,l l-Dihydro-5H-dibenzo[α,- ]cyclohepten-5-yliden)ethyl]-2-[3-fluoro- 4-(methylsulfonylamino)phenyl]propionarnide having following physicochemical properties was synthesized: 76% yield, white solid, mp = 67-69 °C 1H ΝMR (CDC ) δ 7.50 (t, 1 Η, J= 8.3 Ηz), 7.05-7.25 (m, 10 Η), 6.49 (bs, 1 Η), 5.80 (t, 1 Η), 5.40 (bt, 1 Η), 4.13 (m, 1 Η), 3.71 (m, 1 Η), 3.43 (q, 1 Η, J= 7.1 Ηz), 3.2- 3.4 (m, 4 Η), 3.01 (s, 3 Η), 1.46 (d, 3 Η, J= 7.1 Ηz) MS (FAB) m/z 479 (MΗ+)
Example 51: Preparation of N~[2-(3,4-Dimethylbenzyϊ)-3-pivaloyloxypropyl]-2-[4- (methylsulfonylamino)phenyl]propionamide (5-1, CHK-512) The N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-2-[4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 75% yield, white solid, mp = 112-115 °C 1H ΝMR (CDC13) δ 7.28 (m, 2 H), 7.16 (m, 2 H), 6.8-7.05 (m, 3 H), 6.36 (bs, 1 H), 5.77 (bt, 1 H), 3.98 (m, 1 H), 3.77 (m, 1 H), 3.45 (m, 1 H), 2.95-3.35 (m, 2 H), 2.97 (m, 3 H), 2.4-2.6 (m, 2 H), 2.1-2.25 (m, 6 H), 2.04 (m, 1 H), 1.47 (d, 3 H), 1.20 (s, 9 H) MS (FAB) m/z 503 (MH*)
Example 52: Preparation of N-[2-(4-t'-Butylbenzyl)-3-pivaloyloxypropyl]-2-[4- (methylsulfonylamino)phenyl]propionamide (5-2, CHK-514) The N-[2-(4-t-Butylbenzyl)-3-ρivaloyloxyρroρyl]-2-[4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 82% yield, white solid, mp = 97-100 °C 1H ΝMR (CDC13) δ 7.0-7.35 (m, 7 H), 6.38 (bs, 1 H), 5.81 (bs, 1 H), 4.02 (m, 1 H), 3.78 (m, 1 H), 3.47 (m, 1 H), 3.34 (m, 1 H), 2.95-3.1 (m, 4 H,), 2.45-2.55 (m, 2 H), 2.09 (m, 1 H), 1.47 (d, 3 H), 1.30 (s, 9 H), 1.21 (s, 9 H) MS (FAB) m/z 531 (MH4")
Example 53: Preparation of 2-[3-Fluoro-4-(methylsulfonylamino)phenyl]-N-[2- (3,4-dimethylbenzyl)-3-pivaloyloxypropyl]propionamide (5-3, SU-542) The 2-[3-Fluoro-4-(methylsulfonylamino)phenyl]-N-[2-(3,4-dimethylbenzyl)-3- pivaloyloxypropyljpropionamide was prepared by the similar procedure with that described in above Example 1-5. 67% yield, white solid, mp = 46-48 °C 1H NMR (CDC13) δ 7.51 (dt, 1 H), 7.0-7.2 (m, 3 H), 6.8-6.95 (m, 2 H), 6.58 (bs, 1 H), 5.91 (bt, 1 H), 4.05 (m, 1 H), 3.78 (m, 1 H), 3.25-3.5 (m, 2 H), 2.9-3.1 (m, 4 H), 2.45-2.65 (m, 2 H), 2.15-2.3 (m, 6 H), 2.05 (m, 1 H), 1.46 (d, 3 H, J= 7.3 Hz), 1.22 (s, 1 H) MS (FAB) m/z 521 (MH*)
Example 54: Preparation of 2-[3-Fluoro-4-(methylsulfonylamino)phenyl]-N-[2-(4- tert-butylbenzyI)-3~pivaIoyIoxypropyI]propionamide (5-4, SU-564) The 2-[3-Fluoro-4-(methylsulfonylamino)phenyl]-N-[2-(4-tert-butylbenzyl)-3- pivaloyloxypropyljpropionamide was prepared by the similar procedure with that described in above Example 1-5. 82% yield, white solid, mp = 113-115 °C 1H NMR (CDCI3) δ 7.50 (dt, 1 H), 7.30 (d, 2 H, J= 7.8 Hz), 7.15 (dt, 1 H), 7.02-7.1 (m, 3 H), 6.82 (bs, 1 H), 6.00 (bt, 1 H), 4.06 (m, 1 H), 3.80 (m, 1 H), 3.3-3.5 (m, 2 H), 2.95-3.1 (m, 4 H), 2.5-2.6 (m, 2 H), 2.11 (m, 1 H), 1.46 (d, 3 H, J= 7.3 Hz), 1.30 (s, 1 H), 1.22 (s, l H) MS (FAB) m/z 549 (MH+)
Example 55: Preparation of N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]~2-[3- metnoxy-4-(methylsuIfonylamino)phenyl]propionamide (5-5, CHK-479) The N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-2-[3-methoxy-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 87% yield, white solid, mp = 54-57 °C 1H ΝMR (CDCI3) δ 7.44 (m, 1 H), 6.7-7.05 (m, 5 H), 5.86 (bt, 1 H), 3.98 (m, 1 H), 3.85 ( , 3 H), 3.78 (m, 1 H), 3.46 (m, 1 H), 2.95-3.35 (m, 2 H), 2.90 (m, 3 H), 2.4-2.6 (m, 2 H), 2.1-2.25 (m, 6 H), 2.04 (m, 1 H), 1.47 (d, 3 H), 1.19 (s, 9 H) MS (FAB) m/z 533 (MH+)
Example 56: Preparation of N-[2-(4-fer -Butylbenzyι)-3-pivaloyloxypropyl]-2-[3- methoxy-4-(methyIsuIfonyIamino)phenyl]propionamide (5-6, CHK-499) The N-[2-(4-tert-Butylbenzyl)-3-pivaloyloxypropyl]-2-[3-methoxy-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 80%) yield, white solid, mp = 54-57 °C 1H ΝMR (CDC13) δ 7.46 (m, 1 H), 7.29 (m, 2 H), 7.03 (m, 2 H), 6.8-6.95 (m, 2 H), 6.72 (bs, 1 H), 5.83 (bt, 1 H), 4.02 (m, 1 H), 3.88 (m, 3 H), 3.78 (m, 1 H), 3.46 (m, 1 H), 3.33 (m, 1 H), 3.02 (m, 1 H), 2.92 (m, 3 H), 2.45-2.55 (m, 2 H), 2.05 (m, 1 H), 1.48 (d, 3 H), 1.30 (s, 9 H) 1.21 (s, 9 H) MS (FAB) m/z 561 (MH+)
Example 57: Preparation of N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-2-[3- chIoro-4-(methylsulfonylamino)phenyl]propionamide (5-7, KMJ-472) The N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-2-[3-chloro-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 62% yield, white solid, mp = 127-129 °C 1H ΝMR (CDC13) δ 7.60 (m, 1 H), 7.40 (m, 1 H), 7.22 (m, 1 H), 6.8-7.05 (m, 3 H), 6.72 (bs, 1 H), 5.90 (bt, 1 H), 4.06 (m, 1 H), 3.80 (m, 1 H), 3.42 (m, 1 H), 3.30 (m, 1 H), 3.05 (m, 1 H), 2.99 (m, 3 H), 2.45-2.65 (m, 2 H), 2.15-2.3 (m, 6 H), 2.05 (m, 1 H), 1.47 (m, 3 H), 1.22 (s, 9 H) MS (FAB) m/z 537 (M+)
Example 58: Preparation of N-[2-(4-terf-ButylbenzyI)~3-pivaloyIoxypropyI]-2-[3- chloro-4-(methylsulfonylamino)phenyl]propionamide (5-8, KMJ-690) The N-[2-(4-tert-Butylbenzyl)-3-pivaloyloxypropyl]-2-[3-chloro-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 58% yield, white solid, mp = 142-144 °C 1H ΝMR (CDC13) δ 7.59 (m, 1 H), 7.42 (m, 1 H), 7.30 (m, 2 H), 7.22 (m, 1 H), 7.06 (m, 2 H), 6.82 (bd, 1 H), 5.98 (bt, 1 H), 4.07 (m, 1 H), 3.81 (m, 1 H), 3.43 (m, 1 H), 3.32 (m, 1 H), 3.04 (m, 1 H), 2.98 (s, 3 H), 2.5-2.6 (m, 2 H), 2.12 (m, 1 H), 1.46 (m, 3 H), 1.30 (s, 9 H), 1.22 (s, 9 H) MS (FAB) m/z 563 (M+-l)
Example 59: Preparation of N-[(R)-l-Benzyl-2-(pivaloyloxy)ethyl]-(S)-2-[3-fluoro- 4-(methylsuIfonyIamino)phenyI]propionamide (6-1, SU-730) The N-[(R)-l-Benzyl-2-(pivaloyloxy)ethyl]-(S)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 96% yield, white solid, mp = 115 °C, [α] = -1.75 (c 1.00, CHC13) 1H ΝMR (CDC13) δ 7.50 (t, 1 H, J = 8.3 Hz), 6.95-7.25 (m, 7 H), 6.60 (bs, 1 H), 5.54 (d, 1 H, J= 7.8 Hz), 4.42 (m, 1 H), 4.04 (ddd of AB, 2 H), 3.43 (q, 1 H, J= 7.1 Hz), 3.04 (s, 3 H), 2.75 (dd of AB, 2 H), 1.43 (d, 3 H, J= 7.1 Hz), 1.19 (s, 9 H) MS (FAB) m/z 479 (MH+)
Example 60: Preparation of N-[(S)-l-BenzyI-2-(pivaloyloxy)ethyl]-(S)-2-[3-fluoro- 4-(methylsulfonylamino)phenyl]propionamide (6-2, SU-634) The N-[(S)-1 -Benzyl-2-(pivaloyloxy)ethyl]-(S)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 98% yield, white solid, mp = 125- 126 °C, [α] = -12.56 (c 1.00, CHC13) 1H ΝMR (CDC13) 8 7.50 (t, 1 H, J= 8.3 Hz), 7.0-7.32 (m, 7 H), 6.48 (bs, 1 H), 5.60 (d, 1 H, J= 7.8 Hz), 4.38 (m, 1 H), 4.00 (ddd of AB, 2 H), 3.43 (q, 1 H, J= 7.08 Hz), 3.02 (s, 3 H), 2.82 (ddd of AB, 2 H), 1.44 (d, 3 H, J= 7.08 Hz), 1.13 (s, 9 H) MS (FAB) m/z 479 (MH )
Example 61: Preparation of N-[(S)-l-Benzyl-2-(pivaloyloxy)ethyl]-(R)-2-[3-fmoro- 4-(methyIsulfonylamino)phenyl]propionamide (6-3, SU-636) The N-[(S)-1 -Benzyl-2-(pivaloyloxy)ethyl]-(R)-2-[3-fluoro-4-
(methylsulfonylamino)ρhenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 95% yield, white solid, mp = 117-119 °C, [α] = +1.46 (c 1.00, CHC13) The spectral data of the compound 6-3 is identical to that of 6-1. MS (FAB) m/z 479 (MH+)
Example 62: Preparation of N-[(R)-l-Benzyl-2-(pivaloyloxy)ethyl]-(R)-2-[3-fhιoro- 4-(methylsulfonylamino)phenyl]propionamide (6-4, SU-728) The N-[(R)-1 -Benzyl-2-(pivaloyloxy)ethyl]-(R)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 93% yield, white solid mp 124-126 °C, [α] = +11.8 (c 1.00, CHC13) The spectral data of the compound 6-4 is identical to that of 6-2. MS(FAB) m/z 479 (MH+)
Example 63: Preparation of N-[(2R)-2-Benzyl-3-(pivaloyloxy)propyl]-(2S)-2-[3- fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-5, SU-826) The N-[(2R)-2-Benzyl-3-(ρivaloyloxy)proρyl]-(2S)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 87% yield, white solid, mp = 40-42 °C [ ] = +8.2 (c 0.5, CHCl3) 1H ΝMR (CDCI3) δ 7.51 (t, 1 H, J = 8.3 Hz), 7.06-7.32 (m, 7 H), 6.50 (bs, 1 H), 5.93 (bt, 1 H), 4.05 (dd, 1 H, J= 4, 11.5 Hz), 3.76 (dd, 1 H, J= 5, 11.5 Hz), 3.45 (q, 1 H, J= 7.1 Hz), 3.36 (dt, 1 H), 2.9-3.05 (m, 4 H), 2.58 (d, 2 H, J= 7.5 Hz), 2.09 (m, 1 H, CH), 1.47 (d, 3 H, J= 7.1 Hz), 1.22 (s, 9 H) MS (FAB) m/z 493 (MH+)
Example 64: Preparation of N-[(2S)-2-Benzyl-3-(pivaloyloxy)propyl]-(2S)-2-[3- fluoro-4-(methylsulfonylammo)phenyl]propionamide (6-6, SU-830) The N-[(2S)-2-Benzyl-3-(pivaloyloxy)ρropyl]-(2S)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 86% yield, white solid, mp = 92-94 °C [α] = +5.8 (c 0.5, CHC13) 1H ΝMR (CDCI3) δ 7.52 (t, 1 H, J= 8.25 Hz), 7.06-7.32 (m, 7 H), 6.52 (bs, 1 H), 5.92 (bt, 1 H), 4.08 (dd, 1 H, J= 4, 11.5 Hz), 3.79 (dd, 1 H, J= 5, 11.5 Hz), 3.46 (q, 1 H, J= 7.1 Hz), 3.33 (dt, 1 H), 3.03 (dt, 1 H), 3.00 (s, 3 H), 2.48-2.62 (m, 2 H), 2.13 (m, 1 H), 1.47 (d, 3 H, J= 7.1 Hz), 1.22 (s, 9 H) MS (FAB) m/z 493 (MH+)
Example 65: Preparation of N-[(2S)-2-Benzyl-3-(pivaloyloxy)propyl]-(2R)-2-[3- fluoro-4-(methylsulfonylamino)phenyI]propionamide (6-7, SU-838) The N-[(2S)-2-Benzyl-3-(pivaloyloxy)proρyl]-(2R)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 88% yield, white solid, mp = 40-42 °C [α]= -10.5 (c 0.5, CHC13) Its spectral data of the compound 6-7 are identical to those of compound 6-5
Example 66: Preparation of N-[(2R)-2-Benzyl-3-(pivaloyloxy)propyl]-(2R)-2-[3- fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-8, SU-818) The N-[(2R)-2-Benzyl-3-(pivaloyloxy)proρyl]-(2R)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 89% yield, white solid, mp = 92-94 °C [α] = -12.5 (c 0.5, CHC13) Its spectral data of the compound 6-8 are identical to those of compound 6-6.
Example 67: Preparation of N-[(2R)-2-(4-t-Butylbenzyι)-3-(pivaloyloxy)propyI]- (2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-9, MK-271) The N-[(2R)-2-(4-t-Butylbenzyl)-3-(ρivaloyloxy)ρroρyl]-(2S)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 90% yield, white solid, mp = 44-46 °C [α]= +6.6 (c l.0, CHCl3) 1H ΝMR (CDC13) δ 7.51 (t, 1 H, J= 8.25 Hz), 7.31 (d, 2 H), 7.16 (dd, 1 H, J= 11.2, 1.8 Hz), 7.03-7.1 (m, 3 H), 6.41 (bs, 1 H), 5.91 (bt, 1 H), 4.06 (dd, 1 H, J= 4, 11.5 Hz), 3.78 (dd, 1 H, J= 5, 11.5 Hz), 3.43 (q, 1 H, J= 7 Hz), 3.36 (ddd, 1 H), 2.9-3.05 (m, 4 H), 2.55 (d, 2 H, J= 7.5 Hz), 2.08 (m, 1 H), 1.46 (d, 3 H, J= 7 Hz), 1.30 (s, 9 H), 1.22 (s, 9 H) MS (FAB) m/z 549 (MH+)
Example 68: Preparation of N-[(2S)-2-(4-t'-Butylbenzyι)-3-(pivaloyloxy)propyl]- (2S)-2-[3-fluoro-4-(methyIsulfonylamino)phenyl]propionamide (6-10, MK-272) The N-[(2S)-2-(4-t-Butylbenzyl)-3-(ρivaloyloxy)proρyl]-(2S)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]ρropionamide was prepared by the similar procedure with that described in above Example 1-5. 92% yield, white solid, mp = 43-45 °C [α]= +11.0 (c l.0, CHC13) 1H NMR (CDCI3) δ 7.52 (t, 1 H, J= 8.25 Hz), 7.30 (d, 2 H), 7.17 (dd, 1 H, J= 11.2, 1.8 Hz), 7.0-7.1 (m, 3 H), 6.50 (bs, 1 H), 5.90 (bt, 1 H), 4.08 (dd, 1 H, J= 4, 11.5 Hz), 3.81 (dd, 1 H, J= 5, 11.5 Hz), 3.45 (q, 1 H, J= 7 Hz), 3.34 (ddd, 1 H), 2.9-3.1 ( , 4 H), 2.53 (ddd of AB, 2 H), 2.12 (m, 1 H), 1.47 (d, 3 H, J= 7 Hz), 1.30 (s, 9 H), 1.22 (s, 9 H) MS (FAB) m/z 549 (MH )
Example 69: Preparation of N-[(2S)-2-(4-t-Butylbenzyl)-3-(pivaloyloxy)propyl]- (2R)-2-[3-fluoro-4-(methylsulfonyIamino)phenyl]propionamide (6-ll, MK-450) The N-[(2S)-2-(4-t-Butylbenzyl)-3-(pivaloyloxy)proρyl]-(2R)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 87% yield, white solid, mp = 44-46 °C [α]= -8.1 (c l.0, CHCl3) MS (FAB) m/z 549 (MH+) Its spectral data of the compound 6-11 are identical to those of compound 6-9.
Example 70: Preparation of N-[(2R)-2-(4-/-Butylbenzyl)-3-(pivaloyloxy)propyl]- (2R)-2-[3-fluoro-4-(methyIsuIfonylamino)phenyl]propionamide (6-12, MK-452) The N-[(2R)-2-(4-t-Butylbenzyl)-3-(ρivaloyloxy)propyl]-(2R)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 90% yield, white solid, mp = 43-45 °C [α]= -6.7 (c l.0, CHCl3) MS (FAB) m/z 549 (MF ) Its spectral data of the compound 6-12 are identical to those of compound 6-10.
Example 71: Preparation of N-[(2R)-2-(4-/-Butylbenzyl)-3-(pivaloyloxy)propyI]- (2S)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (6-13, MK-453) The N-[(2R)-2-(4-t-Butylbenzyl)-3-(pivaloyloxy)proρyl]-(2S)-2-[3-chloro-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 92% yield, white solid, mp = 61-63 °C [ ]= -3.18 (c 1.0, CHC13) 1H ΝMR (CDC13) δ 7.59 (d, 1 H, J= 8.4 Hz), 7.41 (d, 1 H, J= 2 Hz), 7.31 (d, 2 H) 7.22 (dd, 1 H, J= 8.4, 2 Hz), 7.07 (d, 2 H), 6.74 (bs, 1 H), 5.93 (bt, 1 H), 4.06 (dd, 1 H, J= 4, 11.3 Hz), 3.79 (dd, 1 H, J= 4.8, 11.3 Hz), 3.41 (q, 1 H, J= 7.1 Hz), 3.35 (ddd, 1 H), 2.95-3.05 (m, 4 H), 2.55 (d, 2 H, J= 7.5 Hz), 2.09 (m, 1 H), 1.46 (d, 3 H, J= 7.1 Hz), 1.30 (s, 9 H), 1.22 (s, 9 H) MS (FAB) m/z 566 (MH+)
Example 72: Preparation of N-[(2S)-2-(4-t-Butylbenzyl)-3-(pivaloyloxy)propyl]- (2S)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (6-14, MK-451) The N-[(2S)-2-(4-t-Butylbenzyl)-3-(pivaloyloxy)propyl]-(2S)-2-[3-chloro-4-
(methylsulfonylamino)phenyl]propionamide was prepared by the similar procedure with that described in above Example 1-5. 90% yield, white solid, mp = 55-57 °C [δ]= +3.24 (c 1.0, CHC13) 1H ΝMR (CDCI3) δ 7.61 (d, 1 H, J= 8.4 Hz), 7.42 (d, 1 H, J= 2 Hz), 7.30 (d, 2 H), 7.23 (dd, 1 H, J= 8.4, 2 Hz), 7.05 (d, 2 H), 6.72 (bs, 1 H), 5.91 (bt, 1 H), 4.09 (dd, 1 H, J= 4, 11.3 Hz), 3.81 (dd, 1 H, J= 5, 11.3 Hz), 3.43 (q, 1 H, J= 7.1 Hz), 3.34 (ddd, 1 H), 2.95-3.08 (m, 4 H), 2.53 (ddd of AB, 2 H), 2.12 (m, 1 H), 1.47 (d, 3 H, J= 7.1 Hz,), 1.30 (s, 9 H), 1.22 (s, 9 H) MS (FAB) m/z 566 (Mϊ )
Example 73 : Preparation of 2-[3-Fluoro-4-(methylsuIfonyIamino)phenyI]-2- methylpropionic acid (7-4, CHK-624)
Step 73-1. Preparation of Ethyl 2-(3-fluoro-4-nitrophenyl)-2-methylpropionamide (7-1,
CHK-623S) To a stirred solution of ethyl 2-(4-amino-3-fluorophenyl)propionate compound(l-13, 10 mmol, 20 mmol) and ΝaH(12mmol) in DMF (20 mL) was added a CH3I (15 mmol) at 0 °C dropwise. After being stirred for 10 min at 0 °C, the mixture was quenched by 1 N HCl solution, diluted with water and extracted with diethyl ether several times. The combined organic layers were washed with water and brine, dried over MgSO4, and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:10) as eluant to afford Ethyl 2-(3-fluoro-4- nitrophenyl)-2-methylpropionamide (7-1, CHK-623). 84% yield, yellow oil 1H NMR (CDC13) δ 8.04 (dd, 1 H, J= 7.8, 8.5 Hz), 7.24-7.31 (m, 2 H), 4.15 (q, 2 H, J= 7.1 Hz), 1.60 (s, 6 H), 1.21 (t, 3 H, J= 7.1 Hz)
Step 73-2. Preparation of Ethyl 2-(4-amino-3-fluorophenyl)-2-methylpropionamide (7-2, CHK-633) Through similar procedure to that in Example 1-2 excepting using Ethyl 2-(3-fluoro- 4-nitrophenyl)-2-methylpropionamide(7-l), Ethyl 2-(4-amino-3-fluorophenyl)-2- methylpropionamide having following physicochemical properties was synthesized: 98% yield, redish oil 1H NMR (CDC13) δ 7.01 (dd, 1 H, J= 2.2, 12.9 Hz), 6.93 (dd, 1 H, J= 2.2, 8.3 Hz), 6.75 (t, 1 H, J= 8.5 Hz), 4.10 (q, 2 H, J= 7.1 Hz), 3.62 (bs, 2 H), 1.52 (s, 6 H), 1.19 (t, 3 H, J= 7.1 Hz)
Step 73-3. Preparation of Ethyl 2-[3-fluoro-4-(methylsulfonylamino)phenvH-2- methylpropionamide (7-3, CHK-654) Through similar procedure to that in Example 1-3 excepting using Ethyl 2-(4- amino-3-fluorophenyl)-2-methylpropionamide (7-2), Ethyl 2-[3-fluoro-4- (methylsulfonylamino)phenyl]-2-methylpropionamide having following physicochemical properties was synthesized: 88% yield, white solid, mp = 71-72 °C 1H NMR (CDC13) δ 7.51 (t, 1 H, J= 8.3 Hz), 7.1-7.2 (m, 2 H), 6.56 (bs, 1 H), 4.13 (q, 2 H, J= 7.1 Hz), 3.04 (s, 1 H), 1.56 (s, 6 H), 1.20 (t, 3 H, J= 7.1 Hz)
Step 73-4. Preparation of 2-[3-Fluoro-4-(methylsulfonylamino ρhenyl]-2- methylpropionic acid (7-4, CHK-624) Through similar procedure to that in Example 1-4 excepting using Ethyl 2-[3-fluoro- 4-(methylsulfonylamino)phenyl]-2-methylpropionamide(7-3), 2-[3-Fluoro-4-
(methylsulfonylamino)phenyl]-2-methylpropionic acid having following physicochemical properties was synthesized: 88% yield, white solid, mp = 152-153 °C 1H NMR (CDC13) δ 7.53 (t, 1 H, J = 8.3 Hz), 7.18-7.25 (m, 2 H), 6.59 (bs, 1 H), 3.04 (s, 1 H), 1.59 (s, 6 H)
Example 74: Preparation of 2-[4-(methylsulfonylamino)phenyl]-2-methylpropionic acid (8-11, CHK-518)
Step 74-1. Preparation of 4-Nitrobenzonitrile (8-1) 4-Nitrobenzonitrile is commercially available(sigma Aldrich, No .N 1,200-7)
Step 74-2. Preparation of Methyl (4-nifroρhenyl)acetate (8-3. CHK-500 To a stirred solution of 4-Nitrobenzonitrile (8-1) in MeOH was added a HCl 3-4 drops. After having a reflux for 10 hr, the mixture was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:10) as eluant to afford Methyl (4-nitrophenyl)acetate (8-3, CHK-500). 82 % yield, yellow solid, mp = 49-50 °C 1H NMR (CDC13) δ 8.15 (bd, 2 H), 7.43 (bd, 2 H), 3.71 (s, 2 H), 3.69 (s, 3 H)
Step 74-3. Preparation of Methyl 2-(4-nitrophenyl -2-methylpropionamide (8-5, CHK- 508) Through similar procedure to that in Example 38-1 excepting using Ethyl Methyl (4-nitrophenyl)acetate (8-3), Methyl 2-(4-nitrophenyl)-2-methylpropionamide (8-5, CHK-508) having following physicochemical properties was synthesized: 95 % yield, yellow oil 1H NMR (CDC13) δ 8.18 (bd, 2 H), 7.50 (bd, 2 H), 3.72 (s, 3 H), 1.63 (s, 6 H)
Step 74-4. Preparation of Methyl 2-(4-aminophenyl)-2-methylpropionamide (8-7, CHK- 509) Through similar procedure to that in Example 1-2 excepting using Methyl 2-(4- nitrophenyl)-2-methylpropionamide (8-5), Methyl 2-(4-aminophenyl)-2- methylpropionamide(8-7, CHK-509) having following physicochemical properties was synthesized: 80 % yield, yellow oil 1H NMR (CDC13) δ 7.12 (bd, 2 H), 6.66 (bd, 2 H), 3.62 (s, 3 H), 1.52 (s, 6 H)
Step 74-5. Preparation of Methyl 2-["4-(methylsulfonylamino phenyl]-2- methylpropionamide (8-9, CHK-516) Through similar procedure to that in Example 1-3 excepting using Methyl 2-(4- aminophenyl)-2-methylpropionamide (8-7), Methyl 2-[4-
(methylsulfonylamino)phenyl]-2-methylpropionamide (8-9, CHK-516) having following physicochemical properties was synthesized: 96 % yield, yellow solid, mp = 123-125 °C 1H NMR (CDC13) δ 7.33 (bd, 2 H), 7.18 (bd, 2 H), 6.67 (bs, 1 H), 3.66 (s, 3 H), 3.02 (s, 3 H), 1.57 (s, 6 H)
Step 74-6. Preparation of 2-[4-(methylsulfonylamino phenyl]-2-methylpropionic acid (8-11, CHK-518) Through similar procedure to that in Example 1-4 excepting using Methyl 2-[4- (methylsulfonylamino)phenyl]-2-methylpropionamide (8-9), 2-[4- (methylsulfonylamino)phenyl]-2-methylpropionic acid (8-11, CHK-518) having following physicochemical properties was synthesized: 92% yield, yellow solid, mp = 148-151 °C 1H NMR (CDC13) δ 7.39 (bd, 2 H), 7.19 (bd, 2 H), 6.44 (bs, 1 H), 3.02 (s, 3 H), 1.60 (s, 6 H)
Example 75: Preparation of 2-(3-methoxy-4-(methylsulfonylammo)phenyl)-2- methylpropionic acid (8-12, CHK-491)
Step 75-1. Preparation of 3-Methoxy-4-nitrobenzonitrile (8-2. CHK-78 The 3-Methoxy-4-nitrobenzonitrile (8-2) on the market was prepared from 3- methoxybenzonitryl by previous literature procedure (Gallacher et al., Biogenic Amines, pp49-62, 1995) 44 % yield, yellow solid, mp = 87-89 °C 1H NMR (CDC13) δ 7.88 (d, 1 H, J= 8.3 Hz), 7.07 (d, 1 H, J= 1.7 Hz), 7.00 (dd, 1
H, J= 1.7, 8.3 Hz), 4.00 (s, 3 H), 3.84 (s, 2 H)
Step 75-2. Preparation of Methyl (3-methoxy-4-nitrophenyl)acetate (8-4, CHK-143 Through similar procedure to that in Example 74-2 excepting using 3-Methoxy-4- nitrobenzonitrile(8-2), Methyl (3-methoxy-4-nitrophenyl)acetate (8-4, CHK-143) having following physicochemical properties was synthesized: 79 % yield, yellow oil 1H NMR (CDC13) δ 7.83 (d, 1 H, J= 8.3 Hz), 7.03 (d, 1 H, J= 1.7 H), 6.94 (dd, 1 H,
J= 1.7, 8.3 Hz), 3.97 (s, 3 H), 3.73 (s, 3 H), 3.69 (s, 2 H)
Step 75-3. Preparation of Methyl 2-(3-methoxy-4-nitrophenyl)-2-methylpropionamide (8-6, CHK-469 Through similar procedure to that in Example 73-1 excepting using Methyl (3- methoxy-4-nitrophenyl)acetate (8-4), Methyl 2-(3-methoxy-4-nitrophenyl)-2- methylpropionamide (8-6, CHK-469) having following physicochemical properties was synthesized: 82 % yield, yellow oil 1H NMR (CDC13) δ 7.80 (d, 1 H, J= 8.5 Hz), 7.00 (d, 1 H, J= 2 Hz), 6.96 (dd, 1 H, J= 2, 8.5 Hz), 3.93 (s, 3 H), 3.65 (s, 3 H), 1.58 (s, 6 H)
Step 75-4. Preparation of Methyl 2-(3-methoxy-4-aminophenyl)-2-methylpropionamide (8-8. CHK-481 Through similar procedure to that in Example 1-2 excepting using 2-(3-methoxy-4- nitrophenyl)-2-methylpropionamide (8-6), Methyl 2-(3-methoxy-4-aminophenyl)-2- methylpropionamide (8-8, CHK-481) having following physicochemical properties was synthesized: 82 % yield, yellow oil 1H NMR (CDC13) δ 6.75-6.80 (m, 2 H), 6.66 (d, 1 H, J= 8.4 Hz), 3.84 (s, 3 H), 3.63 (s, 3 H), 1.54 (s, 6 H)
Step 75-5. Preparation of Methyl 2-(3-methoxy-4-(methylsulfonylamino)phenyl -2- methylpropionamide (8-10, CHK-489) Through similar procedure to that in Example 1-3 excepting using Methyl 2-(3- methoxy-4-aminophenyl)-2-methylpropionamide (8-8), Methyl 2-(3-methoxy-4- (methylsulfonylamino)phenyl)-2-methylpropionamide (8-10, CHK-489) having following physicochemical properties was synthesized: 90 % yield, yellow oil 1H NMR (CDC13) δ 7.46 (d, 1 H, J= 8.4 Hz), 6.95 (dd, 1 H, J= 2, 8.4 Hz), 6.88 (d, 1 H, J= 2 Hz), 6.75 (bs, 1 H), 3.88 (s, 3 H), 3.67 (s, 3 H), 2.96 (s, 3 H), 1.57 (s, 6 H)
Step 75-6. Preparation of 2-(3-methoxy-4-(methylsulfonylamino phenyl)-2- methylpropionic acid (8-12. CHK-491 Through similar procedure to that in Example 1-4 excepting using NaOH of Methyl 2-(3-methoxy-4-(methylsulfonylamino)phenyl)-2-methylpropionamide (8-10) as metal salt, 2-(3-methoxy-4-(methylsulfonylamino)phenyl)-2-methylpropionic acid (8-12, CHK-491) having following physicochemical properties was synthesized: 89 % yield, white solid, mp = 122-124 °C 1H NMR (CDC13) δ 7.47 (d, 1 H, J= 8.3 Hz), 7.00 (dd, 1 H, J= 1.8, 8.3 Hz), 6.94 (d, 1 H, J= 1.8 Hz), 6.78 (bs, 1 H), 3.88 (s, 3 H), 2.96 (s, 3 H), 1.60 (s, 6 H)
Example 76: Preparation of N-[2~(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-2-[4- (methylsulfonylamino)phenyl]-2-methylpropionamide (9-1, CHK-520) Through similar procedure to that in Example 1-5 excepting using 2-[4- (methylsulfonylamino)phenyl]-2-methylpropionic acid (8-11), N-[2-(3,4- Dimethylbenzyl)-3-pivaloyloxypropyl]-2-[4-(methylsulfonylamino)phenyl]-2- methylpropionamide (9-1, CHK-520) having following physicochemical properties was synthesized: 89 % yield, yellow solid, mp = 126-130 °C 1H NMR (CDCI3) δ 7.34 (dd, 2 H, J= 8.3, 1 Hz), 7.18 (d, 2 H, J= 8.3, 1 Hz), 6.8- 7.05 (m, 3 H), 6.44 (bs, 1 H), 5.60 (t, 1 H), 3.95 (dt, 1 H), 3.76 (ddd, 1 H), 3.27 (m, 1 H), 3.08 (m, 1 H), 3.00 (d, 3 H), 2.45-2.65 (m, 2 H), 2.15-2.3 (m, 6 H), 2.05 (m, 1 H), 1.53 (s, 6 H), 1.19 (d, 9 H) MS (FAB) rø/z 517 (MH+)
Example 77: Preparation of N-[2-(3,4-Dimethylbenzyι)-3-pivaloyloxypropyl]-2-[3- fluoro-4-(methylsulfonylamino)phenyl]-2-metlιylpropionamide (9-2, CHK-543) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]-2-methylpropionic acid (7-4), N-[2-(3,4-
Dimethylbenzyl)-3-pivaloyloxypropyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2- methylpropionamide (9-2, CHK-543) having following physicochemical properties was synthesized: 82% yield, white solid, mp = 53-55 °C 1H ΝMR (CDCI3) δ 7.52 (dt, 1 H), 6.8-7.2 (m, 5 H), 5.74 (t, 1 H), 4.01 (dt, 1 H), 3.77 (ddd, 1 H), 3.28 (m, 1 H), 2.95-3.15 (m, 4 H), 2.45-2.65 (m, 2 H), 2.15-2.3 (m, 6 H), 2.05 (m, 1 H), 1.52 (s, 6 H), 1.20 (d, 9 H) MS (FAB) m/z 535 (MH )
Example 78: Preparation of N-[2-(3,4-Dimethylbenzyi)-3-pivaloyloxypropyl]-2-[3- methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-3, CHK-493) Through similar procedure to that in Example 1-5 excepting using 2-[3-methoxy-4- (metylsulfonylamino)phenyl]-2-metylpropion acid(8-12), N-[2-(3,4-Dimethylbenzyl)-3- pivaloyloxypropyl]-2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2- methylpropionamide (9-3, CHK-493) having following physicochemical properties was synthesized: 84% yield, white solid, mp = 100-103 °C 1H ΝMR (CDC13) δ 7.48 (dd, 1 H, J= 8.3, 2 Hz), 6.8-7.05 (m, 5 H), 6.74 (bs, 1 H), 5.61 (t, 1 H), 3.95 (ddd, 1 H), 3.86 (s, 3 H), 3.75 (ddd, 1 H), 3.26 (m, 1 H), 3.06 (m, 1 H), 2.96 (d, 3 H), 2.45-2.65 (m, 2 H), 2.15-2.3 (m, 6 H), 2.05 (m, 1 H), 1.54 (s, 6 H), 1.19 (d, 9 H) MS (FAB) m/z 547 (MH+)
Example 79: Preparation of N-[3-(3,4-DimethyIphenyl)propyl]-2~[4- (methylsulfonylamino)phenyl]-2-methylpropionamide (9-4, CHK-591) Through similar procedure to that in Example 1-5 excepting using 2-[4- (metylsulfonylamino)phenyl]-2-metylpropion acid(8-l 1), N-[3-(3,4-
Dimethylphenyl)propyl] -2- [4-(methylsulfonylamino)phenyl] -2-methylpropionamide (9- 4, CHK-591) having following physicochemical properties was synthesized: 83% yield, white solid, mp = 138-139 °C 1H ΝMR (CDC13) δ 7.33 (d, 2 H), 7.19 (d, 2 H), 7.01 (d, 1 H, J= 7.5 Hz), 6.8-6.88 (m, 2 H), 5.17 (bt, 1 H), 3.20 (dd, 2 H), 3.01 (s, 3 H), 2.47 (t, 2 H, J= 7.3 Hz), 2.21 (s, 6 H), 1.71 (m, 2 H), 1.51 (s, 6 H) MS (FAB) m/z 403 (MH+)
Example 80: Preparation of N-[3-(3,4-Dimethylphenyι)propyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]-2-methylpropionamide (9-5,CHK-656) Through similar procedure to that in Example 1-5 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]-2-methylpropionic acid (7-4), N-[3-(3,4-
Dimethylphenyl)propyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2- methylpropionamide (9-5,CHK-656) having following physicochemical properties was synthesized: 89% yield, white solid, mp = 145-146 °C 1H ΝMR (CDC13) δ 7.53 (t, 1 H, J= 8.3 Hz), 7.1-7.17 (m, 2 H), 7.02 (d, 1 H), 6.8- 6.9 (m, 2 H), 6.46 (bs, 1 H), 5.18 (bt, 1 H), 3.23 (dd, 2 H), 3.03 (s, 3 H), 2.49 (t, 2 H, J= 7.5 Hz), 2.22 (s, 6 H), 1.74 (m, 2 H), 1.49 (s, 6 H) MS (FAB) m/z 421 (MH+)
Example 81: Preparation of N-[3-(3,4-Dimethylphenyl)propyl]-2-[3-methoxy-4- (methylsuIfonylamino)phenyl]-2-methylpropionamide (9-6, CHK-600) Through similar procedure to that in Example 1-5 excepting using 2-(3-methoxy-4- (methylsulfonylamino)phenyl)-2-methylpropionic acid (8-12), N-[3-(3,4- Dimethylphenyl)propyl] -2- [3 -methoxy-4-(methylsulfonylamino)phenyl] -2- methylpropionamide (9-6, CHK-600) having following physicochemical properties was synthesized: 86% yield, white solid, mp = 93-95 °C 1H ΝMR (CDC13) δ 7.48 (d, 1 H), 6.75-7.05 (m, 6 H), 5.18 (bt, 1 H), 3.85 (s, 3 H), 3.20 (dd, 2 H), 2.96 (s, 3 H), 2.46 (t, 2 H, J= 7.3 Hz), 2.21 (s, 6 H), 1.71 (m, 2 H), 1.52 (s, 6 H) MS (El) m/z 432 (M+)
Example 82: Preparation of N-(4-fert-Butylbenzyl)-2-[4- (methylsulfonylamino)phenyl]-2-methylpropionamide (9-7, CHK-715) Through similar procedure to that in Example 1-5 excepting using 2-(3-methoxy-4- (methylsulfonylamino)phenyl)-2-methylpropionic acid (8-12), N-[3-(3,4-
Dimethylphenyl)propyl] -2- [3 -methoxy-4-(methylsulfonylamino)phenyl] -2- methylpropionamide (9-6, CHK-600) having following physicochemical properties was synthesized: 92% yield, white solid, mp = 141-143 °C 1H ΝMR (CDC13) δ 7.36 (d, 2 H, J= 8.5 Hz), 7.31 (d, 2 H, J= 7.9 Hz), 7.18 (d, 2 H, J= 8.5 Hz), 7.07 (d, 1 H, J= 7.9 Hz), 6.40 (bs, 1 H), 5.46 (bt, 1 H), 4.36 (d, 1 H, J= 5.7 Hz), 3.00 (s, 3 H), 1.59 (s, 3 H), 1.55 (s, 3 H), 1.30 (s, 9 H) MS (FAB) m/z 403 (MH+)
Example 83: Preparation of N-(4-tert-Butylbenzyl)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]-2-methylpropionamide (9-8, CHK-655) Through similar procedure to that in Example 1-5 excepting using 2-[4- (methylsulfonylamino)phenyl]-2-methylpropionic acid (8-11), N-(4-tert-Butylbenzyl)- 2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-8, CHK-655) having following physicochemical properties was synthesized: 74% yield, white solid, mp = 48-51 °C 1H ΝMR (CDC13) δ 7.53 (t, 1 H, J= 8.2 Hz), 7.33 (d, 2 H), 7.17 (d, 1 H), 7.09 (d, 1 H), 6.45 (bs, 1 H), 5.50 (bt, 1 H), 4.37 (d, 1 H, J= 5.5 Hz), 3.03 (s, 3 H), 1.58 (s, 3 H), 1.55 (s, 3 H), 1.30 (s, 9 H) MS (FAB) m/z 421 (MH+)
Example 84: Preparation of N-(4-tert-Butylbenzyl)-2-[3-methoxy-4- (methylsulfonylamino)phenyl]-2-methylpropionamide (9-9, CHK-1001) Through similar procedure to that in Example 1-5 excepting using 2-(3-methoxy-4- (methylsulfonylamino)phenyl)-2-methylpropionic acid (8-12), N-(4-tert-Butylbenzyl)- 2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-9, CHK- 1001) having following physicochemical properties was synthesized: 76% yield, white solid, mp = 56-58 °C 1H ΝMR (CDC13) δ 7.46 (d, 1 H), 7.30 (d, 2 H), 7.09 (d, 2H), 6.98 (dd, 1 H), 6.83 (d, 1 H), 6.83 (d, 1 H), 6.77 (bs, 1 H), 5.55 (bt, IH), 4.36 (d, IH), 3.80 (s, 3 H), 2.94 (s, 3H), 1.59 (s, 6H), 1.29 (s, 9H)
Example 85: Preparation of l-[3-fluoro-4- (methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (10-5, CHK-996)
Step 85-1. Preparation of methyl 2-(3-fluoro-4-nitophenyl)acetate (10-1, CHK-947) To a stirred slowly solution of nitric acid (11.48mM, 0.49mL) was added a mixture of 3-fluorophenyl acetate (11.48mM, 1930mg) on the market and H2SO4 (3 mmol) at 0 °C dropwise. After being stirred for 2 hr, the mixture was diluted with iced-water and extracted with ethyl acetate. The combined organic layers were washed with water. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:4) as eluant to afford metyl 2-(3-fluoro-4-nitophenyl)acetate (10-1, CHK-947). 76% yield, 321mg 1H NMR (CDC13) δ 8.02 (t, 1 H), 7.15-7.30 (m, 2 H), 3.73 (s, 3H), 3.70 (s, 2 H)
Step 85-2. Preparation of methyl l-(3-fluoro-4-nitophenyl cvcloprophancarboxylate (10-2, CHK-987) To a stirred solution of methyl 2-(3-fluoro-4-nitophenyl)acetate (10-1, 300mg, 1.41 mmol) in anhydrous THF (6 mL) was added NaH (14.1 mM, 338mg) slowly. The mixture was stirred for 10 min and then dibromoethane (7.05mM, 0.6mL) was added. The reaction mixture was allowed to be wanned to room temperature for 30 min and quenched by saturated NH4C1 solution. After aqueous work-up, the residue was purified by flash column chromatography with EtOAc:hexanes (1:5) as eluant to afford methyl l-(3-fluoro-4-nitophenyl)cycloprophancarboxylate (10-2, CHK-987). 76% yield, white solid, mp = 56-58 °C 1H NMR (CDC13) δ 7.47 (dt, 1 H), 7.15-7.30 (m, 2 H), 3.66 (s, 3H), 1.68 (dd, 2H), 1.19 (dd, 2H)
Step 85-3. Preparation of methyl l-(4-amino-3-fluorophenyl cycloprophancarboxylate (10-3, CHK-993)
Through similar procedure to that in Example 1-2 excepting using methyl l-(3-fluoro-4- nitophenyl)cycloprophancarboxylate (10-2) with the corresponding 4- chlorobenzylamine compound as a starting material, methyl l-(4-amino-3- fluorophenyl)cycloprophancarboxylate (10-3, CHK-993) having following physicochemical properties was synthesized: 1H NMR (CDC13) δ 6.9-7.0 (m, 2 H), 6.64 (m, 1 H), 3.89 (bs, 2H), 3.65 (s, 3H), 1.68 (dd, 2H), 1.18 (dd, 2H)
Step 85-4. Preparation of Methyl l-(4-amino-3-fluorophenyl cvclopropanecarboxylate Through similar procedure to that in Example 1-3 excepting using methyl l-(4- amino-3-fluorophenyl)cycloprophancarboxylate (10-3) with the corresponding 4- chlorobenzylamine compound as a starting material, Methyl l-(4-amino-3- fluorophenyl)cyclopropanecarboxylate (10-4) having following physicochemical properties was synthesized: 1H NMR (CDC13) δ 7.05-7.23 (m, 3 H), 6.51 (bs, 1 H), 3.68 (s, 3H), 3.31 (s, 3H), 1.77 (dd, 2H), 1.34 (dd, 2H)
Step 85-5. Preparation of Methyl l-[3-fluoro-4-
(methylsulfonylamino)phenyllcyclopropanecarboxylate (10-5) Through similar procedure to that in Example 1-5 excepting using Methyl l-(4- amino-3-fluoroρhenyl)cyclopropanecarboxylate (10-4) with the corresponding 4- chlorobenzylamine compound as a starting material, Methyl l-[3-fluoro-4- (methylsulfonylamino)phenyl]cyclopropanecarboxylate (10-5) having following physicochemical properties was synthesized: 1H NMR (CDCI3) δ 7.05-7.25 (m, 3 H), 6.50 (bs, 1 H), 3.30 (s, 3H), 1.76 (dd, 2H), 1.33 (dd, 2H) MS (FAB) m/z 421 (MH+)
Example 86: Preparation of l-[4-
(Methylsulfonylamino)phenyl]cyclopropanecarboxyIic acid (11-7, CHK-530)
Step 86-1. Preparation of Methyl l-(4-nitrophenyl)cyclopropanecarboxylate (11-1, CHK-521) Through similar procedure to that in Example 85-2 excepting using Methyl (4- nitrophenyl)acetate (8-3) as a starting material, Methyl l-(4- nitrophenyl)cyclopropanecarboxylate (11-1, CHK-521) having following physicochemical properties was synthesized: 71 % yield, yellow solid, mp = 89-91 °C 1H NMR (CDCI3) δ 8.18 (bd, 2 H), 7.51 (bd, 2 H), 3.65 (s, 3 H), 1.71 (dd, 2 H), 1.24 (dd, 2 H)
Step 86-2. Preparation of Methyl l-(4-aminophenyl)cyclopropanecarboxylate (11-3, CHK-525) Through similar procedure to that in Example 1-2 excepting using Methyl l-(4- nitrophenyl)cyclopropanecarboxylate (11-1) as a starting material, Methyl l-(4- aminophenyl)cyclopropanecarboxylate (11-3, CHK-525) having following physicochemical properties was synthesized: 93 % yield, yellow solid, mp = 62-65 °C 1H NMR (CDC13) δ 7.12 (bd, 2 H), 6.63 (bd, 2 H), 3.65 (bs, 2 H), 3.61 (s, 3 H), 1.54 (dd, 2 H), 1.13 (dd, 2 H)
Step 86-3. Preparation of Methyl l-[4-
(methylsulfonylamino phenyl1cvclopropanecarboxylate (ll-5, CHK-527) Through similar procedure to that in Example 1-3 excepting using Methyl l-(4- aminophenyl)cyclopropanecarboxylate (11-3) as a starting material, Methyl l-[4- (methylsulfonylamino)phenyl]cyclopropanecarboxylate (11-5, CHK-527) having following physicochemical properties was synthesized: 88 % yield, white solid, mp = 118-120 °C 1H NMR (CDCI3) δ 7.33 (bd, 2 H), 7.15 (bd, 2 H), 6.36 (bs, 1 H), 3.63 (s, 2 H), 3.03 (s, 3 H), 1.62 (dd, 2 H), 1.17 (dd, 2 H)
Step 86-3. Preparation of Methyl H4-
(Methylsulfonylamino phenyl]cvclopropanecarboxylic acid (11-7, CHK-530) Through similar procedure to that in Example 1-4 excepting using Methyl l-[4- (methylsulfonylamino)phenyl]cyclopropanecarboxylate (11-5) as a starting material, Methyl l-[4-(Methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (11-7, CHK- 530) having following physicochemical properties was synthesized: 98 % yield, yellow solid, mp = 220-224 °C 1H NMR (DMSO-de) δ 9.69 (bs, 1 H, CO2H), 7.26 (bd, 2 H), 7.10 (bd, 2 H), 2.96 (s, 3 H), 1.41 (dd, 2 H), 1.08 (dd, 2 H)
Example 87: Preparation of l-[3-Methoxy-4-
(methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (11-8, CHK-539)
Step 87-1. Preparation of Methyl l-(3-methoxy-4-nitrophenyl cyclopropanecarboxylate (11-2, CHK-528 Through similar procedure to that in Example 85-2 excepting using Methyl (3- methoxy-4-nitrophenyl)acetate (8-4) as a starting material, Methyl l-(3-methoxy-4- nitrophenyl)cyclopropanecarboxylate (11-2, CHK-528) having following physicochemical properties was synthesized: 70% yield, yellow oil 1H NMR (CDCI3) δ 7.81 (d, 1 H, J= 8.3 Hz), 7.07 (d, 1 H, J= 1.5 Hz), 7.00 (dd, 1 H, J= 8.3, 1.5 Hz), 3.97 (s, 3 H), 3.65 (s, 3 H), 1.68 (dd, 2 H), 1.23 (dd, 2 H)
Step 87-2. Preparation of. Methyl l-(4-amino-3- methoxyphenvDcyclopropanecarboxylate (11-4, CHK-531) Through similar procedure to that in Example 1-2 excepting using Methyl l-(3- methoxy-4-nitrophenyl)cyclopropanecarboxylate (11-2) as a starting material, Methyl 1- (4-amino-3-methoxyphenyl)cyclopropanecarboxylate (11-4, CHK-531) having following physicochemical properties was synthesized: 92% yield, redish oil 1H NMR (CDC13) δ 6.6-6.8 (m, 3 H), 3.85 (s, 3 H), 3.77 (bs, 2 H), 3.62 (s, 3 H), 1.55 (dd, 2 H), 1.15 (dd, 2 H)
Step 87-3. Preparation of. Methyl l-[3-methoxy-4-
(methylsulfonylamino)phenyllcyclopropanecarboxylate (11-6, CHK-534) Through similar procedure to that in Example 1-3 excepting using Methyl l-(4- ammo-3-methoxyphenyl)cyclopropanecarboxylate (11-4) as a starting material, Methyl l-[3-methoxy-4-(methylsulfonylamino)phenyl]cyclopropanecarboxylate (11-6, CHK- 534) having following physicochemical properties was synthesized: 92% yield, redish oil 1H NMR (CDCI3) δ 6.6-6.8 (m, 3 H), 3.85 (s, 3 H), 3.77 (bs, 2 H), 3.62 (s, 3 H), 1.55 (dd, 2 H), 1.15 (dd, 2 H)
Step 87-4. Preparation of. l-[3-Methoxy-4-
(methylsulfonylamino)phenyl]cyclopropaneearboxylic acid (11-8, CHK-539) Through similar procedure to that in Example 1-3 excepting using Methyl l-[3- methoxy-4-(methylsulfonylamino)phenyl]cyclopropanecarboxylate (11-6) as a starting material, l-[3-Methoxy-4-(methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (11-8, CHK-539) having following physicochemical properties was synthesized: 92% yield, redish oil 1H NMR (CDCI3) δ 6.6-6.8 (m, 3 H), 3.85 (s, 3 H), 3.77 (bs, 2 H), 3.62 (s, 3 H), 1.55 (dd, 2 H), 1.15 (dd, 2 H)
Example 88: Preparation of N-[2-(3,4-Dimethylbenzyι)-3-pivaloyloxypropyl]-l-[4- (methylsulfonyϊamino)phenyl]cyclopropanecarboxamide (12-l, CHK-533) Through similar procedure to that in Example 1-5 excepting using l-[4- (Methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (11-7) as a starting material, N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-l-[4-
(methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-1, CHK-533) having following physicochemical properties was synthesized: 80 % yield, white solid, mp = 54-56 °C 1H ΝMR (CDC13) δ 7.38 (d, 2 H, J= 8.3 Hz), 7.21 (d, 2 H, J= 8.3 Hz), 6.75-7.05 (m, 3 H), 6.37 (bs, 1 H), 5.56 (bs, 1 H), 3.93 (m, 1 H), 3.76 (m, 1 H), 3.27 (m, 1 H), 2.95-3.1 (m, 4 H), 2.4-2.6 (m, 2 H), 2.15-2.3 (m, 6 H), 2.05 (m, 1 H), 1.58 (m, 2 H), 1.17 (s, 9 H), 1.00 (m, 2 H) MS (FAB) 7«/z 515 (MH+)
Example 89: Preparation of N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-l-[3- fluoro-4-(methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-2, CHK-538) Through similar procedure to that in Example 1-5 excepting using l-[3-fluoro-4- (methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (10-6) as a starting material, N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-l-[3-fluoro-4-
(methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-2, CHK-538) having following physicochemical properties was synthesized: white solid, mp = 55-56 °C 1H ΝMR (CDC13) δ 7.48 (t, 1 H), 7.1-7.2 (m, 2 H), 6.75-7.05 (m, 3 H), 6.39 (bs, 1 H), 5.58 (bs, 1 H), 3.92 (m, 1 H), 3.77 (m, 1 H), 3.25 (m, 1 H), 2.9-3.1 (m, 4 H), 2.4-2.6 (m, 2 H), 2.15-2.3 (m, 6 H), 2.07 (m, 1 H), 1.58 (m, 2 H), 1.18 (s, 9 H), 1.02 (m, 2 H) MS (FAB) m/z 533 (MET)
Example 90: Preparation of N-[2-(3,4-Dimethylbenzyl)-3-pivaloyloxypropyl]-l-[3- methoxy-4-(methylsulfonylamino)phenyl] cyclopropanecarboxamide (12-3, CHK- 541) Through similar procedure to that in Example 1-5 excepting using l-[3-fluoro-4- (methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (10-6) as a starting material, N- [2-(3 ,4-Dimethylbenzyl)-3 -pivaloyloxypropyl] - 1 - [3 -methoxy-4- (methylsulfonylamino)phenyljcyclopropanecarboxamide (12-3, CHK-541) having following physicochemical properties was synthesized: 82 % yield, white solid, mp = 66-68 °C 1H ΝMR (CDC13) δ 7.50 (dd, 1 H, J= 8.3, 1.3 Hz), 6.75-7.05 (m, 6 H), 5.65 (bt, 1 H), 3.94 (m, 1 H), 3.90 (s, 3 H), 3.76 (m, 1 H), 3.29 (m, 1 H), 2.9-3.1 (m, 4 H), 2.4-2.6 (m, 2 H), 2.15-2.3 (m, 6 H), 2.05 (m, 1 H), 1.58 (m, 2 H), 1.16 (d, 9 H), 1.02 (m, 2 H) MS (FAB) m/z 545 (MH+) Example 91: Preparation of N-[3-(3,4-Dimethylphenyι)propyl]-l-[4- (methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-4, CHK-590) Through similar procedure to that in Example 1-5 excepting using l-[4- (Methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (11-7) as a starting material, N-[3-(3,4-Dimethylphenyl)propyl]-l-[4-
(methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-4, CHK-590) having following physicochemical properties was synthesized: 81 % yield, white solid, mp = 127-128 °C 1H ΝMR (CDC13) δ 7.37 (m, 2 H, J= 8.3 Hz), 7.19 (m, 2 H, J= 8.3 Hz), 6.75-7.05 (m, 3 H), 6.40 (bs, 1 H), 5.25 (bs, 1 H), 3.17 (dd, 2 H), 3.06 (s, 3 H), 2.46 (t, 2 H, J = 7.3 Hz), 2.21 (s, 6 H), 1.68 (m, 2 H), 1.59 (dd, 2 H), 0.99 (dd, 2 H) MS (FAB) m/z 401 (MH+)
Example 92: Preparation of N-[3-(3,4-Dimethylphenyl)propyl]-l-[3-fluoro-4- (methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-5) Through similar procedure to that in Example 1-5 excepting using l-[3-fluoro-4- (methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (10-6) as a starting material, N- [3 -(3 ,4-Dimethylphenyl)propyl] - 1 - [3 -fluoro-4-
(methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-5) having following physicochemical properties was synthesized: 81 % yield, white solid, mp = 127-128 °C 1H ΝMR (CDC13) δ 7.50 (t, IH), 7.1-7.2 (m, 2 H), 6.8-7.1 (m, 3 H), 6.40 (bs, 1 H), 5.30 (bs, 1 H), 3.16 (dd, 2 H), 3.05 (s, 3 H), 2.48 (t, 2 H), 2.25 (s, 6 H), 1.69 (m, 2 H), 1.60 (m, 2 H), 1.00 (dd, 2 H) MS (FAB) m/z 419 (MH+)
Example 93: Preparation of N-[3-(3,4-Dimethylphenyl)propyl]-l-[3-methoxy-4- (methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-6, CHK-632) Through similar procedure to that in Example 1-5 excepting using l-[3-Methoxy-4- (methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (11-8) as a starting material, N- [3 -(3 ,4-Dimethylphenyl)propyl] - 1 - [3 -methoxy-4-
(methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-6, CHK-632) having following physicochemical properties was synthesized: 87 % yield, white solid, mp = 88-89 °C 1H ΝMR (CDC13) δ 7.50 (d, 1 H, J= 8.1 Hz), 6.75-7.05 (m, 6 H), 5.34 (t, 1 H), 3.88 (s, 3 H), 3.18 (dd, 2 H), 3.00 (s, 3 H), 2.47 (t, 2 H, J= 7.5 Hz), 2.21 (s, 6 H), 1.69 (m, 2 H), 1.59 (dd, 2 H), 1.01 (dd, 2 H) MS (FAB) w/z 431 (MH+)
Example 94: Preparation of N-(4-tert-Butylbenzyl)-l-[4-
(methylsulfonylamino)phenyl] cyclopropanecarboxamide (12-7, CHK-719) Through similar procedure to that in Example 1-5 excepting using l-[4- (Methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (11-7) as a starting material, N-(4-tert-Butylbenzyl)-l-[4-(methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-7, CHK-719) having following physicochemical properties was synthesized: 90 % yield, white solid, mp = 200-203 °C 1H ΝMR (DMSO-d6) δ 9.75 (bs, 1 H), 4.15 (d, 2 H, J = 6 Hz), 2.98 (s, 3 H), 1.32 (dd, 2 H), 1.25 (s, 9 H), 0.94 (dd, 2 H) MS (FAB) m/z 401(MH+)
Example 95: Preparation of N-(4-tert-Butylbenzyϊ)-l-[3-fluoro-4- (methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-8, CHK-998) Through similar procedure to that in Example 1-5 excepting using Methyl l-[3- fluoro-4-(methylsulfonylamino)phenyl]cyclopropanecarboxylate (10-5) as a starting material, N-(4-tert-Butylbenzyl)-l-[3-fluoro-4-
(methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-8, CHK-998) having following physicochemical properties was synthesized: 90 % yield, white solid, mp = 200-203 °C 1H ΝMR (CDC13) δ 9.75 (bs, 1 H), 4.15 (d, 2 H, J= 6 Hz), 2.98 (s, 3 H), 1.32 (dd, 2 H), 1.25 (s, 9 H), 0.94 (dd, 2 H) MS (FAB) m/z 401 (MH+)
Example 96: Preparation of N-(4-tέ?rt Butylbenzyl)-l-[3-methoxy-4- (methylsulfonylamino)phenyl]cyclopropanecarboxamide (12-9, CHK-718) Through similar procedure to that in Example 1-5 excepting using l-[3-Methoxy-4- (methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (11-8) as a starting material, N-(4-tert-Butylbenzyl)-l-[3-methoxy-4-
(methylsulfonylamino)phenyl] cyclopropanecarboxamide (12-9, CHK-718) having following physicochemical properties was synthesized: 90 % yield, white solid, mp = 200-203 °C 1H ΝMR (CDC13) δ 7.48 (d, 1 H), 7.31 (bd, 2 H), 7.09 (bd, 2 H), 7.03 (dd, 1 H), 6.94 (bs, 1 H), 6.80 (bs, 1 H), 5.67(bt, 1 H), 4.36 (d, 2 H), 3.86 (s, 3 H), 2.97 (s, 3 H), 1.65 (dd, 2 H), 1.29 (s, 9 H), 1.06 (dd, 2 H) MS (FAB) ;n/z 431 (MH+)
Example 97: Preparation of l-[4-(Methylsulfonylamino)phenyι]ethyl amine (13-11, LJO-302)
Step 97-1. Preparation of 4,-(Methylsulfonylamino)acetophenone (13-5, LJO-298 A cooled solution of 4'-aminoacetophenon (10 mmol) in pyridine (10 mL) at 0 °C was treated with methanesulfonyl chloride (15 mmol) and stirred at room temperature for 2 h. The reaction mixture was diluted with H2O and extracted with EtOAc several times. The combined organic layers were washed with H O and brine, dried over MgSO , filtered, and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes to afford 4'- (Methylsulfonylamino)acetophenone (13-5, LJO-298). 95% yield, mp = 161 °C 1H NMR (CDC13) δ 7.97 (dd, 2 H, J= 2, 6.8 Hz,), 7.26 (dd, 2 H, J= 2, 6.8 Hz), 6.87 (bs, 1 H), 3.10 (s, 3 H), 2.59 (s, 3 H)
Step 97-2. Preparation of 4'-(Methylsulfonylammo acetophenone oxime (13-8, LJO- 299) A mixture of 4'-(Methylsulfonylamino)acetophenone (13-5, 5 mmol) and hydroxylamine hydrochloride (0.695 g, 10 mmol) in pyridine (5 mL) was heated at 70 °C for 3 h. The reaction mixture was cooled to room temperature, diluted with H O, and extracted with EtOAc several times. The combined organic layers were washed with H2O and brine, dried over MgSO4, filtered, and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:1) as eluant to 4'-(Methylsulfonylamino)acetophenone oxime (13-8, LJO-299). 91% yield, white solid, mp = 180 °C 1H NMR (CDCI3) δ 7.65 (dd, 2 H, J= 2, 6.6 Hz,), 7.29 (s, 1 H), 7.20 (dd, 2 H, J= 2, 6.8 Hz), 6.43 (bs, 1 H), 3.03 (s, 3 H), 2.26 (s, 3 H)
Step 97-3. Preparation of l- 4-(Methylsulfonylamino phenyl ethyl amine (13-11, LJO- 302) A suspension of 4'-(Methylsulfonylamino)acetophenone oxime (13-8, 5 mmol) and 10% palladium on carbon (150 mg) in MeOH (25 mL) was treated with concentrated hydrochloric acid (10 drops) was hydrogenated under a balloon of hydrogen for 6 h. The reaction mixture was neutralized with solid NaHCO3, filtered and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using CH2Cl2:MeOH as eluant to afford l-[4- (Methylsulfonylamino)phenyljethyl amine (13-11, LJO-302). 99% yield, white solid, mp = 211 °C 1H NMR (CDC13) δ 7.35 (d, 2 H, J= 8.6 Hz), 7.18 (d, 2 H, J= 8.6 Hz), 4.13 (q, 1 H, J= 7 Hz), 3.00 (s, 3 H), 1.37 (d, 3 H, J= 7 Hz)
Example 98: Preparation of l-[3-Fluoro-4-(methylsulfonylamino)phenyl]ethyl amine (13-12, MK-232)
Step 98-1. Preparation of N-(2-Fluoro-4-iodophenyl)methanesulfonamide (13-3. SH-14 Through similar procedure to that in Example 97-1 excepting using 2-Fluoro-4- iodoanylin (13-1) as a starting material, N-(2-Fluoro-4-iodophenyl)methanesulfonamide
(13-3, SH-14) having following physicochemical properties was synthesized: 96% yield, white solid, mp = 123 °C 1H ΝMR (CDC13) δ 7.43 (bd, 2 H), 7.26 (t, 1 H, J= 8.3 Hz), 6.58 (bs, 1 H), 2.97 (s,
3 H)
Step 98-2. Preparation of 3,-Fluoro-4,-(methylsulfonylamino acetophenone (13-6, LJO- 363) A mixture of N-(2-Fluoro-4-iodophenyl)methanesulfonamide (13-3, 5 mmol) and palladium(II)acetate (0.15nM, 0.034g), 1,3-bisdiphenyl phosphinoprophan (0.3mM, 0.124g), thallium(I)acetate (5.5mM, 1.450g) and butylvinyl ether (lOmM, 1.3mL) in DMF (10 mL) was heated at 95 °C for 19 h. The reaction mixture was cooled to room temperature, diluted with THF, treated with 10% HCl (lOmL) and stirred at room temperature. A mixture was dilluted with EtOAc, washed with ammonium chloride solution three times and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes as eluant to 3'-Fluoro-4'- (methylsulfonylamino)acetophenone (13-6, LJO-363). 78% yield, yellow solid, mp = 141 °C 1H ΝMR (CDC13) δ 7.65-7.80 (m, 3 H), 6.89 (bs, 1 H), 3.12 (s, 3 H), 2.59 (s, 3 H)
Step 98-3. Preparation of 3'-fluoro-4'-(methylsulfonylamino)acetophenone oxime (13-9, LJO-327) Through similar procedure to that in Example 97-2 excepting using 3'-Fluoro-4'- (methylsulfonylamino)acetophenone (13-6) as a starting material, 3'-fluoro-4'- (methylsulfonylamino)acetophenone oxime (13-9, LJO-327) having following physicochemical properties was synthesized: 87% yield, white solid, mp = 173 °C 1H NMR (CDC13) δ 7.59 (t, 1 H, J= 8.3 Hz), 7.4-7.52 (m, 2 H), 6.60 (bs, 1 H), 3.05 (s, 3 H), 2.25 (s, 3 H)
Step 98-4. Preparation of l-r3-Fluoro-4-(methylsulfonylamino)phenyllethyl amine (13- 12, MK-232 Through similar procedure to that in Example 97-3 excepting using 3'-fluoro-4'- (methylsulfonylamino)acetophenone oxime (13-9) as a starting material, 3'-Fluoro-4- (methylsulfonylammo)phenyl]ethyl amine (13-12, MK-232) having following physicochemical properties was synthesized: 98% yield, white solid, mp = 160-167 °C 1H NMR (CD3OD) δ 7.45 (t, 2 H, J= 8.2 Hz), 7.24 (dd, 1 H, J= 11.5, 2 Hz), 7.18 (dd, 1 H, J= 8.3, 2 Hz), 4.15 (q, 1 H, J= 7 Hz), 2.97 (s, 3 H), 1.43 (d, 3 H, J= 7 Hz)
Example 99: Preparation of l-[3-(Methoxycarbonyl)-4-
(methylsulfonylamino)phenyl]ethyl amine (13-13, YHS-181)
Step 99-1. Preparation of N-(2-Fluoro-4-iodophenyl)methanesulfonamide (13-3, SH-14) A solution of 2-amino-4-iodinebenzonic acid (11 mM) in MeOH (50 mL) was added HCl (20 mmol) and H2SO4 (2mmol). The reaction mixture was refluxed and concentrated for a night, diluted with ΝaHCO3 and filtered with MgSO4 several times. The combined organic layers were washed with water, dried over MgSO , filtered, and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes to afford N-(2-Fluoro-4- iodophenyl)methanesulfonamide (13-3, SH-14). 50% yield (13-2) 1H ΝMR (CDC13) δ 8.34 (d, 1 H, J= 2.2 Hz), 7.80 (dd, 1 H, J= 2.2, 8.8 Hz), 7.50 (d, 1 H, J= 8.8 Hz), 3.93 (s, 3 H), 3.04 (s, 3 H) (13-4) 1H ΝMR (CDC13) δ 8.34 (d, 1 H, J= 2.2 Hz), 7.80 (dd, 1 H, J= 2.2, 8.8 Hz), 7.50 (d, 1 H, J= 8.8 Hz), 3.93 (s, 3 H), 3.04 (s, 3 H)
Step 99-2. Preparation of 3-(Methoxycarbonyl)-4'-(methylsulfonylamino acetophenone (13-7, YHS-176 Through similar procedure to that in Example 98-2 excepting using N-[4-Iodo-2- (methoxycarbonyl)phenyl]methanesulfonamide (13-4, YHS-27) as a starting material, 3-(Methoxycarbonyl)-4'-(methylsulfonylamino)acetophenone (13-7, YHS-176) having following physicochemical properties was synthesized: 60% yield, pale yellow solid, mp = 112-115 °C 1H NMR (CDC13) δ 8.67 (d, 1 H, J= 2 Hz), 8.14 (dd, 1 H, J= 2, 8.6 Hz), 7.82 (d, 1 H, J= 8.6 Hz), 3.99 (s, 3 H), 3.15 (s, 3 H), 2.61 (s, 3 H)
Step 99-3. Preparation of 3'-(Methoxycarbonv)-4,-(methylsulfonylamino)acetophenone oxime (13-10, YHS-180) Through similar procedure to that in Example 97-2 excepting using 3- (Methoxycarbonyl)-4'-(methylsulfonylamino)acetophenone (13-7) as a starting material, 3'-(Methoxycarbony)-4'-(methylsulfonylamino)acetophenone oxime (13-10, YHS-180) having following physicochemical properties was synthesized: 82% yield, white solid, mp = 136-137 °C 1H NMR (CDC13) δ 10.54 (bs, 1 H), 8.32 (d, 1 H, J= 2.2 Hz), 7.85 (dd, 1 H, J= 2.2, 8.8 Hz), 7.76 (d, 1 H, J= 8.8 Hz), 3.96 (s, 3 H), 3.09 (s, 3 H), 2.29 (s, 3 H)
Step 99-4. Preparation of. 1 -|"3-(Methoxycarbonyl)-4-
(methylsulfonylamino phenyllethyl amine (13-13, YHS-181) Through similar procedure to that in Example 97-3 excepting using 3'- (Methoxycarbony)-4'-(methylsulfonylamino)acetophenone oxime (13-10) as a starting material, l-[3-(Methoxycarbonyl)-4-(methylsulfonylamino)phenyl]ethyl amine (13-13, YHS-181) having following physicochemical properties was synthesized: 65% yield, colorless oil 1H NMR (CDC13) δ 8.07 (d, 1 H, J= 2.2 Hz), 7.70 (d, 1 H, J= 8.6 Hz), 7.58 (dd, 1 H, J= 2.2, 8.6 Hz), 4.18 (q, 1 H, J= 6.6 Hz), 3.94 (s, 3 H), 3.05 (s, 3 H), 1.41 (d, 3 H, J = 6.6 Hz)
Example 100: Preparation of l-[3-Methoxy-4-(methylsulfonylamino)phenyI] ethyl amine (14-3, CHK-570)
Step 100-1. Preparation of. Benzyl N- { 1 -|~3-methoxy-4-
(methylsulfonylamino phenyllethyllcarbamate (14-1, CHK-567) A 2-(3-methoxy-4-methylsulfonylamino)propion acid (260mg) in toluene (4 mL) was added diphenylphosphoryl azido (0.25 mL), triethylamine (0.33 mmol), was refluxed for 30 min, treated with benzylalchol (1.5 mL) The reaction mixture was refluxed for 5 hr. The combined organic layers were concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes to afford Benzyl N-{l-[3-methoxy-4-(methylsulfonylamino)phenyl]ethyl}carbamate (14-1, CHK-567). 72% yield, yellow oil 1H ΝMR (CDC13) δ 7.47 (d, 1 H, J = 8.3), 7.34 (bs, 5 H), 6.90 (bd, 1 H, J = 8.3), 6.85 (bs, 1 H), 6.73 (bs, 1 H), 5.08 (dd of AB, 2 H), 5.02 (bs, 1 H), 4.81 (m, 1 H), 3.86 (s, 3 H), 2.94 (s, 3 H), 1.47 (d, 3 H, J= 6.8 Hz)
Step 100-2. Preparation of l-[3-Methoxy-4-(methylsulfonylamino)phenyl]ethyl amine (14-3, CHK-570 Through similar procedure to that in Example 1-2 excepting using Benzyl N-{l-[3- methoxy-4-(methylsulfonylamino)phenyl] ethyl} carbamate (14-1) as a starting material, ιD3-Methoxy-4-(methylsulfonylamino)phenyl]ethyl amine (14-3, CHK-570) having following physicochemical properties was synthesized: 97 %> yield, colorless oil 1H ΝMR (CDC13) δ 7.45 (d, 1 H, J= 8.3), 6.97 (d, 1 H, J= 1.7 Hz), 6.90 (dd, 1 H, J = 1.7, 8.3 Hz), 4.13 (q, 1 H, J= 6.8 Hz), 3.90 (s, 3 H), 2.94 (s, 3 H), 1.38 (d, 3 H, J = 6.8 Hz)
Example 101: Preparation of l-[3-Chloro-4-(methyIsulfonyIamino)phenyl]ethyl amine (14-4)
Step 101-1. Preparation of Benzyl N-{l-r3-Chloro-4-
(methylsulfonylammo phenyl]ethyl| carbamate (14-2) The Benzyl N-{l-[3-Chloro-4-(methylsulfonylamino)phenyl]ethyl}carbamate (14-2) was prepared by the similar procedure with that described in above Example 100-1. 1H ΝMR (CDC13) δ 7.47 (d, 1 H), 7.34 (bs, 5 H), 6.90 (bd, 1 H), 6.85 (bs, 1 H), 6.73 (bs, 1 H), 5.08 (dd of AB, 2 H), 5.02 (bs, 1 H), 4.81 (m, 1 H), 3.86 (s, 3 H), 2.94 (s, 3 H), 1.47 (d, 3 H)
Step 101-2. Preparation of l- 3-Chloro-4-(methylsulfonylamino phenyllethyl amine (14-4) Through similar procedure to that in Example 1-2 excepting using Benzyl N-{l-[3- Chloro-4-(methylsulfonylamino)phenyl] ethyl} carbamate (14-2) as a starting materiafιD3-Chloro-4-(methylsulfonylamino)phenyl]ethyl amine (14-4) having following physicochemical properties was synthesized: 1H ΝMR (CDC13) δ 7.53 (d, 1 H), 7.00 (d, 1 H), 6.92 (dd, 1 H), 4.15 (q, 1 H), 2.96 (s, 3 H), 1.40 (d, 3 H)
Example 102: Preparation of N-(4-f-Butylbenzyl)-7V-{l-[4-
(methylsulfonylamino)phenyl]ethyl}thiourea (15-1, LJO-328) A mixture of l-[4-(Methylsulfonylamino)phenyl] ethyl amine (13-11, 1 mmol) and isothiocyanate (1 mmol) in DMF (2 mL) was stirred at room temperature for 2 h. The reaction mixture was diluted with H2O and extracted with EtOAc several times. The combined organic layers were washed with H2O and brine, dried over MgSO4, filtered, and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel with EtOAc -.hexanes (1:1) as eluant to N-(4-t- Butylbenzyl)-N-{ l-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (15-1, LJO-328) 93% yield, white solid, mp = 175 °C 1H ΝMR (CDCI3) δ 7.50 (t, 1 H, J= 8.04 Hz), 7.36 (d, 2 H), 7.14 (d, 2 H), 7.0-7.05 (m, 2 H), 6.48 (s, 1 H), 5.95 (bs, 2 H), 5.17 (bs, I" H), 4.56 (d, 2 H, J= 5.1 Hz), 3.02 (s, 3 H), 1.46 (d, 3 H, J= 6.8 Hz), 1.31 (s, 9 H) MS (FAB) m/z 438 (MH+)
Example 103: Preparation of N-(4-t'-ButylbenzyI)-N'-{l-[3-fluoro-4- (methylsulfonylamino)phenyl] ethyl} thiourea (15-2, CHK-992) Through similar procedure to that in Example 102 excepting using Methyl 2-amino- 5-iodobenzoate (13-2) as a starting material, N-(4-t-Butylbenzyl)-N5-{l-[3-fluoro-4- (methylsulfonylamino)phenyl] ethyl} thiourea (15-2, CHK-992) having following physicochemical properties was synthesized: 92% yield, white solid, mp = 165 °C 1H ΝMR (CDCI3) δ 7.59 (d, 1 H), 7.36 (d, 2 H), 7.32 (d, 1 H), 7.1-7.18 (m, 3 H), 6.75 (s, 1 H), 5.93 (bs, 1 H), 5.16 (bs, 1 H), 4.57 (bs, 1 H), 3.00 (s, 3 H), 1.46 (d, 3 H), 1.31 (s, 9 H) MS (FAB) m/z 455 (MH+)
Example 104: Preparation of N-(4-t-Butylbenzyl)-JV-{l-[3-methoxy-4- (methylsulfonylamino)phenyI]ethyI}thiourea (15-3, CHK-575) Through similar procedure to that in Example 67 excepting using l-[3-Methoxy-4- (methylsulfonylamino)phenyl] ethyl amine (14-3) as a starting material, N-(4-t- Butylbenzyl)-N'-{ l-[3-methoxy-4-(methylsulfonylamino)phenyl]ethyl}thiourea (15-3, CHK-575) having following physicochemical properties was synthesized: 91% yield, white solid, mp = 80-82 °C 1H NMR (CDCI3) δ 7.46 (d, 1 H, J = 8.04 Hz), 7.31 (d, 2 H), 7.03 (d, 2 H), 6.75- 6.85 (m, 3 H), 6.14 (bs, 2 H), 5.80 (bs, 2 H), 4.93 (bs, 1 H), 4.58 (ddd of AB, 2 H), 3.83 (s, 3 H), 2.94 (s, 3 H), 1.49 (d, 3 H, J= 6.6 Hz), 1.30 (s, 9 H) MS (FAB) m/z 450 (MH÷)
Example 105: Preparation of N-(4-t-Butylbenzyl)--V-{l-[3-(methoxycarbonyI)-4- (methylsulfonylamino)phenyl] ethyl} thiourea (15-4, YHS-187) Through similar procedure to that in Example 102 excepting using N-(2-Fluoro-4- iodophenyl)methanesulfonamide (13-3) as a starting material, N-(4-t-Butylbenzyl)-N- {l-[3-(methoxycarbonyl)-4-(methylsulfonylamino)phenyl]ethyl} thiourea (15-4, YHS- 187) having following physicochemical properties was synthesized: 70% yield, white solid, mp = 132-135 °C 1H ΝMR (CDC13) δ 7.99 (d, 1 H, J= 2.2 Hz), 7.31 (d, 1 H, J= 8.6 Hz), 7.41 (dd, 1 H, J= 8.6, 2.2 Hz), 7.33 (d, 2 H), 7.11 (d, 2 H), 6.04 (bs, 1 H), 5.90 (bs, 1 H), 5.15 (bs, 1 H), 4.58 (s, 2 H), 3.94 (s, 3 H), 3.05 (s, 3 H), 1.48 (d, 3 H, J= 6.8 Hz), 1.30 (s, 9 H) MS (FAB) m/z 478 (MH+)
Example 106: Preparation of N-(4-t'-Butylbenzyl)-iV-{l-[3-carboxy-4- (methylsulfonylamino)phenyl] ethyl} thiourea (15-5, YHS-209) Through similar procedure to that in Example 1-4 excepting using N-(4-t- Butylbenzyl)-N-{ l-[3-(methoxycarbonyl)-4-
(methylsulfonylamino)phenyl] ethyl} thiourea (15-4) as a starting material, N-(4-t- Butylbenzyl)-N'-{ l-[3-carboxy-4-(methylsulfonylamino)phenyl]ethyl} thiourea (15-5, YHS-209) having following physicochemical properties was synthesized: 72% yield, white solid, mp = 189-192 °C 1H ΝMR (CD3OD) δ 8.00 (d, 1 H, J= 2.2 Hz), 7.49 (d, 1 H, J= 8.6 Hz), 7.35 (dd, 1 H, J= 8.6, 2.2 Hz), 7.22 (d, 2 H), 7.04 (d, 2 H), 6.78 (bs, 1 H), 5.34 (bs, 1 H), 4.64 (d, 1 H, J= 14 Hz), 4.47 (d, 1 H, J= 15 Hz), 2.88 (s, 3 H), 1.38 (d, 3 H, J= 7 Hz), 1.19 (s, 9 H) MS (FAB) m/z 464 (MH+)
Example 107: Preparation of N-(4-t-Butylbenzyl)-7V-{(lR)-l-[4-
(methylsulfonylamino)phenyl]ethyl}thiourea (16-5, SU-388)
Step 107-1. Preparation of N-(4-t-Butylbenzyl)-N-[(lR)-l-(4- nitrophenvDethyllthiourea (16-1. SU-354) To a stirred solution of (R or S)-c--methyl-4-nitrobenzyl amine hydrochloride (203 mg, 1 mmol) in anhydrous CH2C12 (10 L) was added triethylamine (0.28 mL, 2 mmol) at room temperature. When the reaction mixture became clear, isothiocyanate (1 mmol) was added and stirred overnignt at room temperature. The mixture was evaporated by rotary evaporator and the residue was purified by flash column chromatography on silica gel with EtOAc :hexanes as eluant to N-(4-t-Butylbenzyl)-N"-{(lR)-l-[4- (methylsulfonylamino)ρhenyl] ethyl} thiourea (16-5, SU-388). 98% yield, a sticky colorless oil 1H ΝMR (CDC13) δ 8.12 (d, 2 H, J= 8.76 Hz), 7.34 (bd, 4 H), 7.14 (d, 2 H, J= 8.0 Hz), 6.21 (bs, 2 H), 5.37 (bs, 1 H), 4.54 (m, 2 H), 1.47 (d, 3 H, J= 7.05 Hz), 1.30 (s, 9 H)
Step 107-2. Preparation of N-(4-t-Butylbenzyl)-N,-r(lR)-l-(4- aminophenyl ethyl]thiourea (16-3. SU-358) Aluminium foil (0.05 mm thick, 406 mg, 15 mmol) was roughed with sand paper, cut into 0.5 cm squares, and weighed in the reaction flask, The aluminium was etched with 5%> KOH hydroxide solution until vigorous evolution of H2 occurred and then the basic solution was removed by decantation. The Al was rinsed with H2 and covered with 0.5% HgCl2 solution for 2 min. The HgCl2 solution was poured off and the Al was washed with H2O. HgCl2 solution was reintroduced for 2 min and the solution was decanted away. Al was washed with H2O followed by ethanol and diethyl ether several times. A solution of nitro (0.5 mmol) in diethyl ether (5 mL) was added to the freshly prepared amalgam and then a drop of H2O was introduced and the mixture was refluxed for 10 minutes. After the reaction was completed by TLC, the mixture was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel with EtOAc:hexanes as eluant to N-(4-t-Butylbenzyl)-N'-[(lR)-l-(4- aminophenyl)ethyl]thiourea (16-3, SU-358). 67% yield, a faint yellow oil 1H ΝMR (CDC13) D7.29 (d, 2 H, J= 8.3 Hz), 7.04 (d, 2 H, J= 8.3 Hz), 6.99 (d, 2 H, J = 8.04 Hz), 6.63 (d, 2 H, J = 8.3 Hz), 6.16 (bs, 1 H), 5.73 (bs, 1 H), 4.69 (bs, 1 H), 4.60 (d, 2 H, J= 4.86 Hz), 3.69 (bs, 2 H), 1.45 (d, 3 H, J= 6.84 Hz), 1.30 (s, 9 H)
Step 107-3. Preparation of N-(4-t-Butylbenzyl)-N,-{(lR)-l-r4-
(methylsulfonylamino)phenyl] ethyl) thiourea (16-5, SU-388) A cooled solution of N-(4-t-Butylbenzyl)-N,-[(lR)-l-(4-aminophenyl)ethyl]thiourea (16-3, 0.25 mmol) in pyridine (2 mL) at 0 °C was treated with methanesulfonyl chloride (0.3 mmol) and stirred for 10 min at 0 °C. After aqueous work-up, the residue was purified by flash column chromatography on silica gel with EtOAc :hexanes as eluant 75% yield, white solid, mp = 101 °C The spectral data of compound 16-5 were identical to those of compound 15-1. [α] = - 13.34 (CHC13, c = 1.075)
Example 108: Preparation of N-(4-t-Butylbenzyl)-iV-{(lS)-l-[4-
(methylsulfonylamino)phenyl] ethyl} thiourea (16-6, SU-400)
Step 108-1. Preparation of N-(4-t-Butylbenzyl)-N,-|r(lS)-l-(4-nitrophenyl)ethvnthiourea (16-2. SU-366) The N-(4-t-Butylbenzyl)-N'-[(lS)-l-(4-nitroρhenyl)ethyl]thiourea (16-2, SU-366) was prepared by the similar procedure with that described in above Example 107-1. A sticky white oil The spectral data of compound 16-2 were identical to those of compound 16-1.
Step 108-2. Preparation of N-(4-t-Butylbenzyl)-N,-r(lS)-l-(4- aminophenvDethvHthiourea (16-4, SU-394) The N-(4-t-Butylbenzyl)-N'-[(lS)-l-(4-aminoρhenyl)ethyl]thiourea (16-4, SU-394) was prepared by the similar procedure with that described in above Example 107-1. A faint yellow oil The spectral data of compound 16-4 were identical to those of compound 16-3.
Step 108-3. Preparation of N-(4-t-Butylbenzyl)-N-((lS)-l-[4-
(methylsulfonylamino)phenyl]ethyl}thiourea (16-6, SU-400) The N-(4-t-Butylbenzyl)-N'-{(lS)-l-[4-
(methylsulfonylamino)phenyl]ethyl}thiourea (16-6, SU-400) was prepared by the similar procedure with that described in above Example 107-1. 75% yield, white solid, mp = 101 °C The spectral data of compound 16-6 were identical to those of compound 15-1. [α] = + 10.60 (CHCI3, c = 1.075)
Example 109: Preparation of (R)-N-(4-t-Butylbenzyl)-N'-{l-[3-fluoro-4- (methylsulfonylamino)phenyl] ethyl} thiourea (17-3, CJU-032) Step 109-1. Preparation of (RVSulfonamide (17-1) To a 0.5M solution of Ti(OEt)4 (0.3 mL, 1.44 mmol) and N-(4-acetyl-2-fluoro- phenyl)-methanesulfonamide (0.2 g, 0.87 mmol) in THF (5 mL) under an Ν2 atmosphere was added (R)-(+)-2-methyl-2-propanesulfinamide (0.087 g, 0.72 mmol) and the mixture was heated (70 °C). Upon completion, as determined by TLC, the mixture was cooled to room temperature and then to -40 °C before it was cannulated dropwise into a -40 °C solution of NaBH4 (0.109 g. 2.88 mmol). The mixture was stirred at -40 °C for 12 h, and then MeOH was added dropwise until gas was no longer evolved. The resulting suspension was filtered through a plug of Celite and the filter cake was washed with EtOAc. The filtrate was washed with brine, and the brine layer was extracted with EtOAc. The combined organic portions were dried (Na2SO ), filtered, and concentrated. After silica gel column chromatography (n-hexane/EtOAc), The (R)- sulfonamide (0.105 g, 0.31 mmol, 36%) was isolated 1H-NMR (CDC13) δ 7.53 (t, 1 H, J= 8.4Hz), 7.19 (m, 1 H), 7.15 (m, 1 H), 6.97 (bs, 1 H), 4.53 (m, 1 H), 3.50 (d, 1 H, J= 3.8 Hz), 3.04 (s, 3 H), 1.75 (bs, 1 H), 1.51 (d, 3 H, J= 6.5 Hz), 1.25 (s, 9 H).
Step 109-2. Preparation of (R)-l-l"3-Fluoro-4-(methylsulfonylamino)phenyl]ethyl amine hydrochloride (17-2) To a (R)-sulfonamide (0.105 g, 0.31 mmol) was added 1:1 (v/v) MeOH and HCl dioxane solution (4.0 M, 0.22 mL). The mixture was stirred at room temperature for 30 minutes and was then concentrated to near dryness. Diethyl ether was added to precipitate the amine hydrochloride. The precipitate was then filtered off and washed with diethyl ether to provide analytically pure (R)-l-[3-Fluoro-4- (methylsulfonylamino)phenyljethyl amine hydrochloride (17-2, 0.059 g, 0.22 mmol, 70%, 96.11 ee%) 1H-NMR (DMSO-d6) δ 9.71 (bs, 1 H), 8.60 (bs, 3 H), 7.52 (dd, 1 H, J= 1.9, 11.8 Hz), 7.42 (t, 1 H, J= 8.4 Hz), 7.33 (dd, 1 H, J= 1.8, 8.4 Hz), 4.39 (m, 1 H), 3.62 (m, 1 H), 3.05 (s, 3 H), 1.49 (d, 3 H, J= 6.5 Hz).
Step 109-3. Preparation of N-{4-(l-r3-(4-tert-Butyl-benzyl -thioreido1-ethyl|-2-fluoro- phenyU-methanesulfonamide (17-3, CJU-032) To a stirred solution of 4-[4-(l-Amino-ethyl)-2-fluoro-phenyl]-methanesulfonamide hydrochloride (0.020 g, 0.075 mmol) in DMF (1 mL), Et3N (13 μL, 0.09 mmol), 1-tert- butyl-4-isothiocyanatomethyl benzene (15 mg, 0.075 mmol) were added in the written order. The reaction mixture was stirred for 3 hours at room temperature. And then the reaction solution was extracted by EtOAc and the organic phase was washed with H2O, dried (Na2SO4), filtered and concentrated. After silica gel column chromatography (n- hexane/EtOAc), N- {4- { 1 -[3-(4-tert-Butyl-benzyl)-thioreido]-ethyl} -2-fluoro-phenyl} - methanesulfonamide (26 mg, 0.06 mmol, 85% ) was isolated [α] -19.24 (c 0.7, CHC13), ee% 98.41% 1H-NMR (CDC13) δ 7.42 (t, 1 H, J= 9.0 Hz), 7.35 (m, 1 H), 7.33 (m, 1 H), 7.12 (m, 2 H), 7.00 (m, 2 H), 6.90 (bs, 1 H), 6.45-6.10 (bs, 2 H), 5.18 (bs, 1 H), 4.54 (m, 2 H), 2.98 (s, 3 H), 1.43 (d, 3 H, J = 3.0Hz), 1.29 (s, 9 H).
Example 110: Preparation of (S)-N-(4-t-Butylbenzyl)-iV-{l-[3-fluoro-4- (methylsulfonylamino)phenyl] ethyl} thiourea (17-6, CJU-039)
Step 110-1. Preparation of (S)-Sulfonamide (17-4) The compound 17-4 was prepared from (S)-(-)-2-methyl-2-propanesulfinamide by following the similar procedure with that described in Example 109-1. 31% yield 1H-NMR (CDC13) δ 7.47 (m, 1 H), 7.26 (bs, 1 H), 7.17 -7.08 (m, 2 H), 4.48 (m, 1 H), 3.54 (d, 1 H, J= 3.8 Hz), 2.99 (s, 3 H), 1.47 (d, 3 H, J= 6.5 Hz), 1.21 (s, 9 H).
Step 110-2. Preparation of (S)-l-[3-Fluoro-4-(methylsulfonylamino)phenyl1ethyl amine hydrochloride (17-5) The compound 17-5 was prepared from (S)-Sulfonamide (17-4) by following the similar procedure with that described in Example 109-2. 88% yield, 97.9 ee% The spectral data is identical to that of 17-2.
Step 110-3. Preparation of (S)-N-(4-t-Butylbenzyl)-N,-{l-r3-fluoro-4- (methylsulfonylamino)phenyl] ethyl) thiourea (17-6, CJU-039) The compound 17-6 was prepared from (S)-l-[3-Fluoro-4- (methylsulfonylamino)phenyl]ethyl amine hydrochloride (17-5) by following the similar procedure with that described in Example 1-5. 80% yield, [α] = 16.04 (c 0.7, CHC13), 97.76 ee% The spectral data is identical to that of 17-3.
Example 111: Preparation of N-[(2R)-2-Benzyl-3-(pivaloyloxy)propyl]-iV-{(lR)-l- [4-(methylsulfonylamino)phenyl]ethyI}thiourea (18-1, MK-229) The N-[(2R)-2-Benzyl-3-(pivaloyloxy)propyl]-N- {(lR)-l-[4-
(methylsulfonylamino)phenyl]ethyl} thiourea (18-1) was prepared by the similar procedure with that described in above Example 1-5. 84% yield, white solid, mp = 62-64 °C [δ] = -10.8 (CHCl3, c 1.0) lH NMR (CDCI3) δ 7.1-7.35 (m, 9 H), 6.61 (bs, 1 H), 6.26 (bs, 1 H), 6.15 (bt, 1 H), 4.82 (bs, 1 H), 4.10 (dd, 1 H, J= 11.7, 3.3 Hz), 3.6-3.75 (m, 2 H), 3.24 (m, 1 H), 2.96 (s, 3 H), 2.55 (dd, 1 H), 2.54 (dd, 1 H), 2.36 (dd, 1 H), 2.29 (bs, 1 H), 1.49 (d, 3 H, J= 6.6 Hz), 1.21 (m, 9 H) MS (El) m/z 505 (M+)
Example 112: Preparation of N-[(2S)-2-Benzyl-3-(pivaloyloxy)propyI]-N'-{(lR)-l- [4-(methylsulfonylamino)phenyl] ethyl} thiourea (18-2, MK-202) The N-[(2S)-2-Benzyl-3-(pivaloyloxy)propyl]-N'-{(lR)-l-[4-
(methylsulfonylamino)phenyl]ethyl}thiourea (18-2) was prepared by the similar procedure with that described in above Example 1-5. 76% yield, white solid, mp = 58-62 °C [δ] = +2.04 (CHCl3, c 1.0) 1H ΝMR (CDCI3) δ 7.1-7.35 (m, 9 H), 6.37 (bs, 1 H), 6.11 (bs, 1 H), 4.80 (bs, 1 H), 3.7-3-9 (m, 2 H), 3.58 (m, 1 H), 3.12 (m, 1 H), 2.94 (s, 3 H), 2.54 (ddd, 2 H), 2.17 (bs, 1 H), 1.47 (d, 3 H, J= 6.6 Hz), 1.21 (m, 9 H) MS (FAB) m/z 506 (MH+)
Example 113: Preparation of N-[(2R)-2-Benzyl-3-(pivaloyloxy)propyl]-N'-{(lS)-l- [4-(methylsulfonylamino)phenyl] ethyl} thiourea (18-3, MK-230) The N-[(2R)-2-Benzyl-3-(pivaloyloxy)propyl]-N'-{(lS)-l-[4-
(methylsulfonylamino)phenyl]ethyl}thiourea (18-3) was prepared by the similar procedure with that described in above Example 1-5. 81% yield, white solid, mp = 58-62 °C [α] = -2.48 (CHCl3, c 1.0) The spectral data of compound 18-3 were identical to those of compound 18-2.
Example 114: Preparation of N-[(2S)-2-Benzyl-3-(pivaloyloxy)propyl]-iV-{(lS)-l- [4-(methylsuIfonyIamino)phenyl]ethyl}thiourea (18-4, MK-228) The N-[(2S)-2-Benzyl-3-(pivaloyloxy)propyl]-N-{(lS)-l-[4-
(methylsulfonylamino)phenyl] ethyl} thiourea (18-4) was prepared by the similar procedure with that described in above Example 1-5. 88% yield, white solid, mp = 62-64 °C [α] = +11.61 (CHCl3, c 1.0) The spectral data of compound 18-3 were identical to those of compound 18-1. MS (FAB) m/z 506 (MH+) Example 115: Preparation of N-[2-(3,4-DimethyIbenzyl)-3-(pivaIoyϊoxy)propyl]-N'- {l-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-5, LJO-388) The N-[2-(3,4-Dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{l-[4-
(methylsulfonylamino)phenyl] ethyl} thiourea (18-5) was prepared by the similar procedure with that described in above Example 1-5. 87% yield, white solid, mp = 77 °C 1H ΝMR (CDC13) δ 7.15-7.35 (m, 4 H), 6.8-7.05 (m, 4 H), 6.36 (bs, 1 H), 6.18 (bs, 1 H), 4.79 (bs, 1 H), 3.55-3.75 (bs, 3 H), 3.12 (m, 1 H), 2.95-3.0 (s, 3 H), 2.4-2.6 (m, 2 H), 2.1-2.3 (m, 7 H), 1.4-1.5 (m, 3 H), 1.20 (m, 9 H)
Figure imgf000092_0001
Example 116: Preparation of N-[2-(3,4-Dimethylbenzyl)-3-(pivaloyloxy)propyl]-iV- {(lR)-l-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-6, SU-472) The N-[2-(3,4-Dimethylbenzyl)-3-(pivaloyloxy)propyl]-N-{(lR)-l-[4-
(methylsulfonylamino)phenyl] ethyl} thiourea (18-6) was prepared by the similar procedure with that described in above Example 1-5. white solid, The spectral data of compound 18-6 were identical to those of compound 18-5.
Example 117: Preparation of N-[(2R)-2-(3,4-Dimethylbenzyl)-3-
(pivaloyloxy)propyl]-iV-{(li?)-l-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-7, SU-512) The N-[(2R)-2-(3,4-Dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{(lR)-l-[4-
(methylsulfonylamino)phenyl] ethyl} thiourea (18-7) was prepared by the similar procedure with that described in above Example 1-5. 1H ΝMR (CDC13) δ 7.34 (bd, 2 H), 7.19 (bd, 2 H), 6.7-7.05 (m, 3 H), 6.29 (bs, 1 H), 6.15 (bs, 1 H), 4.81 (bs, 1 H), 4.12 (m, 1 H), 3.5-3.75 (m, 2 H), 3.18 (m, 1 H), 2.96 (s, 3 H), 2.4-2.6 (m, 2 H), 2.1-2.3 (m, 7 H), 1.4-1.5 (d, 3 H), 1.21 (m, 9 H)
Example 118: Preparation of N-[(2S)-2-(3,4-Dimethylbenzyl)-3-
(pivaloyloxy)propyl]-N'-{(lR)-l-[4-(methylsulfonylamino)phenyl]ethyl}thiourea
(18-8) The N-[(2S)-2-(3,4-Dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{(lR)-l-[4-
(methylsulfonylamino)phenyl]ethyl}thiourea (18-8) was prepared by the similar procedure with that described in above Example 1-5. 1H NMR (CDCI3) δ 7.33 (bd, 2 H), 7.18 (bd, 2 H), 6.72-7.05 (m, 3 H), 6.28 (bs, 1 H), 6.12 (bs, 1 H), 4.80 (bs, 1 H), 4.11 (m, 1 H), 3.5-3.75 (m, 2H), 3.19 (m, 1 H), 2.98 (s, 3H), 2.4-2.6 (m, 2 H), 2.1-2.3 (m, 7 H), 1.4-1.5(d, 3H), 1.22 (m, 9H) MS (FAB) m/z 534 (MH+)
Example 119: Preparation of N-[2-(4-tert-ButyIbenzyl)-3-(pivaloyloxy)propyl]-iV- {l-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-9, LJO-401) The N-[2-(4-tert-Butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{l-[4-
(methylsulfonylamino)phenyl] ethyl} thiourea (18-9) was prepared by the similar procedure with that described in above Example 1-5. 84% yield, white solid, mp = 87 °C 1H ΝMR (CDC13) δ 7.0-7.35 (m, 8 H), 6.43 (bs, 1 H), 6.19 (bs, 1 H), 4.83 (bs, 1 H), 3.55-3.75 (bs, 3 H), 3.1-3.3 (m, 1 H), 2.93 (s, 3 H), 2.4-2.6 (m, 2 H), 2.25 (m, 1 H), 1.4- 1.5 (m, 3 H), 1.28 (s, 9 H), 1.20 (s, 9 H) MS (FAB) m/z 562 (MH+)
Example 120: Preparation of N-[2-(4-t'ert-Butylbenzyl)-3-(pivaloyloxy)propyl]-iV- {(lR)-l-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-10, MK-296) The N-[2-(4-tert-Butylbenzyl)-3 -(ρivaloyloxy)propyl] -NT - {( 1R)- 1 -[4-
(methylsulfonylamino)phenyl] ethyl} thiourea (18-10) was prepared by the similar procedure with that described in above Example 1-5. 88% yield, white solid, mp = 88-90 °C 1H ΝMR (CDC13) δ 7.25-7.35 (m, 4 H), 7.15-7.23 (m, 2 H), 7.0-7.1 (m, 2 H), 6.36 (bs, 1 H), 6.15 (bs, 1 H), 4.84 (bs, 1 H), 3.5-3.9 (m, 3 H), 3.1-3.3 (m, 1 H), 2.94 (s, 3 H), 2.3-2.55 (m, 2 H), 2.15 (m, 1 H), 1.48 (m, 3 H, J= 6.8 Hz), 1.29 (s, 9 H), 1.21 (s, 9 H) MS (FAB) m/z 562 (MH+)
Example 121: Preparation of N-[(2R)-2-(4-tert-Butylbenzyl)-3-
(pivaloyloxy)propyI]-iV-{(lR)-l-[4-(methylsulfonylamino)phenyI]ethyI}thiourea (18-11, MK-334) The N-[(2R)-2-(4-tert-Butylbenzyl)-3-(pivaloyloxy)propyl]-N'- {(1R)-1 -[4-
(methylsulfonylamino)phenyl]ethyl}thiourea (18-11) was prepared by the similar procedure with that described in above Example 1-5. 88% yield, white solid, mp = 85-87 °C [α] = -17.3 (c 1.00, CHC13) 1H ΝMR (CDC13) δ 7.28-7.36 (dd, 4 H), 7.19 (d, 2 H), 7.03 (d, 2 H), 6.80 (bs, 1 H), 6.34 (bs, 1 H), 6.15 (bt, 1 H), 4.84 (bs, 1 H), 4.08 (dd, 1 H, J= 3.8, 11.7 Hz), 3.55-3.7 (m, 2 H), 3.24 (ddd, 1 H), 2.95 (s, 3 H), 2.50 (dd, 1 H), 2.34 (dd, 1 H), 2.26 (m, 1 H), 1.48 (d, 3 H, J= 6.8 Hz), 1.29 (s, 9 H), 1.21 (s, 9 H) MS (FAB) m/z 562 (MH+)
Example 122: Preparation of N-[(2S)-2-(4-tert-Butylbenzyl)-3-(pivaloyloxy)propyl]- iV-{(lR)-l-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-12, MK-298) The N-[(2S)-2-(4-tert-Butylbenzyl)-3-(pivaloyloxy)propyl]-N-{(lR)-l-[4-
(methylsulfonylamino)phenyl] ethyl} thiourea (18-12) was prepared by the similar procedure with that described in above Example 1-5. 86% yield, white solid, mp = 88-90 °C [ ] = -3.77 (c 1.00, CHC13) 1H ΝMR (CDC13) δ 7.25-7.35 (dd, 4 H), 7.18 (d, 2 H), 7.05 (d, 2 H), 6.47 (bs, 1 H), 6.15 (bs, 1 H)5 4.84 (bs, 1 H), 3.55-3.9 (m, 3 H), 3.14 (ddd, 1 H), 2.94 (s, 3 H), 2.52 (ddd of AB, 2 H), 2.16 (m, 1 H), 1.47 (d, 3 H, J= 6.8 Hz), 1.29 (s, 9 H), 1.21 (s, 9 H) MS (FAB) m/z 562 (MF )
Example 123: Preparation of N-[2-(3,4-DimethylbenzyI)-3-(pivaloyloxy)propyl]-iV- {l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-13, LJO-344) The N-[2-(3,4-Dimethylbenzyl)-3-(pivaloyloxy)propyl]-N-{l-[3-fluoro-4-
(methylsulfonylamino)phenyl]ethyl}thiourea (18-13) was prepared by the similar procedure with that described in above Example 1-5. 76% yield, white solid, mp = 73 °C 1H ΝMR (CDC13) δ 7.50 (m, 1 H), 6.8-7.2 (m, 5 H), 6.75 (bs, 1 H), 6.30 (bs, 1 HH), 6.22 (bs, 1 H), 4.89 (bs, 1 H), 4.16 (m, 1 H), 3.6-3.9 (m, 2 H), 3.10 (m, 1 H), 3.0 (m, 3 H), 2.45-2.65 (m, 2 H), 2.15-2.3 (m, 7 H), 1.4-1.5 (m, 3 H), 1.22 (m, 9 H) MS (FAB) m/z 552 (MH+)
Example 124: Preparation of N-[2-(4-tert-Butylbenzyl)-3-(pivaloyloxy)propyl]-iV- {l-[3-fluoro-4-(methylsuIfonylamino)phenyl]ethyl}thiourea (18-14, LJO-366) The N-[2-(4-tert-Butylbenzyl)-3-(pivaloyloxy)ρropyl]-N'-{l-[3-fluoro-4-
(methylsulfonylamino)phenyl]ethyl}thiourea (18-14) was prepared by the similar procedure with that described in above Example 1-5. 73% yield, white solid, mp = 78 °C 1H ΝMR (CDC13) δ 7.53 (m, 1 H), 7.0-7.35 (m, 6 H), 6.53 (bs, 1 H), 6.24 (bt, 1 H), 6.17 (bs, 1 H), 4.92 (bs, 1 H), 4.15 (m, 1 H), 3.6-3.9 (m, 2 H), 3.10 (m, 1 H), 3.0 (m, 3 H), 2.4-2.6 (m, 2 H), 2.24 ( , 1 H), 1.4-1.5 ( , 3 H), 1.29 (m, 9 H), 1.22 (m, 9 H) MS (FAB) m/z 580 (MH+)
Example 125: Preparation of N-[(2R)-3-phenyl-l-pivaloyloxy-2-propyl]-N'-[(R)-α- methyI-4-(methylsuIfonyIamino)benzy]thiourea (19-13, SU-692)
Step 125-1. Preparation of (2RV3 -phenyl- l-pivaloyloxy-2-propyl amine (19-1, YHS-43) A solution of (2R)-N-(tert-butoxycarbonyl)phenylalaniol (3.323g) on the market in methylene chloride (50 mL) was added triethylamine (7.4mL) and pivaloy chloride (2.4 mL). The mixture was stirred for 4hr at room temperate.50 °C and then for 10 min. at room temperature. The mixture was directly purified by column chromatography using EtOAc:hexanes (1:4) as eluant to afford ester compound. And then the reaction compound was diluted with methylene chloride (lOmL) was stirred trifluoroacetic acid (2.5mL). The mixture was stirred at room temperature for 2 hours and was concentrated in vacuo to afford (2R)-3 -phenyl- l-pivaloyloxy-2 -propyl amine (19-1, YHS-43). 1H NMR (CDC13) δ 7.15-7.38 (m, 5 H), 4.22 (dd of AB, 2 H), 3.73 (bs, 1 H), 3.03 (ddd of AB, 2 H), 1.22 (s, 9 H)
Step 125-2. Preparation of (2R)-3 -phenyl- l-pivaloyloxy-2-propyl isothiocyanate (19-3, SU-684) A solution of (2R)-3 -phenyl- l-pivaloyloxy-2 -propyl amine (19-1, lmmol) and Et3N (1 mmol) in DMF (1 mL) was added dropwise into the pre-dissolved solution of 1, 1- thiocarbonyl diimidazole (1.2 mmol) in DMF (2 mL) at 50 °C over 1 min. The mixture was stirred for 1 min. at 50 °C and then for 10 min. at room temperature. The mixture was directly purified by column chromatography using EtOAc :hexanes (1:5) as eluant to afford (2R)-3 -phenyl- l-pivaloyloxy-2-propyl isothiocyanate (19-3, SU-684). 89% yield, colorless oil. 1H NMR (CDC13) δ 7.15-7.35 (m, 5 H), 4.22 (dd, 1 H, J= 2.7, 10 Hz), 4.02-4.12 (m, 2 H), 2.94 (d, 2 H, J= 6.3 Hz), 1.25 (s, 9 H)
Step 125-3. Preparation of N-r(2R -3-phenyl-l-ρivaloyloxy-2-ρroρyl1-N,-lYRyα- methyl-4-nitrobenzyl thiourea (19-5, SU-688) To a stirred solution of (R or S)-c--methyl-4-nitrobenzyl amine hydrochloride (1.1 mmol) in CH2CI2 (8 mL) was added Et3Ν (1.1 mmol) at room temperature. The mixture was stirred for 10 minutes. When the reaction mixture became clear, isothiocyanate (1 mmol) in CH2C12 (2 mL) was added. The mixture was stirred overnight at room temperature and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel with EtOAc : hexanes (1 :2 to 1 : 1). 81% yield, yellow oil 1H NMR (CDC13) δ 8.15 (d, 2 H, J = 8.5 Hz), 7.45 (d, 2 H, J= 8.5 Hz), 7.15-7.35 (m, 5 H), 6.60 (bs, 1 H), 6.08 (bs, 1 H), 5.22 (bs, 1 H), 4.47 (bs, 1 H), 4.13 (dd, 1 H, J= 3, 11.8 Hz), 3.86 (dd, 2 H, J= 5.6, 11.8 Hz), 2.96 (dd, 1 H, J= 5.85, 13.5 Hz), 2.80 (dd, 1 H, J= 7.3, 13.5 Hz), 1.49 (d, 3 H, J= 7.1 Hz), 1.16 (s, 9 H)
Step 125-4. Preparation of N-f(2R)-3-ρhenyl-l-pivaloyloxy-2-propyl1-N-r(R)-α- methyl-4-aminobenzylthiourea (19-9. SU-690 Aluminium foil (0.05mm thick, 328 mg, 12.174 mmol) was roughed with sand bar, cut into 0.5 cm squares and was etched with 5 % KOH hydroxide solution until vigorous evolution of H2 occurred. The basic solution was removed by decantation and the Al was rinsed with H2O two times and was covered with 0.5 % HgCi2 solution for 2 minutes. The mercuric chloride was poured off, the Al was washed with H2O two times and HgCl2 solution was reintroduced for 2 minutes. Once again the HgC , solution was decanted away, Al was washed with H2O several times followed by ethanol and diethyl ether several times. A solution ofN-[(2R)-3-phenyl-l-pivaloyloxy-2-propyl]-N-[(R)-D- methyl-4-nitrobenzy]thiourea (19-5, 180 mg, 0.406 mmol) in diethyl ether 10 mL was added to the freshly prepared amalgam then H2O (3 drops) was introduced and the mixture was refluxed for 30 minutes. After the reaction was completed by TLC, the mixture was cooled down to room temperature and filtered through glass funnel spreaded with MgSO (0.7 cm) above celite 545 (0.7 cm). The filtrate was evaporated by rotary evaporator to be dried by vacuum pump. 96% yield, colorless oil 1H ΝMR (CDC13) δ 7.15-7.35 (m, 5 H), 7.00 (d, 2 H, J= 8.3 Hz), 6.63 (d, 2 H, J= 8.3 Hz), 6.30 (bs, 1 H), 5.70 (bs, 1 H), 4.75 (bs, 1 H), 4.52 (bs, 1 H), 3.96 (dd, 1 H, J= 3, 11.2 Hz), 3.79 (dd, 2 H, J= 4.6, 11.2 Hz), 2.97 (dd, 1 H, J= 5.85, 13.9 Hz), 2.77 (dd, 1 H, J= 8, 13.9 Hz), 1.41 (d, 3 H, J= 7.1 Hz), 1.16 (s, 9 H)
Step 125-5. Preparation of N-r(2R)-3-ρhenyl-l-pivaloyloxy-2-propyl1-iV,-|'(R)-α- methyl-4-(methylsulfonylamino)benzy]thiourea (19-13, SU-692) A cooled solution of N-[(2R)-3-phenyl-l-pivaloyloxy-2-propyl]-N-[(R)-α-methyl- 4-aminobenzy]thiourea (19-9, 0.5 mmol) in pyridine (2 mL) at 0 °C was treated dropwise with methanesulfonyl chloride (0.75 mmol) and was stirred for 10 minutes at 0 °C. The mixture was directly purified by flash column chromatography on silica gel with EtOAc:hexanes (1:1) as eluant to N-[(2R)-3-phenyl-l-pivaloyloxy-2-propyl]-N'- [(R)-α-methyl-4-(methylsulfonylamino)benzy]thiourea (19-13, SU-692). 92% yield, pale yellow solid, mp = 59-61 °C, [α] = +18.1 (c 1.00, CHC13) 1H NMR (CDC13) δ 7.1-7.35 (m, 9 H), 6.62 (bs, 1 H), 5.88 (bs, 1 H), 4.84 (bs, 1 H),
4.65 (bs, 1 H), 4.00 (bd, 1 H), 3.76 (dd, 2 H, J= 4.6, 11.2 Hz), 2.9-3.05 (m, 4 H), 2.80
(dd, 1 H, J= 7.1, 13.4 Hz), 1.46 (d, 3 H, J= 7.1 Hz), 1.18 (s, 9 H) MS(FAB) m/z 492 (MH+)
Example 126: Preparation of N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-N'-[(R)-α- methyl-4-(methylsulfonylamino)benzy] thiourea (19-14, SU-704) Step 126-1. Preparation of N-f(2S)-3-phenyl-l-pivaloyloxy-2-propyll-N'-[(R -α-methyl- 4-nitrobenzylthiourea (19-6. SU-698 The N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-N'-[(R)-α-methyl-4- nitrobenzyjthiourea (19-6) was prepared by the similar procedure with that described in above Example 125-1, 125-2 and 125-3. 94% yield, pale yellow solid, mp = 99-100 °C The spectral data of this compound were identical to those of compound 19-5.
Step 126-2. Preparation of N-r(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-N'-[(R)-α-methyl- 4-aminobenzylthiourea (19-10, SU-702
Through similar procedure to that in Example 125-4 excepting using N-[(2S)-3-phenyl- l-pivaloyloxy-2-propyl]-N-[(R)-α-methyl-4-nitrobenzy]thiourea (19-6) as a starting material, N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-iV-[(R)-α-methyl-4- aminobenzyjthiourea (19-10, SU-702) having following physicochemical properties was synthesized: 97%) yield, yellow oil The spectral data of this compound were identical to those of compound 19-9.
Step 126-3. Preparation of N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyll-N'-r(R)-α-methyl- 4-(methylsulfonylamino)benzv1thiourea (19-14, SU-704) Through similar procedure to that in Example 125-5 excepting using 3'- (Methoxycarbony)-4'-(methylsulfonylamino)acetophenone oxime (13-10) as a starting material, N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-N'-[(R)-α-methyl-4-
(methylsulfonylamino)benzy]thiourea (19-14, SU-704) having following physicochemical properties was synthesized: 51% yield, yellow solid, mp = 61-64 °C, [α] = -10.9 (c 1.00, CHC13) The spectral data of this compound were identical to those of compound 19-13. MS (FAB) m/z 492 (MH+)
Example 127: Preparation of N-[(2R)-3-phenyl-l-pivaloyloxy-2-propyl]-iV-[(S)-α- methyI-4-(methyIsulfonylamino)benzy] thiourea (19-15, SU-720)
Step 127-1. Preparation of (2S)-3 -phenyl- l-pivaloyloxy-2-propyl amine (19-2, YHS-45) The (2S)-3 -phenyl- l-pivaloyloxy-2 -propyl amine (19-2, YHS-45) was prepared by the similar procedure with that described in above Example 125-1. 94% yield, pale yellow oil 1H NMR (CDC13) δ 7.15-7.38 (m, 5 H), 4.22 (dd of AB, 2H), 3.73 (bs, 1 H), 3.03 (ddd of AB, 2H), 1.22 (s, 9H)
Step 127-2. Preparation of (2S)-3-phenyl-l-pivaloyloxy-2-propyl isothiocyanate (19-4, SU-686) Through similar procedure to that in Example 92-2 excepting using (2S)-3-phenyl- l-pivaloyloxy-2-propyl amine (19-2) as a starting material, (2S)-3 -phenyl- 1- pivaloyloxy-2 -propyl isothiocyanate (19-4, SU-686) having following physicochemical properties was synthesized: 89%) yield, colorless oil The spectral data of compound 19-4 were identical to that of 19-3.
Step 127-3. Preparation of N-[(2R)-3-phenyl-l-pivaloyloxy-2-propyH-N-[(S)-α- methyl-4-nitiObenzylthiourea (19-7, SU-714) Through similar procedure to that in Example 125-3 excepting using (2S)-3-phenyl- 1 -pivaloyloxy-2 -propyl amine (19-2) as a starting material, N-[(2R)-3-phenyl-l- pivaloyloxy-2-propyl]-N-[(S)-α-methyl-4-nitrobenzy]thiourea (19-7, SU-714) having following physicochemical properties was synthesized: 78% yield, white solid, mp = 100-101 °C 1H ΝMR (CDC13) δ 8.18 (d, 2 H, J= 8.5 Hz), 7.46 (d, 2 H, J= 8.5 Hz), 7.05-7.3 (m, 5 H), 6.64 (bs, 1 H), 6.12 (bs, 1 H), 5.12 (bs, 1 H), 4.62 (bs, 1 H), 4.19 (dd, 1 H, J= 4.9, 11.6 Hz), 4.00 (dd, 2 H, J= 4.1, 11.6 Hz), 2.94 (dd, 1 H, J= 5.34, 13.4 Hz), 2.64 (bs, 1 H), 1.55 (d, 3 H, J= 7.1 Hz), 1.19 (s, 9 H)
Step 127-4. Preparation of N-r(2R)-3-phenyl-l-pivaloyloxy-2-propyl]-N'-[(S)- -methyl- 4-aminobenzylthiourea (19-11, SU-716 Through similar procedure to that in Example 92-4 excepting using N-[(2R)-3- phenyl-l-pivaloyloxy-2-propyl]-N'-[(S)-α-methyl-4-nitrobenzy]thiourea (19-7) as a starting material, N- [(2R)-3 -phenyl- 1 -pivaloyloxy-2-propyl] -N5 - [(S)-α-methyl-4- aminobenzyjthiourea (19-11, SU-716) having following physicochemical properties was synthesized: 86% yield, pale yellow oil 1H ΝMR (CDC13) δ 6.95-7.25 (m, 7 H), 6.67 (d, 2 H, J= 8.3 Hz), 6.42 (d, 1 H, J= 5.1 Hz), 5.80 (d, 1 H, J= 8.3 Hz), 4.83 (bs, 1 H), 4.53 (bs, 1 H), 4.07 (dd, 1 H, J= 5.1, 11.7 Hz), 3.94 (dd, 2 H, J= 3.9, 11.7 Hz), 3.60 (bs, 2 H), 2.84 (dd, 1 H, J= 5.4, 13.7 Hz), 2.49 (dd, 1 H, J= 8.3, 13.7 Hz), 1.44 (d, 3 H, J= 7.1 Hz), 1.20 (s, 9 H)
Step 127-5. Preparation of N-|"(2R)-3-phenyl-l-pivaloyloxy-2-propyl1-N-r(S)-α- methyl-4-(methylsulfonylamino)benzy]thiourea (19-15, SU-720) Through similar procedure to that in Example 125-5 excepting using N-[(2R)-3- phenyl-l-pivaloyloxy-2-propyl]-N'-[(S)- -methyl-4-aminobenzy]thiourea (19-11) as a starting material, N-[(2R)-3-phenyl- 1 -pivaloyloxy-2-propyl]-N-[(S)-α-methyl-4- (methylsulfonylamino)benzy]thiourea (19-15, SU-720) having following physicochemical properties was synthesized: 93% yield, pale yellow solid, mp = 61-64 °C, [α] = +11.5 (c 1.00, CHC13) 1H ΝMR (CDC13) δ 7.45 (bs, 1 H), 7.15-7.3 (m, 7 H), 7.05 (d, 2 H, J= 6.3 Hz), 6.78 (bs, 1 H), 6.02 (bs, 1 H), 4.76 (bs, 2 H), 4.14 (dd, 1 H, J= 5.1, 11.7 Hz), 3.97 (dd, 2 H, J = 4.1, 11.7 Hz), 3.01 (s, 3 H), 2.89 (dd, 1 H, J= 5.4, 13.6 Hz), 2.55 (bs, 1 H), 1.50 (d, 3 H, J= 7.1 Hz), 1.19 (s, 9 H) MS(FAB) m/z 492 (MH+)
Example 128: Preparation of N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-iV-[(S)- - methyl-4-(methylsulfonylamino)benzy]thiourea (19-16, SU-710)
Step 128-1. Preparation of N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-N,-r(S)-α-methyl- 4-nitrobenzyltlύourea (19-8. SU-700) The N-[(2S)-3-phenyl-l-ρivaloyloxy-2-propyl]-N'-[(S)-α-methyl-4- nitrobenzy] thiourea (19-8, SU-700) was prepared by the similar procedure with that described in above Example 127-1, 127-2 and 127-3. 82% yield, yellow oil The spectral data of this compound were identical to those of compound 19-7.
Step 128-2. Preparation of N-r(2S)-3-phenyl-l-ρivaloyloxy-2-propyll-N,-r(S)-α-methyl- 4-aminobenzylthiourea (19-12, SU-706) Through similar procedure to that in Example 125-4 excepting using N-[(2S)-3- phenyl-l-pivaloyloxy-2-propyl]-N-[(S)-α-methyl-4-nitrobenzy]thiourea (19-8) as a starting material, N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-N'-[(S)-α-methyl-4- aminobenzy] thiourea (19-12, SU-706) having following physicochemical properties was synthesized: 93% yield, yellow oil The spectral data of this compound were identical to those of compound 19-11.
Step 128-3. Preparation of N-r(2S)-3-phenyl-l-pivaloyloxy-2-propyl1-N'-[(S)-α-methyl- 4-(methylsulfonylammo benzylthiourea (19-16, SU-710) Through similar procedure to that in Example 125-5 excepting using N-[(2S)-3- phenyl-l-pivaloyloxy-2-propyl]-N-[(S)-α-methyl-4-aminobenzy]thiourea (19-12) as a starting material, N-[(2S)-3-phenyl-l-pivaloyloxy-2-propyl]-N,-[(S)-α-methyl-4- (methylsulfonylamino)benzy]thiourea (19-16, SU-710) having following physicochemical properties was synthesized: 85% yield, white solid, mp = 59-61 °C, [α] = -18.2 (c 1.00, CHC13) The spectral data of this compound were identical to those of compound 19-15. MS (FAB) m/z 492 (Mit)
Example 129: Preparation of N-(4-/'-Butylbenzyl)-N'-{l-[4-(methylsulfonylamino)- 3-fluorophenyI]propyl}thiourea (20-12, LJO-399)
Step 129-1. Preparation of 2-Fluoro-4-vinylaniline (20-1, LJO-324) A solution of 2-fluoro-4-iodoaniline (2.37 g, 10 mmol) in toluene (50 mL) was treated with tetrakis(triphenylphosphine)palladium (0.578 g, 0.5 mmol), tributylvinyltin (3.5 mL, 12 mmol) and a catalytic amount of 2,6-di-tert-butyl-4-methylphenol. After being heated at 100 °C for 1 h, the reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:5) as eluant to afford 2-Fluoro-4- vinylaniline (20-1, LJO-324, 1.275 g, 93%) as a yellow oil. 1H ΝMR (CDC13) δ 7.08 (dd, 1 H, J = 1.95, 12.4 Hz), 6.98 (dd, 1 H, J= 1.47 Hz, 8.04 Hz), 6.71 (t, 1 H, J= 9 Hz), 6.57 (dd, 1 H, J = 10.8, 17.5 Hz), 5.55 (d, 1 H, J= 17.5 Hz), 5.09 (dd, 1 H, J= 10.8 Hz), 3.75 (bs, 2 H)
Step 129-2. Preparation of N-(2-Fluoro-4-vinylphenyl)methanesulfonamide (20-2, LJO- 325) A cooled solution of 2-Fluoro-4-vinylaniline (20-1, 0.96 g, 7 mmol) in pyridine (10 mL) at 0 °C was treated with methanesulfonyl chloride (0.644 L, 8.4 mmol) and stirred at room temperature for 30 min. The reaction mixture was diluted with water and extracted with EtOAc several times. The combined organic layers were washed with water and brine, dried over MgSO4, filtered, and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:3) as eluant to afford N-(2-Fluoro-4- vinylphenyl)methanesulfonamide (20-2, LJO-325, 1.372 g, 91%) as a white solid. mp = 82 °C 1H ΝMR (CDC13) δ 7.53 (t, 1 H, J= 8 Hz), 7.15-7.25 (m, 2 H), 6.64 (dd, 1 H, j = 10.7, 17.5 Hz), 6.50 (bs, 1 H), 5.72 (d, 1 H, J= 17.5 Hz), 5.32 (dd, 1 H, J= 10.7 Hz), 3.03 (s, 3 H)
Step 129-3. Preparation of N-(2-Fluoro-4-formylphenyl methansulfonamide (20-3, LJO- 326) A solution of N-(2-Fluoro-4-vinylphenyl)methansulfonamide (20-2, 1.076g, 5 mmol) in acetone and water (1:1, 20 mL) was treated with a catalytic amount of osmium tetroxide (4 wt% solution in hydroxyperoxide) and sodium periodate (2.139 g, 10 mmol). After being stirred at room temperature for 1 h, the mixture was concentrated into a small volume in vacuo. The residue was treated with aqueous sodium thiosulfate solution and then extracted with EtOAc several times. The combined organic layers were washed with water and brine, dried over MgSO4, filtered, and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1 :2) as eluant to afford N-(2-Fluoro-4- formylphenyl)methanesulfonamide (20-3, LJO-326, 0.521 g, 48%) as a white solid. mp = 151 °C 1H ΝMR (CDCI3) δ 9.92 (d, 1 H, J= 2.2 Hz), 7.78 (t, 1 H, J= 8.6 Hz), 7.65-7.74 (m, 2 H), 6.92 (bs, 1 H), 3.15 (s, 3 H)
Step 129-4. Preparation of N- 2-fluoro-4-(l-hydroxypropyl)phenyl1methansulfonamide (20-4, LJO-337) A cooled solution of N-(2-Fluoro-4-formylphenyl)methansulfonamide (20-3, 0.424 g, 2 mmol) in THF (20 mL) at 0 °C was treated with Grignard reagent (4 mmol) and stirred at 0 °C for 30 min. The reaction mixture was quenched with saturated ammonium chloride solution, diluted with water and extracted with EtOAc several times. The combined organic layers were washed with water and brine, dried over MgSO , filtered, and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:1) as eluant to N- [2-fluoro-4-(l-hydroxypropyl)phenyl]methanesulfonamide (20-4, LJO-337). 92%) yield, colorless oil 1H ΝMR (CDC13) δ 7.53 (t, 1 H, J= 8.22 Hz), 7.19 (dd, 1 H, J= 1.8, 11.2 Hz), 7.12 (dd, 1 H, J= 1.8 Hz, 8 Hz), 6.45 (bs, 1 H), 4.61 (m, 1 H), 3.02 (s, 3 H), 1.87 (m, 1 H), 1.7-1.8 (m, 2 H), 0.93 (t, 3 H, J= 7.3 Hz)
Step 129-5. Preparation of N- 2-fluoro-4-(l-azidopropyl)phenyl1methanesulfonamide (20-8, LJO-397 A cooled solution of the alcohol (1 mmol) in toluene (10 mL) at 0 °C was treated with diphenylphosphorylazide (0.26 mL, 1.2 mmol) followed by 1,8- diazabicyclo[5,4,0]undec-7-ene (0.18 mL, 1.2 mmol) and stirred for 2 h at 0 °C . After being further stirred for 20 h at room temperature, the reaction mixture was diluted with EtOAc. The organic layere was washed with 5% HCl (10 mL), water and brine, dried over MgSO4, filtered, and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:3) as eluant to afford N-[2-fluoro-4-(l-azidopropyl)phenyl]methanesulfonamide (20-8, LJO- 397) . 91%o yield, colorless oil 1H ΝMR (CDC13) δ 7.56 (t, 1 H, J= 8.04 Hz), 7.0-7.1 (m, 2 H), 6.70 (bs, 1 H), 4.34 (t, 1 H, J= 7.32 Hz), 3.03 (s, 3 H), 1.7-1.8 (m, 2 H), 0.93 (t, 3 H, J= 7.3 Hz)
Step 129-6. Preparation of N-(4-t-Butylbenzyl -N'-{l-[4-(methylsulfonylamino)-3- fluorophenyllpropyl) thiourea (20-12. LJO-399) A suspension of the azide (1 mmol) and 10% palladium on carbon (50 mg) in MeOH (10 mL) was hydrogenated under a balloon of hydrogen for 1 h. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was dissolved in DMF (3 mL) and then added 4-tert-butylbenzyl isothiocyanate (0.205 g, 1 mmol). After being stirred at room temperature for 3 h, the reaction mixture was diluted with water and extracted with EtOAc several times. The combined organic layers were washed with water and brine, dried over MgSO4, filtered, and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel with EtOAc:hexanes (1:1) as eluant to afford N-(4-t-Butylbenzyl)-N'-{l-[4- (methyIsulfonylamino)-3 -fluorophenyljpropyl} thiourea (20-12, LJO-399) 82% yield, white solid, mp = 85 °C 1H ΝMR (CDC13) δ 7.45 (t, 1 H, J= 8.04 Hz), 7.34 (d, 2 H, J= 8.04 Hz), 7.12 (d, 2 H, J= 8.04 Hz), 6.9-7.0 ( , 2 H), 6.76 (bs, 1 H), 6.24 (bs, 2 H), 4.88 (bs, 1 H), 4.55 (bs,
2 H), 3.00 (s, 3 H), 1.7-1.8 (m, 2 H), 1.30 (s, 9 H), 0.82 (t, 3 H, J= 7.05 Hz) MS (FAB) m/z 452 (MH+)
Example 130: Preparation of iV-(4-ι'-Butylbenzyl)-N-{l-[4-(methyIsulfonylamino)- 3-fluorophenyl]-2-methylpropyl}thiourea (20-13, LJO-402)
Step 130-1. Preparation of N-| -fluoro-4-(l-hvdroxy-2- methylpropyDphenyllmethanesulfonamide (20-5, LJO-396) Through similar procedure to that in Example 129-5 excepting using N-(2-Fluoro-4- formylphenyl)methanesulfonamide (20-3) as a starting material, N-[2-fluoro-4-(l- hydroxy-2-methylpropyl)phenyl]methanesulfonamide (20-5, LJO-396) having following physicochemical properties was synthesized: 90% yield, colorless oil 1H ΝMR (CDC13) δ 7.50 (t, 1 H, J = 8.28 Hz), 7.15 (dd, 1 H, J = 1.95, 11.2 Hz), 7.07 (dd, 1 H, J= 1.8 Hz, 8 Hz), 6.62 (bs, 1 H), 4.38 (d, 1 H, J= 6.36 Hz), 3.01 (s, 3 H), 1.80 (m, 2 H), 0.95 (d, 3 H, J= 6.8 Hz), 0.83 (d, 3 H, J= 6.8 Hz)
Step 130-2. Preparation of N-[2-fluoro-4-(l-azido-2- methylpropyDphenyllmethanesulfonamide (20-9. LJO-398 Through similar procedure to that in Example 129-5 excepting using N-[2-fluoro-4- (l-hydroxy-2-methylpropyl)phenyl]methanesulfonamide (20-5) as a starting material, N-[2-fluoro-4-(l -azido-2-methylpropyl)phenyl]methanesulfonamide (20-9, LJO-398) having following physicochemical properties was synthesized: 85% yield, colorless oil Η ΝMR (CDC13) δ 7.57 (t, 1 H, J= 8.07 Hz), 7.05-7.15 (m, 2 H), 6.64 (bs, 1 H), 4.15 (d, 1 H, J= 7.56 Hz), 3.05 (s, 3 H), 1.93 (m, 1 H), 0.99 (d, 3 H, J= 6.8 Hz), 0.81 (d,
3 H, J= 6.8 Hz)
Step 130-3. Preparation of N-(4-t-Butylbenzyl -N-{l-[4-(methylsulfonylamino)-3- fluorophenyll-2-methylpropyl}thiourea (20-13, LJO-402) Through similar procedure to that in Example 129-6 excepting using N-[2-fluoro-4- (l-azido-2-methylpropyl)phenyl]methanesulfonamide (20-9) as a starting material, N- (4-t-Butylbenzyl)-N- { 1 -[4-(methylsulfonylamino)-3 -fluorophenyl] -2- methylpropyl}thiourea (20-13, LJO-402) having following physicochemical properties was synthesized: 87% yield, white solid, mp = 84 °C 1H NMR (CDCI3) δ 7.45 (t, 1 H, J= 8.04 Hz), 7.36 (d, 2 H, J= 8.04 Hz), 7.14 (d, 2 H, J= 8.04 Hz), 6.85-6.95 (m, 2 H), 6.78 (bs, 1 H), 6.25 (bs, 2 H), 4.81 (bs, 1 H, 4.53 (bs, 2 H), 3.01 (s, 3 H), 1.92 (m, 1 H), 1.30 (s, 9 H), 0.77 (m, 6 H) MS (FAB) m/z 466 (MH+)
Example 131: Preparation of N-(4-t-Butylbenzyl)-N'-{[4-(methyIsuIfonyIamino)-3- fluorophenyl](phenyl)methyl} thiourea (20-14, LJO-403)
Step 131-1. Preparation of N-{2-fluoro-4- [hvdroxy(phenyl methyllphenyl}methanesulfonamide (20-6, LJO-330) Through similar procedure to that in Example 129-4 excepting using Grignard reagent (R=Ph) of N-(2-Fluoro-4-formylphenyl)methanesulfonamide (20-3) as a starting material, N- {2-fluoro-4-[hydroxy(phenyl)methyl]phenyl}methanesulfonamide (20-6, LJO-330) having following physicochemical properties was synthesized: 100% yield, white solid, mp = 91 °C 1H ΝMR (CDC13) δ 7.52 (t, 1 H, J= 8.25 Hz), 7.3-7.38 (m, 5 H), 7.22 (dd, 1 H, J= 1.6, 11.2 Hz), 7.17 (dd, 1 H, J= 1.6 Hz, 8 Hz), 6.46 (bs, 1 H), 5.81 (s, 1 H), 3.00 (s, 3 H), 1.99 (bs, I H)
Step 131-2. Preparation of N-{2-fluoro-4- [azido(phenyl)methyllphenyl)methanesulfonamide (20-10, LJO-335) Through similar procedure to that in Example 129-5 excepting using N-{2-fluoro-4- [hydroxy(phenyl)methyl]phenyl}methanesulfonamide (20-6) as a starting material, N- {2-fluoro-4-[azido(phenyl)methyl]phenyl}methanesulfonamide (20-10, LJO-335) having following physicochemical properties was synthesized: 84%o yield, white solid, mp = 60 °C 1H ΝMR (CDC13) δ 7.56 (t, 1 H, J= 8.25 Hz), 7.25-7.45 (m, 5 H), 7.1-7.15 (m, 2 H), 6.48 (bs, 1 H), 5.68 (s, 1 H), 3.03 (s, 3 H)
Step 131-3. Preparation of N-(4-t-Butylbenzyl -N'-(['4-(methylsulfonylamino)-3- fluorophenylKphenypmethyl} thiourea (20-14, LJO-403) Through similar procedure to that in Example 129-6 excepting using N-{2-fluoro-4- [hydroxy(phenyl)methyl]phenyl}methanesulfonamide (20-6) as a starting material, N- (4-t-Butylbenzyl)-N'-{[4-(methylsulfonylamino)-3- fluorophenyl](phenyl)methyl} thiourea (20-14, LJO-403) having following physicochemical properties was synthesized: 92% yield, white solid, mp = 191 °C 1H NMR (CDCI3) δ 7.50 (t, 1 H, J= 8.55 Hz), 7.25-7.4 (m, 7 H), 7.13 (d, 2 H, J = 8.04 Hz), 6.9-7.0 (m, 2 H), 6.51 (bs, 1 H), 6.30 (bs, 1 H), 6.23 (bs, 1 H), 4.58 (bs, 2 H), 3.02 (s, 3 H), 1.31 (s, 9 H) MS (FAB) m/z 500 (MH)
Example 132: Preparation of N-(4-t-Butylbenzyl)-N'-{l-[4-(methylsuIfonylamino)- 3-fluorophenyl]-2-phenylethyl}thiourea (20-15, LJO-395)
Step 132-1. Preparation of N-r2-fluoro-4-(l-hvdroxy-2- phenylethyl)phenyl]methanesulfonamide (20-7, LJO-336) Through similar procedure to that in Example 129-4 excepting using Grignard reagent (R=Ph) of N-(2-Fluoro-4-formylphenyl)methanesulfonamide (20-3) as a starting material, N-[2-fluoro-4-(l -hydroxy-2-phenylethyl)phenyl]methanesulfonamide (20-7, LJO-336) having following physicochemical properties was synthesized: 94% yield, yellow solid, mp = 123 °C 1H ΝMR (CDC13) δ 7.54 (t, 1 H, J = 8.22 Hz), 7.1-7.35 (m, 7 H), 6.44 (bs, 1 H), 4.89 (m, 1 H), 3.02 (s, 3 H), 2.98 (ddd of AB, 2 H), 1.98 (d, 1 H, J= 2.9 Hz)
Step 132-2. Preparation of. N-[2-fluoro-4-(l-azido-2- phenylethyl)phenyl]methanesulfonamide (20-11, LJO-394) Through similar procedure to that in Example 129-5 excepting using N-[2-fluoro-4- (l-hydroxy-2-phenylethyl)phenyl]methanesulfonamide (20-7) as a starting material, N- [2-fluoro-4-(l -azido-2-phenylethyl)phenyl]methanesulfonamide (20-11 , LJO-394) having following physicochemical properties was synthesized: 94% yield, white solid, mp = 74 °C 1H ΝMR (CDCI3) δ 7.55 (t, 1 H, J= 8.04 Hz), 7.0-7.3 (m, 7 H), 6.62 (bs, 1 H ), 4.66 (t, 1 H, J= 6.84 Hz), 3.04 (s, 3 H), 3.00 (ddd of AB, 2 H)
Step 132-3. Preparation of N-(4-t-Butylbenzyl)-N,-(l- 4-(methylsulfonylamino)-3- fluorophenyll-2-ρhenylethyl)thiourea (20-15, LJO-395) Through similar procedure to that in Example 129-6 excepting using N-[2-fluoro-4- (l-azido-2-phenylethyl)phenyl]methanesulfonamide (20-11) as a starting material, N-(4- t-Butylbenzyl)-N'-{l-[4-(methylsulfonylamino)-3-fluorophenyl]-2- phenylethyl} thiourea (20-15, LJO-395) having following physicochemical properties was synthesized: 93%> yield, white solid, mp = 116°C 1H ΝMR (CDC13) δ 7.43 (t, 1 H, J= 8.04 Hz), 7.33 (d, 2 H, J= 8.04 Hz), 7.2-7.3 ( , 5 H), 7.06 (d, 2 H, J= 8.04 Hz), 6.9-7.0 (m, 2 H), 6.63 (bs, 1 H), 6.11 (bs, 1 H), 5.45 (bs, 1 H), 4.43 (bs, 2 H), 3.06 (d, 2 H, J= 5.6 Hz), 3.00 (s, 3 H), 1.31 (s, 9 H) MS (FAB) m/z 514 (MH+)
Example 133: Preparation of N-(4-t-Butylbenzyl)-iV-{l-methyl-l-[4- (methylsulfonylamino)phenyl]ethyl}thiourea (21-7, CHK-593) Step 133-1. Preparation of Benzyl N- (1 -Methyl- 1 4- (methylsulfonylamino)phenyl] ethyl) carbamate (21-1, CHK-582) A solution of 2-[4-(methylsulfonylamino)phenyl]-2-methylpropionic acid (8-11, 1 mmol) in toluene (6 mL) was treated with 4A molecular sieve (200 mg), Et3Ν (1.3 mmol) and diphenylphosphoryl azide (1.3 mmol) and heated at 110 °C for 1 h. The mixture was cooled to room temperature and BnOH (20 mmol) was added. After the mixture was heated to 110 °C for 12 hours and concentrated in vacuo. The residue was purified by by column chromatography on silica gel with EtOAc:hexanes as eluant to afford Benzyl N- {1 -Methyl- 1- [4 -(methylsulfonylamino)phenyl]ethyl}carbamate (21-1, CHK-582) 1H ΝMR (CDC13) δ 7.25-7.4 (m, 7 H), 7.12 (bd, 2 H), 6.60 (bs, 1 H), 5.22 (bs, 1 H), 5.02 (s, 2 H), 2.98 (s, 3 H), 1.65 (s, 6 H)
Step 133-2. Preparation ofN-(4-t-Butylbenzyl)-N-U-methyl-l-r4- (methylsulfonylamino)phenyll ethyl} thiourea (21-7, CHK-593) A suspension of Benzyl N- {1 -Methyl- 1- [4-
(methylsulfonylamino)phenyl] ethyl} carbamate (21-1, 0.5 mmol) and 5% palladium on carbon (100 mg) in MeOH (10 mL) was hydrogenated under a rubber balloon of hydrogen for 1 h. After the solvent was evaporated by rotary evaporator, the residue was dissolved in DMF (5 mL) and treated with 4-t-butylbenzyl isothiocyanate (0.5 mmol). After being stirred overnight, the mixture went to aqueous work-up and the residue was purified by by column chromatography on silica gel with EtOAc:hexanes as eluant to afford N-(4-t-Butylbenzyl)-N'-{l-methyl-l-[4-
(methylsulfonylamino)phenyl]ethyl}thiourea (21-7, CHK-593) 94 % yield, white solid, mp = 161-164 °C 1H ΝMR (CDC13) δ 7.42 (d, 2 H), 7.22 (dd, 4 H), 6.83 (bs, 1 H), 6.80 (d, 2 H), 6.63 (bs, 1 H), 5.23 (bt, 1 H), 4.58 (d, 2 H, J= 4.9 Hz), 2.97 (s, 3 H), 1.65 (s, 6 H), 1.28 (s, 9 H) MS (FAB) m/z 434 (MH*) Example 134: Preparation of N-(4-t-Butylbenzyl)-iV-{l-methyl-l-[3-fluoro-4- (methylsulfonyIamino)phenyl]ethyl}thiourea (21-8, CHK-660)
Step 134-1. Preparation of Benzyl N-U-Methyl-l-r3-fluoro-4- (methylsulfonylamino)phenyl] ethyl) carbamate (21-2, CHK-657) Through similar procedure to that in Example 133-1 excepting using 2-[3-Fluoro-4- (methylsulfonylamino)phenyl]-2-methylproρionic acid (7-4) as a starting material, Benzyl N- { 1 -Methyl-1 -[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}carbamate (21- 2, CHK-657) having following physicochemical properties was synthesized: 1H ΝMR (CDC13) δ 7.50 (t, 1 H, J= 8.3 Hz), 7.34 (bs, 5 H), 7.15-7.2 (m, 2 H), 6.45 (bs, 1 H), 5.18 (bs, 1 H), 5.02 (s, 2 H), 3.02 (s, 3 H), 1.63 (s, 6 H)
Step 134-2. Preparation of N-(4-t-Butylbenzyl)-N-a-methyl-l-r3-fluoro-4- (methylsulfonylamino phenyl"|ethyl}thiourea (21-8, CHK-660) Through similar procedure to that in Example 133-2 excepting using Benzyl N-{1- Methyl-l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}carbamate (21-2) as a starting material, Benzyl N-{1 -Methyl-1 -[3 -fluoro-4-
(methylsulfonylamino)phenyl] ethyl} carbamate (21-2, CHK-657) having following physicochemical properties was synthesized: 80% yield, white solid, mp = 83-85 °C 1H ΝMR (CDC13) δ 7.52 (t, 1 H, J= 8.2 Hz), 7.18-7.3 (m, 4 H), 6.86 (d, 2 H, J= 7.9 Hz), 6.50 (bs, 1 H), 5.20 (bs, 1 H), 4.59 (d, 2 H, J= 4.8 Hz), 2.98 (s, 3 H), 1.65 (s, 6 H), 1.29 (s, 9 H) MS m/z 486 (MΝa+)
Example 135: Preparation of N-(4-t-Butylbenzyl)-iV-{l-methyl-l-[3-methoxy-4- (methylsulfonylamino)phenyl]ethyl}thiourea (21-9, CHK-629)
Step 135-1. Preparation of Benzyl N-{1 -Methyl-1- [3 -methoxy-4- (methylsulfonylamino)phenyllethyl) carbamate (21-3, CHK-646) Through similar procedure to that in Example 133-1 excepting using 2-(3-methoxy- 4-(methylsulfonylamino)phenyl)-2-methylpropionic acid (8-12) as a starting material, Benzyl N- { 1 -Methyl- 1 -[3-methoxy-4-(methylsulfonylamino)phenyl]ethyl} carbamate (21-3, CHK-646) having following physicochemical properties was synthesized: 1H ΝMR (CDC13) δ 7.44 (d, 1 H, J= 8.3 Hz), 7.34 (bs, 5 H), 6.98 (dd, 1 H, J= 2, 8.3 Hz), 6.91 (d, 1 H, J= 2 Hz), 6.74 (bs, 1 H), 5.21 (bs, 1 H), 5.02 (s, 2 H), 3.79 (s, 3 H), 2.93 (s, 3 H), 1.65 (s, 6 H) Step 135-2. Preparation of N-(4-t-Butylbenzyl)-N-{l-methyl-l-r3-methoxy-4- (methylsulfonylamino)phenyllethyl}thiourea (21-9, CHK-629) Through similar procedure to that in Example 135-1 excepting using Benzyl N-{1- Methyl-l-[3-methoxy-4-(methylsulfonylamino)phenyl]ethyl}carbamate (21-3) as a starting material, N -(4-t-Butylbenzyl)-N-{l -methyl- l-[3-methoxy-4- (methylsulfonylamino)phenyl]ethyl}thiourea (21-9, CHK-629) having following physicochemical properties was synthesized: 69 % yield, white solid, mp = 148-150 °C 1H ΝMR (CDC13) δ 7.47 (d, 1 H, J= 8.2 Hz), 7.23 (d, 1 H), 6.94-7.0 (m, 2 H), 6.80 (d, 3 H), 6.50 (bs, 1 H), 5.31 (t, 1 H), 4.57 (d, 2 H, J= 5.1 Hz), 3.77 (s, 3 H), 2.89 (s, 3 H), 1.65 (s, 6 H), 1.29 (s, 9 H) MS (FAB) m/z 464 (MH+)
Example 136: Preparation of N-(4-^-Butylbenzyl)-iV-{l-[4-
(methylsulfonylamino)phenyϊ]cyclopropyl}thiourea (22-7, CHK-579)
Step 136-1.' Preparation of. Benzyl N-(l-["4-
(methylsulfonylamino)phenyl"lcyelopropyl} carbamate (22-1. CHK-577) Through similar procedure to that in Example 135-1 excepting using l-[4- (Methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (11-7, CHK-530) as a starting material, N-(4-t-Butylbenzyl)-N'-{l-methyl-l-[3-methoxy-4- (methylsulfonylamino)phenyl]ethyl} thiourea (21-9, CHK-629) having following physicochemical properties was synthesized: 77% yield, white solid, mp = 142-143 °C 1H ΝMR (CDC13) δ 7.35 (bs, 5 H), 7.24 (bd, 2 H), 7.13 (bd, 2 H), 6.32 (bs, 1 H), 5.46 (bs, 1 H), 5.09 (s, 2 H), 2.98 (s, 3 H), 1.2-1.35 (m, 4 H)
Step 136-2. Preparation of N-(4-t-Butylbenzyl)-N,-{l-[4-
(methylsulfonylamino)phenyllcyclopropyllthiourea (22-7, CHK-579) Through similar procedure to that in Example 133-2 excepting using l-[4- (Methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (11-7) as a starting material, N-(4-t-Butylbenzyl)-N- { 1 -[4-(methylsulfonylamino)phenyl]cycloρropyl} thiourea (22-7, CHK-579) having following physicochemical properties was synthesized: 78 % yield, white solid, mp = 110-113 °C 1H ΝMR (CDC13) δ 7.33 (d, 2 H), 7.17 (m, 4 H), 7.05 (d, 2 H), 4.58 (m, 2 H), 3.01 (s, 3 H), 1.7-1.9 (m, 2 H), 0.85 (t, 2 H, J= 7.5 Hz) MS (FAB) m/z 433 (M++2) Example 137: Preparation of N-(4-?-Butylbenzyl)-iV-{l-[3-fluoro-4- (methylsulfonylamino)phenyl]cyclopropyl}thiourea (22-8)
Step 137-1. Preparation of Benzyl N-(l-[3-fluoro-4-
(Methylsulfonylamino)phenyllcyclopropyll carbamate (22-2) Through similar procedure to that in Example 133-2 excepting using l-[3-fluoro-4- (methylsulfonylamino)phenyl]cycloρropanecarboxylic acid (10-6) as a starting material, Benzyl N- { 1 -[3-fluoro-4-(Methylsulfonylamino)phenyl]cyclopropyl} carbamate (22-2) having following physicochemical properties was synthesized: 1H ΝMR (CDC13) δ 7.50 (t, 1 H), 7.35 (bs, 5 H), 6.90 (d, 1 H), 6.84 (dd, 1 H), 6.68 (bs, 1 H, ΝHSO2), 5.48 (bs, 1 H), 5.12 (s, 2 H), 2.93 (s, 3 H), 1.2-1.3 (m, 4H)
Step 137-2. Preparation of N-(4-t-Butylbenzyl -N,-{l-r3-fluoro-4-
(methylsulfonylamino)phenyllcyclopropyl|thiourea (22-8) Through similar procedure to that in Example 133-2 excepting using Benzyl N-{1- [3-fluoro-4-(Methylsulfonylamino)phenyl]cyclopropyl}carbamate (22-2) as a starting material, N-(4-t-Butylbenzyl)-N-{l-[3-fluoro-4-
(methylsulfonylamino)phenyljcyclopropyl} thiourea (22-8) having following physicochemical properties was synthesized: 1H ΝMR (CDC13) δ 7.53 (t, 1 H), 7.34 (d, 1 H), 7.05 (d, 2 H), 6.75-6.90 (m, 3 H), 6.23 (bs, 1 H), 5.80 (bs, 1 H), 4.58 (ddd, 2 H), 2.95 (s, 3 H), 1.7-1.9 (m, 2H), 1.30 (s, 9H), 0.88 (t, 2H) MS (FAB) m/z 450 (MH+)
Example 138: Preparation of N-(4-ϊ-ButylbenzyI)-iV-{l-[3-methoxy-4- (methylsulfonylamino)phenyl] cyclopropyl} thiourea (22-9, CHK-631)
Step 138-1. Preparation of. Benzyl N- { 1 -[3-methoxy-4-
(Methylsulfonylamino)phenyl)cyclopropyl| carbamate (22-3, CHK-627) Through similar procedure to that in Example 133-1 excepting using l-[3-Methoxy- 4-(methylsulfonylamino)phenyl]cyclopropanecarboxylic acid (11-8) as a starting material, Benzyl N-{l-[3-methoxy-4-
(Methylsulfonylamino)ρhenyl] cyclopropyl} carbamate (22-3, CHK-627) having following physicochemical properties was synthesized: 86% yield, white solid, mp =100-103 °C 1H ΝMR (CDC13) δ 7.42 (d, 1 H, J= 8.3 Hz), 7.35 (bs, 5 H), 6.88 (d, 1 H, J= 1.8 Hz), 6.82 (dd, 1 H, J= 1.8, 8.3 Hz), 6.68 (bs, 1 H), 5.46 (bs, 1 H), 5.09 (s, 2 H), 3.79 (s, 3 H), 2.91 (s, 3 H), 1.2-1.3 (m, 4 H)
Step 138-2. Preparation of N-(4-t-Butylbenzyl)-N-{l-r3-methoxy-4- (methylsulfonylamino)phenyl1cvclopropyl}thiourea (22-9, CHK-631) Through similar procedure to that in Example 133-2 excepting using Benzyl N-{1- [3-methoxy-4-(Methylsulfonylamino)phenyl]cyclopropyl} carbamate (22-3) as a starting material, N-(4-t-Butylbenzyl)-N- { l-[3-methoxy-4-
(methylsulfonylamino)phenyl]cyclopropyl}thiourea (22-9, CHK-631) having following physicochemical properties was synthesized: 86 % yield, white solid, mp = 100-103 °C 1H ΝMR (CDC13) δ 7.46 (d, 1 H), 7.31 (d, 1 H), 7.02 (d, 2 H), 6.7-6.85 (m, 3 H),6.20 (bs, 1 H), 5.78 (bs, 1 H), 4.58 (ddd, 2 H), 3.83 (s, 3 H), 2.94 (s, 3 H), 1.7-1.9 (m, 2 H), 1.30 (s, 9 H), 0.88 (t, 2 H, J= 7.5 Hz) MS (FAB) m/z 463 (M++2)
Example 139: Preparation of N-(4-t-Butylbenzyl)-iV-{l-[4-
(methylsulfonylamino)phenyl]ethyl}urea (23-1, MK-82) Through similar procedure to that in Example 133-2 excepting using l-[4- (Methylsulfonylamino)phenyljethyl amine (13-11) as a starting material, N-(4-t- Butylbenzyl)-N-{ I [4-(methylsulfonylamino)phenyl] ethyl} urea (23-1, MK-82) having following physicochemical properties was synthesized: 83% yield, white solid, mp = 95-98 °C 1H ΝMR (CDC13) δ 7.34 (d, 2 H, J= 8.3 Hz), 7.23 (d, 2 H, J= 8.5 Hz), 7.16 (d, 2 H, J= 8.3 Hz), 7.11 (d, 2 H, J= 8.5 Hz), 6.86 (s, 1 H), 4.82 (m, 1 H), 4.63 (m, 2 H,), 4.31 (d, 2 H, J= 4.4 Hz), 2.97 (s, 3 H), 1.40 (d, 3 H, J= 6.8 Hz), 1.30 (s, 9 H) MS (El) m/z 403 (M+)
Example 140: Preparation of N-(4-t-Butylbenzyl)-N'-{l-[3-fluoro-4- (methylsulfonylamino)phenyl]ethyl}urea (23-2, MK-205) Through similar procedure to that in Example 102 excepting l-[3-Fluoro-4- (methylsulfonylamino)phenyl]ethyl amine (13-12) as a starting material, N-(4-t- Butylbenzyl)-N-{ l-[4-(methylsulfonylamino)phenyl]ethyl}urea (23-1, MK-82) having following physicochemical properties was synthesized: 70% yield, white solid, mp = 152-154°C 1H ΝMR (CDC13) δ 7.44 (t, 1 H, J= 8.2 Hz), 7.34 (bd, 2 H, J= 8.5 Hz), 7.18 (bd, 2 H, J= 8.3 Hz), 7.0-7.08 (m, 2 H), 6.66 (s, 1 H), 4.84 (m, 1 H), 4.75 (m, 2 H), 4.30 (ddd, 2 H), 2.99 (s, 3 H), 1.38 (d, 3 H, J= 6.8 Hz), 1.30 (s, 9 H) MS (FAB) m/z 422 (MH+)
Example 141: Preparation of N-{l-[3-Fluoro-4-
(methylsulfonylamino)phenyl] ethyl}-3-(4-tβrt-butylphenyl)acetamide (24-1 , KMJ- 586) The N-{l-[3-Fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert- butylphenyl)acetamide (24-1) was prepared by the similar procedure with that described in above Example 1-5. 36% yield, white solid, mp = 134-136 °C 1H ΝMR (CDC13) δ 7.48 (t, 1 H, J= 8.8 Hz), 7.39 (bd, 2 H, J= 8.3 Hz), 7.18 (bd, 2 H, J= 8.3 Hz), 6.92-7.02 (m, 2 H), 6.44 (bs, 1 H), 5.58 (d, 1 H, J= 7.8 Hz), 5.06 (m, 1 H), 3.56 (s, 2 H), 3.00 (s, 3 H), 1.37 (d, 3 H, J= 7 Hz), 1.33 (s, 9 H) MS (FAB) m/z 407 (MH+)
Example 142: Preparation of N-{l-[3-Fluoro-4-
(methylsulfonylamino)phenyl]ethyl}-3-(4-tert'-butylphenyl)propanamide (24-2,
KMJ-552) The N-{l-[3-Fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert- butylphenyl)propanamide (24-2) was prepared by the similar procedure with that described in above Example 1-5. 29% yield, white solid, mp = 152-154 °C 1H ΝMR (CDC13) δ 7.44 (t, 1 H, J= 8 Hz), 7.31 (bd, 2 H, J= 8.3 Hz), 7.11 (bd, 2 H, J= 8.3 Hz), 6.95-7.02 (m, 2 H), 6.82 (bs, 1 H), 5.72 (d, 1 H, J= 7.1 Hz), 5.02 (m, 1 H), 3.00 (s, 3 H), 2.93 (t, 2 H, J= 7.1 Hz), 2.50 (m, 2 H), 1.34 (d, 3 H, J= 7 Hz), 1.30 (s, 9 H) MS (FAB) m/z 421 (MH+)
Example 143: Preparation of N-{l-[3-Fluoro-4-
(methylsulfonylamino)phenyl]ethyl}-3-(4-t£?rt'-butylphenyl)-2-propenamide (24-3, KMJ-570) The N-{l-[3-Fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert-butylphenyl)- 2-propenamide (24-3) was prepared by the similar procedure with that described in above Example 1-5. 67% yield, white solid, mp = 154-156 °C 1H ΝMR (CDC13) δ 7.62 (d, 1 H, J= 15.5 Hz), 7.52 (t, 1 H, J= 8 Hz), 7.41 (dd, 4 H), 7.12-7.18 (m, 2 H), 6.54 (bs, 1 H), 6.37 (d, 1 H, J= 15.5 Hz), 5.88 (d, 1 H, J= 7.1 Hz), 5.21 (m, 1 H), 3.02 (s, 3 H), 1.53 (d, 3 H, J= 7 Hz), 1.32 (s, 9 H) MS (FAB) m/z 419 (MH+)
Example 144: Preparation of N-{l-[3-Fluoro-4-
(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)propanamide (24-4, CHK-602) The N- { 1 - [3 -Fluoro-4-(methylsulfonylamino)phenyl] ethyl } -3 -(3 ,4- dimethylphenyl)propanamide (24-4) was prepared by the similar procedure with that described in above Example 1-5. 70% yield, white solid, mp = 176-177 °C 1H ΝMR (CDC13) δ 7.47 (t, 1 H, J= 8 Hz), 6.9-7.1 (m, 5 H), 6.43 (bs, 1 H), 5.46 (d, 1 H), 5.03 (m, 1 H), 3.01 (s, 3 H), 2.90 (t, 2 H, J= 7.3 Hz), 2.49 (dt, 2 H), 2.23 (d, 6 H, J= 3.8 Hz), 1.37 (d, 3 H, J= 7 Hz) MS (FAB) m/z 393 (MH+)
Example 145: Preparation of N-{l-[3-Fluoro-4-
(methylsulfonylamino)phenyI]ethyl}-3-(3,4-dimethylphenyl)-2-propenamide (24-5, CHK-651) The N-{l-[3-Fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)- 2-propenamide (24-5) was prepared by the similar procedure with that described in above Example 1-5. 74% yield, white solid, mp = 212-213 °C 1H ΝMR (CDC13) δ 7.59 (d, 1 H, J= 15.6 Hz), 7.54 (t, 1 H, J= 8 Hz), 7.1-7.26 (m, 5 H), 6.46 (bs, 1 H), 6.35 (d, 1 H, J= 15.6 Hz), 5.77 (d, 1 H, J= 7.7 Hz), 5.22 (m, 1 H), 3.02 (s, 3 H), 2.27 (bs, 6 H), 1.53 (d, 3 H, J= 7 Hz) MS (FAB) m/z 391 (MH+)
Example 146: Preparation of N-{l-[3-Fluoro-4-
(methylsuIfonylamino)phenyl]ethyl}-3-(4-chlorophenyl)propenamide (24-6, KMJ- 534) The N- { 1 -[3-Fluoro-4-(methylsulfonylamino)phenyl]ethyl} -3-(4- chlorophenyl)propenamide (24-6) was prepared by the similar procedure with that described in above Example 1-5. 65% yield, white solid, mp = 170-172 °C 1H ΝMR (CDC13) δ 7.48 (t, 1 H, J= 8 Hz), 7.23 (d, 2 H, J= 8.3 Hz), 7.10 (d, 2 H, J = 8.3 Hz), 6.92-7.0 (m, 2 H), 6.44 (bs, 1 H), 5.47 (d, 1 H), 5.03 (m, 1 H), 3.03 (s, 3 H), 2.94 (t, 2 H, J= 7.3 Hz), 2.48 (m, 2 H), 1.38 (d, 3 H, J= 7 Hz) MS (FAB) m/z 399 (MH+)
Example 147: Preparation of N-{l-[3-Fluoro-4-
(methylsulfonylamino)phenyl]ethyl}-3-(4-chlorophenyl)-2-propenamide (24-7,
KMJ-558) The N- { 1 -[3-Fluoro-4-(methylsulfonylamino)phenyl]ethyl} -3-(4-chlorophenyl)-2- propenamide (24-7) was prepared by the similar procedure with that described in above Example 1-5. 57% yield, white solid, mp = 219-221 °C 1H ΝMR (CDC13) δ 7.59 (d, 1 H, J= 15.7 Hz), 7.56 (t, 1 H, J= 8 Hz), 7.42 (d, 2 H, J= 8.3 Hz), 7.34 (d, 2 H, J= 8.3 Hz), 7.12-7.18 (m, 2 H), 6.44 (bs, 1 H), 6.37 (d, 1 H, J = 15.7 Hz,), 5.77 (d, 1 H), 5.22 (m, 1 H), 3.02 (s, 3 H), 1.54 (d, 3 H, J= 7 Hz) MS (FAB) m/z 397 (MH+)
Example 148: Preparation of N-{l-[3-FIuoro-4-
(methylsulfonyIamino)phenyl]ethyI}-3-(3,4-dimethylphenyl)butanamide (24-8,
CHK-647) The N-{l-[3-Fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4- dimethylphenyl)butanamide (24-8) was prepared by the similar procedure with that described in above Example 1-5. 81% yield, mp = 152-154 °C 1H ΝMR (CDC13) δ 7.52 (t, 1 H, J= 8 Hz), 6.85-7.1 (m, 5 H), 6.46 (bs, 1 H), 5.56 (d, 1 H, J= 7 Hz), 5.08 (m, 1 H), 3.01 (s, 3 H), 2.58 (t, 2 H, J= 7.3 Hz), 2.23 (s, 6 H), 2.19 (t, 2 H, J= 7.9 Hz), 1.94 (m, 2 H), 1.44 (d, 3 H, J= 7 Hz) MS (FAB) m/z 407 (MH+)
Experimental Example 1: Receptor binding affinity assayVanilloid Receptor 1 Binding Assays Cell Culture The pUHG102 NR1 plasmid was transfected into CHO cells containing the pTet Off regulatory plasmid (Clontech). In these cells, expression of the NR1 is repressed in the presence of tetracycline but is induced upon removal of the antibiotic. Stable clones were isolated in culture medium containing puromycin (10 μg/mL) and maintained in HAM F12 medium supplemented with tetracycline (1 μg/mL), 5 μg/ml geniticin, 25 mM HEPES, 10% FBS. Cells utilized for assays were grown in culture medium without antibiotic for 48 h before use. Cells were seeded in T75 cell culture flasks in media without antibiotics and grown to approximately 90% confluence. The flasks were then washed with PBS and harvested in 0.25% trypsin, 1 mM EDTA. The cells were pelleted by gentle centrifugation and stored at -20 °C until assay.
Competition binding assay Binding studies with [3H]resiniferatoxin (RTX) were carried out as described previously with minor modifications (Szallasi et al., 1992). Binding assay mixtures were set up on ice and contained 50-100 pM [3H]RTX, various concentrations of competing ligands, 0.25 mg mL BSA (Cohn fraction N), and about 5x 105 VR1 - transfected cells. The final volume was adjusted to 350 μL with DPBS with Ca2+ and Mg2+ and 0.25 mg/mL bovine serum albumin. Non-specific binding was determined in the presence of 100 nM nonradioactive RTX. The binding reaction was initiated by transferring the assay mixtures to a 37 °C water bath and was terminated after a 60 min incubation period by cooling the tubes on ice. To reduce non-specific binding, 200 μg/ml α-glycoprotein was added. Membrane-bound RTX was then separated from the free by pelleting the membranes in a Beckman 12 benchtop centrifuge (15 min, maximal velocity), the tips of the tubes containing the pellets were cut off, and the radioactivity was determined by scintillation counting. Equilibrium binding parameters (Kj and cooperativity) were determined by fitting the Hill equation to the measured values with the aid of the program MicroCal Origin 6.0.
Compound preparation Initial stocks were dissolved in DMSO. For the binding assays, compounds were diluted in with DPBS with Ca2+ and Mg2+ and 0.25 mg/mL bovine serum albumin. For the calcium uptake assays, compounds were diluted in DMEM with 0.25 mg/mL bovine serum albumin.
Experimental Example 2: Functional characterization for Agonist/antagonist activity 45Ca2+-uptake assay Molecules were characterized to determine whether they were full agonists, partial agonists, or antagonists. For studies of 45Ca2+ uptake by CHO/VR1 cells (Tet-off cells), the cells were plated in 24-well plates to yield a cell density 20-40%o of that required to produce confluence. The next day the medium was changed to remove the tetracycline and induce VR1 expression. Experiments were performed approximately 36-40 hours after induction. For 45Ca2+ uptake assay, cells were incubated for 5 min at 37 °C in a total volume of 400 μL of serum free DMEM (containing 1.8 mM CaCl2) in the presence of 0.25 mg/mL BSA (Sigma), 1 μCi/mL 45Ca2+ (5-30 Ci/g from ICN, CA), and increasing concentrations of the compound to be tested. Immediately after the incubation, extracellular 5Ca2+ was removed by washing the cells three times with cold DPBS (containing 1.8 mM CaCl2). Then 400 μl RTPA buffer (50 mM Tris pH 7.4; 150 mM NaCl; 1% Triton X-100; 0.1% SDS; 1 % sodium deoxycholate) was added to each well in order to lyse the cells. Plates were shaken slowly for 20 min; then 300 μL of cell lysate was transfeπed from each well into a scintillation vial and radioactivity was determined by scintillation counting. For each data point in each experiment, four wells were assayed. Data from these experiments were analyzed by computer fit to the Hill equation. At least 3 separate experiments were carried out for each compound. In order to determine antagonist activity, studies were performed in exactly the same fashion with the exception that 50 nM capsaicin was added to the assay mixture to stimulate 45Ca2+ uptake.
Experimental Example 3: Analgeisc Assay
Acetic acid-Induced Writhing Test Experimental protocols involving animals in this study were reviewed by the Animal Care and Use Committee of the College of Pharmacy, Seoul National University according to the NIH guidelines (NTH publication number 85-23, revised 1985) of "Principles of Laboratory Animal Care". Male ICR mice (Bio Genomics, Korea), weighing -25 g, were maintained on a 12 hr light-dark cycle (light on between 6:00 p.m. and 6:00 a.m.) and allowed free access to food and water. The temperature and humidity of the animal room were maintained at 22 + 2 °C and 50 + 5%, respectively. Mice were allowed to habituate for -30 min in the testing room on the day of experimentation. Animals then received an intraperitoneal injection of 0.3 mL of an acetic acid solution (1.2%, diluted in 0.9% saline), and were placed in a transparent acrylic cage. 5 min later the number of writhing movements (abnormal stretching) was counted for a 20 min period. Animals (10 animals/dose) were pretreated with test compounds or vehicle (0.2 L, i.p.) 30 min before the injection of acetic acid. Test compounds were dissolved in either ethanol/Tween-80/saline (10/10/80) mixture or Cremophor EL/DMSO/distilled water (10/10/80) mixture. The effect of each compound was tested at 4-7 different doses. A reduction in the number of writhing movements compared to the vehicle-treatment group (the mean number of writhing movements in this group was 35) was considered to be indicative of an antinociceptive effect of a compound. The percentage antinociceptive efficiency (eff) was calculated as follows: % eff = 100-[(# of writhing movements / # of writhing movement control) x 100]. Data are expressed as ED50 values that indicate the concentration at which a given compound reduces the number of writhing by 50% compared to that of a vehicle- treatment group. ED50 values were obtained based on dose-response curves using mean data and fitted to by nonlinear regression analysis (Winnonlin version 3.1, Pharsight Corp., Mountainview, CA) on a PC. Table 1 shows the potencies of vanilloid ligands for binding to rat VR1 and for inducing calcium influx in CHO/VR1 cells.
[Table 1] Compound # K (nM) Ki(nM) Binding Affinity Antagonism capsazepine 1300 520 1-51 KMJ-372 58.4 5.47 1-52 KMJ-470 30.7 29.5 1-53 SH-173 7.41 24.9 1-54 SH-168 23.3 29.9 1-55 SH-285 19.9 7.38 1-56 SH-219 344 467 1-57 KMJ-806 6731 NE 1-58 KMJ-788 NE NE 1-59 KMJ-838 1606 951 1-60 KMJ-836 3712 WE 1-61 YS-65 WE WE 1-62 YS-49 WE WE 1-63 YS-76 WE WE 1-64 YS-79 NE NE 1-65 CHK-717 536 232 1-66 KMJ-708 358 120 1-67 KMJ-698 1423 4480 2-7 KMJ-750 105 17.5 2-8 YS-85 3500 1089 2-9 YS-97 1652 253 3-5 SU-834 43.9 6.87 -6 SU-824 458 102-1 SH-291 1055 367-2 SH-290 729 447-3 SH-335 541 296-4 SH-94 199 115-5 SH-286 289 176-6 SH-337 226 89.6-7 SH-351-8 KMJ-928 127 143-9 SH-353 WE 1350-10 SH-93 657 274-11 KMJ-498 1746 261-12 SH-92 959 239-13 SH-112 NE NE-14 KMJ-374 553 42.6-15 SU-770 412 97.4-16 SU-774 (R) 944 204-17 SU-776 (S) 236 33.7-18 KMJ-686 277 152-19 KMJ-518 466 135-20 KMJ-732 897 384-21 SH-109 9417 WE-22 SH-130 5859 WE-23 SH-116 1697 2487-24 KMJ-378 128 36.6-25 KMJ-724 21.5 14.2-26 KMJ-908 36.0 8.03-27 SH-135 43.3 29.3-28 SH-199 141 121-1 CHK-512 119 38.0-2 CHK-514 55.2 52.0-3 SU-542 33.1 10.78-4 SU-564 13.6 3.24-5 CHK-479 71.2 13.6-6 CHK-499 24.0 NE-7 KMJ-472 11.3 35.7 -8 KMJ-690 3.62 12.3-1 SU-730 12792 1468-2 SU-634 WE WE-3 SU-636 WE WE-4 SU-728 NE NE-5 SU-826 43.4 8.55-6 SU-830 20.3 10.0-7 SU-838 372 205-8 SU-818 297 98.3-9 MK-271 4.24 0.58-10 MK-272 6.58 10.9-11 MK-450 63.8 142-12 MK-452 53.0 30.3-13 MK-453 1.83 5.23-14 MK-451 3.29 12.1 -1 CHK-520 372 103-2 CHK-543 276 65.4 -3 CHK-493 152 133 -4 CHK-591 1696 573-5 CHK-656 960 418 -6 CHK-600 838 366 -7 CHK71 425 2552-8 CHK-655 1069 467-9 CHK-2-1 CHK-533 396 1972-2 CHK-538 1577 5672-3 CHK-541 238 1172-4 CHK-590 1735 11032-52-6 CHK-632 1699 12422-7 CHK-719 608 17632-8 CHK-6592-9 CHK-718 745 22525-1 LJO-303 59.3 14.75-2 LJO-328 54 9.165-3 CHK-575 66.5 28.6 -4 YHS-187 163 65.8-5 YHS-209 2769 NE-5 SU-388 40.8 4.52-6 SU-400 3594 NE-7 CJU-032 32.8 39.4-8 CJU-039 2579 4314-1 MK-229 22.7 44.5-2 MK-202 19.4 89-3 MK-230 1138 3474-4 MK-228 706 133-5 LJO-388 37.2 25.9-6 SU-472 6.1 6.86-7 SU-512 15.2 7.14-8-9 LJO-401 42.7 28.7-10 MK-296 9.95 23.9-11 MK-334 15.7 53.0-12 MK-298 8.09 30.6-13 LJO-344 37 7.09-14 LJO-366 37 9.34-13 SU-692 420 193-14 SU-704 272 290-15 SU-720 NE WE-16 SU-710 NE WE-12 LJO-399 230 54.3-13 LJO-402 338 223-14 LJO-403 100 861-15 LJO-395 1741 695-7 CHK-593 WE 1827-8 CHK-660 7741 983-9 CHK-629 2888 663-7 CHK-579 171 60.3-8-9 CHK-631 372 243-1 MK-82 1193 544-2 MK-205 447 298 24-1 KMJ-586 2129 2216 24-2 KMJ-552 376 103 24-3 KMJ-570 104 23.9 24-4 CHK-602 NE 4129 24-5 CHK-651 2525 1354 24-6 KMJ-534 WE 5651 24-7 KMJ-558 773 938 24-8 CHK-647 3529 988
NE: not effecive, WE: weakly effective
Experimental Example 4: Toxicity test The acute toxicity tests on ICR mice (mean body weight 25 ± 5g) and Sprague- Dawley rats (235 ± lOg) were performed using the compounds 35 and 37. Each group consisting of 3 mice or rats was administrated intraperitoneally with 20 mg/kg, 10 mg/kg and 1 mg/kg of test compounds or solvents (0.2 mi, i.p.), respectively and observed for 24 hrs.
There were no treatment-related effects on mortality, clinical signs, body weight changes and gross findings in any group or either gender. These results suggested that the compounds prepared in the present invention were potent and safe.
Hereinafter, the formulating methods and kinds of excipients will be described, but the present invention is not limited to them. The representative preparation examples were described as follows.
Preparation of powder Compound 35 500mg Corn Starch lOOmg Lactose lOOmg Talc lOmg Powder preparation was prepared by mixing above components and filling sealed package.
Preparation of tablet Compound 37 lOOmg Corn Starch lOOmg Lactose lOOmg Magnesium Stearate 2mg Tablet preparation was prepared by mixing above components and entabletting.
Preparation of capsule Compound 35 50mg Lactose 50mg Magnesium Stearate lmg Tablet preparation was prepared by mixing above components and filling gelatin capsule by conventional gelatin preparation method.
Preparation of injection Compound 37 1 OOmg Distilled water for injection optimum amount PH controller optimum amount Injection preparation was prepared by dissolving active component, controlling pH to about 7.5 and then filling all the components in 2 ml ample and sterilizing by conventional injection preparation method.
Preparation of liquid Compound 35 1 g Sugar 10 g Citric acid 0.05-0.3% Vitamin C 0.1-1% Lemon flavor optimum amount Distilled water optimum amount Liquid preparation was prepared by dissolving active component, adding lemon flavor and distilled water and then filling all the components in 100 mi brown bottle and sterilizing by conventional liquid preparation method.
The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.
Industrial Applicability The novel 4-(methylsulfonylamino) phenyl analogues as vanilloid antagonist and the pharmaceutical composition comprising same according to the present invention act as vanilloid receptor- 1 antagonists and analgesics so the inventive compounds are useful in the prevention, alleviation or treatment of pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease or urgent urinary incontinence, etc.

Claims

1. A compound represented by the following general formula (I), the pharmaceutically acceptable salt or the isomer thereof:
Figure imgf000123_0001
wherein, A is CONH, NHCO, NHC(=S)NH, NHC(=O)NH; R\ to P is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring; R5 and R6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R5 and R6 are not hydrogen atom simultaneously; B is a group selected from
Figure imgf000124_0001
in which R7 to Rj7 is independently at least one selected from a hydrogen, halogen atom and straight or branched alkyl group having 1 to 6 carbon atoms optionally substituted with more than one halogen atom, C is a group selected from alkyl, alkenyl and alkynyl group having 1 to 5 carbon atoms which may includes one or more heteroatoms, m, n, p, q, r and s is an integer of 0 to 3; an asteric mark * and ( ) mark indicate a chiral carbon atom, and double bond or single bond chain respectively.
2. The compound according to claim 1 represented by the following general formula (II), the pharmaceutically acceptable salt or the isomer thereof:
Figure imgf000125_0001
wherein, R1 to R is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring; R5 and R6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R5 and R6 are not hydrogen atom simultaneously; B is a group selected from the group (1-1) to (1-6) defined in general formula (I) as set forth in claim 1; the asteric mark * indicates a chiral carbon atom.
3. The compound according to claim 2 wherein said compound is at least one selected from the group consisting of;
N-(4-tert-butylbenzyl)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(l -51 , KMJ-372), N-(4-tert-butylbenzyl)-2- [3-chloro-4-(methylsulfonylamino)phenyl]propionamide(l-52, KMJ-470), N-(4-tert- butylbenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide(l-53, SH-173), N-(4-tert-butylbenzyl)-2-[3-iodo-4-(methylsulfonylamino)phenyl]propionamide(l-54, SH-168), N-(4-tert-butylbenzyl)-2-[3,5-difluoro-4-
(methylsulfonylamino)phenyl]propionamide(l-55, SH-285), N-(4-tert-butylbenzyl)-2- [3-cyano-4-(methylsulfonylamino)phenyl]propionamide(l-56, SH-219), N-(4-tert- butylbenzyl)-2-[3-(tert-butoxycarbonyl-4-
(methylsulfonylamino)phenyl]propionamide(l -57, KMJ-806), N-(4-tert-butylbenzyl)-2- [3-carboxyl-4-(methylsulfonylamino)phenyl]propionamide(l-58, KMJ-788), N-(4-tert- butylbenzyl)-2-[3-methoxycarbonyl-4-(methylsulfonylamino)phenyl]propionamide(l- 59, KMJ-838), N-(4-tert-butylbenzyl)-2-[3-(benzylamino)carbonyl-4- (methylsulfonylamino)phenyl]propionamide(l -60, KMJ-836), N-(4-tert-butylbenzyl)-2- [3-piperidino-4-(methylsulfonylamino)phenyl]propionamide(l-61, YS-65), N-(4-tert- butylbenzyl)-2-[3-morpholino-4-(methylsulfonylamino)phenyl]propionamide(l-62, YS- 49), N-(4-tert-butylbenzyl)-2-[3-(N-Boc)piperazino-4-
(methylsulfonylamino)phenyl]propionamide(l -63, YS-76), N-(4-tert-butylbenzyl)-2-[3- piperazino-4-(methylsulfonylamino)phenyl]propionamide( 1 -64, YS-79), N-(4-tert- butylbenzyl)-2-[3-methoxy-4-(methylsulfonylamino)phenyl]propionamide(l-65, CHK- 717), N-(4-tert-butylbenzyl)-2-[2-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(l -66, KMJ-708), N-(4-tert-butylbenzyl)-2- [2-chloro-4-(methylsulfonylamino)phenyl]propionamide(l -67, KMJ-698), N-(4-tert- butylbenzyl)-2-[4-(methylsulfonylamino)phenyl]propionamide(2-7, KMJ-750), N-(4- chloro)-2-[4-(methylsulfonylamino)phenyl]propionamide (2-8, YS-85), N-(3,4- dichloro)-2-[4-(methylsulfonylamino)phenyl]propionamide (2-9, YS-97), N-(4-tert- butylbenzyl)-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(3-5, SU- 834), N-(4-tert-butylbenzyl)-(2R)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(3-6, SU-824), N-(4-chlorobenzyl)-2-[3- fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-l , SH-291), N-(4- chlorobenzyl)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide(4-2, SH-290), N-(4-chlorobenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide(4-3, SH-335), N-(3,4-dichlorobenzyl)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-4, SH-94), N-(3,4-dichlorobenzyl)-2-[3- chloro-4-(methylsulfonylamino)phenyl]propionamide(4-5, SH-286), N-(3,4- dichlorobenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide(4-6, SH- 337), N-(4-methylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(4- 7, SH-351), N-(4-isopropylbenzyl)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-8, KMJ-928), N-(4-methoxybenzyl)-2- [3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-9, SH-353), N-(4- trifluoromethylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-10, SH-93), N-(4-phenylbenzyl)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-l 1, KMJ-498), N-(l-naphthylmethyl)- [3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-12, SH-92), N-(l, 2,3,4- tetrahydro- 1 -naphthalenyl)-2-[3-fluoro-4-
(methylsulfonylamino)ρhenyl]propionamide(4-13, SH-112), N-[2-(4-tert- butylphenyl)ethy] -2-[3 -fluoro-4-(methylsulfonylamino)phenyl]propionamide(4- 14, KMJ-374), N-[3-(3,4-dimethylphenyl)propyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(4-15, SU-770), N-[3-(3,4- dimethylphenyi)propyl]-(2R)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-16, SU-774), N-[3-(3,4- dimethylphenyl)propyl]-(2S)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-17, SU-776), N-[3-(3,4- dimethylphenyl)-2-prophenyl]-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-l 8, KMJ-686), N-[3-(4- chlorophenyl)propyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-19, KMJ-518), N-[3-(4-chlorophenyl)-2-prophenyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(4-20, KMJ-732), N-benzyloxy-2-[3- fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-21 , SH- 109), N-(benzhydryl)- 2-[3 -fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-22, SH- 130), N-(2,2- diphenylethy)-2- [3 -fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-23 , SH- 116), N-(3,3-diρhenylpropyl)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-24, KMJ-378), N-(3,3-diphenyl-2- prophenyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(4-25, KMJ-724), N-[3,3-di(4-methylphenyl)-2-prophenyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(4-26, KMJ-908), N-[3,3-di(4- fluorophenyl)-2-prophenyl]-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(4-27, SH-135), N-[2-(10,l l-dihydro-5H- dibenzo [a,d] cyclohepten- 5 -yliden)ethy] -2- [3 -fiuoro-4- (methylsulfonylamino)phenyl]propionamide(4-28, SH-199), N-[2-(3,4- dimethylbenzyl)-3-pivaloxypropyl]-2-[4-
(methylsulfonylamino)phenyl]propionamide(5-l , CHK-512), N-[2-(4-tβrt-butylbenzyl)- 3 -pivaloxypropyl] -2- [4-(methylsulfonylamino)phenyl]propionamide(5 -2, CHK-514), 2- [3-fluoro-4-(methylsulfonylamino)phenyl]-N-[2-(3,4-dimethylbenzyl)-3- pivaloxypropyl]propionamide(5-3, SU-542), 2-[3-fluoro-4- (methylsulfonylamino)phenyl]-N-[2-4-tert-butylbenzyl)-3- pivaloxypropyl]propionamide(5-4, SU-564), N-[2-(3,4-dimethylbenzyl)-3- pivaloxypropyl]-2-[3-methoxy-4-(methylsulfonylamino)phenyl]propionamide(5-5, CHK-479), N-[2-(4-tert-butylbenzyl)-3-ρivaloxyproρyl]-2-[3-methoxy-4- (methylsulfonylamino)phenyl]propionamide(5-6, CHK-499), N-[2-(3,4- dimethylbenzyl)-3-pivaloxypropyl]-2-[3-chloro-4-
(methylsulfonylamino)phenyl]propionamide(5-7, KNJ-472), N-[2-(4-tert-butylbenzyl)- 3-pivaloxypropyl]-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide(5-8, KMJ-690), N-[(1R)-1 -benzyl-2-(pivaloxy)ethy]-(2S)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(6- 1 , SU-730), N-[(l S)- 1 -benzyl-2- (pivaloxy)ethy]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(6-2, SU-634), N-[(lS)-l-benzyl-2-(pivaloxy)ethy]-(2R)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(6-3, SU-636), N-[(1R)-1 -benzyl -2- (pivaloxy)ethy]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]ρropionamide(6-4, SU-728), N-[(2R)-2-benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(6-5, SU-826), N-[(2S)-2-benzyl-3- (pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsuIfonylamino)phenyl]propionamide(6-6, SU-830), N-[(2S)-2-benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(6-7, SU-838), N-[(2R)-2-benzyl-3- (pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide(6-8, SU-818), N-[(2R)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4- (methylsulfonylamino)phenyl]propionamide(6-9, MK-271), N-[(2S)-2-(4-tert- butyl)benzyl-3-(pivaloxy)ρropyl]-(2S)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(6-10, MK-272), N-[(2S)-2-(4-tert- butyl)benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(6-l 1, MK-450), N-[(2R)-2-(4-tert- butyl)benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide(6-12, MK-452), N-[(2R)-2-(4-tert- butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-chloro-4-
(methylsulfonylamino)phenyl]propionamide(6-13, MK-453), N-[(2S)-2-(4-tert- butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-chloro-4- (methylsulfonylamino)phenyl]propionamide(6-14, MK-451), 2-[3-fluoro-4- (methylsulfonylamino)phenyl]-2-methylpropion acid(7-4, CHK-624), 2-[4- (methylsulfonylamino)phenyl]-2-methylpropion acid(8-l 1), 2-[3-methoxy-4- (methylsulfonylamino)phenyl]-2-methylpropion acid(8- 12), N-[2-(3,4-dimethylbenzyl)- 3 -pivaloxypropyl] -2- [4-(methylsulfonylamino)phenyl] -2-methylpropionamide(9- 1 , CHK-520), N-[2-(3,4-dimethylbenzyl)-3-pivaloxyρropyl]-2-[3-fluoro-4- (methylsulfonylamino)phenyl]-2-methylpropionamide(9-2, CHK-543), N-[2-(3,4- dimethylbenzyl)-3-pivaloxypropyl]-2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2- methylproρionamide(9-3, CHK-493), N-[3-(3,4-dimethylphenyl)propyl]-2-[4- (methylsulfonylamino)phenyl]-2-methylpropionamide(9-4, CHK-591), N-[3-(3,4- dimethylphenyl)propyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2- methylpropionamide(9-5, CHK-656), N-[3-(3,4-dimethylphenyl)propyl]-2-[3-methoxy- 4-(methylsulfonylamino)phenyl]-2-methylpropionamide(9-6, CHK-600), N-(4-tert- butylbenzyl)-2-[4-(methylsulfonylamino)phenyl]-2-methylpropionamide(9-7, CHK- 715), N-(4-tert-butylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2- methylpropionamide(9-8, CHK-655), N-(4-tert-butylbenzyl)-2-[3-methoxy-4- (methylsulfonylamino)phenyl]-2-methylpropionamide(9-9), l-[3-fluoro-4- (methylsulfonylamino)phenyl]cycloprophan carboxic acid(10-5), l-[4- (methylsulfonylamino)ρhenyl]cycloprophan carboxic acid(ll-7, CHK-530), l-[3- methoxy-4-(methylsulfonylamino)phenyl]cycloprophan carboxic acid(ll-8), N-[2-(3,4- dimethylbenzyl)-3-pivaloxypropyl]-l-[4-(methylsulfonylamino)phenyl]cycloprophan carboxiamide(12-l, CHK-533), N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-l-[3- fluoro-4-(methylsulfonylamino)phenyl]cycloprophan carboxiamide(12-2, CHK-538), N- [2-(3 ,4-dimethylbenzyl)-3 -pivaloxypropyl] - 1 - [3 -methoxy-4- (methylsulfonylamino)ρhenyl]cycloprophan carboxiamide(12-3, CHK-541), N-[3-(3,4- dimethylρhenyl)propyl]-l-[4-(methylsulfonylamino)ρhenyl]cycloρrophan carboxiamide(12-4, CHK-590), N-[3-(3,4-dimethylphenyl)ρropyl]-l-[3-fluoro-4- (methylsulfonylamino)phenyl]cycloprophan carboxiamide(12-5), N-[3-(3,4- dimethylphenyl)propyl] - 1 - [3 -methoxy-4-(methylsulfonylamino)phenyl] cycloprophan carboxiamide(12-6, CHK-632), N-(4-ter/-butylbenzyl)-l-[4-
(methylsulfonylamino)phenyl]cycloprophan carboxiamide(12-7, CHK-719), N-(4-tert- butylbenzyl)- 1 -[3 -fluoro-4-(methylsulfonylamino)phenyl] cycloprophan carboxiamide(12-8, CHK-659), N-(4-ter/-butylbenzyl)-l-[3-methoxy-4- (methylsulfonylamino)ρhenyl]cycloproplιan carboxiamide(12-9, CHK-718).
4. The compound according to claim 1 represented by the following general formula (III), the pharmaceutically acceptable salt or the isomer thereof:
Figure imgf000129_0001
wherein, R1 to is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring providing that all of Rj to R4 are not hydrogen atoms simultaneously; R5 and R6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R5 and R6 are not hydrogen atom simultaneously; B is a group selected from the group (1-1) to (1-6) defined in general formula (I) as set forth in claim 1; the asteric mark * indicates a chiral carbon atom.
5. The compound according to claim 4 wherein said compound is at least one selected from the group consisting of;
N-(4-tert-butylbenzyl)-N, - { 1 -[3-fluoro-4- (methylsulfonylamino)phenyl]ethyl}thiourea(l 5-1 , LJO-328), N-(4-tert-butylbenzyl)- N,-{l-[3-chloro-4-(methylsulfonylamino)phenyl]ethyl}thiourea(15-2, CHK-992), N-(4- tert-butylbenzyl)-Nλ - { 1 -[3-methoxy-4-(methylsulfonylamino)phenyl]ethyl} thiourea(l 5- 3, CHK-575), N-(4-tert-butylbenzyl)-NΛ - { 1 -[3-(methoxycarbonyl)-4- (methylsulfonylamino)phenyl]ethyl}thiourea(15-4, YHS-187), N-(4-te7-t-butylbenzyl)- N,-{l-[3-carboxy-4-(methylsulfonylamino)phenyl]ethyl}thiourea(15-5, YHS-209), N- (4-tert-butylbenzyl)-N,-{(lR)-l-[4-(methylsulfonylamino)phenyl]ethyl}thiourea(16-5, SU-388), N-(4-tert-butylbenzyl)-Nλ-{(lS)-l-[4-
(methylsulfonylamino)phenyl]ethyl}thiourea(l 6-6, SU-400), N-(4-tert-butylbenzyl)-NΛ- {(lR)-l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}thiourea(17-3, CJU-032), N- (4-tert-butylbenzyl)-NΛ-{(lS)-l-[3-fluoro-4-
(methylsulfonylamino)phenyl]ethyl}thiourea(17-6, CJU-039), N-[(2R)-2-benzyl-3- (pi valoyloxy)prophyl] -N' - {( 1 R)- 1 - [4-(methylsulfonylamino)phenyl] ethyl} thiourea( 18- l, MK-229), N-[(2S)-2-benzyl-3-(pivaloyloxy)prophyl]-N,-{(lR)-l-[4- (methylsulfonylamino)phenyl]ethyl}thiourea(l 8-2, MK-202), N-[(2R)-2-benzyl-3- (pivaloyloxy)prophyl] -N' - {( 1 S)- 1 - [4-(methylsulfonylamino)phenyl] ethyl} thiourea( 18-3, MK-230), N-[(2S)-2-benzyl-3-(pivaloyloxy)prophyl]-N - {(1 S)-l -[4- (methylsulfonylamino)phenyl]ethyl}thiourea(l 8-4, MK-228), N-[2-(3,4- dimethylbenzyl)-3-(pivaloyloxy)prophyl]-N'-{l-[4- (methylsulfonylamino)phenyl] ethyl} thiourea(l 8-5, LJO-388), N-[2-(3,4- dimethylbenzyl)-3-(pivaloyloxy)prophyl]-N,-{(lR)-l-[4- (methylsulfonylamino)phenyl]ethyl}thiourea(l 8-6, SU-472), N-[(2R)-2-(3,4- dimethylbenzyl)-3-(pivaloyloxy)prophyl]-Nλ-{(lR)-l-[4- (methylsulfonylamino)phenyl]ethyl}thiourea(l 8-7, SU-512), N-[(2S)-2-(3,4- dimethylbenzyl)-3-(pivaloyloxy)prophyl]-N -{(lR)-l-[4- (methylsulfonylamino)phenyl]ethyl}thiourea(18-8), N-[2-(4-tert-butylbenzyl)-3- (pivaloyloxy)prophyl] -N - { 1 -[4-(methylsulfonylamino)phenyl] ethyl} thiourea(l 8-9, LJO-401), N-[2-(4-tert-butylbenzyl)-3-(pivaloyloxy)prophyl]-N,-{l(R)-[4- (methylsulfonylamino)phenyl]ethyl}thiourea(18-10, MK-296), N-[2(R)-(4-tert- butylbenzyl)-3-(pivaloyloxy)ρrophyl]- , - { 1 (R)-[4-
(methylsulfonylamino)ρhenyl]ethyl}thiourea(18-l 1, MK-334), N-[2(S)-(4-tert- butylbenzyl)-3-(ρivaloyloxy)ρrophyl]-INr - { 1 (R)-[4- (methylsulfonylamino)phenyl]ethyl}thiourea(18-12, MK-298), N-[2-(3,4- (dimethylbenzyl)-3 -(pi valoyloxy)prophyl] -NΛ - { 1 - [3 -fluoro -4- (methylsulfonylamino)phenyl]ethyl}thiourea(18-13, LJO-344), N-[2-(4-tert- butylbenzyl)-3-(pivaloyloxy)prophyl]-N,- { l-[3-fluoro -4-
(methylsulfonylamino)phenyl]ethyl}thiourea(l 8-14, LJO-366), N-[(2R)-3 -phenyl- 1- pivaloyloxy-2-prophyl]-N,-[(R)-α-methyl-4-(methylsulfonylamino)benzyl]thiourea(19- 13, SU-692), N-[(2S)-3-phenyl-l-pivaloyloxy-2-prophyl]-N,-[(R)-α:-methyl-4- (methylsulfonylamino)benzyl]thiourea(19-14, SU-704), N-[(2R)-3-phenyl-l- pivaloyloxy-2-prophyl]-N"-[(S)-α-methyl-4-(methylsulfonylamino)benzyl]thiourea(19- 15, SU-720), N-[(2S)-3-phenyl-l-pivaloyloxy-2-prophyl]-N,-[(S)-c.-methyl-4- (methylsulfonylamino)benzyl]thiourea( 19-16, SU-710), N-(4-tert-butylbenzyl)-N" - { 1 - [4-(methylsulfonylamino)-3-fluoiOphenyl]prophyl}thiourea(20-12, LJO-399), N-(4-/ert- butylbenzyl)-Nr - { 1 -[4-(methylsulfonylamino)-3-fluorophenyl]-2- methylprophyl} thiourea(20- 13, LJO-402), N-(4-tert-butylbenzyl)-N, - { [4- (methylsulfonylamino)-3-fluorophenyl](phenyl)methyl}thiourea(20-14, LJO-403), N- (4-tert-butylbenzyl)-N'l-{l-[4-(methylsulfonylamino)-3-fluorophenyl]-2- phenylethyl} thiourea(20- 15, LJO-395), N-(4-tert-butylbenzyl)-NΛ - { 1 -methyl- 1 -[4- (methylsulfonylamino)phenyl] ethyl} thiourea(21 -7, CHK-593), N-(4-/ert-butylbenzyl)- N' - { 1 -methyl- 1 - [3 -fluoro-4-(methylsulfonylamino)phenyl] ethyl} thiourea(21 -8 , CHK- 660), N-(4-tβrt-butylbenzyl)-Nλ - { 1 -methyl-1 -[3 -methoxy-4-
(methylsulfonylamino)phenyl] ethyl} thiourea(21 -9, CHK-629), N-(4-tert-butylbenzyl)- N'- {l-[4-(methylsulfonylamino)phenyl]cycloprophyl}thiourea(22-7, CHK-579), N-(4- tert-butylbenzyl)-Nλ - { 1 -[3-fluoro-4-
(methylsulfonylamino)phenyl]cycloprophyl}thiourea(22-8), N-(4-tert-butylbenzyl)-NΛ- {l-[3-methoxy-4-(methylsulfonylamino)phenyl]cycloprophyl}thiourea(22-9, CHK-631).
6. The compound according to claim 1 represented by the following general formula (IV), the pharmaceutically acceptable salt or the isomer thereof:
Figure imgf000132_0001
wherein, R to R is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring; R5 and R6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R5 and R<s are not hydrogen atom simultaneously; B is a group selected from the group (1-1) to (1-6) defined in general formula (I) as set forth in claim 1 ; the asteric mark * indicates a chiral carbon atom.
7. The compound according to claim 6 wherein said compound is at least one selected from the group consisting of;
N-(4-tert-butylbenzyl)-NΛ - { 1 -[4-(methylsulfonylamino)phenyl] ethyl} urea (23- 1 , MK-82), N-(4-tert-butylbenzyl)-NΛ- { 1 - [3 -fluoro-4-(methylsulfonylamino)phenyl] ethyl} urea (23-2, MK-205).
8. The compound according to claim 1 represented by the following general formula (V), the pharmaceutically acceptable salt or the isomer thereof:
Figure imgf000133_0001
wherein, Ri to R4 is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring; R5 and R6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon, providing that both of R5 and R6 are not hydrogen atom simultaneously; B is a group selected from the group (1-1) to (1-6) defined in general formula (I) as set forth in claiml ; the asteric mark * indicates a chiral carbon atom.
9. The compound according to claim 8 wherein said compound is at least one selected from the group consisting of;
N-{l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert- butylphenyl)acetamide (24-1, KMJ-586), N- { 1 - [3 -fluoro-4-(methylsulfonylanιino)phenyl] ethyl} -3 -(4-tert- butylphenyl)prophanamide (24-2, KMJ-552), N- { 1 -[3-fluoro-4-(methylsulfonylamino)phenyl] ethyl} -3 -(4-tert-butylphenyl)-2- prophenamide (24-3, KMJ-570), N-{l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4- dimethylphenyl)prophanamide (24-4, CHK-602), N- { 1 - [3 -fluoro-4-(methylsulfonylamino)ρhenyl] ethyl} -3 -(3 ,4-dimethylphenyl)-2- prophenamide (24-5, CHK-651), N- { 1 -[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl} -3-(4- chlorophenyl)prophenamide (24-6, KMJ-534), N-{l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-chlorophenyl) -2- prophenamide (24-7, KMJ-558), N-{l-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4- dimethylρhenyl)buthanamide (24-8, CHK-647).
10. The compound according to any one of claims 1, 2, 4, 6 and 8 wherein said R\ to R-t is independently at least one selected from a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, five or six- member heterocyclic ring.
11. The compound according to any one of claims 1, 2, 4, 6 and 8 wherein said R5 and R6 is independently at least one selected from a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms and phenyl or benzyl group optionally substituted with at least one selected from halogen atom, amine group and alkyl group having 1 to 6 carbon.
12. A pharmaceutical composition comprising the compound of general formula (I) as set forth in claim 1 as an active ingredient in amount effective amount for an antagonist of vanilloid receptor together with phannaceutically acceptable carriers or diluents.
13. The pharmaceutical composition according to claim 12 wherein said pain disease is at least one selected from the group consisting of pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, coughing, stomach-duodenal ulcer, inflammatory bowel disease caused by the vanilloid receptor antagonistic activity.
14. A pharmaceutical composition comprising the compound of any one of claims 1, 2, 4, 6 and 8 as an active ingredient in amount effective for analgesic and anti- inflammation together with pharmaceutically acceptable carriers or diluents.
PCT/KR2004/001641 2003-07-02 2004-07-02 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same WO2005003084A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IL172671A IL172671A (en) 2003-07-02 2004-07-02 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonists showing excellent analgesic activity and pharmaceutical compositions comprising the same
NZ544943A NZ544943A (en) 2003-07-02 2004-07-02 4-(methylsulfonylamino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same
CA2533547A CA2533547C (en) 2003-07-02 2004-07-02 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same
AU2004253808A AU2004253808B2 (en) 2003-07-02 2004-07-02 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same
US10/562,698 US8642657B2 (en) 2003-07-02 2004-07-02 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same
JP2006518539A JP4850702B2 (en) 2003-07-02 2004-07-02 4- (Methylsulfonylamino) phenyl analog as vanilloid antagonist showing excellent analgesic action and pharmaceutical composition containing the same
EP04748386A EP1658265A4 (en) 2003-07-02 2004-07-02 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same
BRPI0412229-1A BRPI0412229A (en) 2003-07-02 2004-07-02 4- (methylsulfonylamino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and pharmaceutical compositions comprising the same
IS8216A IS8216A (en) 2003-07-02 2005-12-30 4- (methylsulfonyl amino) phenyl analogues as vanilloid antagonists, showing excellent analgesic activity, and pharmaceutical compositions containing them
NO20060122A NO332602B1 (en) 2003-07-02 2006-01-09 4- (methyl sulfonyl amino) phenyl analogs as vanilloid antagonist exhibiting excellent analgesic activity and pharmaceutical compositions including the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20030044552 2003-07-02
KR10-2003-0044552 2003-07-02

Publications (1)

Publication Number Publication Date
WO2005003084A1 true WO2005003084A1 (en) 2005-01-13

Family

ID=36141774

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2004/001641 WO2005003084A1 (en) 2003-07-02 2004-07-02 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same

Country Status (16)

Country Link
US (1) US8642657B2 (en)
EP (1) EP1658265A4 (en)
JP (1) JP4850702B2 (en)
KR (1) KR100707123B1 (en)
CN (1) CN100537528C (en)
AU (1) AU2004253808B2 (en)
BR (1) BRPI0412229A (en)
CA (1) CA2533547C (en)
EC (1) ECSP066321A (en)
IL (1) IL172671A (en)
IS (1) IS8216A (en)
NO (1) NO332602B1 (en)
NZ (1) NZ544943A (en)
RU (1) RU2362768C2 (en)
WO (1) WO2005003084A1 (en)
ZA (1) ZA200600895B (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097817A1 (en) 2005-03-17 2006-09-21 Pfizer Japan Inc. N- (n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
WO2006098554A1 (en) * 2005-03-16 2006-09-21 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
WO2006101321A1 (en) * 2005-03-19 2006-09-28 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
DE102005050408A1 (en) * 2005-10-19 2007-04-26 Grünenthal GmbH New methanesulfonamide derivatives are vanilloid-receptor 1-ligands useful for the treatment and prophylaxis of e.g. pain, depressions, neurodegenerative diseases, respiratory diseases, psoriasis and cognitive dysfunctions
US7214824B2 (en) 2004-11-10 2007-05-08 Pfizer Inc. Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists
WO2007045462A3 (en) * 2005-10-19 2007-06-21 Gruenenthal Gmbh Novel vanilloid receptor ligands and their use for producing medicaments
WO2007142426A1 (en) * 2006-06-02 2007-12-13 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
WO2007133637A3 (en) * 2006-05-10 2008-01-03 Renovis Inc Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2008046647A1 (en) * 2006-10-19 2008-04-24 Grünenthal GmbH VR1 RECEPTOR LIGANDS AND µ OPIOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN
WO2008050199A2 (en) 2006-10-23 2008-05-02 Pfizer Japan Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
JP2008532994A (en) * 2005-03-10 2008-08-21 ファイザー株式会社 Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds
WO2008121859A1 (en) * 2007-03-30 2008-10-09 Xenon Pharmaceuticals Inc. Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (en) 2007-04-13 2008-10-16 Grünethal GmbH Novel vanilloid receptor ligands and their use in the preparation of medicines
DE102007018149A1 (en) 2007-04-16 2008-10-23 Grünenthal GmbH Substituted compound for producing pharmaceuticals for treating or prophylaxis of pain, nerve injuries, respiratory disorder, has general formulae
DE102007018151A1 (en) 2007-04-16 2008-10-23 Günenthal GmbH Novel vanilloid receptor ligands and their use in the preparation of medicines
WO2008125295A2 (en) * 2007-04-13 2008-10-23 Grünenthal GmbH Novel vanilloid receptor ligands, and their use for the production of pharmaceuticals
EP1992228A1 (en) * 2007-05-14 2008-11-19 Bayer CropScience AG Insecticidal substituted thiourea derivatives
WO2009064449A1 (en) * 2007-11-13 2009-05-22 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009096701A3 (en) * 2008-01-28 2009-09-24 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
JP2009542798A (en) * 2006-07-11 2009-12-03 ファイザー株式会社 Substituted N-bicyclic alkyl bicyclic carboxamide compounds
JP2009544696A (en) * 2006-07-27 2009-12-17 株式會社アモーレパシフィック Novel compounds, isomers or pharmaceutically acceptable salts thereof as vanilloid receptor antagonists; and pharmaceutical compositions containing the same
JP2010505742A (en) * 2006-05-18 2010-02-25 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ (2R) -2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them
WO2010056044A2 (en) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 Novel compound acting as a vanilloid receptor antagonist, isomer or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same
EP2307394A2 (en) * 2008-07-02 2011-04-13 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
WO2011051375A1 (en) * 2009-10-28 2011-05-05 Dompé S.p.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
US7964732B2 (en) 2006-11-17 2011-06-21 Pfizer Inc. Substituted bicyclocarboxyamide compounds
US7994167B2 (en) 2005-05-20 2011-08-09 Gruenenthal Gmbh Pentafluorosulphanyl-substituted compound and its use for producing medicaments
US8178558B2 (en) 2006-09-15 2012-05-15 Pfizer Inc. Substituted pyridylmethyl bicycliccarboxyamide compounds
KR101367057B1 (en) 2009-03-17 2014-02-25 (주)아모레퍼시픽 Composition for Reducing Skin Irritation
WO2021064189A3 (en) * 2019-10-02 2021-05-20 Domain Therapeutics Prostaglandin e2 (pge2) ep4 receptor antagonists
DE102022104759A1 (en) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-crystal screening method, in particular for the production of co-crystals

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE404546T1 (en) * 2004-11-10 2008-08-15 Pfizer SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXYACETAMIDE COMPOUNDS
WO2008103773A1 (en) * 2007-02-20 2008-08-28 Haiyun Tang Digital predistortion for cognitive radio
JP5365509B2 (en) * 2007-10-25 2013-12-11 東レ株式会社 Membrane filtration prediction method, prediction apparatus, and membrane filtration prediction program
US8653099B2 (en) * 2008-08-19 2014-02-18 Janssen Pharmaceutica Cold menthol receptor antagonists
CN105820076A (en) * 2015-01-05 2016-08-03 齐鲁工业大学 N-[2,5-diethoxy-4-(3-p-tolyl-ureidomethyl)-phenyl]-methanesulfonamide new compound and preparation method and application thereof
CN105820088A (en) * 2015-01-05 2016-08-03 齐鲁工业大学 N-(4-bromo-phenyl)-5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxylbenzamide new compound and preparation method and application thereof
CN105820069A (en) * 2015-01-05 2016-08-03 齐鲁工业大学 N-{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-dibutoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof
CN105820073A (en) * 2015-01-05 2016-08-03 齐鲁工业大学 N-{[2,5-diethoxy-4-[(3-phenyl-ureido)-methyl]-phenyl}-methanesulfonamide new compound and preparation method and application thereof
CN105820087A (en) * 2015-01-05 2016-08-03 齐鲁工业大学 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-p-methylphenyl-benzamide new compound and preparation method and application thereof
CN106344552B (en) * 2015-07-15 2021-04-30 齐鲁工业大学 Novel sulfonamide compound, preparation method and application of sulfonamide compound as protein tyrosine phosphatase1B inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016318A1 (en) * 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
WO2002016319A1 (en) * 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea compounds and the pharmaceutical compositions containing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU763824B2 (en) * 1999-02-22 2003-07-31 Medifron Dbt Co., Ltd. Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof
GB0110901D0 (en) * 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016318A1 (en) * 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
WO2002016319A1 (en) * 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea compounds and the pharmaceutical compositions containing the same

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CATERÍNA, M. J. ET AL., NATURE, vol. 389, 1997, pages 816
GALLACHER ET AL., BIOGENIC AMINES, 1995, pages 49 - 62
LEE J. ET AL.: "N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thio urea analogues: novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 14, 3 July 2003 (2003-07-03), pages 3116 - 3126, XP002385179 *
LEE, J. W., BIOORGANIC & MEDICINAL CHEMISTRY, 2001, pages 1713 - 1720
See also references of EP1658265A4
SZALLASI ET AL., PHARMACOL. EXP. THER, vol. 262, 1992, pages 883 - 888
TOMINAGA M. ET AL., NATURE, vol. 21, 1998, pages 531 - 543
WANG Y. ET AL.: "High affinity partial agonist of the vanilloid receptor", MOLECULAR PHARMACOLOGY, vol. 64, no. 2, August 2002 (2002-08-01), pages 325 - 333, XP009057763 *
WANG Y. ET AL.: "High effinity antagonists of the vanilloid receptor", MOLECULAR PHARMACOLOGY, vol. 62, no. 4, 2002, pages 947 - 956, XP008037189 *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214824B2 (en) 2004-11-10 2007-05-08 Pfizer Inc. Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists
JP2008532994A (en) * 2005-03-10 2008-08-21 ファイザー株式会社 Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds
US7566739B2 (en) 2005-03-10 2009-07-28 Pfizer Inc. Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists
WO2006098554A1 (en) * 2005-03-16 2006-09-21 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
US7915448B2 (en) * 2005-03-17 2011-03-29 Pfizer Inc. Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists
US7622589B2 (en) 2005-03-17 2009-11-24 Pfizer Inc. Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists
KR100927915B1 (en) * 2005-03-17 2009-11-19 화이자 인코포레이티드 N-(n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
WO2006097817A1 (en) 2005-03-17 2006-09-21 Pfizer Japan Inc. N- (n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
JP2008535801A (en) * 2005-03-17 2008-09-04 ファイザー株式会社 N- (N-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
WO2006101318A1 (en) * 2005-03-19 2006-09-28 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US7763657B2 (en) 2005-03-19 2010-07-27 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US7960584B2 (en) 2005-03-19 2011-06-14 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2006101321A1 (en) * 2005-03-19 2006-09-28 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
JP2008537547A (en) * 2005-03-19 2008-09-18 アモーレパシフィック コーポレイション Novel compounds as vanilloid receptor antagonists, isomers thereof or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing the same
US7994167B2 (en) 2005-05-20 2011-08-09 Gruenenthal Gmbh Pentafluorosulphanyl-substituted compound and its use for producing medicaments
CN103382176A (en) * 2005-10-19 2013-11-06 格吕伦塔尔有限公司 Novel vanilloid receptor ligands and their use for producing medicaments
CN101331124B (en) * 2005-10-19 2013-08-14 格吕伦塔尔有限公司 Novel vanilloid receptor ligands and their use for producing medicaments
EP2388258A1 (en) 2005-10-19 2011-11-23 Grünenthal GmbH Novel vanilloid receptor ligands and their use for producing medicaments
AU2006303437B2 (en) * 2005-10-19 2012-06-28 Grunenthal Gmbh Novel vanilloid receptor ligands and their use for producing medicaments
KR101347102B1 (en) * 2005-10-19 2014-01-03 그뤼넨탈 게엠베하 Novel vanilloid receptor ligands and their use for producing medicaments
US8710233B2 (en) 2005-10-19 2014-04-29 Gruenenthal Gmbh Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations
WO2007045462A3 (en) * 2005-10-19 2007-06-21 Gruenenthal Gmbh Novel vanilloid receptor ligands and their use for producing medicaments
JP2009512654A (en) * 2005-10-19 2009-03-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Novel vanilloid receptor ligands and their use in the manufacture of pharmaceuticals
DE102005050408A1 (en) * 2005-10-19 2007-04-26 Grünenthal GmbH New methanesulfonamide derivatives are vanilloid-receptor 1-ligands useful for the treatment and prophylaxis of e.g. pain, depressions, neurodegenerative diseases, respiratory diseases, psoriasis and cognitive dysfunctions
JP2009536657A (en) * 2006-05-10 2009-10-15 レノビス， インコーポレイテッド Amide derivatives as ion channel ligands and pharmaceutical compositions and methods using the same
WO2007133637A3 (en) * 2006-05-10 2008-01-03 Renovis Inc Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
JP2010505742A (en) * 2006-05-18 2010-02-25 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ (2R) -2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them
WO2007142426A1 (en) * 2006-06-02 2007-12-13 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
JP2009542798A (en) * 2006-07-11 2009-12-03 ファイザー株式会社 Substituted N-bicyclic alkyl bicyclic carboxamide compounds
JP2009544696A (en) * 2006-07-27 2009-12-17 株式會社アモーレパシフィック Novel compounds, isomers or pharmaceutically acceptable salts thereof as vanilloid receptor antagonists; and pharmaceutical compositions containing the same
US7858621B2 (en) 2006-07-27 2010-12-28 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US8178558B2 (en) 2006-09-15 2012-05-15 Pfizer Inc. Substituted pyridylmethyl bicycliccarboxyamide compounds
WO2008046647A1 (en) * 2006-10-19 2008-04-24 Grünenthal GmbH VR1 RECEPTOR LIGANDS AND µ OPIOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN
WO2008050199A2 (en) 2006-10-23 2008-05-02 Pfizer Japan Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
US8158650B2 (en) 2006-10-23 2012-04-17 Pfizer Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
US7964732B2 (en) 2006-11-17 2011-06-21 Pfizer Inc. Substituted bicyclocarboxyamide compounds
WO2008121859A1 (en) * 2007-03-30 2008-10-09 Xenon Pharmaceuticals Inc. Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions
WO2008125295A3 (en) * 2007-04-13 2009-02-05 Gruenenthal Gmbh Novel vanilloid receptor ligands, and their use for the production of pharmaceuticals
US8252816B2 (en) 2007-04-13 2012-08-28 Gruenenthal Gmbh Vanilloid receptor ligand compounds, pharmaceutical compositions containing them, a method of producing them and the use thereof to treat pain and various other conditions
DE102007017884A1 (en) 2007-04-13 2008-10-16 Grünethal GmbH Novel vanilloid receptor ligands and their use in the preparation of medicines
WO2008125296A1 (en) 2007-04-13 2008-10-23 Grünenthal GmbH Vanilloid receptor ligands and the use thereof for the production of pharmaceuticals
US8735426B2 (en) 2007-04-13 2014-05-27 Gruenenthal Gmbh Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions
WO2008125295A2 (en) * 2007-04-13 2008-10-23 Grünenthal GmbH Novel vanilloid receptor ligands, and their use for the production of pharmaceuticals
US8642623B2 (en) 2007-04-13 2014-02-04 Gruenenthal Gmbh Vanilloid receptor ligand compounds, pharmaceutical compositions containing them, a method of producing them and the use thereof to treat pain and various other conditions
JP2010523726A (en) * 2007-04-16 2010-07-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Novel vanilloid receptor ligands and their use in the manufacture of medicaments
DE102007018151A1 (en) 2007-04-16 2008-10-23 Günenthal GmbH Novel vanilloid receptor ligands and their use in the preparation of medicines
DE102007018149A1 (en) 2007-04-16 2008-10-23 Grünenthal GmbH Substituted compound for producing pharmaceuticals for treating or prophylaxis of pain, nerve injuries, respiratory disorder, has general formulae
US8791268B2 (en) 2007-04-16 2014-07-29 Gruenenthal Gmbh Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions
EP1992228A1 (en) * 2007-05-14 2008-11-19 Bayer CropScience AG Insecticidal substituted thiourea derivatives
WO2008138499A1 (en) * 2007-05-14 2008-11-20 Bayer Cropscience Ag Insecticidal substituted thiourea derivatives
WO2009064449A1 (en) * 2007-11-13 2009-05-22 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
JP2011503072A (en) * 2007-11-13 2011-01-27 レノビス， インコーポレイテッド Amide derivatives as ligands for ion channels and pharmaceutical compositions and methods using the same
WO2009096701A3 (en) * 2008-01-28 2009-09-24 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US8557872B2 (en) 2008-01-28 2013-10-15 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP2307394A2 (en) * 2008-07-02 2011-04-13 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
EP2307394A4 (en) * 2008-07-02 2011-07-27 Amorepacific Corp Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
US8691855B2 (en) 2008-07-02 2014-04-08 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
WO2010056044A3 (en) * 2008-11-11 2010-10-21 (주)아모레퍼시픽 Novel compound acting as a vanilloid receptor antagonist, isomer or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same
WO2010056044A2 (en) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 Novel compound acting as a vanilloid receptor antagonist, isomer or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same
KR101367057B1 (en) 2009-03-17 2014-02-25 (주)아모레퍼시픽 Composition for Reducing Skin Irritation
WO2011051375A1 (en) * 2009-10-28 2011-05-05 Dompé S.p.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
AU2010311466B2 (en) * 2009-10-28 2016-03-03 Dompe' Farmaceutici S.P.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
WO2021064189A3 (en) * 2019-10-02 2021-05-20 Domain Therapeutics Prostaglandin e2 (pge2) ep4 receptor antagonists
DE102022104759A1 (en) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-crystal screening method, in particular for the production of co-crystals

Also Published As

Publication number Publication date
CA2533547C (en) 2013-09-10
US8642657B2 (en) 2014-02-04
KR100707123B1 (en) 2007-04-16
BRPI0412229A (en) 2006-08-22
CN100537528C (en) 2009-09-09
ZA200600895B (en) 2009-07-29
AU2004253808A1 (en) 2005-01-13
RU2006102868A (en) 2007-08-10
NZ544943A (en) 2009-07-31
CA2533547A1 (en) 2005-01-13
AU2004253808B2 (en) 2011-02-03
NO20060122L (en) 2006-01-09
EP1658265A1 (en) 2006-05-24
NO332602B1 (en) 2012-11-12
IS8216A (en) 2005-12-30
JP2007521288A (en) 2007-08-02
JP4850702B2 (en) 2012-01-11
KR20050004006A (en) 2005-01-12
IL172671A (en) 2013-08-29
EP1658265A4 (en) 2006-11-29
IL172671A0 (en) 2006-04-10
CN1852891A (en) 2006-10-25
RU2362768C2 (en) 2009-07-27
ECSP066321A (en) 2006-07-28
US20060258884A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
AU2004253808B2 (en) 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same
US7067553B2 (en) Thiourea compounds and the pharmaceutical compositions containing the same
EP0920424B1 (en) Non-peptide bombesin receptor antagonists
CA2418652C (en) Novel 3-substituted urea derivatives and medicinal use thereof
EP2234961A2 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
AU2003241453A1 (en) Aminotetralin-derived urea modulators of vanilloid vr1 receptor
EP1624868B1 (en) &#34;(2-hydroxy-2-(4-hydroxy-3-hydoxymethylphenyl)-ethylamino)- propyl]phenyl derivatives as beta2 agonists
CA2693032A1 (en) Nmda receptor antagonists for neuroprotection
JP2008538109A (en) Novel compounds as vanilloid receptor antagonists, isomers thereof or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing the same
CA2989146A1 (en) Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
EP1727790A1 (en) Phenylaminoethanol derivatives as beta2 receptor agonists
CA2660994A1 (en) Substituted acetylenic compounds useful for the treatment of diseases
AU2010311466B2 (en) 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
CZ279630B6 (en) Amidine derivatives, processes of their preparation and pharmaceutical compositions
AU2005223488A1 (en) Phenylethanolamine derivatives as Beta-2 agonists
CA2232090A1 (en) Selective .beta.3 adrenergic agonists
US5389682A (en) Agents acting at cholecystokinin receptors
WO2006098554A1 (en) Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
US6872748B2 (en) Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same
MXPA06000160A (en) 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same
WO2003027064A1 (en) Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical co mpositions containing the same
NL1028559C2 (en) Compounds useful for the treatment of diseases
AU1010702A (en) Therapeutics Guanidines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480024599.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172671

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004748386

Country of ref document: EP

Ref document number: 5995/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006518539

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004253808

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2533547

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/000160

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2004253808

Country of ref document: AU

Date of ref document: 20040702

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004253808

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 544943

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200600895

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2006102868

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2006258884

Country of ref document: US

Ref document number: 10562698

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004748386

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0412229

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10562698

Country of ref document: US